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Abstract 
Several countries across the world have developed and implemented 
frameworks of non-medical prescribing. In the United Kingdom, pharmacist 
prescribing was introduced in 2003 as supplementary prescribing, with this 
extended to include independent prescribing in 2006. Pharmacist prescribing 
has been proven to be safe, clinically appropriate, and highly regarded by 
patients and other members of the healthcare team.  
In Qatar, pharmacy practice is rapidly evolving in an attempt to better utilise 
pharmacists’ skills thus improve patient health outcomes. Qatar National 
Vision 2030 aims to establish “a comprehensive world-class healthcare 
system whose services are accessible to the whole population”. To facilitate 
achievement of this goal, there is potential for the development and 
implementation of frameworks of pharmacist prescribing in Qatar. 
The overall aim of this doctoral research was to explore the development of 
pharmacist prescribing frameworks in Qatar.  
A multi-modal research design was implemented across four phases with the 
findings of each phase informing the next.  
The first phase was an umbrella review of published systematic reviews on 
non-medical prescribing. Seven systematic reviews reported aspects of 
prescribing decision-making, processes of prescribing, barriers, and 
facilitators to implementation. Three of the reviews explored patient 
outcomes that were noted to be equivalent or better to physician prescribing. 
Given the absence of systematic review of views and experiences of key 
stakeholders, the second phase was a systematic review of 65 studies to 
address this gap in knowledge. The majority of studies pre- and post-
implementation reported positive findings. One key limitation of the studies 
was the general lack of any consideration of theories of implementation in 
study design, execution, and reporting. 
The third phase was grounded in the Consolidated Framework of 
Implementation Research, involving semi-structured qualitative interviews 
with key stakeholders in positions of power and influence in Qatar. Data 
saturation was achieved on completion of 37 interviews, the findings of which 
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highlighted support for the development and implementation of pharmacist 
prescribing in Qatar, with many potential benefits described. 
Findings of all three phases were incorporated into a final phase Delphi study 
aiming to determine the levels of agreement amongst key stakeholders in 
Qatar around the development of pharmacist prescribing frameworks. The 
scope of the framework developed included: definitions, models and scope of 
prescribing; education and training; prescribing practice and governance. 
High levels of agreement were achieved for Delphi statements relating to the 
Collaborative Pharmacist Prescribing model, thus indicating it as being the 
most appropriate for Qatar.  
In conclusion, this research has provided original, robust and rigorous 
findings which can support implementation of frameworks of pharmacist 
prescribing in Qatar and beyond. Further research-based developmental work 
is required to translate this framework into an approved education and 
training course and practice. 
 
Keywords: pharmacy, professional role, multi-modal design, theory, Middle 
East  
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Forward 
This thesis describes the research undertaken in pursuit of a PhD degree from 
Robert Gordon University (RGU), Aberdeen, UK. 
During the past three years, I investigated aspects of non-medical prescribing 
with a focus on the potential to implement pharmacist prescribing in Qatar. I 
obtained my Bachelor of Science (Pharmacy) with Distinction from the 
College of Pharmacy at Qatar University in 2015. During my studies, I was 
exposed to clinical pharmacy research and co-authored a published study 
around developing pharmacists’ research capacity in Qatar. As well as this 
experience developing my research skills, I realised that my future career 
path lay in academia thus required me to further develop my research 
knowledge and skills. There is a need to provide high quality evidence of the 
contribution that pharmacists can make to healthcare. Due to the above 
reasons, I have decided to pursue a PhD in Pharmacy Practice. 
The developments in pharmacist prescribing globally have provided evidence 
of the contribution of that pharmacists can make as front line clinicians. 
Given the reputation of RGU in the field of pharmacist prescribing, I chose 
this as a base for the PhD.  
Throughout my journey at RGU, I have been introduced to a range of 
research philosophies, methodologies, and methods which have shaped and 
extended my research expertise. I have had the opportunity to present the 
research at national and international forums, and network with a range of 
people. This, along with constant feedback from my research team and fellow 
students, has further enhanced my research experience.  
I believe that the programme of research reported in thesis has the potential 
to make a positive impact on the healthcare system in Qatar, in line with the 
Qatar National Vision 2030 of making healthcare more accessible and 
affordable by utilising the skills and expertise of the healthcare workforce. 
A multi-modal research design was adopted, and the thesis reported in seven 
chapters as follows: 
Chapter 1 provides a brief overview of the healthcare structure in the ‘Arab 
World’ and specifically in Qatar, and describes the concept of pharmacist 
xiii 
 
prescribing, citing the UK experience. The overall doctoral research aim and 
the aims of the four linked phases are described. 
Chapter 2 describes and justifies the research philosophies, methodologies, 
methods, and theoretical frameworks employed in the programme of studies. 
Measures to enhance research robustness and rigour are described as well. 
Chapter 3 presents Phase 1, an original umbrella review of systematic 
reviews of aspects of non-medical prescribing. Detailed coverage of the 
search strategy and findings are reported. Gaps in published systematic 
reviews informed the remainder of the doctoral research.  
Chapter 4 is Phase 2, a systematic review of stakeholders’ views and 
experiences of pharmacist prescribing. The systematic review protocol was 
registered in the PROSPERO database at the University of York. The review 
findings identified a lack of the consideration of theories of implementation 
and qualitative research on this topic.  
Chapter 5 is Phase 3, which was grounded in the Consolidated Framework of 
Implementation Research. This was a qualitative study of semi-structured 
interviews with key individuals in positions of power and influence related to 
healthcare. Their views were sought on the potential to develop and 
implement frameworks of pharmacist prescribing in Qatar.  
Chapter 6, the final phase, is a consensus-based Delphi study. Statements 
relating to frameworks of pharmacist prescribing were developed from 
previous research phases.  
The final chapter (Chapter 7) summarises the overall aim and key findings of 
the doctoral research, and outlines the pharmacist prescribing framework (as 
per the Delphi findings) which could be adopted in Qatar. The originality, 
potential impact, and future research are described.  
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1. Introduction to the chapter 
The overall aim of this doctoral research was to explore the development of 
frameworks for pharmacist prescribing in Qatar. This introductory chapter, 
therefore, provides a brief overview of pharmacy practice in the ‘Arab World’ 
and describes the current healthcare system in Qatar. The concept of 
pharmacist prescribing along with the different models practised 
internationally is described in the chapter. The chapter ends with the overall 
aim of the doctoral research and the specific aims of each of the study 
phases. 
1.1. Pharmacy practice in the ‘Arab World’ 
1.1.1. Background 
In 2016, the total population of the ‘Arab World’ was estimated at just over 
400 million (World Bank 2016). Geographically, the ‘Arab World’ is defined as 
extending from the Arabian Gulf to the Atlantic Ocean, from Iraq and the Gulf 
states in the east to Morocco's Atlantic coast in the west. From north to 
south, the ‘Arab World’ extends from Syria to Sudan. It consists of 22 
nations: Algeria, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, 
Morocco, Oman, Qatar, Saudi Arabia, Sudan, Syria, Tunisia, the United Arab 
Emirates, Yemen, Somalia, Djibouti, Mauritania, Comoros, and Palestine 
(Figure 1.1). 
The latest World Bank statistics published in 2016 revealed that the ‘Arab 
World’ continues to grow economically, with an estimated aggregated Gross 
Domestic Product (GDP) of $2.869 trillion in 2014. 
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Figure 1.1: Map of the ‘Arab World’ (Wikimedia Commons 2016) 
1.1.2. Description of health indicators in the ‘Arab World’ 
Health indicators in the ‘Arab World’ have improved significantly during the 
last decade. Oman, Saudi Arabia, Tunisia, Algeria, and Morocco rank among 
the top 10 world leaders in development gains, mostly due to advances in 
their health and education systems. Non-communicable diseases are the 
main causes of mortality in the ‘Arab World’, attributed largely to high 
tobacco use (cigarettes and waterpipes), calorie consumption, and low levels 
of physical activity (Jabbour 2013). The key health indicators are summarised 
in Table 1.1.  
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Table 1.1: Health indicators of the Arab World (Jabbour 2013) 
Health Indicator Description 
Population growth -Over 354 million (more than tripled since 1970) 
Population characteristics  -Youthful: 
• 31% under the age of 15 years 
• over 50% under 25 years of age 
Life expectancy  -Increased from 51 years to almost 70 years 
-Ranges from 50 to 57.1 years in Somalia and Sudan 
and 78.2 to 81.5 in Qatar and Lebanon  
Maternal mortality ratio (per 
100 000 live births) 
-Ranges from less than 15 in several Gulf countries to 
between 1044 and 1107 in Somalia and Sudan 
Mortality rates of children 
under five years 
(per 100 000 live births) 
-Ranges from 8.5 in Qatar to 180 in Somalia 
Non-communicable diseases 
(NCDs) 
-Dominant causes of mortality 
-Causes of more than 50% of deaths, at least a third of 
which are premature, occurring before the age of 70 
years 
-Expected to see the second largest increase in NCDs 
(second to Africa) this decade 
-Three of the top 20 countries in the world with the 
highest prevalence of overweight/ obesity are in the 
‘Arab World’ 
-Four of the top countries in the world with the highest 
prevalence of diabetes mellitus are in the ‘Arab World’ 
1.1.3. Overview of pharmacy practice in the ‘Arab World’ 
Pharmacy education in the ‘Arab World’ has advanced considerably in recent 
years with the launch of new schools of pharmacy, fuelled, in part, by an 
increased demand for pharmacists. Egypt has the highest number of schools 
of pharmacy and ranks highest in terms of the number of pharmacists per 
capita, with the majority of graduates working in the community setting 
(Abdel-Latif and Sabra 2016). 
Pharmacists’ scope of practise vary greatly across the ‘Arab World’, driven 
partly by differences in legislative frameworks. To understand these 
differences, a review of the legislation governing pharmacy practise in each 
of the ‘Arab World’ countries was conducted. Table 1.2 gives the key findings 
as per various Ministries of Health websites in June 2016. This information 
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should be interpreted with caution as several countries did not have a 
Ministry of Health website and in some cases, access required login details. 
Furthermore, it could be that the information is not current or no longer 
reflects the pharmacy practise.  
Table 1.2: Pharmacists’ scope of practice in Arab countries 
Country Scope of practise  Legislation 
Year 
Algeria • No information available on scope of practise ---- 
Bahrain • Dispensing role only for drugs approved by the 
Ministry (no prescribing allowed) (Al Khalifa 1997) 
1997 
Comoros • Website could not be accessed ---- 
Djibouti • Website could not be accessed ---- 
Egypt • Dispensing role only for drugs approved by the 
Ministry (no prescribing allowed) (Council of Ministers 
1955) 
1995 
Iraq • Pharmacists are allowed to dispense any drug with or 
without a prescription 
• If licensed, they can also perform chemical analysis 
(Al Bakr 1970) 
1970 
Jordan • Pharmacists are allowed to dispense any drug with or 
without a prescription except narcotics and 
hallucinators (Al Hussein 2013) 
2001 
Kuwait • Website could not be accessed ---- 
Lebanon • Dispensing role only for drugs approved by the 
Ministry (no prescribing allowed) (Al Hariri 1994, 
Ministry of Public Health 2016) 
1994 
Libya • Website could not be accessed (website has been 
hacked) 
---- 
Mauritania • Dispensing role only for drugs approved by the 
Ministry (no prescribing allowed) (Al-Hariri 2004) 
2004 
Morocco • No information available on scope of pharmacist in 
legislations 
---- 
Oman • Dispensing role only for drugs approved by the 
Ministry (no prescribing allowed) (Directorate 
General of Medical Supply 2009) 
2009 
Palestine • Dispensing role only for drugs approved by the 
Ministry (no prescribing allowed) (Fatouh 2004) 
2004 
Qatar • Dispensing role only for drugs approved by the 
Ministry (no prescribing allowed) (Al Thani 1983) 
1983 
Saudi Arabia • Dispensing role only for drugs approved by the 
Ministry (no prescribing allowed) (Al Saud 2006) 
2005 
Somalia • Website could not be accessed ---- 
Sudan • Dispensing role only for drugs approved by the 
Ministry (no prescribing allowed) (Federal Ministry of 
Health 2001) 
2001 
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Syria • No information available on scope of pharmacist in 
legislations 
---- 
Tunisia • Dispensing role only for drugs approved by the 
Ministry (no prescribing allowed) (Bourquiba 1973, 
Bourquiba 1975) 
1973 
United Arab 
Emirates 
• Dispensing role only for drugs approved by the 
Ministry (no prescribing allowed) (Al Nahian 1983) 
1983 
Yemen • Dispensing role only for drugs approved by the 
Ministry (no prescribing allowed) (Bajmal 2004) 
2005 
 
1.2. Qatar’s profile and its healthcare system 
Given that data generation and collection for the doctoral research was 
conducted in Qatar, this section provides further detail on the country’s 
profile, with focus on its healthcare structure. 
1.2.1. Geography and climate 
The State of Qatar is a peninsula situated halfway along the western coast of 
the Arabian Gulf, covering an area of 11,521 square kilometres (Figure 1.2). 
While the Kingdom of Saudi Arabia is the only neighbouring country by land 
boarder, Qatar shares marine borders with Bahrain, the United Arab Emirates 
and Iran (infoqat.com 2016). 
 
Figure 1.2: Location of Qatar 
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Doha, the capital of Qatar, is located on the east coast, the setting of the 
major commercial and cultural institutions, the ministries and governmental 
establishments, and specialised healthcare facilities (Qatar Statistics 
Authority 2009a). Other major cities in Qatar are Al Wakrah, Al Khor, 
Dukhan, Al Shamal, Mesaieed, and Ras Lafan (Qatar Ministry of Interior 
2015). 
Qatar’s terrain is flat, with deserts occupying the majority of land from east 
to central regions. Vegetation is only found in the northern sectors, where 
farming areas are located. The soil in the remainder of Qatar is calcareous 
hence cannot support agricultural processes (Crystal 2015). 
The climate in Qatar is hot and humid with temperatures reaching over 40°C 
during summer months and humidity levels up to 70% in January, February 
and December (World Weather and Climate Information 2015). In winter, 
temperatures can fall to around 15°C; rainfall is rare, occurring mostly in 
September (Weather Online 2016). 
1.2.2. Major sources of economic development 
According to the World Bank (2016), Qatar’s GDP per capita has been the 
highest globally for the past 10 years, reaching US$96,732.4 in 2014 (Figure 
1.3). 
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Figure 1.3: Qatar’s GDP per capita compared to Europe and North America (World Bank 
2016) 
 
Oil and natural gas are the major sources of income in Qatar, with 2014 
figures of an estimated 25 billion barrels of oil and 25 trillion cubic metres of 
natural gas reserves. Oil and natural gas account for more than 50% of the 
GDP, approximately 85% of export earnings and 50% of government 
revenues. Qatar has around a 1.5% share of the global oil reserves and 13% 
of global gas reserves making it the third largest globally (Index Mundi 
2015). 
In 2014, the expenditure on health was 2.2% of the GDP, equivalent to US$ 
3071 (World Health Organization 2019). 
1.2.3. Political structure 
The State of Qatar is a monarchy ruled by an Emir, with power being 
inherited from father (the Emir) to the son (Heir Apparent). His Highness 
Sheikh Tamim Bin Hamad Bin Khalifa Al Thani is currently the Emir of Qatar 
and the Commander-in-Chief of the armed forces (Qatar Civil Aviation 
Authority 2013). 
Executive power is entrusted to the Emir, the Heir Apparent and the Council 
of Ministers. Legislative authority is delegated to the Advisory Council which 
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is responsible for drafting and approving laws, with judicial affairs delegated 
to the Supreme Judicial Council (Hukoomi: Qatar e-Government 2016). 
Qatar’s constitution was drafted in 1999, stating that Qatar is independent, 
follows the instructions of Islam, uses Arabic as its first language and follows 
the principles of democracy where people are the source of power (Qatar 
Ministry of Foreign Affairs 2013). 
Currently, Qatar is an active member of many regional and global 
organisations including: 
• Organization of the Petroleum Exporting Countries (OPEC) (1961) 
• Arab League (1971) 
• World Intellectual Property Organization (WIPO) (1976) 
• Gulf Cooperation Council (GCC) (1981) 
• World Trade Organization (WTO) (1996) 
1.2.4. Demographics of the population 
In 2015, the population of Qatar was 2.23 million (Abdul-Hamid et al. 2015), 
with almost 40% residing in the capital, Doha (Ministry of Development 
Planning and Statistics 2015). 
 
Figure 1.4: Percent of Qatar’s population municipality  
(Qatar Ministry of Development Planning and Statistics 2015) 
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Around 40% of the population (Qatari and expatriates) is Arab, 18% Indian, 
18% Pakistani, 10% Iranian and 14% other ethnic groups, with the most 
prevalent religion in Qatar being Islam (Muslim 77.5%) followed by 
Christianity (8.5%) (Central Intelligence Agency 2016).  
1.2.5. Qatar National Vision 2030: Healthcare focus 
Over the past decade, Qatar has taken action to transform healthcare in 
order to achieve better patient care outcomes for current and future 
generations. The Qatar National Vision 2030 aims to “transform Qatar into an 
advanced country by 2030, capable of sustaining its own development and 
providing for a high standard of living for all of its people for generations to 
come” by “balancing the accomplishments that achieve economic growth with 
the human and natural resources” (Qatar General Secretariat for 
Development Planning and Statistics 2008). The National Vision seeks to 
address five main challenges: 
• Modernisation while preserving traditions 
• Needs of current and future generations 
• Managed growth and uncontrolled expansion 
• Size and quality of the expatriate labour force 
• Economic growth, social development and environmental management 
The Vision is based on four key pillars as illustrated in Figure 1.5 (Qatar 
General Secretariat for Development Planning and Statistics 2008). 
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Figure 1.5: Pillars of Qatar National Vision 2030 (Qatar General Secretariat 
for Development Planning and Statistics 2008) 
 
Healthcare system development is a main goal stated within the first pillar, 
Human Development. The strategic goals and desired outcomes related to 
this pillar are presented in Table 1.3. Under the second strategic goal of “A 
Healthy Population”, the government aims to establish “a comprehensive 
world-class healthcare system whose services are accessible to the whole 
population”. There is emphasis on a shift in care from secondary and tertiary 
care to primary care. The second outcome of this strategic goal relates to 
creating “an integrated system of healthcare offering high-quality services 
through public and private institutions operating under the direction of a 
national health policy that sets and monitors standards for social, economic, 
administrative and technical aspects of health care”. Early diagnosis, effective 
treatment and research are the three main pillars for improving disease 
management. The third outcome also includes improving care through skilled 
and motivated workforce by encouraging continuing professional education 
and training as well as regulating licensing (Qatar Supreme Council of Health 
2013a, Qatar National Research Fund 2014). 
 
•Development of a competitive 
and diversified economy capable 
of meeting the needs of and 
securing a high standard of 
living for all its people both for 
the present and for the future
•Management of the 
environment such that there 
is harmony between 
economic growth, social 
development and 
environmental protection
•Development of a just and 
caring society based on high 
moral standards, and capable of 
playing a significant role in 
global partnerships for 
development
•Development of all its people 
to enable them to sustain a 
prosperous society 
1. Human 
Development
2. Social 
Development
3. Economic 
Development
4. 
Environmental 
Development
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Table 1.3: Goals of the Human Development Pillar of the Qatar National Vision 2030 (Qatar General Secretariat for Development Planning 
and Statistics 2008) 
Strategic Goal Outcomes 
An Educated Population -A world-class educational system that equips citizens to achieve their aspirations and to meet the needs of Qatar’s 
society, including: 
• Educational curricula and training programmes responding to the current and future needs of the labour market 
• High quality educational and training opportunities appropriate to each individual’s aspirations and abilities 
• Accessible educational programmes for life-long learning 
-A national network of formal and non-formal educational programmes that equip Qatari children and youth with the 
skills and motivation to contribute to society, fostering: 
• A solid grounding in Qatari moral and ethical values, traditions and cultural heritage 
• A strong sense of belonging and citizenship 
• Innovation and creativity 
• Participation in a wide variety of cultural and sports activities 
-Well-developed, independent, self-managing and accountable educational institutions operating under centrally-
determined guidelines. 
-An effective system for funding scientific research shared by the public and private sectors and conducted in 
cooperation with specialised international organisations and leading international research centres. 
-A significant international role in cultural and intellectual activity and scientific research. 
A Healthy Population: 
Physically and Mentally 
-A comprehensive world-class healthcare system whose services are accessible to the whole population, including: 
• Effective and affordable services in accordance with the principle of partnership in bearing the costs of 
healthcare 
• Coverage of preventive and curative healthcare, both physical and mental, taking into account the differing 
needs of men, women and children 
• High quality research directed at improving the effectiveness and quality of healthcare 
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-An integrated system of healthcare offering high-quality services through public and private institutions operating 
under the direction of a national health policy that sets and monitors standards for social, economic, administrative and 
technical aspects of healthcare. 
-A skilled national workforce capable of providing high quality health services. 
-Continued commitment by the State to provide sufficient funds for maintaining the health of Qatar’s population in 
accordance with the principle of partnership in bearing the costs of healthcare. 
A Capable and Motivated 
Workforce 
-Increased and diversified participation of Qataris in the workforce through: 
• Broad investments in certification and training programmes by public and private institutions 
• Incentives for Qataris to enter professional and management roles in business, health and educational sectors 
• High quality training opportunities for all citizens, corresponding to their ambitions and abilities 
• Increased opportunities and vocational support for Qatari women 
-Targeted participation of expatriate labour: 
• Recruitment of the right mix of expatriate labour, protecting their rights, securing their safety, and retaining 
those who are outstanding among them 
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To realise the ambitions of the National Vision for a healthy population, Qatar 
launched its National Health Strategy in 2011, providing guidance to 
transform the entire healthcare system (Qatar Supreme Council of Health 
2013a). In order to achieve a comprehensive world-class healthcare system, 
the government initiated six projects, as summarised in Table 1.4. Project 
1.1 aims to establish primary care as the foundation for healthcare, while 
Project 1.6 aims to strengthen the role of pharmacists in supporting patients, 
as well as improving the quality of healthcare system by making it more 
accessible and less costly.  
Table 1.4: Projects as described in ‘A comprehensive world-class healthcare system’ 
outcome of Qatar National Strategy (Qatar Supreme Council of Health 2013a) 
Project Targets 
Establish primary care 
as the foundation for 
healthcare 
-Increase the number of general practice physicians from 0.193 
per 1,000 population to 0.555 per 1,000 
-Ensure that the percentage of patients seen at secondary and 
tertiary healthcare facilities only after referral from primary 
healthcare facilities is no more than 50% for outpatients and 40% 
for inpatients 
Improve the 
configuration of 
hospital services 
-Prepare a national clinical services framework 
-Establish national centres of excellence for three of the top five 
priority areas 
Improve continuing 
care design 
-Increase the number of rehabilitation beds to 25 per 100,000 
population 
-Increase the number of continuing care beds to 8.23 per 1,000 
population 
Improve mental health 
services design 
-Ensure that the number of psychiatric beds is at least 12.5 per 
100,000 population 
-Implement the approved model of care by 2016 
Improve the provision 
of emergency and 
trauma services 
-Ensure that the response time for emergency medical services 
calls from patients with potentially life threatening conditions is 
within 10 minutes for 75% of calls and within 15–20 minutes for 
95% of calls in urban areas, and within 15 minutes for 75% of 
calls in rural areas 
-Keep the number of deaths among patients reporting to the 
emergency department with a diagnosis of heart attack below 
77.5 per 1,000 population 
Improve the efficiency 
of and access to 
community pharmacies 
-Bring the number of community pharmacies to 0.17 per 1,000 
population, dispensing 70% of all prescriptions  
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Recently, the Ministry of Public Health published an updated strategy for 
2018-2022 entitled “Our Health, Our Future: Improved health for Qatar’s 
population, meeting the needs of existing and future generations” (Qatar 
Ministry of Public Health 2018). As shown in Figure 1.6, this strategy aims to 
change the healthcare structure from disease-centred to a more integrated 
patient-oriented care. 
 
 
Figure 1.6: Health vision according to the 2018-2022 strategy (Qatar Ministry 
of Public Health 2018) 
 
1.2.6. Qatar’s healthcare challenges and priorities 
According to the recently published Qatar National Health Strategy 2018-
2022, a number of medical conditions are highly prevalent, namely 
cardiovascular diseases, cancer, and diabetes as shown in Figure 1.7.  
The Qatar National Research Strategy prioritises research in these areas in 
order to improve healthcare and outcomes (Qatar National Research Fund 
2014). 
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Figure 1.7: Challenges to the healthcare system (Qatar Ministry of Public 
Health 2018) 
 
1.2.7. Healthcare structure 
All health-related matters in Qatar are regulated by the Ministry of Public 
Health (MoPH), previously known as the Supreme Council of Health. MoPH is 
responsible for guiding reform in Qatar’s healthcare system by setting a clear 
health vision and leading policy development. MoPH oversees the quality and 
effectiveness of services delivered by primary care, hospitals and other public 
and private health providers to ensure that standards are met and 
performance targets are achieved (See Figure 1.8). It also oversees public 
health programmes related to the control of infectious diseases and 
coordinates with other agencies on environmental and public safety 
promotion (Qatar Ministry of Public Health 2016). 
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Figure 1.8: Healthcare structure in Qatar 
 
As part of the Qatar Healthcare Facilities Master Plan 2013-2033, the Ministry 
has developed a model detailing the most appropriate setting in which to 
deliver patient care (Qatar Supreme Council of Health 2014). This model of 
care is designed to guarantee: 
• Continuity, coordination, timeliness, accessibility and effectiveness of 
care 
• Primary care as the foundation 
• Availability of clinical information at all clinical encounters 
• Patient-centred approach 
• Patient experience 
• Focus on prevention 
• Focus on wellness 
• Transparency 
This model is summarised in the following Figure 1.9. 
 
Ministry of Public 
Health
Hospitals
Private Hospitals Public Hospitals (HMC)
Primary Health 
Centres
Qatar Petroleum 
(QP) medical 
centres
Primary Health 
Care Corporation 
(PHCC)
Ministry of 
Interior Health 
Centre
Qatar Red 
Crescent Society 
Services
Private Practice Pharmacies Pharmaceutical Companies
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Figure 1.9: The agreed model of care in Qatar (Qatar Supreme Council of Health 2014) 
*ICU: Intensive Care Unit, NICU: Neonatal Intensive Care Unit, PICU: Paediatric Intensive Care Unit, A&E: Accident & 
Emergency 
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a. Hospitals 
Hospital provision, services and bed capacity currently available in Qatar are 
summarised in Table 1.5. Public and private hospitals in Qatar are available 
for all citizens and residents of the State. 
As part of its efforts to make healthcare more accessible, the government 
opened four new specialised hospitals in 2017 which are expected to be fully 
operational by the end of 2018 (Hamad Medical Corporation 2018, Sidra 
Medicine 2018). These include: 
• Ambulatory Care Centre, an innovative facility that offers patients the 
latest and advanced clinical and surgical practices within the same day 
and in a single dedicated location 
• Qatar Rehabilitation Institute, the region’s largest tertiary rehabilitation 
hospital that offers integrated rehabilitation services to patients with 
stroke, traumatic brain or spinal cord injury or any other event 
• Sidra Medicine, a care centre that addresses the growing need for 
more comprehensive patient-focused medical services for women and 
children in Qatar 
• Women Wellness and Research Centre, the largest women’s tertiary 
hospital in the country that provides services from preconception to 
childbirth, post-natal care, to women’s wellness and beyond the 
reproductive phase of life. Once fully operational, it will replace the 
current Women’s Hospital in caring for Qatar’s female population 
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Table 1.5: Services provided by each hospital in Qatar (Qatar Supreme Council of Health 2014) 
Hospital Level of Care Services Bed Capacity 
Public/Governmental: Hamad Medical Corporation Hospitals 
Hamad General Hospital Tertiary • Trauma 
• Emergency Medicine 
• Paediatrics 
• Critical Care 
• Specialised Surgery 
• Specialised Medicine 
• Laboratory Medicine 
• Radiology 
• Accident & Emergency (A & E) 
595 
Rumailah Hospital Secondary • Adult Rehabilitation 
• Children’s Rehabilitation 
• Burns and Plastics 
• Dental, Ear, Nose and 
Throat and Ophthalmic 
Surgery 
• Geriatric Medicine 
• Psychiatry 
• Residential Care 
429 
Women’s Hospital Tertiary • Obstetrics 
• Gynaecology 
• Neonatal Care 
• Emergency Care 
• New-born Screening 
322 
Al Wakra Hospital Secondary • General Medicine 
• General Surgery 
• Obstetrics 
• Gynaecology 
• Paediatrics 
• A & E 
139 
Heart Hospital Tertiary • Specialist Cardiology 
• Cardiothoracic services 
115 
Al Khor Hospital Secondary • General Medicine 
• General Surgery 
• Emergency Medicine 
• Paediatrics and Obstetrics 
• A & E 
 
118 
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National Centre for Cancer 
Care & Research 
Tertiary • General Medicine 
• General Surgery 
• Emergency Medicine 
• Paediatrics 
• Obstetrics 
62 
Cuban Hospital Secondary • General Medicine 
• General Surgery 
• Emergency Medicine 
• Paediatrics 
• Obstetrics 
80 
Communicable Disease 
Centre 
Tertiary • Infectious conditions (caused by bacteria, viruses and other 
microbes) 
• Travel clinic 
65 
Semi-public 
Aspetar Tertiary • Family Medicine/ General 
Medicine 
• General Surgery 
• Orthopaedics 
• Internal Medicine 
50 (currently 25 
available) 
Private 
Al Ahli Hospital Secondary • Primary Care Family 
Medicine/ GP clinic 
• Cardiology 
• Cardiovascular and 
Thoracic Surgery 
• Dermatology 
• Endocrinology 
• Ear, Nose and Throat 
(ENT) 
• Family Medicine/ General 
Medicine 
• Gastroenterology 
• General Surgery 
• Orthopaedics 
• Psychiatry 
• Pulmonology (respiratory 
medicine) 
• Rheumatology 
• Urology 
• Physical medicine and 
rehabilitation 
• Dentistry 
• General Paediatrics 
• Obstetrics and Gynaecology 
• Paediatric Subspecialties 
• Speech and language therapy 
250 
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• Haematology 
• Internal Medicine 
• Neurology 
• Ophthalmology 
• A & E 
Al Emadi Hospital Secondary • Dentistry 
• General Paediatrics 
• Cardiology 
• Obstetrics and 
Gynaecology 
• Plastic Surgery 
• Dermatology 
• Endocrinology 
• ENT 
• Family Medicine/ General 
Medicine 
• General Surgery 
• Infectious Diseases 
• Internal Medicine 
• Neurology 
• Ophthalmology 
• Orthopaedics 
• Pain clinic 
• Pulmonology (respiratory 
medicine) 
• Rheumatology 
• Urology 
• A & E 
64 
American Hospital Secondary • Dentistry 
• General Paediatrics 
• Obstetrics and 
Gynaecology 
• ENT 
• Family Medicine/ General 
Medicine 
• General Surgery 
• Internal Medicine 
• Urology 
20 
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Doha Clinic Hospital Secondary • Primary Care Family 
Medicine/ GP clinic 
• Cardiology 
• Cardiovascular and 
Thoracic Surgery 
• Dermatology 
• Endocrinology 
• ENT 
• Family Medicine/ General 
Medicine 
• General Surgery 
• Internal Medicine 
• Neurology 
• Ophthalmology 
• Orthopaedics 
• Pain clinic 
• Well baby clinic 
• Psychiatry 
• Rheumatology 
• Urology 
• Physical medicine and 
rehabilitation 
• Dentistry 
• General Paediatrics 
• Obstetrics and Gynaecology 
• Paediatric Subspecialties 
• Plastic Surgery 
• A & E 
51 
24 
 
b. Primary Healthcare Centres 
Qatar has several public and private primary healthcare centres. All 
governmental (public) centres provide services for all citizens and residents. 
Private sector centres, such as Qatar Petroleum, provide services to their own 
employees (Qatar Petroleum 2015, Primary Health Care Corporation 2018b). 
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Table 1.6: Services provided by all primary healthcare settings in Qatar (Qatar Supreme Council of Health 2014, Qatar Petroleum 2015, 
Primary Health Care Corporation 2017) 
Provider Services 
Primary Health Care Centres (PHCC): 23 
centres currently operational with 4 more 
expected to open within the next year 
Depending on branch: 
• Disease management 
• Dental clinic 
• Ultrasound 
• Diabetic clinic 
• Radiology 
• Paediatric care 
• Smoking cessation 
• Weight management 
• Trauma 
• Pharmacy 
• Laboratory services 
• Ophthalmology 
• Physiology 
• Dermatology 
• Premarital clinic 
• Psychiatry 
• Cardiology 
• Dialysis 
Ministry of Interior Medical Clinic: 1 main 
centre and 6 outpatient clinics 
• Dermatology 
• Endocrinology 
• Ear, Nose and Throat (ENT) 
• Family Medicine/ General Medicine 
• General Surgery 
• Dentistry 
• General Paediatrics 
• Obstetrics and Gynaecology 
• Haematology 
• Internal Medicine 
• Ophthalmology 
• Orthopaedics 
• Psychiatry 
• Rheumatology 
• Urology 
• Physical medicine and rehabilitation 
• Urgent Care 
Qatar Petroleum (QP) Clinics: 6 clinics • Family Medicine/ General Medicine 
• Dentistry 
• General Paediatrics 
• ENT 
• Gynaecology/Antenatal 
• Dermatology 
• Infectious Diseases 
• Psychiatry 
26 
 
Qatar Red Crescent Society Services: 4 
clinics 
• Family Medicine/ GP clinic 
• Ophthalmology 
• Dentistry 
• Urgent Care 
Private Clinics: 253 clinics either part of a 
private hospital or separate practice 
• Family Medicine/ General Medicine 
• Cardiology 
• Dermatology 
• Internal Medicine 
• Orthopaedics 
• Paediatrics 
• Urology 
• Obstetrics and Gynaecology 
• Dentistry 
• Physiotherapy 
• Ophthalmology 
• Diagnostics 
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c. Pharmacies 
According to data published in 2014, there are over 250 community 
pharmacies in addition to hospital pharmacies (Qatar Supreme Council of 
Health 2014), distributed geographically as follows: 
• Doha: 162 pharmacies  
• Al Rayyan: 64 pharmacies  
• Al Wakra: 11 pharmacies  
• Al Khor: 8 pharmacies  
• Umm Slal: 6 pharmacies  
The scope of practise of pharmacists in the country largely depends on their 
setting, as outlined in Table 1.7. Note that practise may have advanced since 
publication of this paper. 
Table 1.7: Services provided by pharmacists in Qatar (Kheir and Fahey 2011) 
Hospital Pharmacist  
Community 
Pharmacist 
Clinical Pharmacist Inpatient/ Outpatient 
Pharmacist 
• Attending rounds 
• Reviewing cases 
• Recommending 
medicines 
• Monitoring 
treatment 
• Counselling 
• Providing drug 
information 
• Compounding 
• Dispensing 
• Counselling 
• Promoting healthy 
lifestyle 
• Offering preventative 
care 
• Providing drug 
information 
• Prescribing over the 
counter medicines 
• Compounding 
• Dispensing 
• Counselling 
• Promoting healthy 
lifestyle 
• Offering preventative 
care 
• Providing drug 
information 
 
1.2.8. Pharmacy practice in Qatar 
In 2013, the number of pharmacists registered in Qatar was 1023 in the 
public and 991 in the private sectors giving an estimated 1.01 pharmacists 
per 1000 population (Qatar Ministry of Development Planning and Statistics 
2013, Qatar Supreme Council of Health 2013b). 
28 
 
The Qatar Council for Healthcare Practitioners (QCHP) was established in 
2013 to regulate all healthcare practitioners, including pharmacists, working 
in the State (registration and licensing) and to accredit governmental and 
private healthcare sectors (Qatar Council for Healthcare Practitioners 2016). 
A cross-sectional study, published in 2011, reported that 84% of respondent 
pharmacists had graduated more than five years previously, 86% held a 
baccalaureate degree in pharmacy as their highest qualification and was 
obtained mainly from one of five countries; Egypt, Jordan, India, Sudan, or 
Pakistan. Just under half (45%) were practising in hospitals and one third 
(33%) in community (El Hajj et al. 2011). As noted earlier, these data may 
no longer represent the current status.  
A commentary published in 2011 by Kheir and Fahey reported that the 
pharmacists’ role in Qatar had evolved over the past years. Practise had 
evolved from one mainly concerned with drug preparation and dispensing to 
being centred on patient care including counselling and treatment decisions.  
In the same year, a cross-sectional study was conducted in Hamad Medical 
Corporation to identify physicians’ perceptions and expectations of 
pharmacists. The majority of physicians surveyed (89%) expected the 
pharmacist to educate patients about safe and appropriate use of drugs, 
while 57% expected the pharmacist to be available for healthcare team 
consultation during bedside rounds (Zaidan et al. 2011).  
These first two sections of the introduction have provided information on the 
key healthcare challenges and priorities in Qatar, described the healthcare 
structures, and the position of pharmacy within those structures. The 
National Vision 2030 and the National Health Strategy highlight an ambitious 
plan of development. Hence, there is real potential to extend further the 
clinical role of pharmacists in Qatar to include prescribing. The next 
introductory section describes the developments in pharmacist prescribing 
globally, with particular emphasis on the UK. Many of the models and 
processes around pharmacist prescribing, training, and governance could be 
relevant to Qatar and are the subject of the doctoral research.  
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1.3. Pharmacist prescribing 
1.3.1. Background 
The roles and responsibilities of all health professionals have undergone 
tremendous transformation in recent years. One key development has been 
the implementation of prescribing by non-medical health professionals, 
including pharmacists, across many countries including the United Kingdom 
(UK), United States of America (USA), Canada, and New Zealand. It is 
believed that, due to their extensive knowledge and skills, pharmacists 
involved in prescribing will impact positively on patient care by reducing 
prescribing errors, improving adherence to guidelines, reducing waiting time 
for the public, thus providing higher quality patient-centred care (Tonna et al. 
2007, Rosenthal et al. 2015). 
There are varying models of pharmacist prescribing (PP) globally in terms of 
legal restrictions and regulations. Depending on the level of pharmacist 
responsibility, there are three different levels of prescribing: independent 
prescribing (IP); supplementary prescribing (SP); and collaborative 
prescribing (CP) (Dawoud et al. 2011). Details of the models of pharmacist 
prescribing which have been implemented in the UK, USA, Canada and New 
Zealand are given in Table 1.8, highlighting the diverse scope of prescribing 
rights. 
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Table 1.8: Summary of the different models of pharmacist prescribing practise globally 
Country Models of Prescribing Available Definition 
United Kingdom 
(UK) 
Supplementary Prescribing (SP) The UK Department of Health defines SP as “A voluntary partnership between an independent 
prescriber (e.g. doctor or dentist) and a supplementary prescriber to implement an agreed 
patient-specific clinical management plan (CMP) with the patient’s agreement” (2003). 
Likewise, the Health & Care Professions Council states that “A supplementary prescriber is able 
to prescribe medicines in accordance with a clinical management plan (CMP) for a specific 
patient. The CMP is agreed between the supplementary prescriber, a doctor and the patient” 
(2016).  
Independent Prescribing (IP) The UK Department of Health defines independent prescribing as “prescribing by a practitioner 
(e.g. doctor, dentist, nurse, pharmacist) responsible and accountable for the assessment of 
patients with undiagnosed or diagnosed conditions and for decisions about the clinical 
management required, including prescribing” (UK Department of Health 2006). 
Another definition defines “an independent prescriber is someone who is able to prescribe 
medicines on their own initiative from the British National Formulary (BNF). Independent 
prescribers include doctors and dentists, as well as some non-medical health professionals” 
(Health & Care Professions Council 2016). Qualifying as an independent prescriber permits 
practise as a supplementary prescriber. 
United States of 
America (USA) 
Collaborative Drug Therapy 
Management (CDTM) 
Defined by the American College of Clinical Pharmacy as “a collaborative practice agreement 
between one or more physicians and pharmacists wherein qualified pharmacists working within 
the context of a defined protocol are permitted to assume professional responsibility for 
performing patient assessments; ordering drug therapy-related laboratory tests; administering 
drugs; and selecting, initiating, monitoring, continuing, and adjusting drug regimens” 
(Hammond et al. 2003, Centers for Disease Control and Prevention 2013). 
According to the Centers for Disease Control, in 2012, majority of states allow CDTM for health 
conditions as specified in a written provider protocol in any setting (Alaska, Arizona, Arkansas, 
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California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Idaho, Indiana, 
Iowa, Kentucky, Louisiana, Maryland, Massachusetts, Minnesota, Mississippi, Missouri, Montana, 
Nebraska, New Jersey, New Mexico, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, 
Rhode Island, South Dakota, Utah, Vermont, Virginia, Washington, Wyoming), some limit it to 
certain health settings (New Hampshire, New York, Nevada, North Dakota, Texas, West Virginia) 
while others authorise extremely limited collaborative practice for pharmacists under protocol 
such as immunisations and emergency contraception regardless of setting (Delaware, Illinois, 
Kansas, Maine, Wisconsin) (Centers for Disease Control and Prevention 2013). 
Canada According to Canadian Pharmacists 
Association (2016), the types and 
scope of practice of prescribing is 
variable according to province 
Legislations in Canada now allow pharmacists to prescribe within their area of competence and 
with sufficient clinical knowledge of the patient. 
The prescribing practice differ from one province to another. Pharmacists with additional training 
are able to prescribe any schedule 1 drug (except drugs under the Controlled Drugs and 
Substances Act) or alter another prescriber’s original prescription independently only in Alberta 
and under a collaborative agreement in Alberta, Saskatchewan, Manitoba, New Brunswick and 
Nova Scotia. Moreover, they can change a drug’s dosage, formulation or regimen across the 
country, except in Northwest Territories, Yukon and Nunavut. Furthermore, in Alberta, Manitoba, 
Quebec and Nova Scotia, pharmacist are allowed to order and interpret laboratory tests 
(Canadian Pharmacists Association 2016). 
New Zealand Pharmacist Prescriber 
(Collaborative Prescribing) 
According to Pharmacy Council of New Zealand (2010), “pharmacist prescribers work in a 
collaborative health team environment with other healthcare professionals and are not the 
primary diagnostician. They can write a prescription for a patient in their care to initiate or 
modify therapy (including discontinuation or maintenance of therapy originally initiated by 
another prescriber). They can also provide a wide range of assessment and treatment 
interventions which includes, but is not limited to:  
• Ordering and interpreting investigation (including laboratory and related tests) 
• Assessing and monitoring a patient’s response to therapy 
• Providing education and advice to a patient on their medicine therapy” 
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1.3.2. Pharmacist prescribing: the UK model 
Pharmacist prescribing in the UK is described within a framework of non-
medical prescribing, which was first proposed in 1986 by the Cumberlege 
Report and later by two Crown Reports, published in 1998 and 1999, which 
recommended extending prescribing privileges to other health professions. 
Key driving forces were: the expanding clinical skills of many non-medical 
professions; the increased prevalence of multi-disciplinary team working; and 
changing patient expectations of seamless and safe care. The second Crown 
review (Review of Prescribing, Supply and Administration of Medicines) 
recommended prescribing rights should normally be limited to medicines in 
specific therapeutic areas related to the competence and expertise of the 
professional. The need for sharing of clinical information between prescribers 
was also highlighted. This review culminated in legislative changes enabling 
the implementation of supplementary prescribing (SP) in 2003 and 
independent prescribing (IP) in 2006 (Department of Health And Social 
Security 1986, Crown 1999, Cope, Abuzour and Tully 2016). Figure 1.10 
illustrates key developments in non-medical prescribing.  
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Figure 1.10: History of the development of non-medical prescribing in the UK 
(Cope, Abuzour and Tully 2016) 
 
According to the UK Department of Health (2006), the aims of implementing 
non-medical prescribing are to: 
• Improve patient care without compromising patient safety 
• Make it easier for patients to get the medicines they need 
• Increase patient choice in accessing medicines 
• Make better use of the skills of health professionals 
• Contribute to the introduction of more flexible team working across the 
National Health Service (NHS) 
 
 
 
1986
•Cumberlege Report
1992
•Extended Formulary for Nurse Prescribers
1998
•First Crown Report
1998
•Nurse Prescriber's Formulary
1999
•Second Crown Report
2003
•Supplementary Prescribing for nurses and pharmacists
2005
•Supplementary Prescribing by physiotherapists and podiatrists
2006
•Independent Prescribing for nurses and pharmacists
2007
•Independent Prescribing by optometrists
2016
•Independent Prescribing by therapeutic radiographers
•Supplementary Prescribing by dietitians
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a. Models of non-medical prescribing in the UK 
There are two models of non-medical prescribing; supplementary and 
independent. Both models require completion of an accredited supplementary 
or independent prescribing programme and that non-medical prescribers 
must practise within their competence. As of September 2016, there were 
approximately 383 supplementary and 3102 independent pharmacist 
prescribers registered in the UK (General Pharmaceutical Council, personal 
communication, 20 September 2016). Key similarities and differences 
between the two models of prescribing in the UK are presented in Table 1.9. 
While a range of health professionals can now train and register as non-
medical prescribers, this doctoral research focuses solely on pharmacists.  
Table 1.9: Differences between non-medical prescribing practices in the UK 
(Adapted from Stewart, MacLure and George 2012, Royal Pharmaceutical Society 
2016) 
 Supplementary Prescribing Independent Prescribing 
All eligible health 
professionals  
Nurses, pharmacists, 
optometrists, physiotherapists, 
podiatrists, radiographers and 
dieticians 
Nurses, pharmacists, 
optometrists, physiotherapists, 
therapeutic radiographers or 
podiatrists 
Clinical conditions 
managed 
Any, within their clinical 
competence 
Any, within their clinical 
competence 
Diagnosis 
responsibilities 
A doctor (or dentist) must 
diagnose the condition before 
prescribing can commence 
The independent prescriber can 
assess and manage patients 
with diagnosed or undiagnosed 
conditions 
Need for Clinical 
Management Plan 
(CMP) 
A written or electronic patient-
specific CMP must be in place 
and be agreed with the doctor 
(or dentist) and patient before 
prescribing can commence 
No need for a CMP 
Drugs prescribed Any, within their clinical 
competence 
Any licensed medicines within 
their clinical competence. 
Nurse and pharmacist 
independent prescribers in 
particular can also prescribe 
unlicensed medicines and 
controlled drugs 
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b. Pharmacist prescribing training programmes 
Pharmacist prescribing training programmes in the UK must be delivered by a 
higher education institution and accredited by a professional regulatory body 
(General Pharmaceutical Council 2018). 
According to the General Pharmaceutical Council (2018), the training 
programme to gain prescribing authority typically compromises two 
components. The first is the educational component where participants must 
attend classes as well as use self-directed study for 26 days delivered over a 
period of between three and six months. The main learning outcomes of this 
component of the course are summarised in Table 1.10. Assessment methods 
are varied and may include examinations, written submissions and objective 
structured clinical examinations (OSCEs). 
Table 1.10: Learning outcomes of prescribing course in the UK (Stewart, MacLure 
and George 2012, General Pharmaceutical Council 2018) 
Context/ Topic Content 
Consultation, decision 
making, assessment 
and review 
History taking, compliance, differential diagnosis, referral, 
decision making, monitoring and pharmacovigilance 
Influences on and 
psychology of 
prescribing 
Patients’ needs and demands, local and national influences, 
personal attitudes 
Prescribing in a team 
context 
Understanding other team members, communication skills, 
conflict management and budget considerations 
Applied therapeutics Pathophysiology, pharmacokinetics and pharmacodynamics, 
selection and optimisation of drug regimens and adverse drug 
reactions 
Evidence-based practice 
and clinical governance 
Evidence-based practice, critical appraisal, clinical governance 
policies and procedures, risk management and clinical audit 
Legal, policy, 
professional and ethical 
aspects 
Professional competence, accountability and responsibility, 
statutory prescribing frameworks, ethics and continuing 
professional development 
Prescribing in the public 
health context 
Patient access to healthcare and medicines, public health 
policies and inappropriate use of medicines 
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The second component of the training programme is a ‘period of learning in 
practice’ of a minimum of 12 days under the supervision and support of a 
designated medical practitioner (DMP). This period aims to develop and 
assess competence in the specific therapeutic area in which they will 
prescribe (Stewart, MacLure and George 2012, General Pharmaceutical 
Council 2018). 
c. Eligibility criteria for training programme 
In order to be eligible to undertake the prescribing training programme, 
pharmacists must: 
• Be registered with the corresponding regulatory body (such as the 
General Pharmaceutical Council (GPhC) or the Pharmaceutical Society 
of Northern Ireland (PSNI) for pharmacists) 
• Have at least two years' appropriate patient-orientated experience in a 
UK hospital, community or primary care setting following their pre-
registration year 
• Have identified an area of clinical practice in which to develop their 
prescribing skills and have up-to-date clinical, pharmacological and 
pharmaceutical knowledge relevant to their intended area of 
prescribing practice 
• Demonstrate how they reflect on their own performance and take 
responsibility for their own continuing professional development (CPD) 
• Have a DMP with training and experience appropriate to their role and 
have agreed to provide supervision, support and shadowing 
opportunities, and be familiar with GPhC requirements and learning 
outcomes for the programme 
1.3.3. UK prescribers’ competency framework 
After the introduction of non-medical prescribing in the UK, an updated single 
competency framework was designed to support all prescribers (medical and 
non-medical). The framework sets out the skills and characteristics 
prescribers should possess in order to ensure effective performance (Royal 
Pharmaceutical Society 2016).  
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The competencies of prescribers are grouped into two domains; the 
consultation and the prescribing governance as shown in Figure 1.11. 
 
Figure 1.11: Competency framework for all UK prescribers 
(Royal Pharmaceutical Society 2016) 
 
The specific competencies of each domain are presented in Table 1.11.  
Table 1.11: The prescribing competency framework’s domains 
(Royal Pharmaceutical Society 2016) 
Domains Competencies 
The consultation 1. Assess the patient 
2. Consider the options 
3. Reach a shared decision 
4. Prescribe 
5. Provide information  
6. Monitor and review 
Prescribing governance 7. Prescribe safely 
8. Prescribe professionally 
9. Improve prescribing practice 
10. Prescribe as part of a team 
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Furthermore, in 2010, the British Pharmacological Society published 
‘Principles of Good Prescribing’ for all prescribers (Table 1.12).  
Table 1.12: Principles of good prescribing (British Pharmacological Society 2010) 
• Be clear about the reasons for prescribing 
• Take into account the patient’s medication history before prescribing 
• Take into account other factors that might alter the benefits and risks of treatment 
• Take into account the patient’s ideas, concerns and expectations 
• Select effective, safe and cost-effective medicines individualised for the patient 
• Adhere to national guidelines and local formularies were appropriate 
• Write unambiguous legal prescriptions using the correct documentation 
• Monitor the beneficial and adverse effects of medicines 
• Communicate and document prescribing decisions and the reasons for them 
• Prescribe within the limitations of your knowledge, skills and experience 
 
Given the increasing workloads placed on physicians in Qatar, pharmacists 
are well positioned to take on a greater role in the management of diseases, 
health promotion and disease prevention. As such, regulated prescribing 
authority can be an important step in the evolution of pharmacy practice in 
the State in order to help achieve a more patient-centred model that is likely 
to generate additional value for the healthcare system in Qatar.  
 
1.4. Aims and objectives of this doctoral research 
The overall aim of the doctoral research was to explore the development of 
frameworks of pharmacist prescribing in Qatar. Table 1.13 describes each 
phase of the research in terms of the research designs and the associated 
aims and objectives.  
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Table 1.13: Design, aim and objectives of each phase of this doctoral project 
Phase/Design Aim Objectives 
1. Umbrella review Critically appraise, synthesise and 
present the evidence on aspects of 
non-medical prescribing 
• To explore all aspects of non-medical prescribing, including, but not limited 
to: 
o Models and definitions of NMP: The legal frameworks that regulates 
NMP and allow allied healthcare professionals to practice 
prescribing 
o Outcomes and benefits of implementing NMP 
o Perceptions and satisfaction of different health stakeholders (such 
as public, patients, health professionals and decision makers) 
regarding NMP 
o Facilitators and barriers to implementing NMP 
2. Systematic review Systematically review the available 
evidence on the views and 
experiences of stakeholders pre- and 
post-implementation of pharmacist 
prescribing globally 
• To determine the views of stakeholders (e.g. patients, the general public, 
health professionals, policy makers, educators etc.) on pharmacist 
prescribing, irrespective of implementation status 
• To explore the reported experiences of stakeholders in countries that have 
already implemented pharmacist prescribing 
• To report the potential barriers and facilitators of implementing pharmacist 
prescribing 
3. Qualitative Study 
(face-to-face 
semi-structured 
interviews) 
Determine key health stakeholders’ 
(patients, physicians, nurses, 
pharmacists, hospital administrators, 
regulatory bodies’ representatives) 
expectations, attitudes and beliefs 
around implementing pharmacist 
prescribing in Qatar 
• To explore stakeholders’ awareness, experiences and views of prescribing 
by non-medical health professionals 
• To determine stakeholders’ views and perceptions of clinical roles of 
pharmacists in Qatar 
• To investigate stakeholders’ views and perceptions of expanding the remit 
of pharmacists in Qatar to include prescribing 
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• To examine stakeholders’ views and perceptions of facilitators, barriers and 
solutions to the development and implementation of pharmacist prescribing 
in Qatar 
4. Quantitative 
Study (Delphi) 
Develop a pharmacist prescribing 
framework tailored to Qatar’s setting 
• To develop and validate a series of statements in relation to the framework 
of pharmacist prescribing 
• To determine the levels of agreement of key stakeholders around these 
statements 
• To determine any additional statements derived from the expert panel 
members’ feedback 
• To determine any reasons for not achieving consensus 
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Chapter 2:  
Methodology 
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2. Introduction to the chapter 
This chapter describes the theoretical basis for the doctoral research, aligned 
to the Medical Research Council Framework for Developing and Evaluating 
Complex Interventions. Justification is provided for the selection of research 
paradigms, methodologies, key methodological approaches, and the use of 
the Consolidated Framework for Implementation Research (CFIR).  
2.1. The Medical Research Council Framework for Developing and 
Evaluating Complex Interventions 
2.1.1. Introduction 
The Medical Research Council (MRC) is a non-departmental public body 
funded by the UK government, which aims to improve human health through 
world-class medical research (MRC 2016). 
In 2000, the MRC published the first version of the Framework for Developing 
and Evaluating Complex Interventions, which was revised in 2008. The 
Framework intends to help: “researchers choose and implement appropriate 
methods, given the state of existing knowledge and the nature of their target 
intervention”; “research funders to understand the constraints on evaluation 
design and recognise appropriate methodological choices”; and “policy 
makers, practitioners and other commissioners and users of evaluation to 
weigh up the available evidence in the light of these methodological and 
practical constraints, and to consider carefully how their own decisions affect 
the quality of the evidence that evaluation of complex interventions can 
provide” (Craig et al. 2008).  
Interventions of interest in this framework, according to Craig et al. (2008), 
must have some dimensions of complexity, which include: 
• Number of and interactions between components within the 
experimental and control interventions 
• Number and difficulty of behaviours required by those delivering or 
receiving the intervention 
• Number of groups or organisational levels targeted by the intervention 
• Number and variability of outcomes 
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• Degree of flexibility or tailoring of the intervention permitted 
There are several reasons for considering the development and 
implementation of pharmacist prescribing in Qatar as a complex intervention; 
hence, providing justification for employing the MRC framework in this 
doctoral research. First, this expanded role for pharmacists can cause 
significant disruption to the already complex healthcare system in the State. 
Moreover, its implementation will require several policy changes which is 
often a laborious process. In addition, due to its novelty in the ‘Arab World’, it 
is also difficult to determine its most appropriate design and delivery as well 
as its expected outcomes on Qatar’s population.  
2.1.2. The MRC cycle  
The MRC framework comprises the following key elements: 
 
Figure 2.1: The development-evaluation-implementation process 
 
a. Development  
Sufficient emphasis should be placed on the stage of developing the 
intervention prior to any further testing. Development includes: 
• Identifying the evidence base. Researchers must first identify existing 
literature (ideally through a systematic review) related to the topic 
researched. 
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• Identifying/developing appropriate theory. Developing a theoretical 
understanding of the likely process of change, by drawing on existing 
evidence and theory, supplemented if necessary by new primary 
research (e.g. interviews with stakeholders) is more likely to result in 
an effective intervention.  
• Modelling process and outcomes. Modelling the intervention on a small 
scale can aid optimising the final design.  
b. Assessing feasibility and piloting methods 
The aim of this stage of the MRC framework is to test the intervention in 
order to determine acceptability, compliance, delivery and effect size. This 
can address the main uncertainties that were identified in the development 
phase. Depending on the results, a series of studies may be required to 
progressively refine the design, prior to full-scale evaluation.  
c. Evaluation 
Including a process evaluation is important to explain discrepancies between 
expected and observed outcomes, to understand how context influences 
outcomes, and to provide insights to aid implementation. Moreover, it is also 
essential to report a detailed account of the intervention and evaluation to 
enable replication or wider scale implementation. 
d. Implementation 
Implementation relates to three main elements: dissemination, monitoring, 
and long-term outcomes. Strategies to encourage implementation should be 
based on a scientific understanding of the behaviours that need to change, 
relevant decision-making processes, and the barriers and facilitators of 
change. Once translated to routine practice, monitoring is essential in order 
to detect adverse events or long-term outcomes that could not be observed 
directly in the original evaluation, or to assess whether the effects observed 
in the study are replicated in routine practice. 
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As described in Chapter 1, the aim of this doctoral research project is to 
explore the development of frameworks of pharmacist prescribing in Qatar. 
The research will therefore focus on the development phase of the MRC 
framework: 
• Identifying the evidence base: In order to ensure the successful 
implementation of pharmacist prescribing in Qatar, the first two phases 
of the current project were to review the literature in order to identify 
the existing evidence base around non-medical prescribing in general 
and on views and experiences around pharmacist prescribing. This 
helped identify key facilitators and barriers to implementation that 
must be taken into consideration while designing this project. 
• Identifying/developing appropriate theory: The subsequent phase was 
to then investigate key health stakeholders’ views on this expanded 
role in Qatar in order to explore the feasibility and acceptability of 
implementation in the State. Additionally, this project also involved the 
use of a theoretical framework that will be later described in detail in 
order to investigate facilitators and barriers to pharmacist prescribing. 
• Modelling process and outcomes: The last phase of this project was to 
determine the pharmacist prescribing framework best suited for Qatar 
healthcare system by exploring the most appropriate model for its 
implementation in the State. 
2.2. Literature review (Phase 1 and 2) 
2.2.1. Introduction 
According to the first element of the MRC framework, it is important to 
review the existing literature to appraise the current knowledge base. Two 
separate reviews were conducted for this doctoral research. The first was an 
umbrella review of systematic reviews exploring any aspects of non-medical 
prescribing (NMP). This review aimed to summarise what was published and 
also helped identify the need for the second review, a systematic review of 
stakeholders’ views and experiences of pharmacist prescribing. The findings 
of both reviews informed the later phases of the doctoral research.  
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A literature review has been described as an analysis of the available 
research outputs on a specific topic to either determine current evidence or 
provide justification for future research (Cronin, Ryan and Coughian 2008). 
According to Booth, Papaioannou and Sutton (2012), conducting a literature 
review can: 
• Summarise the available information on a topic 
• Place a body of work in context of available knowledge 
• Identify new approaches to interpret or identify gaps in the literature 
• Identify and resolve any conflicts in previous publications 
• Avoid duplication in work by collating previous efforts 
2.2.2. Categories of literature review 
While the term ‘literature review’ is widely used, there are many 
classifications of review, the most common of which are described in Table 
2.1. 
Table 2.1: Categories of literature review (Grant and Booth 2009) 
 Aim Benefits Limitations 
Literature 
Review 
Generic term: published 
materials that provide 
examination of recent or 
current literature. Can 
cover wide range of 
subjects at various levels 
of completeness and 
comprehensiveness. May 
include research 
ﬁndings. 
-Can identify what 
has been 
accomplished 
previously. 
-Allows for 
consolidation, for 
building on previous 
work, for summation, 
for avoiding 
duplication and for 
identifying omissions 
or gaps. 
-Lacks an explicit 
intent to maximise 
scope or analyse data 
collected. 
-Susceptible to bias. 
Mapping 
Review/ 
Systematic 
Map 
Maps out and 
categorises existing 
literature from which to 
commission further 
reviews and/or primary 
research by identifying 
gaps in research 
literature. 
-Enables the 
contextualisation of 
in-depth systematic 
literature reviews. 
-Identifies gaps in the 
evidence base. 
-Characterises 
studies in other ways 
such as according to 
theoretical 
perspective. 
-Shows whether the 
total population of 
studies is sufﬁciently 
similar for a coherent 
synthesis. 
 
-Characterises studies 
at a broad descriptive 
level. 
-Does not usually 
include a quality 
assessment process. 
-Characterises studies 
only based on study 
design. 
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Meta-
analysis 
Technique that 
statistically combines the 
results of quantitative 
studies to provide a 
more precise effect of 
the results. 
-Assimilates 
individual studies, not 
in themselves enough 
to impact practice 
into a composite 
evidence base. 
-Time efficient for 
decision makers. 
-Cannot be better than 
its included studies 
allow. 
Overview Generic term: summary 
of the literature that 
attempts to examine the 
literature and describe 
its characteristics. 
-Provides a broad and 
often comprehensive 
summation of a topic 
area. 
-Can have different 
degrees of rigour, 
robustness and 
quality. 
Scoping 
Review 
Preliminary assessment 
of potential size and 
scope of available 
research literature. Aims 
to identify nature and 
extent of research 
evidence (usually 
including ongoing 
research). 
-Can inform decision 
on whether a full 
systematic review is 
needed. 
-Attempts to be 
systematic, 
transparent and 
replicable. 
-Susceptible to bias 
due to limitations in 
rigour. 
-Does not include a 
process of quality 
assessment. 
-Findings cannot be 
used to recommend 
policy/practice 
changes. 
Systematic 
Review 
Seeks to search 
systematically for, 
appraise and synthesise 
research evidence, often 
adhering to guidelines 
on the conduct of a 
review. 
-Draws together all 
known knowledge on 
a topic area. 
-Subjecting the 
resultant literature to 
critical review. 
 
 
 
-Restricting studies for 
inclusion to a single 
study design can limit 
the application of this 
methodology. 
Umbrella 
review 
Speciﬁcally refers to 
compiling evidence from 
multiple reviews into one 
accessible and usable 
document. Focuses on 
broad condition or 
problem for which there 
are competing 
interventions and 
highlights reviews that 
address these 
interventions and their 
results. 
-Allows the reader a 
quick overview (and 
an exhaustive list) of 
reviews relevant to 
the topic. 
-Not suitable for many 
areas of library and 
information practice. 
2.2.3. Review types selected for this doctoral research 
Two literature reviews were conducted as part of this doctoral research, an 
umbrella review of systematic reviews and a targeted systematic review. 
Systematic reviews can generate the highest level of evidence, as highlighted 
in Figure 2.2. It should, however, be noted that this figure refers to 
systematic reviews of quantitative studies employing randomised controlled 
methodologies. 
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Figure 2.2: Hierarchy of evidence in the context of evidence-based medicine 
(Glover et al. 2006) 
The methods, results and conclusions from these reviews are described in 
detail in Chapters 3 (umbrella review) and Chapter 4 (systematic review).  
2.3. Quantitative and qualitative approaches 
2.3.1. Introduction 
The two main classifications of research approaches are qualitative and 
quantitative. Green and Thorogood (2009) state that these approaches 
cannot be characterised by the type of data collected (language vs numerical 
data), sample size (small or large) or by the data collection method used 
since these can be shared between the different approaches. They argue, 
however, that the most basic way to define and characterise these is through 
consideration of the research aims and questions. Qualitative researchers 
seek answers related to the ‘what’, ‘how’ or ‘why’, while quantitative 
researchers focus on the ‘how many’ or ‘how much’. Onwuegbuzie and Frels 
(2016) similarly state that quantitative studies primarily involve numerical 
data with goals that include describing, explaining and predicting, while 
qualitative studies primarily involve non-numerical data generated from 
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documents, talk, observations and drawings/photographs/videos. 
Increasingly, mixed methodological approaches (quantitative and qualitative 
used sequentially or concurrently) are being employed. 
A comparison of quantitative and qualitative approaches is given in Table 2.2.  
Table 2.2: Difference between quantitative and qualitative methods (Polgar and 
Thomas 2013, Yilmaz 2013, O’Leary 2014) 
 Quantitative Qualitative 
Main paradigm -Positivism -Constructivism 
Perception of 
variables in 
question 
-Reductionistic, identifying and 
defining concepts 
-Holistic, studied in its social 
context 
Researcher -Objective observer -Subjective observer 
Database -Quantitative, interrelationships 
among specific variables 
-Qualitative, personal meaning of 
actions 
Theories -Normative, explaining causal 
relationships between variables 
-Interpretive, providing insights into 
the nature and social contexts of 
variables 
Theory testing -Controlled, supporting or opposing 
hypotheses deduced from theories 
-Consensual, linking researcher’s 
interpretations to participants 
Analysis -Statistical  -Thematic exploration 
Applications -Prediction and control of health-
related factors in applied settings 
-Interacting with persons in a 
consensual, value-consonant 
fashion in healthcare settings 
Assumptions -Reality is single and tangible 
-Inquiry is objective 
-Variables can be identified and 
measured 
-Realities are multiple and holistic 
-Inquiry is subjective 
-Variables are complex and difficult 
to measure 
Purpose -Generalisability 
-Prediction 
-Causal explanations 
-Contextualisation 
-Interpretation 
-Understanding perspectives 
Approach -Begins with hypothesis 
-Deductive 
-Seeks consensus or the norm 
-Reduces data to numerical indices 
-Abstract language in write-up 
-Often ends with hypothesis 
-Inductive 
-Seeks pluralism or complexity 
-Makes minor use of numerical 
indices 
-Descriptive write-up 
Research role -Detachment and impartiality 
-Objective portrayal 
-Etic (outsider’s point of view) 
-Personal involvement and partiality 
-Empathic understanding 
-Emic (Insider’s point of view) 
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2.3.2. Defining the research terminologies 
A variety of terminologies are used in describing both quantitative and 
qualitative research (Table 2.3). 
Table 2.3: Terminologies used in research (Corbin and Strauss 2008 p. 1, 
Cambridge Dictionary 2016) 
Term Definition 
Hypothesis An idea or explanation for something that is based on known facts 
but has not yet been proven. 
Theory A formal statement of the rules on which a subject of study is based 
or of ideas that are suggested to explain a fact or event or, more 
generally, an opinion or explanation. 
Methodology A way of thinking about and studying social phenomena. 
Methods Techniques and procedures for collecting, gathering and analysing 
data. 
Philosophical 
orientation 
A worldview that underlines and informs methodology and methods. 
Paradigm A set of theories that explain the way a subject is understood at a 
particular time. 
2.3.3. Paradigms used in research 
Research paradigms are selected appropriate to the research aim, questions 
and approach (Table 2.4). 
Table 2.4: Paradigms in quantitative and qualitative research (Creswell 2013, Mills and 
Birks 2014) 
Paradigm Definition 
Positivism -The researcher in this approach asserts the existence of a single reality that 
is there to be discovered. 
-This paradigm more commonly underlines a quantitative approach. 
Postpositivism -This approach is logical and emphasises robust data collection and analysis. 
-It is also cause-and-effect oriented and depends on a priori theories. 
-Inquiry is viewed from multiple perspectives rather than a single reality. 
Constructivism -Researchers investigate different views rather than place ideas into narrow 
categories. 
-A theory may be generated at the end of the research. 
-It also focuses on the context of the answers (historical and cultural 
settings).  
-Researchers’ background and experience can also influence their 
interpretation. 
Advocacy/ 
Participatory 
-The major characteristic of this approach is that it focuses on marginalised 
groups. 
-The researchers collaborate with the participants to provide the 
participants’ voice. 
Pragmatism -The focus of this approach is the outcome of the research rather than the 
process. 
-Researchers often use mixed methods to answer their inquiry. 
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2.3.4. Research approaches and paradigms selected  
Following the literature review phases, a multi-modal research approach was 
selected for the generation and collection of primary research data presented 
in Table 2.5. 
Table 2.5: Multi-modal research design of Phase 3 and 4 of the doctoral project 
 Phase 3 Phase 4 
Aim Determine key health 
stakeholders’ expectations, 
attitudes and beliefs around 
implementing pharmacist 
prescribing in Qatar 
Develop a pharmacist 
prescribing framework tailored 
to Qatar’s setting 
Methodology used Phenomenological qualitative 
approach 
Survey-based quantitative 
approach (Delphi consensus 
technique) 
Paradigm Constructivism Positivism 
Methods employed Face-to-face semi-structured 
interviews 
A modified Delphi technique 
While at the outset of the doctoral studies, the student was more comfortable 
with a positivist, quantitative approach, this was not considered most 
appropriate for all phases of the research. Furthermore, it was considered by 
the supervisory team beneficial to challenge the student on this stance and 
further develop research awareness and skills through also adopting a 
qualitative constructivist approach. 
In order to explore stakeholders’ views and perceptions around the possibility 
of implementing pharmacist prescribing in Qatar, a qualitative approach was 
considered more appropriate due to many advantages as outlined by Saks 
and Allsop (2013). First, qualitative research provides researchers with new 
ways of thinking by allowing them to make observations and generate new 
ideas rather than just testing pre-existing notions. Moreover, they can adjust 
their interpretation approach if they find themes or patterns contradicting 
their initial assumptions. Furthermore, due to the lack of current literature on 
pharmacist prescribing, qualitative approach is more appropriate since it 
allows the investigators to gain an in-depth insight into the participants’ 
views by exploring their responses and asking for clarification or feedback 
thus enriching the findings of the project. 
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A quantitative approach was also utilised in this doctoral work since it can aid 
in the development of a framework for pharmacist prescribing in Qatar. 
Moreover, this method was chosen for multiple reasons as reported by Saks 
and Allsop (2013) which will be discussed in details later in this chapter. In 
addition, this phase complemented the previous research done by the 
investigation team utilising qualitative method to gain an in-depth insight into 
the possible implementation of pharmacist prescribing in Qatar. Thus, it 
helped in testing the statements collected in order to conclude whether they 
are appropriate and relevant. 
All phases of this doctoral research are underpinned by a theoretical 
framework that will be discussed later in the chapter, which was highlighted 
in the first element of the UK MRC Framework for the Development and 
Evaluation of Complex Interventions. 
The employed multi-modal study design is summarised in Figure 2.3. 
 
 
 
 
 
Figure 2.3: Multi-modal design employed in this doctoral research 
2.4. Qualitative Approach (Phase 3) 
2.4.1. Philosophical assumptions 
In addition to considering research approaches and paradigms, philosophical 
assumptions should also be considered prior to selecting specific 
methodologies and methods. Table 2.6 describes key assumptions in relation 
to qualitative research, as adopted for Phase 3.  
 
 
Literature 
Reviews 
Qualitative 
Data 
Generation 
and Analysis 
Quantitative 
Data 
Collection 
and Analysis 
Overall 
interpretation 
Build 
to 
Build 
to 
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Table 2.6: Philosophical assumptions in qualitative research (Creswell 2013) 
Philosophical 
assumptions 
Question Characteristics Implications for 
practice 
Ontological What is the 
nature of 
reality? 
Reality is subjective 
based on participants 
in the study. 
Researcher uses quotes 
and provides evidence of 
multiple views. 
Epistemological What is the 
relationship 
between the 
researcher and 
the participant? 
Researcher tries to 
get closer to 
participants. 
Researcher spends time in 
field with participants, and 
becomes a member. 
Axiological What is the role 
of value? 
Research is value-
laden and biases are 
present. 
Researcher includes 
his/her interpretation with 
that of subjects. 
Methodological What is the 
process of 
research? 
Research is inductive 
and involves the 
environment 
surrounding the 
participants. 
Researcher describes in 
detail the context of the 
study and continually 
revises questions from 
experiences in the field. 
Phase 3 of this research was based on an ontological philosophy since the 
aim of this phase was to determine key health stakeholders’ expectations, 
attitudes and beliefs around implementing pharmacist prescribing in Qatar. 
2.4.2. Research methodologies in qualitative approach 
The most common qualitative research methodologies include narrative, 
phenomenology, grounded theory, ethnography, and case study. These 
different methodologies are described in Table 2.7. 
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Table 2.7: Characteristics of the different qualitative methodologies (Creswell 2013) 
characteristics Narrative research Phenomenology  Grounded theory Ethnography  Case study 
Focus Exploring the life of an 
individual 
Understanding the essence 
of the experience 
Developing a theory 
grounded in data from 
the field 
Describing and interpreting a 
culture-sharing group 
Developing an in-
depth description 
and analysis of a 
case or multiple 
cases 
Type of study best 
suited for design 
Aiming to tell stories of 
individual experiences 
Aiming to describe the 
essence of a lived 
phenomenon 
Grounding a theory in 
the views of 
participants 
Describing and interpreting 
the shared patterns of 
culture of a group 
Providing an in-
depth 
understanding of a 
case or cases 
Discipline background Drawing from the 
humanities including 
anthropology, 
literature, history, 
psychology and 
sociology 
Drawing from philosophy, 
psychology and education 
Drawing from 
sociology 
Drawing from anthropology 
and sociology 
Drawing from 
psychology, law, 
political science and 
medicine 
Unit of analysis Studying one or more 
individuals 
Studying several 
individuals who have 
shared the experience 
Studying a process, 
an action or an 
interaction involving 
many individuals 
Studying a group that shares 
the same culture 
Studying an event, 
a programme, an 
activity or more 
than one individual 
Forms of data 
generation 
Using primarily 
interviews and 
documents 
Using primarily interviews 
with individuals although 
documents, observations 
and art may also be 
considered 
Using primarily 
interviews 
Using primarily observations 
and interviews but perhaps 
collecting other sources 
during extended time in field 
Using multiple 
sources such as 
interviews, 
observations, 
documents and 
artefacts 
Data analysis 
strategies 
Analysing data for 
stories, “restoring” 
stories and developing 
themes often using a 
chronology 
Analysing data for 
significant statements, 
meaning units, textual and 
structural description and 
description of the 
“essence” 
Analysing data 
through open coding, 
axial coding and 
selective coding 
Analysing data through 
description of the culture-
sharing group and themes 
about the group 
Analysing data 
through description 
of the case and 
themes of the case 
as well as cross-
case themes 
Written report Developing a narrative 
about the stories of an 
individual’s life 
Describing the “essence” 
of the experience 
Generating a theory 
illustrated in a figure 
Describing how a culture-
sharing group works 
Developing a 
detailed analysis of 
one or more cases 
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2.4.3. Phase 3 research methodology  
The aim of Phase 3 of this doctoral project was to determine key health 
stakeholders’ (patients, physicians, nurses, pharmacists, hospital administrators, 
regulatory bodies’ representatives) expectations, attitudes and beliefs around 
implementing pharmacist prescribing in Qatar. Thus, it was deemed that a 
phenomenological approach was the most appropriate to address the research 
aim and enable better understand of this concept and the possible facilitators 
and barriers to the implementation of pharmacist prescribing in the State. 
Different methods could be used in qualitative research as described in Table 
2.8. However, based on the qualitative methodology chosen and to achieve the 
above stated aim, interviews were conducted to generate data since they permit 
full exploration of stakeholders’ views and permit analysing their responses for 
significant statements and themes that could help in developing the next phase 
of the project. 
Table 2.8: Types of qualitative research (Creswell 2014) 
Data 
generation 
category 
Choices within 
category 
Strengths Weaknesses 
Observations -Complete participant, 
researcher’s role is 
concealed. 
-Observer as 
participant, 
researcher’s role is 
known. 
-Participant as 
observer, observation 
is secondary to 
participant role. 
-Complete observer, 
researcher only 
observes. 
-Investigator has a 
direct encounter with 
subjects. 
-Information is recorded 
as it happens. 
-Unusual aspects can be 
noted. 
-Useful for 
uncomfortable issues for 
discussion. 
-Researcher may be seen as 
intrusive. 
-Private information cannot be 
recorded. 
-Researcher’s skills can affect 
results. 
-Certain participants (e.g. 
children) may be difficult. 
Interviews -Face-to-face interview 
-Telephone interview 
-Focus group 
-Electronic interview 
-Beneficial when 
participants cannot be 
observed. 
-Historical data can be 
collected. 
-Questioning can be 
controlled. 
-Provides indirect information 
filtered through the views of 
interviewees. 
-Setting is designated and 
often not usual environment. 
-Researcher’s presence may 
bias results. 
-Not all participants are 
expressive. 
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Documents -Public documents, 
minutes of meetings or 
newspapers 
-Private documents, 
journals, diaries, or 
letters 
-Language and words of 
participants can be 
obtained. 
-Convenient source of 
information. 
-No need for 
transcribing since it is 
written. 
-Documents might be 
unavailable to public. 
-Information might be hard to 
locate. 
-Data may be incomplete. 
-Documents may not be 
dependable or precise. 
Audio-visual 
materials 
-Photographs 
-Videotapes 
-Art objects 
-Computer messages 
-Sounds 
-Film 
-May be a convenient 
method of gathering 
data. 
-Allows participants to 
directly share 
information. 
-Creative and attractive. 
-May be difficult to interpret. 
-May not be publicly available. 
-The presence of an observer 
may affect responses. 
Compared to focus groups, interviews were more appropriate since they allow 
generation of data from individuals separately, thus, fully exploring their point of 
view. They also help to avoid logistical issues in organising for key stakeholders 
from different locations across the country to gather and attend focus group 
discussions. Given the seniority of the interviewees, face-to-face interviews were 
considered more appropriate than telephone or online interviews, allowing 
rapport building and detection of non-verbal cues. 
2.4.4. Types of interviews 
Face-to-face interviews, the method of data generation chosen for Phase 3 of 
this doctoral project, can either be structured, semi-structured or unstructured, 
as described in Table 2.9 (Stuckey, 2013).  
Table 2.9: Types of interviews (Stuckey 2013) 
 Definition 
Structured -The researcher follows a specific set of questions in a predetermined 
order with a limited number of response categories. 
-This is more appropriate when interviews require that the participant 
give a response to each ordered question.  
-Questions are usually short and very specific. 
Semi-structured -The researcher sets the outline for the topics covered, but the 
interviewee’s responses determine the way in which the interview is 
directed. 
-This is the most commonly used type of interview in qualitative 
research. 
Unstructured -Involves stories that are based on the unfolding of events or actions 
from the perspective of a participant’s life experience. 
-Unstructured interviews allow the participant to guide the interview, 
thus revealing information that could not have been predicted. 
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Semi-structured interviews were most appropriate for this phase of the doctoral 
research, allowing in-depth description and understanding of the participants’ 
perspectives leading to the generation of very rich data (Jensen and Laurie, 
2016). This approach allowed the doctoral student to probe responses further 
gaining further detail, to clarify any issues or ambiguities and to add additional 
questions.  
2.4.5. Approaches to sampling 
Probability and non-probability sampling are the two main techniques of 
selecting a sample from a population. While probability sampling is more 
commonly applied to quantitative research, both techniques are described in 
Table 2.10 for completeness. 
Table 2.10: Types of sampling methods (Jensen and Laurie 2016) 
 Definition Advantages Limitations 
1- Probability sampling 
Simple random 
sampling 
Process where 
members of a 
population are 
chosen using a 
random number 
generator to ensure 
all members of the 
population have an 
equal chance of 
being selected. 
-Reduces risk of 
sampling bias. 
-Considered the most 
robust form of 
sampling. 
-Requires little or no 
information about the 
population’s 
characteristics. 
-Can be affordable for 
easily accessible 
populations. 
-Often difficult in 
practice to achieve a 
purely random sample. 
-Can be prohibitively 
expensive for dispersed 
populations. 
-May not yield enough 
respondents categories 
of interest for statistical 
analysis. 
Stratified random 
sampling 
Divides the 
sampling frame into 
categories relevant 
to the analysis. 
-More targeted than 
simple random 
sampling. 
-Useful when 
comparing attitudes of 
groups is the primary 
motivation in the 
research. 
-Can be used to 
compare groups of 
different sizes. 
-May still be relatively 
expensive. 
-Requires more 
knowledge about the 
population than simple 
random sampling. 
-Choice of variables to 
use to stratify the 
sample may be 
complicated. 
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Cluster sampling Random sampling of 
a geographical 
cluster. 
-Enables face-to-face 
probability sampling 
when the researcher 
does not have contact 
details for the potential 
participants. 
-If structured 
effectively, it can have 
similar strengths to 
simple random 
sampling. 
-Can be complicated to 
undertake. 
-Can be prohibitively 
expensive. 
Multistage sampling Represents a 
combination of 
different sampling 
techniques. 
-Enables the 
researcher to address 
constraints and 
analysis requirements. 
-Complex to define and 
implement. 
-Probably not a good 
choice for novice 
researchers. 
Systematic sampling Relies on selection 
rules but not 
random selection. 
-Easy to implement or 
to ask others to do 
when collecting data. 
-Can be more efficient 
and easier to 
implement in real-
world situations than 
any other form of 
random sampling. 
-Avoids risk of 
selection bias. 
-Widely considered 
good enough to treat 
data as if they were 
from a probability 
sample. 
-Does not employ truly 
random selection. 
-It is possible that 
selecting every Xth 
person systematically 
excludes certain people. 
2- Non probability sampling 
Convenience 
sampling 
The researcher 
selects the 
members of a 
population that are 
easiest to access. 
-Often the lowest-cost 
option. 
-Easy to do. 
-Useful for getting 
initial ideas. 
-Major risk of non-
representative sample. 
-Results probably 
cannot be generalisable. 
Quota sampling Selecting a 
convenience sample 
but within the 
bounds of 
predetermined 
quotas. 
-Only a little harder to 
do than convenience 
sampling. 
-Quotas ensure that 
you have enough 
people from different 
categories relevant to 
the research. 
-Unlikely to produce a 
more representative 
sample than 
convenience sampling. 
Snowball sampling Employs 
participants in the 
research as 
gatekeepers to find 
new participants. 
-A useful means of 
locating participants 
among stigmatised or 
otherwise hard-to-
access groups. 
-Helps establish some 
trust and credibility. 
-Major risk of non-
representative sample. 
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Purposive/theoretical 
sampling 
Uses the 
researcher’s 
judgement to select 
participants who will 
offer valuable 
insights. 
-Can gain insights that 
are useful for 
developing theoretical 
explanations by 
targeting specific 
individuals or groups 
within a population. 
-Researcher can 
exercise explicit 
judgement in 
identifying who would 
be most interesting to 
include in the sample. 
-Major risk of non-
representative sample. 
-The researcher’s 
judgement may 
inadvertently skew the 
selection of participants. 
In Phase 3, two approaches to sampling were combined: purposive to recruit 
those individuals who could contribute most to the specific research aim and 
objectives; and by snowballing whereby interviewees were asked to suggest 
other key individuals they thought would be appropriate to interview. These 
interviewees were considered to be in positions of responsibility in Qatar related 
to the implementation of pharmacist prescribing.  
2.4.6. Sample size determination in qualitative research 
Sample size for qualitative research is commonly determined by the principle of 
data saturation. According to Sanders et al. (2018), saturation refers to the 
criterion for judging when to stop sampling, recruiting and generating data. 
There are four models of saturation which are commonly reported (Table 2.11). 
Table 2.11: Models of saturation in qualitative research (Saunders et al. 2018) 
Model Description 
Theoretical saturation -Rooted in traditional grounded theory. 
-Uses the development of categories and the emerging theory in the 
analysis process as the criterion for additional data collection. 
Inductive thematic 
saturation 
-Focuses on the identiﬁcation of new codes or themes rather than the 
completeness of existing theoretical categories. 
-Mainly conﬁned to data analysis/generation. 
A priori thematic saturation -Data are collected to exemplify pre-determined codes or themes 
rather than to develop or reﬁne theory. 
Data saturation -Identifies if new data repeat that expressed in previous data 
(redundancy in the data). 
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Based on the qualitative methodology chosen and the aim of this phase, data 
saturation was chosen as the stopping criteria for recruitment of stakeholders 
for Phase 3 (interviews) following the four principles described by Francis et al. 
(2010) (Figure 2.4). 
 
Figure 2.4: Principles for data saturation (Francis et al. 2010) 
Initial analysis sample is the a priori sample size at which the first round of 
analysis is considered to be complete. This number is determined based on the 
complexity of the research question and interview topic guide, diversity of 
sample and the nature of the analysis. 
Stopping criteria is referred to as the a priori number of interviews that will be 
conducted without any new ideas or themes emerging before concluding that 
data are saturated. 
The third principle focuses on performing the analysis of responses by at least 
two independent coders. The level of agreement must be reported in order to 
ensure that the analysis is rigorous. 
Initial 
Analysis 
Sample
Stopping 
Criteria
Independent 
Coding and 
Agreement
Report of 
Analysis and 
Results
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The last principle is concerned with reporting the methods and findings of the 
data saturation. This helps the reader to evaluate the evidence described. 
For the purpose of Phase 3 of this doctoral research, five members from each 
professional group were interviewed as the initial analysis sample. This sample 
size was believed to represent adequate diversity based on the participants’ 
professions. Afterwards, one additional interview was performed for each 
profession before the stopping criterion was tested. Responses were coded and 
analysed independently by two research team members in order to confirm that 
data saturation was achieved. 
2.4.7. Types of transcription methods 
Transcribing is a key element in qualitative studies, defined by Howitt (2016, p. 
135) as “the process by which a sound or a video recording of the spoken word 
is turned into written language for subsequent analysis”. According to Mann 
(2016), there are different reasons to produce a transcript for qualitative 
interviews: 
• Prompting initial analysis by listening to the original interview data 
• Encouraging close attention and noticing small details by closely looking 
at the data 
• Considering what is said and what is not said through focusing not only on 
what is said but also on how it was said 
• Offering interviewees the opportunity to review responses to avoid 
misrepresentation 
• Inducing further comment in the following interviews 
• Revisiting data at a later date 
Standardised (or paraphrased) transcription reports only the content discussed 
and removes all non-verbal cues such as pauses and fillers. Verbatim (or exact) 
transcription records the interview word for word as well as includes non-verbal 
speech elements. This method allows those not present during the data 
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generation to gain more insight into the way the interviewees expressed 
themselves (Jensen and Laurie 2016). 
For the purpose of this study, data were transcribed verbatim to also capture 
the non-verbal speech elements.  
2.4.8. Data generation 
According to Corbin and Strauss (2008), analysis is a dynamic process of 
“examining a substance and its components in order to determine their 
properties and functions, then using the acquired knowledge to make inferences 
about the whole” (p.45). This involves the creative use of different procedures to 
systematically construct a coherent and explanatory concepts. 
According to Lyons and Coyle (2015), there are five main approaches to 
analysing qualitative data (Table 2.12) 
Table 2.12: Approaches of qualitative data analysis (Lyons and Coyle 2015). 
 Descriptions and aim(s) 
Thematic analysis Technique or method for identifying or interpreting patterns of 
meaning or themes in qualitative data. 
Discourse analysis How people use language to construct versions of their worlds 
to offer a critical interrogation of the status quo. 
Narrative analysis  Focuses on analysing individual experience and meanings in 
depth rather than looking for commonalities between different 
people. 
Interpretative 
phenomenological analysis 
Provides detailed description of the participants’ lived 
experiences and examines how participants are making sense 
of their personal and social world. 
Grounded theory Involve closely examining qualitative data in order to develop 
theory on a given topic inductively. 
The thematic approach was selected and was carried according to the steps 
outlined by Ritchie and Spencer (1994) and Howitt (2016), summarised in 
Figure 2.5.  
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Figure 2.5: Stages of thematic analysis (Ritchie and Spencer 1994, Howitt 2016) 
Step 6: Report writing
The report, whether it is a dissertation or an article, must include a detailed description of the all the stages of the research.
Step 5: Theme definition and labelling
Labelling emerging themes.
Step 4: Review of themes
The themes generated in step 3 examined against the original data by cutting-and-pasting the responses collected under the 
corresponding themes.
Step 3: Search for themes based on the initial coding
More analytical effort employed to transform the initial codes into meaningful tentative themes.
Step 2: Initial coding generation
Data are coded line-by-line which, leading to the generation of themes. As the doctral research was theory-led, the structure of
initial coding was determined by the key elements of the theory being applied.
Step 1: Data familiarisation
The researcher becomes familiar with the close details of the transcript and other text to be used in the analysis
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2.5. Quantitative approach (Phase 4) 
2.5.1. Philosophical assumption 
The main philosophical assumption underlying quantitative research is 
positivism which assumes that phenomena and behaviours can be observed 
and measured (Bowling 2009). According to Castellan (2010), positivism is 
the belief that reality is objective and independent of the researchers’ 
influence. In quantitative approaches, investigators are considered as outside 
observers of events, with neutral and distant roles from those of research 
participants. 
2.5.2. Advantages of quantitative research 
Advantages of quantitative approaches are summarised by Saks and Allsop 
(2013) as follows: 
• Measurement, output measuring quantity is often reliable 
• Robustness, the methods are clear, logical, and mathematically and 
statistically sound 
• Internal validity, the methods are often able to explain phenomena 
(e.g. cause and effect, inference and association) 
• Generalisability (external validity), study findings can often be 
generalised to a larger population 
• Replicability, methods are transparent hence studies can be replicated 
by others building knowledge. Replication increases the reliability and 
validity of research findings 
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2.5.3. Research methodologies in quantitative approach 
The main methodologies in quantitative research are described in Table 2.13. 
Table 2.13: Quantitative research methodologies (Song and Chung 2010, Watson 2015) 
 Description 
Randomised 
controlled trials 
-Best method to test cause and effect in clinical interventions. 
-Employ randomisation and a control group. 
-Rated near the top of the hierarchy of evidence, as a method of 
providing high level evidence for clinical practice. 
Cohort studies -Collect data from a group of people with defined characteristics who are 
followed up to determine incidence of an outcome. 
-More informative about how individuals change over time and for  
simultaneously examining rare exposures or multiple outcomes. 
-Costly (needs large sample size, potentially long follow-up duration) 
and susceptible to attrition. 
Case-control studies -Collect data about exposure to a risk factor or several risk factors 
retrospectively from two different groups (exposed and non-exposed). 
-Investigate rare outcomes or outcomes with a long latency period, 
relatively quick and inexpensive. 
-Susceptible to selection and information bias and difficult to validate 
information. 
Survey based 
studies (including 
consensus studies) 
-Useful for gathering large amounts of data to describe samples and 
populations using a set of questions. 
-Cannot easily distinguish between cause and effect. 
2.5.4. Phase 4 research methodology 
The most appropriate methodology selected for Phase 4 was a quantitative, 
survey-based consensus approach. Given the prior work of literature reviews 
and qualitative interviews, all findings were collated into key statements for 
the final phase of the doctoral research. The responses to these statements 
from a panel of key experts in Qatar were considered to form a framework 
for the development and implementation of pharmacist prescribing in Qatar.  
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2.5.5. Defining the consensus approach 
According to Campbell and Cantrill (2001), consensus methods are “group 
facilitation techniques designed to explore the level of consensus among a 
group of experts by synthesising and clarifying expert opinion”. The key 
features of consensus methods, as described by Jones and Hunter (1995), 
are: 
• Anonymity, avoiding dominance  
• Iteration, occurs in rounds allowing individuals to alter responses 
• Controlled feedback, illustrating distribution of the group’s response  
• Statistical group response, expressing judgment using summary 
measures of all responses  
Consensus approaches gather together experts and/or the public in order to 
explore a topic and determine the extent of agreement. Since perfect 
agreement is rarely reached, variation is possible among individuals (Jones 
and Hunter 1995, Keeney, McKenna and Hasson 2011).  
Consensus approaches are particularly useful in a number of circumstances 
(Campbell and Cantrill 2001, Nair, Aggarwal and Khanna 2011) which 
include: 
• Enhancing decision-making and developing policies 
• Facilitating the development of quality indicators or review criteria 
• Supporting quality assessment, improvement and clinical governance 
• Synthesising accumulated expert opinion/professional norms 
• Identifying and stimulating debate around areas where there is 
uncertainty, controversy or incomplete evidence  
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2.5.6. Types of consensus approach 
The key methods in consensus studies are described in Table 2.14. 
Table 2.14: Types of consensus approach (Nair, Aggarwal and Khanna 2011) 
 Description Advantages Limitations 
Delphi method Designed to obtain 
the most reliable 
consensus of 
opinion in a 
systematic 
manner. This is 
achieved by series 
of well-defined 
questionnaires. 
-Involves large number of 
experts. 
-Opinions are expressed 
freely and impersonally. 
-No influence of highly 
opinionated individuals. 
-Moderator has minimal 
influence on experts. 
-Ability to express and 
reflect on ideas. 
-Cheap and convenient 
when experts cannot be 
grouped into a single 
room. 
-Dependent on 
questionnaire design. 
-Coordinating large group 
can be complicated. 
-No personal contact 
between experts is 
allowed. 
Nominal group 
technique 
Face-to-face group 
meeting of experts 
which is led by a 
skilful moderator. 
Experts first 
independently 
generate ideas 
then share and 
rank them. 
-All experts can voice 
opinions. 
-Personal contact 
between experts is 
allowed. 
-Group voting can occur if 
desired. 
-Moderator must be skilful. 
-Few questions can be 
discussed since it is limited 
by time. 
-Arranging meetings can 
be costly. 
-Can be difficult to arrange 
for experts to meet face-
to-face. 
RAND/UCLA 
appropriateness 
method (RAM) 
Mainly used to 
assess the 
appropriateness of 
medical procedures 
(e.g. coronary 
angiography). It 
involves two 
interdependent 
groups. The core 
panel provides 
information to the 
expert panel to 
reach consensus. 
-Synthesis of published 
literature is performed. 
-Allows for individual as 
well as group rating. 
-Can be reproducible. 
-Time consuming. 
-Can be costly. 
-Highly opinionated 
individual can dominate 
the discussion. 
-Complex issues can be 
difficult to discuss. 
-Potential bias in 
participant selection. 
National institutes 
of health (NIH) 
consensus 
development 
conference (CDC) 
methodology 
Involves experts as 
well as public to 
reach consensus 
on medical 
procedures, 
devices and drugs. 
-Involves experts as well 
as consumers. 
-Unbiased panel. 
-Interaction is 
unstructured. 
-Aggregation methodology 
lacks feedback. 
-Potential bias in 
participant selection. 
Given the need to recruit key stakeholders in Qatar to the consensus study, 
and considering the logistics in getting such individuals together, the Delphi 
technique was selected. This would also maintain anonymity and allow for 
easy communication.  
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2.5.7. Types of Delphi technique 
The Delphi technique was originally designed to increase the accuracy of 
forecasts by the RAND Air Force Corporation in America in the 1950s. The 
project ‘Delphi’ was established to estimate key nuclear targets in America 
from a Soviet perspective (Campbell and Cantrill 2001). However, over the 
years, it has evolved with a number of modifications, as shown in Table 2.15, 
and has become more widely used across a range of healthcare areas. 
Table 2.15: Types of Delphi technique (Keeney, McKenna and Hasson 2011, Avella 
2016) 
Type of Delphi Main characteristics 
Classical Delphi -Employs a first round to generate ideas and three or more 
rounds via post or email. 
Modified Delphi -Similar to the classical Delphi, except that the statements 
used are not generated after consulting the expert panel but 
through other means (e.g. literature review, face-to-face 
interviews or focus group). 
Decision Delphi -Similar to the classical Delphi, except that the aim is to make 
decisions rather than come to consensus. 
Policy Delphi -The main aim of this type of Delphi is to agree on future 
policy on a given topic. 
Real Time or Conference 
Delphi 
-Similar to the classical Delphi, except that the experts may 
be in the same room rather than using post. 
e-Delphi -Similar to the classical Delphi, except that it is conducted 
electronically (email or online web survey). 
Technological Delphi -Similar to the real time Delphi, except that the experts use 
technology (i.e. keypads) to receive instant feedback thus 
they can re-vote immediately. 
Argument Delphi -Derived from the policy Delphi, except that it focuses on the 
production of relevant factual arguments. 
Disaggregative Delphi -Conducts various scenarios of the future for discussion and it 
does not aim to reach consensus. 
Since the aim of this phase was to reach consensus in order to develop a 
pharmacist prescribing framework tailored to Qatar’s setting and given that 
the Delphi statements were derived from previous research phases, a 
modified Delphi technique was employed in Phase 4.  
2.5.8. Panel of experts 
Delphi studies do not always aim for representation of all the population, but 
mainly employ stakeholders or experts who are specialists or have knowledge 
of the area researched (Keeney, McKenna and Hasson 2011). A 'stakeholder' 
in the context of health research is defined by the Agency for Healthcare 
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Research and Quality (2014) as “persons or groups that have a vested 
interest in a clinical decision and the evidence that supports that decision”. 
Examples of health stakeholders include patients, caregivers, clinicians, 
researchers, advocacy groups and policy makers. Stakeholders are especially 
important when conducting research since they are considered the main 
individuals to either structure, deliver or experience a certain intervention. 
Campbell and Cantrill (2001) reported that the panel of experts in a Delphi 
study must reflect the constituency of stakeholders it is intended to 
represent. Thus, it could include any individual with relevant 
knowledge/experience or individuals who are highly regarded in the topic 
studied. Likewise, Delbecq, Van de Ven and Gustafson (1975) also stated 
that the panel usually involves participants who: 
• Feel personally involved in the problem of concern 
• Have pertinent information to share 
• Are motivated to include the Delphi task within their schedule of 
competing tasks 
• Feel that the aggregation of judgements of a respondent panel will 
include information which they too value and to which they would not 
otherwise have access 
2.5.9. Sample size determination 
The sample size needed for a Delphi study varies, depending on the purpose 
of the research. Moreover, there is no consensus on the ideal number of 
experts to include in a given Delphi study nor has it ever been established 
what constitutes a large or small panel. However, Delphi panels usually 
involve 10 to 100 members and consist of either two or three expert groups 
(Avella 2016). Overall, it is recommended to restrict the number of 
participants to a minimally sufficient number of respondents to address the 
research objectives. 
2.5.10. Delphi rounds 
The Delphi technique employs questionnaires comprising of a list of 
statements which are updated and shared with the experts until consensus is 
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reached or the final scheduled round is complete. In each of the round of the 
Delphi, the questionnaire as well as the feedback from the previous rounds 
are sent for the expert panellists to review to aid them in reaching a final 
decision. 
There is no consensus in the literature on the optimal number of rounds 
(Gerrish and Lathlean 2015). Traditionally, Delphi studies used four rounds, 
but this has been modified by many researchers given factors of study 
duration and sustaining the interest and involvement of the panellists 
(Keeney, McKenna and Hasson 2011).  
2.5.11. Data analysis 
According to Von der Gracht (2012), there are different descriptive and 
inferential methods to determine consensus described in Table 2.16. 
Table 2.16: Consensus measurements (Von der Gracht 2012) 
Methods Description 
Subjective criteria and descriptive statistics 
Stipulated number of rounds The researchers estimate the number of iterations sufficient 
to identify points of consensus. 
Subjective analysis The researchers believe that another round would not 
significantly add to the results and therefore terminate the 
process. 
Certain level of agreement The researchers determine consensus based on previous 
studies employing a Delphi technique. 
Average Percent of Majority 
Opinions (APMO) Cut-off Rate 
The point of consensus is determine based on the majority of 
agreements and disagreements. 
Mode, mean/median ratings 
and rankings, standard 
deviation 
Measures of central tendency can also be used to determine 
consensus. However, this method is controversial since Likert 
data are ordinal and not interval. 
Interquartile range (IQR) For 10-unit scale, an IQR of 2 or less is considered a 
consensus while an IQR of 1 or less is regarded as a suitable 
consensus indicator for 4- or 5-unit scales. 
Coefficient of variation A consistent decrease of the coefficients of variation between 
the first and the second round, indicated an increase in 
consensus. 
Post-group consensus The extent to which individuals individually agree with the 
final group aggregate, their own final round estimates or the 
estimates of other panelists after the Delphi was complete. 
Inferential statistics 
Chi square test of 
independence 
A nonparametric test to assess whether there is a 
relationship between the Delphi rounds and the responses 
obtained in them. 
McNemar change test A nonparametric test used when Chi square cannot be used 
(if samples are dependent). 
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Wilcoxon matched-pairs 
signed-ranks test 
A nonparametric alternative to the paired Student's t-test for 
repeated measurements on a single sample and compares 
two dependent samples, using the ranks of the pairs of 
scores formed by the matched pairs in the sample. 
Intra-class correlation 
coefficient, kappa statistics 
Designed to assess consistency or conformity of responses 
and the levels of agreement among panelists. 
Spearman's rank-order 
correlation coefficient 
Mainly used to indicate the extent to which a change in the 
value of one round is related to a change in the value of the 
other round in case of interval or ratio variables. 
Kendall's W coefficient of 
concordance 
A nonparametric statistic used to assess agreement among 
raters as well as its strength and change. A coefficient of 0.1 
indicates very weak agreement, whereas 0.7 is referred to as 
strong agreement. 
t-statistics A parametric test for interval or ratio data that tests for 
significant differences between the means for Delphi’s 
successive rounds and to compare subgroups or the data of 
two different Delphi studies. 
F-tests A parametric tests for interval or ratio data. F-test for the 
equality of more than two means (one-way ANOVA) can be 
used to examine the significant mean differences among 
more than two groups (or subgroups). 
As discussed by Von der Gracht (2012), there are is no agreement on how to 
measure consensus. The most frequently reported technique is descriptive 
using the certain level of agreement, hence this was selected for Phase 4. 
Delphi consensus is typically set between 55 to 100% agreement, with 70% 
considered the standard, representing all agreements within +/- 1 standard 
deviation of the mean (Vernon 2009). Thus, a cut-off of 70% in the 
agreement (agree or strongly agree) and less than 15% disagreement 
(disagree/strongly disagree) was set as being consensus for each statement.  
2.6. Theoretical frameworks in research 
2.6.1. Introduction 
According to the MRC framework described earlier, the consideration of 
theory is important in developing any intervention, ensuring that individual 
data have a meaningful context and contribute towards building an integrated 
body of knowledge (Nilsen 2015). Theory can be considered at any stage of 
research from justifying the rationale for the research, developing the data 
collection and generation tools to data analysis and interpretation (Stewart 
and Klein 2015). 
According to Nilsen (2015), a theory is “a set of analytical principles or 
statements designed to structure our observation, understanding and 
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explanation of the world [thus] provides a clear explanation of how and why 
specific relationships lead to specific events”. A framework usually denotes “a 
structure, overview, outline, system or plan consisting of various descriptive 
categories (e.g. concepts, constructs or variables) and the relations between 
them that are presumed to account for a phenomenon”. The major difference 
between the two terminologies is that frameworks only describe, not explain, 
a phenomena whereas theories are both explanatory and descriptive.  
There are five main categories of theoretical approaches, as described in 
Table 2.17.  
Table 2.17: Main categories of theoretical frameworks (Nilsen 2015) 
Theoretical 
Framework Category 
Description 
Process models Describe and/or guide the process of translating research into 
practice. The action models, a subset of process models, offer 
practical guidance in the planning and execution of 
implementation endeavours and/or implementation strategies. 
Determinant 
frameworks 
Describe general types of determinants that are hypothesised or 
have been found to influence implementation outcomes such as 
the barriers and/or enablers that can impact on implementation 
outcomes. 
Classic theories Describe change mechanisms and explain how change occurs 
without ambitions to actually bring about change. They usually 
originate from other disciplines such as psychology or sociology. 
Implementation 
theories 
Developed or adapted by researchers for potential use in 
achieving enhanced understanding and explanation of certain 
aspects of implementation. 
Evaluation 
frameworks 
Provide a structure for evaluating implementation endeavours. 
2.6.2. Implementation framework selected for this doctoral 
research  
Determinant frameworks were selected for Phases 3 and 4 given that the 
overall aim was to explore the development of frameworks of pharmacist 
prescribing in Qatar by exploring the views and perceptions as well as 
determining the possible facilitators and barriers to implementing this role 
globally as well as in Qatar. The most commonly cited determinant 
frameworks that focus on the successful intervention implementation as an 
outcome are summarised in Table 2.18. 
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Table 2.18: Common determinant frameworks characteristics (adapted from Nilsen 2015) 
 Characteristics of 
the implementation 
object 
Characteristics of 
the users (e.g. 
health practitioners) 
Characteristics of 
the end users (e.g. 
patients) 
Characteristics of 
the context 
Characteristics of 
strategy of 
facilitating 
implementation 
Promoting Action on 
Research 
Implementation in 
Health Services 
(PARIHS) 
Framework 
Characteristics of the 
evidence 
Characteristics of the 
clinical experience 
Characteristics of 
patient experience 
Characteristics of the 
context (culture, 
leadership and 
evaluation) 
Characteristics of the 
facilitation (process of 
enabling the 
implementation) 
Conceptual Model Innovation attributes Aspects of adopters 
and assimilation by 
organisations 
Not addressed Characteristics of the 
inner context 
(organisational 
readiness for 
innovation) and outer 
context (political 
directives) 
Influences (opinion 
leaders) lying on a 
continuum from 
diffusion to 
dissemination 
Ecological 
Framework 
Characteristics of the 
innovation 
Provider characteristics Not addressed Community level 
factors (general 
organisational 
features, specific 
staffing considerations) 
Features of the 
prevention support 
system (comprising 
training and technical 
assistance) 
Consolidated 
Framework for 
Implementation 
Research (CFIR) 
Intervention 
characteristics 
Characteristics of 
individuals 
Patient needs and 
resources 
Characteristics of the 
inner setting 
(structural 
characteristics, 
culture) and outer 
setting (incentives, 
external policies) 
Effectiveness of 
process by which 
implementation is 
accomplished 
(comprising planning, 
engaging, executing, 
reflection and 
evaluating) 
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The Consolidated Framework for Implementation Research (CFIR) was 
considered the most appropriate and comprehensive, being based on other 
determinant frameworks and relevant theories in various disciplines such as 
Promoting Action on Research Implementation in Health Services (PARiHS) 
and the Conceptual Model.  
2.6.3. Overview of the development of the Consolidated 
Framework of Implementation Research 
While many implementation theories exist, they utilise different 
terminologies, are often overlapping and lack one or more key constructs. 
There was therefore a need for a comprehensive, overarching framework. 
CFIR was developed by implementation researchers affiliated with Veterans 
Affairs (VA) Diabetes Quality Enhancement Research Initiative (QUERI) in 
2009 (Damschroder et al. 2009, Consolidated Framework for Implementation 
Research 2016). CFIR development involved reviewing all published models, 
theories and frameworks that facilitate translation of research findings into 
practice, mainly in the healthcare sector. Theories described in peer-reviewed 
papers on dissemination, innovation, organisational change, implementation, 
knowledge translation and research uptake were identified. Contact was also 
made with colleagues engaged in implementation research, all generating a 
list of the 19 theories and models (Table 2.19). Identified constructs were 
either combined or separated in order to develop readily operationalised 
definitions used in implementation studies, and repeated until theme 
saturation was reached. Thus, the CFIR embraces, not replaces, the 
significant and meaningful contribution of existing implementation theories.  
CFIR is considered to be pragmatic meta-theoretical framework that can be 
utilised in order to identify potential influences on implementation. It has a 
comprehensive taxonomy of specific constructs that can positively or 
negatively influence implementation to synthesise and build knowledge 
across multiple settings thus providing a richer understanding of the 
complexities of implementing an intervention (Damschroder et al. 2009). 
Moreover, the CFIR “provides a menu of constructs that can be used in a 
range of applications such as a practical guide for systematically assessing 
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potential barriers and facilitators in preparation for implementing an 
innovation” (Consolidated Framework for Implementation Research 2016). 
Table 2.19: Theories and models reviewed to develop the CFIR (Damschroder et al. 
2009) 
• Conceptual model for considering the determinants of diffusion, dissemination and 
implementation of innovations in health service delivery and organisation 
• Conceptual model for implementation effectiveness 
• Dimensions of Strategic Change 
• Theory-based Taxonomy for Implementation 
• PARiHS Framework: Promoting Action on Research Implementation in Health 
Services 
• Ottawa Model of Research Use 
• Conceptual Framework for Transferring Research to Practice 
• Diagnositic/Needs Assessment 
• Stetler Model of Research Utilisation 
• Technology Implementation Process Model 
• Replicating Effective Programs Framework 
• Organisational Transformation Model 
• Implementation of Change: A Model 
• Framework of Dissemination in Health Services Intervention Research 
• Conceptual Framework for Implementation of Defined Practices and Programs 
• Will it Work Here? A Decision-maker's Guide to Adopting Innovations 
• Availability, Responsiveness and Continuity: An Organisational and Community 
Intervention Model 
• A Practical, Robust Implementation and Sustainability Model (PRISM) 
• Multi-level Conceptual Framework of Organisational Innovation Adoption 
2.6.4. Domains of the Consolidated Framework of 
Implementation Research 
There are five main domains of CFIR (Damschroder et al. 2009): intervention 
characteristics, outer setting, inner setting, characteristics of the individuals 
involved, and the process of implementation. 
a. Intervention characteristics 
This domain encompasses: 
• Intervention source: Whether the intervention is internally (developed 
as a good idea, solution to a problem) or externally (developed by a 
vendor or a research group) developed 
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• Evidence strength and quality: Quality and validity of evidence 
supporting the belief that the intervention will have desired outcomes 
• Relative advantage: Advantage of implementing the intervention 
versus an alternative solution 
• Adaptability: Degree to which an intervention can be adapted, tailored, 
refined or reinvented to meet local needs 
• Trialability: Ability to test the intervention on a small scale in the 
organisation and to be able to reverse course if warranted 
• Complexity: Difficulty of implementation reflected by duration, scope, 
radicalness, disruptiveness, centrality and intricacy and number of 
steps required to implement 
• Design quality and packaging: Excellence in how the intervention is 
bundled, presented and assembled 
• Cost: Cost of the intervention and costs associated with implementing 
that intervention (investment, supply, opportunity costs) 
 
b. Outer setting 
Changes in the outer setting can affect implementation. Examples include 
changes in economic, political and social structures. This domain has four 
main sub-constructs: 
• Patient needs and resources: Accounting for patient characteristics and 
needs as well as barriers and facilitators to meet those needs 
• Cosmopolitanism: The degree to which an organisation is networked 
with other external organisations 
• Peer pressure: The degree of competitiveness with other organisations 
• External policies and incentives: External strategies to spread 
interventions such as policy, regulation and incentives 
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c. Inner setting 
This domain focuses on how the different constructs interact within the 
organisation comprising: 
• Structural characteristics: The organisation’s social architecture, 
administrative intensity, age, maturity, size, etc. 
• Networks and communications: The nature and quality of social 
networks, formal and informal communications within an organisation, 
connections between individuals 
• Culture: Norms, values and basic assumptions and thinking of an 
organisation 
• Implementation climate: The absorptive capacity for change, the 
extent to which an intervention will be supported within a given 
organisation. Under this domain, a further six sub-constructs can 
influence implementation climate: 
1. Tension for change, degree of stakeholders’ perception of 
current situation as intolerable or needing change 
2. Compatibility, how the value of an intervention align with 
existing workflow and individuals’ own norms, value and 
perceived risks and needs 
3. Relative priority, individuals’ perception of the importance 
of the implementation 
4. Organisational incentives and rewards, such as goal-
sharing rewards, performance reviews, promotions, salary 
raise, increased stature or respect 
5. Goals and feedback, how goals are communicated, acted 
upon and fed back to staff 
6. Learning climate, does the climate allow leaders express 
their own fallibility and need for assistance and input, 
team members to feel that they are essential and valued 
in implementation, enough time and space for reflective 
thinking and evaluation 
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• Readiness for implementation: Indicators of organisation commitment 
to implementation which consists of three further sub-constructs: 
1. Leadership engagement, commitment, involvement and 
accountability of managers at any level within an 
organisation 
2. Available resources, including money, training, education, 
physical space and time 
3. Access to information and knowledge, such as from 
experts, other experienced staff, training, documentation, 
etc. 
d. Characteristics of individuals 
This domain focuses on understanding the dynamic interplay between 
individuals and the organisation within which they work and how it influences 
their behaviour change. Specifically, this construct includes: 
• Knowledge and beliefs about the intervention: Individuals’ familiarity 
with, attitudes toward and value placed on the intervention 
• Self-efficacy: Individuals’ belief in their own capabilities to perform 
tasks related to implementation 
• Individual stage of change: The degree of individuals’ skills and 
enthusiasm towards a sustained use of the intervention 
• Individual identification with organisation: Individuals’ perception of 
their organisation and their commitment to it 
• Other personal attributes: Such as tolerance of ambiguity, intellectual 
ability, motivation, competence and innovativeness. 
 
e. Process 
The implementation process can be summarised in four essential steps: 
• Planning: The degree and quality a scheme or method of behaviour 
and tasks for implementation are developed in advanced 
• Engaging: The strategies of social marketing and education used to 
attract and involve appropriate individuals in the implementation 
79 
 
• Executing: The degree to which the implementation is accomplished 
according to plan 
• Reflecting and evaluating: The feedback about the progress and quality 
of the implementation 
A summary of the five CFIR constructs is presented in Figure 2.6. 
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Figure 2.6: CFIR constructs (Damschroder et al. 2009) 
The Consolidated Framework for Implementation Research Constructs 
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2.6.5. Uses of the Consolidated Framework of Implementation 
Research 
The CFIR has many uses according to Damschroder et al. (2009): 
• To understand more what works where and why 
• To be better able to predict implementation effectiveness across 
disparate context. Moreover, it can also be used prior to 
implementation 
• To identify potential barriers and facilitators for the implementation of 
an intervention by exploring its capacity and needs from the 
perspective of the individuals and organisations involved 
• To guide exploration of what factors influenced implementation and 
how implementation influenced performance of the intervention 
• To organise and promote synthesis of research findings thus 
stimulating further theory development since it consists of clear 
definitions and terminologies 
In the current doctoral research, the CFIR was used throughout Phases 3 and 
4, including conceptualising the idea, formulating the research questions, 
developing the data generation and collection tools, and analysing and 
presenting data. 
2.6.6. Consolidated Framework of Implementation Research in 
practice 
Since development in 2009, CFIR has been used in over 350 implementation 
and evaluation studies. A comprehensive list can be found on the CFIR 
website (http://cfirguide.org/examp.html). 
A systematic review published in 2016 investigated the extent to which CFIR 
had been used in implementation research (Kirk et al. 2016). Twenty-six 
published, peer-reviewed papers were included, 15 post-implementation, 8 
during implementation and 2 pre-implementation. While it was applied for 
diverse study objectives, settings, methods (qualitative, quantitative and 
mixed methods) and units of analysis, most studies only referred to CFIR 
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during analysis. There is therefore scope to use CFIR more widely within a 
single research study to also advance implementation research. 
2.7. Quality in research 
2.7.1. Introduction 
Regardless of the theory used, there are four main criteria to assess the 
quality of research studies; truth value, applicability, consistency and 
neutrality. These terms are applied differently in qualitative and quantitative 
approaches, as shown in Table 2.20. 
Table 2.20: Quality assessment criteria in research (Noyes et al. 2011) 
Criteria Qualitative Term Quantitative Term 
Truth value Credibility Internal validity 
Applicability Transferability External validity or 
generalisability 
Consistency Dependability Reliability 
Neutrality Confirmability Objectivity 
The qualitative terms of credibility, transferability, dependability and 
confirmability are also captured under the umbrella term trustworthiness.  
2.7.2. Quality in qualitative research 
According to Noyes et al. (2011), credibility is concerned with whether or not 
the representation of data fits the views of the participants studied. 
Techniques used to assess the credibility of findings include external auditors, 
peer debriefing, attention to negative cases, independent analysis of data by 
more than one researcher, verbatim quotes, persistent observation. 
Transferability focuses on whether results can be applied to other people or 
settings. Techniques involved in assessing transferability include providing 
details of the study participants to enable readers to evaluate for which 
target groups the study provides valuable information, providing contextual 
background information, demographics, the provision of thick description 
about both the sending and the receiving context. 
Dependability is the extent to which the research process, especially the 
method, is logical and clearly documented. Thus, it is the degree to which 
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different researchers are able to produce the same data on a specific topic. 
To assess this, researchers might employ peer review, debriefing, audit trails, 
triangulation in the context of the use of different methodological approaches 
to look at the topic of research, reflexivity to keep a self-critical account of 
the research process, calculation of inter-rater agreements etc. 
Confirmability considers the extent to which findings are qualitatively 
confirmable through the analysis being grounded in the data and through 
examination of the audit trail. Techniques include assessing the effects of the 
researcher during all steps of the research process, reflexivity, providing 
background information on the researchers such as their background, 
education, perspective, and school of thought. 
2.7.3. Quality in quantitative research 
Validity refers to the accuracy of instruments, data and findings in research 
(Bernard 2013). According to Tashakkori and Teddlie (1998), internal validity 
refers to the degree of confidence in the conclusions of the research (changes 
in an outcome can be attributed to a preceding variable rather than to other 
potential causal factors). External validity refers to the degree to which the 
results can be generalised to people who were not part of the study 
undertaken (Bernard 2013).  
Reliability refers to internal consistency (whether the items’ responses are 
consistent across constructs) and test-retest correlations (are scores stable 
over time when the instrument is administered a second time) as well as 
consistency in test administration and scoring (Creswell 2014). Reliability 
refers to whether or not the same answers are generated by using the same 
instrument more than once (Bernard 2013). 
Payne and Payne (2004) define objectivity as ensuring that the researchers’ 
personality, beliefs and values do not interfere with the study, when possible. 
Thus, the findings should only depend on the nature of what was studied. 
2.7.4. Quality control measures for the doctoral research 
To ensure the quality of this project, all data generation and collection tools 
used in Phase 3 and Phase 4 as part of this doctoral project were carefully 
84 
 
designed based on the literature searched as well as the theoretical 
framework (CFIR). Moreover, the expertise of the research team was also 
utilised since they have a vast experience and numerous publications in the 
areas of qualitative and quantitative research as well as in non-medical 
prescribing development, implementation and evaluation. In addition, all data 
collection tools were also validated and piloted to ensure that they are clear, 
appropriate and comprehensive.  
In addition, careful considerations were made in the selection and 
recruitment of participants in Phase 3 and Phase 4 in order to ensure 
comprehensiveness and representation. 
When conducting both the qualitative and quantitative studies, each model of 
pharmacist prescribing was defined in order to ensure that all stakeholders 
have a unified understanding of their differences. Additionally, analysis for all 
phases was mapped to the CFIR constructs and independently reviewed by at 
least one supervisor to ensure accuracy. 
Furthermore, the final report included details on all the different aspects of 
the research such as when and how data were collected and analysed as well 
as any underpinning phenomena that might have influenced the results. 
Moreover, the researchers presented the differing views reported by 
participants on pharmacist prescribing by eliciting their knowledge and 
understandings. For example, in Phase 3, participants’ insights were stated in 
their own words to ensure accuracy and transparency in reporting findings. 
Similarly, for the Delphi study, all feedback received was shared throughout 
the rounds with the different experts and subsequently included in the final 
report to avoid introducing bias into the results. 
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2.8. Summary of methods employed in the doctoral research  
The research designs that were employed in this project are summarised in figure 2.7: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Summary of project’s methods 
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published systematic reviews on 
aspects of non-medical prescribing 
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3. Introduction to the chapter 
Many countries have implemented non-medical prescribing (NMP) and many 
others are scoping prescribing practices with a view to developing NMP. This 
chapter describes the findings of an umbrella review of aspects of NMP. As 
discussed in Chapter 2, umbrella reviews provide synthesis of the findings of 
systematic reviews (Aromataris et al. 2015). Conducting such a review 
involves examining the quality of the included systematic review but does not 
require repeating the searches, assessment of study eligibility or quality 
assessment of the included reviews. The focus is on providing an overall 
picture of findings around the umbrella review aim. 
3.1. Aim 
The aim of this umbrella review was to collate and summarise all the 
published systematic reviews on NMP in order to report aspects, including, 
but not limited to: models and definitions; legal frameworks; outcomes and 
benefits; perceptions and satisfaction of different stakeholders (e.g. general 
public, patients, health professionals and decision makers); and facilitators 
and barriers to implementing NMP. The search was conducted between March 
and November 2016.  
3.2. Methods  
3.2.1. Search strategy 
Systematic reviews meeting the above criteria and published in English were 
included in the review. The following electronic bibliographic databases were 
searched: Medline, Cumulative Index of Nursing and Allied Health Literature 
(CINAHL), Science Direct, International Pharmaceutical Abstracts and Google 
Scholar. The Cochrane Library, the Centre for Reviews and Dissemination 
(Prospero) and Joanna Briggs Institute databases were also searched to 
identify any registered systematic review protocols. The reference lists of the 
retrieved reviews were examined to locate any further reviews. 
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Table 3.1 describes the scope of the databases searched. 
 
Table 3.1: Scope of selected databases 
Database Scope 
Medline MEDLINE is the U.S. National Library of Medicine (NLM) premier 
bibliographic database. It contains references to journal articles in life 
sciences with a concentration on biomedicine and health. This is broadly 
defined to encompass those areas of the life sciences, behavioral 
sciences, chemical sciences, and bioengineering (ProQuest 2016). 
CINAHL CINAHL Database provides indexing of the top nursing and allied health 
literature available including nursing journals and publications from the 
National League for Nursing and the American Nurses Association. 
Literature covers a wide range of topics including nursing, biomedicine, 
health sciences librarianship, alternative/complementary medicine, 
consumer health and 17 allied health disciplines. 
 
In addition, CINAHL Database provides access to healthcare books, 
nursing dissertations, selected conference proceedings, standards of 
practice, audiovisuals and book chapters. It includes full-text journals, 
legal cases, clinical innovations, critical paths, research instruments and 
clinical trials (EBSCO Health 2016). 
ScienceDirect® ScienceDirect hosts over 3,800 journals and more than 35,000 books—
over 14 million peer-reviewed publications (and growing) from Elsevier. 
 
It is Elsevier’s leading information solution for researchers, teachers, 
students, healthcare professionals and information professionals. It 
combines authoritative, full-text scientific, technical and health 
publications with smart, intuitive functionality (Elsevier 2016). 
International 
Pharmaceutical 
Abstracts 
The International Pharmaceutical Abstracts (IPA) database provides 
comprehensive coverage of worldwide pharmaceutical and related 
healthcare literature and is used by professionals in every area of 
healthcare by medical librarians and researchers in the pharmaceutical 
and cosmetic industries. Topics range from drug use, adverse reactions 
and drug interactions to pharmacy practice, drug research and 
technology. The scope of topics covered ranges from clinical, practical 
and theoretical to economic and scientific (ProQuest 2016). 
Cochrane Library The Cochrane Library is a collection of six databases that contain different 
types of high-quality, independent evidence to inform healthcare 
decision-making, and a seventh database that provides information about 
Cochrane groups (Cochrane Library 2016). 
PROSPERO 
Database 
PROSPERO is an international database of prospectively registered 
systematic reviews in health and social care. PROSPERO aims to provide 
a comprehensive listing of systematic reviews registered at inception to 
help avoid unplanned duplication and enable comparison of reported 
review methods with what was planned in the protocol ( Centre for 
Reviews and Dissemination 2015). 
Joanna Briggs 
Institute Database 
of Systematic 
Reviews 
The JBI Database of Systematic Reviews and Implementation Reports is a 
refereed, online journal that publishes systematic review protocols and 
systematic reviews of healthcare research. The JBI Database of 
Systematic Reviews and Implementation Reports also publishes the 
Institute's implementation reports that present the findings of projects 
that seek to implement the best available evidence into practice (Wolters 
Kluwer 2016). 
Google Scholar Google Scholar provides a simple way to broadly search for scholarly 
literature across many disciplines and sources. It contains articles, 
theses, books, abstracts and court opinions, from academic publishers, 
professional societies, online repositories, universities and other web sites 
(Google 2016). 
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The search strategy included only terms relating to or describing NMP, with 
no limits placed on the search. Alerts were created to check for further 
reviews for inclusion while conducting the review. An example of the search 
for Medline is given in Box 3.1. 
Box 3.1. Medline search string 
("non-medical prescrib*" OR "non medical prescrib*" OR NMP OR "pharmac* prescrib*" OR 
"nurse* prescrib*" OR "midwi* prescrib*" OR "podiatrist* prescrib*" OR "chiropodist* 
prescrib*" OR "optometrist* prescrib*" OR "orthoptist* prescrib*" OR "optician* prescrib*" 
OR "physiotherapist* prescrib*" OR "physical therapist* prescrib*" OR "dieti* prescrib*" OR 
"occupational therapist* prescrib*" OR "paramedic* prescrib*" OR "radiographer* prescrib*" 
OR "respiratory therapist* prescrib*" OR "audiologist* prescrib*") AND (review) 
 
Title, abstract and full text screening and assessment for inclusion was 
conducted by one of the reviewers (TJ), with another (DS) reviewing 
independently a 10% random sample to ensure sensitivity 
(comprehensiveness of search) and specificity (precision and relevance of 
reviews retrieved). Any disagreements were resolved through discussion 
without having to consult a third reviewer. 
3.2.2. Assessment of methodological quality 
The quality of systematic reviews that met the inclusion criteria was assessed 
using the Critical Appraisal Skills Programme (CASP) tool (CASP 2016) 
(Appendix 3A). Quality assessment was conducted independently by two 
reviewers (TJ and DS or KM or SC or AA or ARP) and disagreements resolved 
through discussion without having to consult a third reviewer. 
3.2.3. Data extraction 
The characteristics of the included reviews were extracted and summarised in 
tables. Data extracted were: authors; year of publication; country/countries 
of focus; type of review; objectives; NMP definition; databases searched; 
number of articles; and major findings. As with the quality assessment, data 
extraction was undertaken independently by two reviewers. 
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3.2.4. Data synthesis 
Due to heterogeneity of reviews in terms of objectives and data, a narrative 
synthesis was most appropriate.  
3.3. Results 
Searching identified 528 studies, which was reduced to 453 after removing 
duplicates. Four hundred and five were excluded on review of titles and 
abstracts (no search strategy included or not related to NMP) leaving 48, with 
two more identified from reference lists making 50. Full-text screening 
excluded a further 26 (reasons as before). Of the remaining 24, there were 
13 non-systematic reviews, 4 were protocols leaving 7 systematic reviews for 
quality assessment, data extraction and synthesis. The PRISMA flow chart is 
provided in Figure 3.1. 
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Figure 3.1: PRISMA flow chart detailing the inclusion process 
  
Systematic reviews (n=7)  
Systematic review 
protocols (n=4)  
Other types of review 
(n=13) 
Full-text articles included 
in qualitative synthesis 
(n=24) 
Records identified 
through database 
searching 
(n=528) 
Records excluded (n=405) 
- not NMP related (n=303) 
- not a review (n=102) 
Records for screening 
(duplicates removed) 
(n=453) 
Full-text assessed for 
eligibility 
(n=48) 
Full-text excluded (n=26) 
- not NMP related (n=9) 
- not a review (n=12) 
- not in English (n=1) 
- no full text available (n=4) 
Records identified 
through reference list 
searching  
(n=2) 
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3.3.1. Quality of included studies 
The quality assessment of the seven systematic reviews is given in Table 3.2. 
Most were deemed of high quality, although one would have benefited from 
searching country specific databases and lacked quality assessment (Kroezen 
et al. 2011), and qualitative findings could have been subjected to meta-
synthesis in another (Ness et al. 2016).  
3.3.2. Characteristics and key findings of included studies 
The data extraction is given in Table 3.3. Five focused solely on nurse 
prescribing (Van Ruth et al. 2007, Kroezen et al. 2011, Darvishpour et al. 
2014, Gielen et al. 2014, Ness et al. 2016) with two  discussing all non-
medical prescribers (McIntosh et al. 2016, Weeks et al. 2016). While five 
included all studies irrespective of country or setting (Van Ruth et al. 2007, 
Darvishpour et al. 2014, Gielen et al. 2014, Ness et al. 2016, Weeks et al. 
2016), one included only those conducted in Western European and Anglo-
Saxon countries (Kroezen et al. 2011), and one was restricted to the UK 
(McIntosh et al. 2016). The number of studies reviewed ranged from three to 
124. Two reviews focused on aspects of influences on prescribing decision-
making generally (McIntosh et al. 2016) and prescribing behaviour related to 
antimicrobials (Ness et al. 2016). One reported the extent of implementation 
of nurse prescribing (Kroezen et al. 2011), one processes of prescribing and 
associated barriers and facilitators to implementation (Darvishpour et al. 
2014), with three on various patient outcome measures (Van Ruth et al. 
2007, Gielen et al. 2014, Weeks et al. 2016).  
3.3.3. Synthesis of findings 
Decision making and prescribing behaviours were reported as complex with 
many, and often conflicting, influences (McIntosh et al. 2016, Ness et al. 
2016). Of the three studies reviewed by McIntosh et al. (2016) decision-
making was not the primary aim for any. Acknowledging the paucity of 
studies and limited evidence base, key influences on decision-making 
included non-medical prescribers’ experience, evidence based guidelines and 
treatment protocols, peer support and encouragement from medical 
practitioners, and patients. Ness et al. (2016) reported similar influences on 
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decision-making in relation to antibiotic prescribing in the seven studies 
reviewed. Patient and parent pressure was noted as a key influence in both 
the decision to prescribe and which antibiotic to prescribe. These two 
systematic reviews have highlighted the need for further research on the 
decision-making processes, decisions and prescribing behaviours of non-
medical prescribers to inform NMP education, training and practice.  
Facilitators of NMP included perceived improved patient care, professional 
autonomy and potential to apply expertise while barriers included lack of 
clearly defined roles of non-medical prescribers, time for prescribing activities 
and other resource pressures such as lack of funding to support prescribing 
roles, other competing tasks, lack of confidence of some NMPs, and the lack 
of acceptance of the role by other health professionals and patients. 
(Darvishpour et al. 2014). This review was a meta-synthesis of 11 qualitative 
studies. There would be merit in updating this review to incorporate 
qualitative, quantitative and mixed methodology studies but with focus on 
how facilitators are enabled and barriers overcome. Findings would assist 
greatly the development and implementation of NMP in new settings and 
countries.  
Three systematic reviews have now been published reporting data on patient 
outcomes. (Van Ruth et al. 2007, Gielen et al. 2014, Weeks et al. 2016). 
Despite the largely positive findings on a variety of outcome measures, the 
review authors all highlighted the absence of well-designed RCTs and high 
levels of bias associated with many of the studies included in their reviews 
which often resulted in the outcomes findings being downgraded. In addition, 
the review authors noted the issue of often poor definition and description of 
‘prescribing’ and the ‘prescribing process’ within many studies, and the 
difficulty in separating NMP effects from the contributions of other members 
of the healthcare team. Review findings should therefore be interpreted with 
great caution. In 2007, Van Ruth et al. reported their review of 23 studies of 
nurse prescribing. Of the nine studies reporting clinical outcomes, there were 
no differences between nurses and GPs in terms of resolution of symptoms, 
health status rating, and clinical improvement over two weeks. These studies 
included ‘various’ patients, those presenting acutely with sore throats, need 
for contraception and the chronic condition of diabetes mellitus hence limiting 
94 
 
the opportunity for data pooling. In 2014, Gielen et al. reported a systematic 
review of 35 studies of nurse prescribing. Of the 13 studies reporting clinical 
outcomes, there were no differences between nurse and physician prescribing 
in a variety of conditions including diabetes, hypertension, asthma, sore 
throat and contraception. The heterogeneity of patient populations and 
outcome measures limited the potential for any data pooling. Very recently, 
Weeks et al. (2016) reported a Cochrane review of 46 studies (26 nurse and 
20 pharmacist prescribers) of clinical, patient-reported, and resource use 
outcomes of NMP for managing acute and chronic health conditions in 
primary and secondary care settings compared with medical prescribing. A 
meta-analysis of outcome measures of chronic disease showed positive 
intervention group effects. There was a moderate-certainty of evidence for 
studies of blood pressure at 12 months (12 studies, 4229 participants) and 
low-density lipoprotein (7 studies, 1469 participants). Patients were generally 
satisfied with non-medical prescriber care (14 studies, 7514 participants). A 
wide variety of resource use measures were reported across studies with little 
difference between groups for hospitalisations, emergency department visits, 
and outpatient visits. The authors concluded that there remains a need for 
well designed, conducted and reported randomised controlled trials of NMP 
compared to medical prescribing. However, as NMP is implemented 
increasingly into practice, there may be less desire from policy makers, 
healthcare leaders and funders to support such studies, preferring instead 
robust, rigorous evaluation of real life practice. 
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Table 3.2: Quality assessment of the seven systematic reviews (CASP 2016) 
 
 
Authors 
(Year) 
Are the results of the review valid? What are the results? Will the results help 
locally? 
Review 
addressed 
a clearly 
focused 
issue  
Search 
relevant 
Important 
and 
relevant 
studies 
included 
Rigorous 
assessment 
of quality of 
included 
studies 
Reasonable to 
combine 
results of 
review 
Overall 
results of 
review 
Precision of 
results 
appropriate 
Applicable 
to local 
population 
All 
important 
outcomes 
considered 
Van Ruth et 
al. (2007) 
Yes Yes Yes Yes 
 
Yes, pooled if 
homogenous 
(for one review 
question)  but 
noted high risk 
of bias in some 
studies 
Very clear 
presentation 
of results 
according to 
aim  
Yes (pooled 
data) 
N/A Yes 
Kroezen et al. 
(2011) 
Yes Partially 
(peer 
reviewed 
literature 
less 
appropriate 
for some 
questions, 
e.g. extent 
of legal, 
educational 
conditions)  
Partially No explicit 
coverage of 
quality 
assessment 
N/A as no 
meta-analysis 
or meta-
synthesis 
Very clear 
presentation 
of results 
according to 
aim 
N/A as no 
pooling  
N/A Yes 
Gielen et al. 
(2014) 
Yes Yes Yes Yes Yes, pooled if 
homogenous 
but noted high 
risk of bias in 
some studies 
Very clear 
presentation 
of results 
according to 
aim 
Yes (pooled 
data) 
N/A Yes 
Darvishpour 
et al. (2014) 
Yes Yes Yes Yes Yes, qualitative 
meta-synthesis 
Very clear 
presentation 
of results 
N/A for 
meta-
synthesis 
N/A Yes 
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according to 
aim 
McIntosh et 
al. (2016) 
Yes Yes Yes Yes Yes, qualitative 
meta-synthesis 
Very clear 
presentation 
of results 
according to 
aim 
N/A for 
meta-
synthesis 
N/A Yes 
Ness et al. 
(2016) 
Yes Yes Yes Yes No meta-
synthesis of 
qualitative 
studies given  
Very clear 
presentation 
of results 
according to 
aim 
N/A for 
meta-
synthesis 
(although 
not 
conducted) 
N/A Yes 
Weeks et al. 
(2016) 
Yes Yes Yes Yes 
 
Yes, pooled if 
homogenous 
but noted high 
risk of bias in 
some studies 
Very clear 
presentation 
of results 
according to 
aim  
Yes (pooled 
data) 
N/A Yes 
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Table 3.3: Data extraction of seven systematic reviews 
Authors 
(Year) 
Aims/ Objective(s) Country NMP  Databases searched and 
search terms used 
Number 
of 
articles  
Findings 
Van Ruth et 
al. (2007) 
Aimed to review the effects of 
medication being prescribed by 
nurses. 
 
The following research questions 
were addressed: what are the 
effects of nurse prescribing 
compared to physician 
prescribing, on the quantity and 
types of medication being 
prescribed?; what are the effects 
of nurse prescribing on patient 
outcomes?; what are the effects 
of nurse prescribing on physician 
and nurse outcomes?; what are 
the effects of nurse prescribing 
on characteristics of the health 
care system? 
Review of 
all studies, 
irrespective 
of country 
Nurse 
prescribing 
Pubmed, Embase, CINAHL, 
Cochrane Library, Picarta, SCI, 
Invert, Biomed central, Virginia 
Henderson Library, Current 
Control Trials, NIVEL catalog, UK 
Department of Health, World 
Health Organisation, Nurse 
Prescriber website, Google 
 
For Pubmed, the following search 
terms were used: (“Nurse 
prescribing”) OR (Nurs* [tiab] 
AND Prescri* [tiab]) 
OR (Nurs* AND prescriptions, 
drug [MeSH]) 
23 Nurses sometimes differed 
from physicians in the 
number of patients they 
prescribe for and in the 
choice of type of 
medication. 
Clinical parameters were 
the same or better for 
treatment by nurses 
compared to physicians 
across a range of 
conditions (diabetes and 
‘various’) 
Perceived quality of care 
by nurses was similar or 
better. 
The effects on 
professionals or on the 
health care system could 
not be described. 
Kroezen et 
al. (2011) 
Aimed to gain insight into the 
scientific and professional 
literature describing the extent to 
and the ways in which nurse 
prescribing has been realised or 
is being introduced in Western 
European and Anglo-Saxon 
countries.  
 
 
Western 
European 
and Anglo-
Saxon 
countries 
Nurse 
prescribing 
PubMed, Embase, CINAHL, Web 
of Science, EBSCO, NIVEL, 
Virginia Henderson International 
Nursing Library, WHO website, 
Health professionals’ website, 
Google scholar. 
 
 
 
124 Seven countries had 
implemented nurse 
prescribing of medicines. 
The Netherlands and Spain 
were in the process of 
introducing nurse 
prescribing. 
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Secondly, to identify possible 
mechanisms underlying the 
introduction and organisation of 
nurse prescribing on the basis of 
Abbott’s theory on the division of 
professional labour. 
The following keywords were 
used: “nurse prescribing”, 
“independent (nurse) 
prescribing”, “autonomous 
prescribing”, “supplementary 
(nurse) prescribing”, “dependent 
(nurse) prescribing”, 
“collaborative prescribing”, 
“group protocols” “patient group 
directions”, “time and dose 
prescribing”, “nurse formulary” 
A diversity of external and 
internal forces had led to 
the introduction of nurse 
prescribing internationally. 
The legal, educational and 
organisational conditions 
under which nurses 
prescribe medicines varied 
considerably between 
countries; from situations 
where nurses prescribed 
independently to situations 
in which prescribing by 
nurses was only allowed 
under strict conditions and 
supervision of physicians. 
Darvishpour 
et al. (2014) 
Aimed to obtain new insights on 
nurse prescribing drugs, and to 
present a schematic model of 
Nurse prescribing that could be a 
useful framework for its 
implementation.  
The following research questions 
were addressed: what is the 
overall view on nurse 
prescribing?; what are the 
positive and negative outcomes 
of nurse prescribing?; what are 
the barriers and facilitators for its 
implementation? 
Review of 
all studies, 
irrespective 
of country 
Nurse 
prescribing 
Integrated Digital National 
Library of Medicine, CINAHL, 
Medline, Cochrane Library, 
Scopus, Web of science, Elsevier, 
Emelard, JAMA journals, Wiley, 
Oxford journals, Springer and 
Thieme journals, WHO website, -
Nurse prescriber website, Google 
scholar, Cambridge journals 
website 
 
The following were used: review 
AND nurs* prescri*. 
11 Studies revealed eight 
themes namely: leading 
countries in prescribing, 
views, features, 
infrastructures, benefits, 
disadvantages, facilitators 
and barriers of nursing 
prescribing. 
Despite the positive view 
on nurse prescribing, there 
were still issues such as 
legal, administrative, weak 
research and educational 
deficiencies in academic 
preparation of nurses. 
Gielen et al. 
(2014) 
 
 
Aimed to identify, appraise and 
synthesise the evidence 
presented in the literature on the 
effectiveness of nurse prescribing 
compared to physician 
prescribing. 
Review of 
all studies, 
irrespective 
of country 
Nurse 
prescribing 
BioMed Central, CINAHL, 
Cochrane Database of 
Systematic Reviews, Current 
Controlled Trials, Embase, 
INVERT (Dutch nursing literature 
index), NIVEL catalogue, PiCarta 
(Dutch library system), PubMed, 
35 Nurses prescribed in 
comparable ways to 
physicians. They 
prescribed for equal 
numbers of patients and 
prescribe comparable 
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The following research questions 
were addressed: what are the 
effects of nurse prescribing on 
the quantity and types of 
medication being prescribed?; 
what are the effects of nurse 
prescribing on patient outcomes?  
Science Citation Index and the 
Virginia Henderson International 
Nursing Library, and the website 
of the UK Department of Health, 
the website of the World Health 
Organisation, a website for 
health professionals and Google 
Scholar  
 
For Pubmed: 
(“Nurse prescribing”) OR (Nurs* 
[tiab] AND Prescri* [tiab]) OR 
(Nurs* AND prescriptions, drug 
[MeSH]) 
 
types and doses of 
medicines.  
Studies comparing the 
total amount of medication 
prescribed by nurses and 
doctors show mixed 
results.  
There appeared to be few 
differences between nurses 
and physicians in patient 
health outcomes: clinical 
parameters were the same 
or better for treatment by 
nurses, perceived quality 
of care was similar or 
better and patients treated 
by nurses were just as 
satisfied or more satisfied. 
McIntosh et 
al. (2016) 
To critically appraise, synthesise 
and present evidence on the 
influences on prescribing 
decision-making among 
supplementary and independent 
non-medical prescribers in the 
UK. 
UK All non-
medical 
prescribers  
Medline, PsycARTICLES, CINAHL, 
International Pharmaceutical 
Abstracts, Education Resources 
Information Centre, Cochrane 
Library, Google Scholar, 
reference lists 
 
 
The following search terms were 
used: prescrib* and 
(pharmacist* or nurse* or 
physiotherapist* or podiatrist* or 
radiographer* or optometrist*) 
and (influenc* or decision* or 
decid* or judge* or factor*) 
3 While all studies reported 
aspects of prescribing 
decision-making, this was 
not the primary research 
aim for any. 
Studies were carried out in 
primary care almost 
exclusively among nurse 
prescribers (n = 67). 
Complex influences were 
evident such as experience 
in the role, the use of 
evidence-based guidelines 
and peer support and 
encouragement from 
doctors; these helped 
participants to feel more 
knowledgeable and 
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confident about their 
prescribing decisions. 
Opposing influences 
included prioritisation of 
experience and concern 
about complications over 
evidence base, and peer 
conflict. 
Ness et al. 
(2016) 
To present the findings of a 
systematic review which explored 
the influences on the 
antimicrobial prescribing 
behaviour of independent nurse 
prescribers. 
Review of 
all studies, 
irrespective 
of country 
Independent 
nurse 
prescribing 
Medline, CINAHL, AMED, 
HealthSource Nursing/Academic 
Edition, Proquest Health, 
Internurse, Cochrane Database, 
Web of Knowledge, Index to 
Thesis, ETHOS, reference lists 
 
Search terms included: 
Prescri* AND Antibiotic OR 
antimicrobial OR antibacterial 
AND Nurs* 
7 Three articles expected 
that an antimicrobial would 
be given and therefore 
influences discussed were 
on the choice of the 
antimicrobial. 
Guidelines/protocols, 
safety, tolerability and 
efficacy of the 
antimicrobial itself, 
patient/parent pressure 
and training/experience 
were mentioned as 
influencing factors within 
the reported studies. 
The other four studies 
explored influences on 
whether to prescribe an 
antimicrobial or not and 
also found that 
guidelines/protocols were 
an influencing factor, 
however, the influence 
occurring most frequently 
was diagnostic uncertainty. 
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Weeks et al. 
(2016) 
To assess clinical, patient-
reported, and resource use 
outcomes of non-medical 
prescribing for managing acute 
and chronic health conditions in 
primary and secondary care 
settings compared with medical 
prescribing (usual care). 
Review of 
all studies, 
irrespective 
of country 
Healthcare 
providers 
who were 
not medical 
doctors, 
undertaking 
prescribing 
including, 
nurses, 
optometrist, 
pharmacists, 
physician 
assistants, 
and other 
allied health 
professionals 
or categories 
not 
specifically 
mentioned 
whose roles 
met the 
definition of 
non-medical 
prescribing 
Cochrane Database, DARE, HTA, 
Medline, Embase, PsycINFO, 
CINAHL. grey literature, trial 
registries 
 
 
46 A meta-analysis of 
surrogate markers of 
chronic disease (systolic 
blood pressure, glycated 
haemoglobin, and low-
density lipoprotein) 
showed positive 
intervention group effects. 
While there appeared little 
difference in medication 
adherence across studies, 
a meta-analysis of 
continuous outcome data 
from four studies showed 
an effect favouring patient 
adherence in the non-
medical prescribing group. 
Patients were generally 
satisfied with non-medical 
prescriber care. 
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3.4. Discussion 
3.4.1. Summary of key findings 
The review identified seven systematic reviews of influences on prescribing 
decision-making, processes of prescribing, and barriers and facilitators to 
implementation. Decision making was reported as complex with many, and 
often conflicting, influences (McIntosh et al. 2016, Ness et al. 2016). 
Facilitators of NMP included perceived improved patient care and professional 
autonomy, while barriers included lack of defined roles and resource 
pressures (Darvishpour et al. 2014). Three systematic reviews explored 
patient outcomes that were noted to be equivalent or better to physician 
prescribing (Van Ruth et al. 2007, Gielen et al. 2014, Weeks et al. 2016). 
Despite positive findings, authors highlighted high bias, poor definition and 
description of ‘prescribing’ and the ‘prescribing process’ and difficulty in 
separating NMP effects from the contributions of other healthcare team 
members.  
3.4.2. Strengths and weaknesses 
This umbrella review is the first published review to collate all the published 
systematic reviews around NMP globally. It provides a comprehensive 
description of the different aspects of NMP hence assists in identifying gaps in 
the evidence base. Furthermore, the quality of included systematic reviews 
was deemed of high quality thus strengthening the validity of the conclusion 
derived from this umbrella review. The umbrella review is limited only by the 
number of published systematic reviews. 
3.4.3. Systematic reviews published since November 2016 
Since completion of this systematic review in November 2016, five additional 
systematic reviews have been published hence add to the evidence base 
around aspects of non-medical prescribing. Data extraction from these 
reviews is presented in the Table 3.4, illustrating the varied focus in terms of 
non-medical prescribers targeted, countries and specific review aims. 
 
103 
 
Table 3.4: Data extraction of five systematic reviews published after November 2016 
Authors 
(Year) 
Aims/ Objective(s) Country NMP  Databases searched and 
search terms used 
Number of 
articles  
Findings 
Abuzour, 
Lewis and 
Tully (2017) 
To explore whether the theory of 
expertise development model is 
applicable to non-medical 
independent prescribing and to 
assess the factors underpinning 
expertise development reported 
in the literature. 
UK Pharmacist 
and nurse 
independent 
prescribing 
EMBASE, Medline, AMED, 
CINAHL, IPA and PsychInfo 
were searched for articles 
published between 2006 and 
2016. 
 
 
Search terms included 
nonmedical prescribe*/non 
medical prescribe*, 
independent prescrib*, nurs* 
independent prescrib*, 
pharmac* independent 
prescrib*, education, 
curriculum, courses, training, 
clinical competen*, 
competen*, diagnos*, 
assess*. 
34 Knowledge, pre-
registration education, 
experience, support and 
confidence were intrinsic 
and extrinsic influences. 
Difficulty in transferring 
theory to practice was 
attributed to lack of basic 
pharmacology and 
bioscience content in pre-
registration nursing rather 
than the prescribing 
programme. 
Students considered 
interventions using virtual 
learning or learning in 
practice most useful. 
 
IPs were able to develop 
their expertise when 
integrating their 
competencies in a 
workplace context with 
support from colleagues. 
Cleary et al. 
(2017) 
To identify and summarise 
qualitative research that focused 
on mental health nurse 
prescribing, synthesise findings, 
and outline key themes 
discerned 
UK Nurse 
prescribing 
PubMed, Excerpta Medica, 
(Embase), Cumulative 
Index to Nursing and Allied 
Health Literature, Scopus, 
PsycINFO and reference lists. 
 
 
 
12 Three themes emerged 
from the review: (i) 
patient-centred care; (ii) 
professional role; and (iii) 
professional support. 
Nurse prescribers 
embraced a patient-
centred approach, 
providing timely and 
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Boolean operators and/or 
were used to combine search 
terms, including qualitative 
research, nursing, nurse*, 
psychiatric nursing, nurse 
prescrib*, and mental health. 
effective medication 
management. 
Adequate education and 
continuing professional 
development inclusive of 
clinical supervision enable 
competency development 
in nurse prescribing, 
supportive professional 
relationships, and patient 
safety. 
Noblet et al. 
(2017) 
The review question was, what 
are the factors that affect the 
implementation or utilisation of 
independent non-medical 
prescribing (iNMP)? 
Review of 
all studies, 
irrespective 
of country 
Independent 
non-medical 
prescribing 
Databases (CINAHL, EMBASE, 
MEDLINE, AMED, NICE, 
Medicines Complete, HMIC, 
ASSIA, Web of Science, 
Health and Safety Science 
Abstracts), Internet sites 
(PUBMED, Turning Research 
into Practice, Google Scholar, 
Royal College of Nursing, 
Royal Pharmaceutical 
Society, King’s Fund, National 
Institute of Clinical 
Excellence, Department of 
Health, National Prescribing 
Centre, Chartered Society of 
Physiotherapy, Society of 
Chiropodists and Podiatrists, 
American Association of 
Nurse Practitioners, 
Australian College of Nurse 
Practitioners, Canadian 
Pharmacists Association, 
Optometry Australia, British 
Optometry Association), 
National Research Register, 
Hand searching of key 
journals, System for 
Information on Grey 
43 
qualitative 
and seven 
quantitative 
studies 
Qualitative data were 
synthesised into four 
themes (and subthemes): 
systems (government and 
political, organisational, 
formulary); education and 
support (non-medical 
prescribing (NMP) 
courses/continuous 
professional development 
(CPD)); personal and 
professional (medical 
profession, NMP 
professions, service 
users); and financial 
factors. 
Quantitative data 
corroborated the 
qualitative themes. 
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Literature, unpublished 
research, Expert opinion, 
Reference lists of all included 
papers 
 
The search terms developed 
in MEDLINE are presented in 
Appendix 1. 
Noblet et al. 
(2018) 
To evaluate the clinical and cost-
effectiveness of non-medical 
prescribing (NMP). 
Review of 
all studies, 
irrespective 
of country 
Non-medical 
prescribing 
CINAHL, EMBASE, MEDLINE, 
AMED, NHS Economic 
Evaluation database, NICE, 
Medicines Complete Cochrane 
Central Register of Controlled 
Trials), Selected internet sites 
(PUBMED, Turning Research 
into Practice, Current 
Controlled Trials website 
(York), Google Scholar, the 
Royal college of Nursing, 
Royal Pharmaceutical 
Society, King’s Fund, National 
Institute of Clinical 
Excellence, Department of 
Health, National prescribing 
Centre, Chartered Society of 
Physiotherapy, Society of 
Chiropodists and Podiatrists, 
American Association of 
Nurse Practitioners, 
Australian College of Nurse 
Practitioners, Canadian 
Pharmacists Association, 
Optometry Australia, British 
Optometry Association), 
National Research Register, 
Expert Opinion, Hand 
searches- key journals 
 
Full electronic search strategy 
for Medline OvidSP was 
presented in the paper. 
3 RCTs Participants demonstrated 
significant improvement in 
outcomes when receiving 
NMP compared to 
treatment as usual (TAU) 
in all RCTs. 
An associated cost analysis 
showed NMP to be more 
expensive than TAU 
(regression coefficient p = 
0.0000), however 
experimental groups 
generated increased QALYs 
compared to TAU. 
106 
 
Tabesh et al. 
(2018) 
To examine the effectiveness of 
nurse-led clinics, in which nurses 
were involved in prescribing, on 
haemoglobin A1c (HbA1c) among 
people with type 2 diabetes. 
Review of 
all studies, 
irrespective 
of country 
Nurse 
prescribing 
Medline, the Cochrane 
Central Register of Controlled 
Trials (CENTRAL), EMBASE 
and Allied Health Literature 
database guide (CINAHL) and 
reference lists. 
 
The literature search strategy 
involved Medical Subject 
Heading (MESH) and text 
words that include “diabetes” 
and “nurse” or “nursing 
practitioners” and “trials”. 
9 RCTs In the five RCTs in which 
nurse prescribers 
supplemented a team, 
there was no significant 
difference in change of 
HbA1c compared to usual 
care (-0.34 percentage 
points; 95% CI: −0.71, 
0.02). 
In the four RCTs in which 
nurses replaced doctors, 
the outcomes of nurse 
prescribers were 
comparable to those of 
doctors. 
No data on adverse events 
were available. 
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The findings of these systematic reviews augment those of the umbrella 
review, further expanding the evidence base particularly in relation to 
education, implementation and impact on specific outcomes. Given that the 
umbrella review identified only three systematic reviews reporting patient 
outcomes (Van Ruth et al. 2007, Gielen et al. 2014, Weeks et al. 2016), 
these additional outcomes based systematic reviews are worthy of further 
consideration. While Noblet et al. sought to review the clinical and cost-
effectiveness of NMP, only three studies were identified (Noblet et al. 2018). 
Of these, one was rated as high bias and one unclear and one was of poor 
quality, hence the findings given in Table 3.4 should be interpreted with 
caution. Tabesh et al. (2018) aimed to review the impact of nurse prescribing 
on glycaemic outcomes in patients with Type 2 diabetes mellitus. All nine 
studies had a medium degree of bias. Of the five in which the nurse 
prescribers worked alongside physicians (prescribing models not clearly 
defined), there was no significant difference in outcomes. In the remaining 
four studies in which the nurse prescribers replaced the physicians (again 
model not clearly described), outcomes were comparable.  
3.5. Conclusion 
This umbrella review (together with the findings of systematic reviews since 
completion and publication of the umbrella review) has identified an 
accumulation of evidence of aspects of non-medical prescribing. While the 
studies included within the reviews are not all of the highest quality, there is 
evidence of successful implementation and merging evidence of outcomes. It 
is, however, important for future studies to clearly define ‘prescribing’, 
models of prescribing, associated training and scope of practice.  
3.6. Implications for next phase 
To date, no published systematic review has synthesised studies on 
stakeholders’ views and experiences of non-medical prescribing either pre- or 
post-implementation. Given that the primary doctoral research will focus on 
pharmacist prescribing in Qatar, such a systematic review on pharmacist 
prescribing would be beneficial.  
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Chapter 4:  
Stakeholders’ Views and 
Experiences of Pharmacist 
Prescribing: A Systematic Review 
 
  
Phase 1 Phase 2 Phase 3 Phase 4
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4. Introduction to the chapter 
The findings of the umbrella review presented in Chapter 3 provided evidence 
of effectiveness and safety of non-medical prescribers, including pharmacists. 
There is, however, a gap in relation to synthesised evidence on the views and 
experiences of key stakeholders. Evidence may facilitate the development 
and implementation of pharmacist prescribing in those countries where 
prescribing is not yet within legal or practice frameworks. This chapter 
provides the aim, method, findings and conclusion of such a systematic 
review.  
4.1. Aim 
The aim of this systematic review was to critically appraise, synthesise, and 
present the available evidence on the views and experiences of stakeholders 
on pharmacist prescribing, including potential facilitators and barriers, 
regardless of implementation status. 
4.2. Methods 
A systematic review protocol was developed, in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses Protocol 
(PRISMA-P) standards, and registered on International Prospective Register 
of Systematic Reviews (PROSPERO) at the Centre for Reviews and 
Dissemination in the UK (CRD42016048072) (Jebara et al. 2016) as shown in 
Appendices 4A and 4B respectively. 
4.2.1. Inclusion criteria 
Studies reporting views and/or experiences of any stakeholder group (e.g. 
patients, general public, physicians, nurses, pharmacists) pertaining to 
pharmacist prescribing, irrespective of the stage of implementation (pre or 
post), model of prescribing (e.g. supplementary, independent or 
collaborative), with no date or language limit up to November 2017, were 
included in this systematic review. All peer-reviewed, primary research 
studies were included, while literature reviews, narrative reports, and 
editorials were excluded. The inclusion process was performed by TJ and 
reviewed by DS. 
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4.2.2. Search strategy 
The search string applied to Medline is given in Box 4.1; and adapted for 
Cumulative Index to Nursing and Allied Health Literature (CINAHL), 
International Pharmaceutical Abstracts (IPA), PsychArticles, and Google 
Scholar. The reference lists of all identified articles in the full text screening 
were searched manually for potentially eligible studies meeting the review 
criteria. 
Box 4.1: Search string applied to Medline (title, abstract, keywords, subject 
heading) 
((view* OR perspective* OR perception* OR opinion* OR attitude* OR belief* OR thought* 
OR feel* OR impress* OR stance* OR viewpoint* OR standpoint* OR position* OR support* 
OR concern* OR confiden* OR expect*) 
OR 
(experience* OR satisf* OR reflect* OR react* OR content* OR understand* OR encounter* 
OR evaluat* OR feedback)) 
AND 
"pharmacist* prescrib*" 
 
The scope of the databases searched (Medline, CINAHL, IPA and Google 
Scholar) was discussed previously in Chapter 3. Table 4.1 describes the 
scope of the additional database searched: 
Table 4.1: Major area of focus of searched databases 
Database Major area of focus 
PsychArticles PsychArticles includes more than 180,000 full-text articles from more than 
100 journals as well as the American Psychological Association, Canadian 
Psychological Association and Hogrefe Publishing Group scholarly journals. 
It covers the full spectrum of research in the area of psychology and 
behavior from preeminent scholars to the historical underpinnings of the 
behavioural and social sciences (American Psychological Association 2016). 
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4.2.3. Assessment of methodological quality 
Quality assessment was conducted independently by two reviewers (TJ and 
one of either DS, KM, SC, AA, ARP) using the Mixed Methods Appraisal Tool 
(MMAT) (Pluye et al. 2011), which permits the appraisal of qualitative, 
quantitative, and mixed methods studies (Appendix 4C). Consensus was 
reached through discussion or by a consultation with a third reviewer. The 
MMAT was developed based on a theory, a literature review, workshops as 
well as consultations with experts, followed by testing for content validity, 
efficiency and reliability. The different criteria in the MMAT allow researchers 
aiming to conduct a mixed methods systematic review to critical appraise 
studies with diverse designs including qualitative, quantitative and mixed 
methods. Thus, it overcomes the difficulties associated with using different 
critical appraisal tools for the different designs (Pluye and Hong 2014). Since 
the current systematic review was likely to include different study designs, 
the latest version (2011) of the MMAT was chosen to assess methodological 
quality. 
4.2.4. Data extraction 
Data extraction was performed by two independent reviewers, with a third 
included if any disagreement occurs. Data items extracted were: stated 
aim/objective, phase of implementation (pre vs post), country of focus, 
model of prescribing, stakeholder group, study design, and key findings. 
4.2.5. Data synthesis 
Due to heterogeneity of phase of implementation, models of prescribing, 
study designs, and variability of data collection tools, a meta-analysis 
approach of quantitative findings was not possible. Hence, a narrative 
approach to data synthesis was applied. Pooling of qualitative research 
findings involved the aggregation or synthesis of findings to generate a set of 
statements that represented that aggregation, through assembling and 
categorising findings based on similarity in meaning.  
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4.3. Results 
The electronic search yielded 331 studies. Removal of duplicates resulted in 
273 articles, 226 of which were excluded based on title, abstract, or full-text 
review. An additional 18 studies were identified from other sources (e.g. 
reference lists) resulting in 65 eligible studies for quality assessment and 
data extraction. The Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) flow chart is provided in Figure 4.1. 
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*PP: Pharmacist Prescribing 
 
 
Figure 4.1: PRISMA flow chart detailing the inclusion process 
  
 
Additional records (n = 18) 
- Google Scholar (n = 3) 
- Reference list (n = 10) 
- Alerts (n = 5) 
Records excluded (n = 195) 
- Not related to PP* (n = 36) 
- Not related to views or 
experiences around PP* (n = 88) 
- Not primary literature (n = 71) 
Full-text articles assessed for 
eligibility  
(n = 78) Full-text articles excluded (n = 31) 
- No full text could be accessed 
even through interlibrary loan 
service  
(n = 19) 
- Did not discuss PP* (n = 5) 
- Not related to views or 
experiences around PP* (n = 7) 
Records identified through 
database searches  
(n = 331) 
Records after duplicates 
removed  
(n = 273) 
Record titles and abstracts 
screened  
(n = 273) 
Studies included in synthesis  
(n = 65) 
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4.3.1. Quality of included studies 
Most studies employed quantitative designs, largely questionnaire-based 
survey methodology (n=41) (Pennock et al. 1988, Segal and Grines 1988, 
Spencer and Edwards 1992, White-Means and Okunade 1992, Erwin, Britten 
and Jones 1996, Child, Hirsch and Berry 1998, Child and Cantrill 1999, Child 
2001, George et al. 2006a, George et al. 2006b, Hobson and Sewell 2006a, 
Hobson and Sewell 2006b, Kay, Bajorek and Brien 2006, Smalley 2006, 
George et al. 2007, Nguyen and Bajorek 2008, Stewart et al. 2008, Weeks 
and Marriott 2008, Stewart et al. 2009a, Hoti et al. 2010, McCann et al. 
2011, McIntosh et al. 2011, Perepelkin 2011, Stewart et al. 2011, Hutchison 
et al. 2012, Erhun, Osigbesan and Awogbemi 2013, Hoti, Hughes and 
Sunderland 2013, MacLure et al. 2013, Tinelli et al. 2013, Auta et al. 2014, 
Hill et al. 2014, Moore, Kennedy and McCarthy 2014, Mansell et al. 2015, 
Bourne et al. 2016, Hale et al. 2016, Ung et al. 2016, Khan et al. 2017, Auta 
et al. 2018, Isenor et al. 2018), with fewer qualitative designs (n=21) (Eng, 
McCormick and Kimberlin 1990, Lloyd and Hughes 2007, Tully et al. 2007, 
Blenkinsopp et al. 2008, Stewart et al. 2009b, Weiss and Sutton 2009, 
Hobson, Scott and Sutton 2010, Lloyd, Parsons and Hughes 2010, Tonna et 
al. 2010, Weeks, Marriott and George 2010, Dawoud et al. 2011, Hoti, 
Hughes and Sunderland 2011, McCann et al. 2012a, McCann et al. 2012b, 
Hatah et al. 2013, Makowsky et al. 2013, Pojskic et al. 2014, Bajorek et al. 
2015, Deslandes, John and Deslandes 2015, Auta, Strickland-Hodge and Maz 
2016, Feehan et al. 2016, McIntosh and Stewart 2016, Le, Braunack-Mayer 
and Laurence 2017). The remaining three studies were sequential 
explanatory mixed methods studies all with survey followed by either focus 
group discussions (Hanes and Bajorek 2005, Baqir 2010) or interviews 
(Vracar and Bajorek 2008). Quality assessments given in Figure 4.2 highlight 
the largely robust and rigorous nature of the studies reviewed.  
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Figure 4.2: Cumulative quality assessment of the 65 studies, grouped according to study design 
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The key limitations of the survey studies were the lack of details around 
sampling strategies and the stages of questionnaire development, review, 
and piloting. Only 14 studies had achieved the MMAT target response rate of 
60% (Segal and Grines 1988, Eng, McCormick and Kimberlin 1990, Spencer 
and Edwards 1992, George et al. 2006a, Hobson and Sewell 2006a, Hobson 
and Sewell 2006b, Smalley 2006, George et al. 2007, McCann et al. 2011, 
Hutchison et al. 2012, Auta et al. 2014, Mansell et al. 2015, Hale et al. 2016, 
Khan et al. 2017). Qualitative studies lacked details of approaches to 
ensuring data trustworthiness and the mixed methods studies provided 
limited information on integrating quantitative and qualitative data. Based on 
the MMAT assessments, all 65 studies were included in the stages of data 
extraction and synthesis.  
4.3.2. Characteristics and key findings of included studies 
The extracted data are summarised in Tables 4.2, 4.3 and 4.4 for the 
quantitative, qualitative, and mixed methods studies respectively. 
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Table 4.2: Characteristics and key findings of included quantitative studies (n=41) 
Author 
(Year of 
publication) 
Aim(s)/Objective(s) Definition and 
model of PP 
discussed 
Country 
of focus 
Stakeholder 
population 
studied (sample 
size) 
Study design 
and methods 
Key findings 
Pre-implementation of pharmacist prescribing 
Pennock et 
al. (1988)  
Explore to what extent will pharmacist 
prescribing be accepted by consumers  
No standardised 
definition 
provided 
USA  Consumers 
(n=400, response 
rate (RR) 53%) 
Questionnaire Consumers’ relationships with 
pharmacists is important in 
determining acceptance of 
prescribing role. 
Segal and 
Grines 
(1988)  
Identify attitudes of organised 
pharmacy, organised medicine and 
pharmaceutical industry about 
prescribing authority for pharmacists 
Models of PP in 
each US state 
presented 
USA Different pharmacy 
and medical 
associations and 
boards, 
Pharmaceutical 
Manufacturers 
Association (PMA), 
manufacturers and 
non-PMA-member 
generic 
manufacturers 
(n=307, RR 63%) 
Questionnaire Hospital pharmacy 
associations/boards to a lesser 
extent in support; non-PMA-
member generic 
manufacturers/US state 
pharmacy associations 
relatively neutral. Medical 
associations/PMA-member 
companies in opposition.  
Spencer and 
Edwards 
(1992)  
Ascertain GPs’ attitudes to an extended 
role for community pharmacists 
No standardised 
definition 
provided 
UK  Doctors (n=1087, 
RR 68.4%) 
Questionnaire Pharmacists are too influenced 
by commercial pressures, 
should stick to dispensing and 
not supervise repeat 
prescriptions. However, GPs 
supported pharmacists 
prescribing nicotine chewing 
gum.  
Child, Hirsch 
and Berry 
(1998)  
Identify the attitudes of hospital-based 
healthcare professionals involved in 
drug therapy towards prescription 
writing and initiation of drug treatment 
(“prescribing”) by the pharmacist, 
explore the perceived barriers to PP, 
and to examine the potential future 
role of the pharmacist in drug therapy 
management 
No standardised 
definition 
provided 
UK  Doctors (n=195, 
RR 48.7%), nurses 
(n=200, RR 
57.5%), 
pharmacists 
(n=87, 77%) 
Questionnaire Postgraduate 
education/training and 
attachment to clinical area are 
important requirements for PP. 
Barriers are pharmacists’ 
willingness to accept this role, 
education/training and 
accountability. 
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Child and 
Cantrill 
(1999)  
Examine the reasons behind hospital 
doctors’ perceived barriers to PP in the 
UK 
No standardised 
definition 
provided 
UK Hospital doctors 
(n=193, RR 49%) 
Questionnaire Awareness of clinical and 
patient details, communication, 
doctor writing initial 
prescription, clinical 
responsibility and review of 
treatment were reported. 
Child (2001)  Examine hospital nurses' perceptions of 
PP in the UK 
No standardised 
definition 
provided 
UK  Nurses at five NHS 
teaching hospitals 
(n=200, RR 
57.5%) 
Questionnaire Pharmacists’ knowledge, review 
of treatment, pharmacists' 
workload, communication and 
accountability issues were 
discussed. 
George et al. 
(2006b)  
Investigate community pharmacists’ 
awareness, views and attitudes relating 
to IP by community pharmacists and 
their perceptions of competence and 
training needs for the management of 
some common conditions 
Provided 
definition of UK 
models 
UK  Community 
pharmacists 
(n=500, RR 
43.4%) 
Questionnaire Confidence in abilities to IP, 
training, consultation skills and 
communication were 
highlighted. Facilitators include 
practising more hours/week as 
a pharmacist, training, and 
involvement in Scottish 
Executive pharmaceutical care 
model schemes. 
Kay, Bajorek 
and Brien 
(2006)  
Identify Australian pharmacists’ 
awareness of their international 
colleagues’ prescribing practices and 
explore their views about the feasibility 
and utility of PP privileges within the 
scope of their current practice 
Provided 
definition of 
dependent 
prescribing 
Australia Pharmacists 
(n=4158, RR 
6.4%) 
Questionnaire 74% and 52% supported 
dependent and independent 
prescribing respectively. 86% 
believed they could justify their 
prescribing while 73% believed 
they would benefit from 
prescribing authority. 
Nguyen and 
Bajorek 
(2008)  
Explore the clinical utility and capacity 
of pharmacists to undertake 
prescribing functions in anticoagulation 
management in the hospital setting 
(Pilot study) 
No standardised 
definition 
provided 
Australia  Pharmacists 
(n=16), graduates 
(n=2) and final 
year pharmacy 
students (n=6) 
Questionnaire Inpatient PP can be useful but 
outpatient and dependent 
models were more appropriate. 
58% of prescribing was 
clinically inappropriate. Barriers 
include training, experience and 
doctors’ opposition. 
Weeks and 
Marriott 
(2008)  
Explore the views of Society of Hospital 
Pharmacy Australia pharmacist 
members on collaborative prescribing 
and the extent of de facto prescribing 
at their institution 
Provided 
definition for 
collaborative 
and de facto 
prescribing 
Australia Pharmacists 
(n=1367, RR 40%) 
Questionnaire 95% thought collaborative 
prescribing could circumvent 
hospital delays with timely 
service delivery. If a framework 
existed, 75% would consider 
PP. 
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Hoti et al. 
(2010)  
Evaluate the views of Australian 
pharmacists on expanded PP roles and 
identify important drivers and barriers 
to its implementation 
Current practice 
of Australian 
pharmacists 
presented 
Australia  Pharmacists 
(n=2592, RR 
40.4%) 
Questionnaire 83.9% supported PP and 
97.1% needed training. 
Inadequate training in patient 
assessment, diagnosis and 
monitoring were barriers to PP. 
Hoti, Hughes 
and 
Sunderland 
(2011)  
Examine the views of regular pharmacy 
clients on PP and employ agency 
theory in considering the relationship 
between the stakeholders involved 
Current practice 
of Australian 
pharmacists 
presented 
Australia  Patients (n=1153, 
RR 34.7%) 
Interview 
(Quantitative 
approach) 
71% trusted PP, while 66% 
supported doctor diagnosing 
first. Pharmacist diagnosing 
and prescribing was limited to 
pain management and 
antibiotics. 64% highlighted 
improved access to prescription 
medicines with PP. 
Perepelkin 
(2011)  
Better understand public perceptions of 
pharmacists, and the acceptance of 
possible expanded roles for 
pharmacists, including prescribing 
authority 
No standardised 
definition 
provided 
Canada  General public 
(n=1283, RR 
31.4%) 
Questionnaire Emergency situations, renewal 
of long-term medications and 
changing medications’ 
frequency or strength were the 
most accepted scenarios for PP. 
Erhun, 
Osigbesan 
and 
Awogbemi 
(2013)  
Determine the views of pharmacists 
and physicians on PP, appropriateness 
and the possible contribution to the 
healthcare system if pharmacists 
prescribe 
No standardised 
definition 
provided 
Nigeria Pharmacists 
(n=300, RR 61%) 
and physicians 
(n=400, RR 40%) 
Questionnaire 77.5% of pharmacists 
supported while 74.4% of 
physicians opposed PP. 
However, if there was no 
doctor, some physicians 
supported PP. Reasons for 
opposition were legal provision 
and professional incompetence. 
Hoti, Hughes 
and 
Sunderland 
(2013) 
Compare the attitudes of hospital and 
community pharmacists regarding an 
expanded prescribing role 
An overview of 
international 
models 
presented 
Australia Pharmacists 
(n=2592, RR 
40.4%) 
Questionnaire Community pharmacists 
supported IP and emergency 
prescribing. Hospital 
pharmacists supported SP for 
heart failure and anticoagulant 
therapies; and IP for 
anticoagulant therapies. 
Auta et al. 
(2014)  
Explore the views of patients of 
community pharmacists on their 
consultation experiences, and the 
possible extension of prescribing rights 
to pharmacists in Nigeria 
No standardised 
definition 
provided 
Nigeria Patients (n=432, 
RR 86.6%) 
Questionnaire 92.5% supported PP. 79.7% 
favored restricted formulary 
prescribing, and 71.9% prefer 
to see a doctor if their 
conditions get worse. 
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Moore, 
Kennedy and 
McCarthy 
(2014)  
Explore GP–pharmacist relationship, 
gain insight into communication 
between the professions and evaluate 
opinion on extension of the role of the 
community pharmacist 
No standardised 
definition 
provided 
Ireland Doctors (n=500, 
RR 52%) and 
community 
pharmacists 
(n=335, RR 62%) 
Questionnaire Compared to doctors, 
pharmacists were more 
supportive of PP. 82% of GPs 
and 96% of pharmacists 
favored pharmacists dealing 
with minor ailments. 
Hale et al. 
(2016)  
Assess whether patient satisfaction 
with the pharmacist as a prescriber and 
patient experiences in two settings of 
collaborative doctor-pharmacist 
prescribing may be barriers to 
implementation of PP 
No standardised 
definition 
provided 
Australia Patients in pre-
admission (n=200, 
RR 91%) and 
sexual health 
(n=17, RR 85%) 
clinics 
Questionnaire Almost all patients (98% in 
pre-admission and 97% in 
sexual health clinic) were 
satisfied with the consultation. 
Ung et al. 
(2016)  
Explore how pharmacists can prescribe 
oral antibiotics to treat a limited range 
of infections whilst focusing on their 
confidence and appropriateness of 
prescribing 
Current practice 
of Australian 
pharmacists 
presented 
Australia  Pharmacists 
(n=240, RR 
34.2%) 
Questionnaire High levels of appropriate 
antibiotic prescribing were 
shown for uncomplicated 
urinary tract infections 
(97.2%), cellulitis (98.2%) and 
adolescent acne (100%). 
Khan et al. 
(2017)  
Assess the attitudes of rural population 
towards PP and their interest in using 
expanded PP services 
No standardised 
definition 
provided 
India  General public 
(n=480, RR 
85.4%) 
Questionnaire 81.5% supported PP. 
Participants with low income 
and tertiary education showed 
more interest towards PP 
(p<0.05). 
Auta et al. 
(2018)  
Explore the views of pharmacists in 
Nigeria on the extension of prescribing 
authority to them, determine their 
willingness to be prescribers and 
identify the potential facilitators and 
barriers to introducing PP in Nigeria 
Provided 
definition of UK 
models 
Nigeria Pharmacists 
(n=775, RR 
40.6%) 
Questionnaire 97.1% supported PP. 
Facilitators for PP were 
increasing patients’ access to 
care and better utilisation of 
pharmacists’ skills. Barriers 
were medical resistance and 
pharmacists’ inadequate 
diagnosis skills. 
Post-implementation of pharmacist prescribing 
Eng, 
McCormick 
and 
Kimberlin 
(1990)  
Examine the attitudes and self-
reported prescribing activities of a 
sample of Florida pharmacists 
interviewed 6 months and 12 months 
after enactment of the Florida 
Pharmacist Self-Care Consultant Law 
(SCCL) 
No standardised 
definition 
provided 
USA  Pharmacists 
(prescribers and 
non-prescribers) 
(n=200, RR 97% 
for Phase 1; n= 
131, RR 66% for 
Phase 2) 
Interview 
(Quantitative 
approach) 
Prescribers perceive that the 
law positively affected their 
relationships with patients. 
Both prescribers and non-
prescribers believed that the 
law has not affected their 
relationships with physicians. 
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White-Means 
and Okunade 
(1992)  
Assess the current status of IP by 
Florida pharmacists two years after the 
law was enacted, examine correlates of 
the choice to prescribe, and discuss 
policy implications of the findings 
Provided a 
description of 
the SCCL 
USA  Pharmacists 
(prescribers and 
non-prescribers) 
(n=1800, RR 
32.3%) 
Questionnaire Prescribers are more likely to 
perceive they have enough 
training to prescribe and to 
view their skills as comparable 
to those of physicians, but less 
likely to think a PharmD is 
needed. 
Erwin, 
Britten and 
Jones 
(1996)  
Explore GPs’ views on various drugs 
being dispensed by community 
pharmacists without a prescription to 
determine whether these views have 
changed since 1990 
No standardised 
definition 
provided 
UK  Doctors (not 
exposed to PP) 
(n=250, RR 69% 
for fundholding, 
n= 600, RR 57% 
for non-
fundholding 
practices) 
Questionnaire GPs overall level of approval for 
PP had increased. GPs from 
fundholding practices agreed to 
a slightly wider range of drugs 
being made available over-the-
counter than those from non-
fundholding practices. 
George et al. 
(2006a)  
Explore SP pharmacists’ early 
experiences of prescribing and their 
perceptions of the prescribing course 
Provided 
definition of UK 
models 
Great 
Britain 
SP pharmacist 
(n=518, RR 
82.2%) 
Questionnaire Better patient management and 
funding issues were the main 
benefit and barrier respectively. 
Predictors of SP included time 
since SP registration; 
confidence and practicing in a 
setting other than community 
pharmacy. 
Hobson and 
Sewell 
(2006a)  
Study the implementation of SP by 
pharmacists within primary care trusts 
(PCTs) and secondary care trusts 
(SCTs) in England 
Provided 
definition of UK 
models 
UK  Pharmacists (not 
exposed to PP) 
(n=143, RR 68% 
for SCT; n= 271, 
RR 68% for PCT) 
Questionnaire Additional training required 
around the clinical area of 
practice for SCT and the 
completion of continuing 
professional development for 
PCT respondents. 
Hobson and 
Sewell 
(2006b)  
Provide data on the views of chief 
pharmacists and PCT pharmacists on 
the risks and concerns surrounding SP 
An overview of 
global 
experiences 
presented 
UK  Chief pharmacists 
and PCT 
pharmacists (not 
exposed to PP) 
(n=143, RR 68% 
for SCT; n= 271, 
RR 68% for PCT) 
Questionnaire There was a positive attitude 
about implementing SP but 
concerns rose over training and 
professional 
competency/responsibility. 
Smalley 
(2006)  
Evaluate patients’ experience of our 
established pharmacist-led SP 
hypertension clinic 
No standardised 
definition 
provided 
UK Patients who 
experienced SP 
(n=127, RR 87%) 
Questionnaire 91% continued to attend. 57% 
found the care they received 
was better than previous care. 
86% understood their condition 
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more, were more involved in 
decision-making and could 
easily schedule appointment. 
George et al. 
(2007)  
Investigate the challenges experienced 
by pharmacists in delivering SP 
services, explore their perceptions of 
benefits of SP and obtain feedback on 
both SP training and implementation 
Provided 
definition of UK 
SP model 
Great 
Britain 
SP pharmacists 
(n=488, RR 
82.2%) 
Questionnaire Better patient management 
was the main benefit. Barriers 
include lack of organisational 
recognition of SP and funding. 
Greater emphasis on clinical 
skills development should be 
part of the SP course. 
Stewart et 
al. (2008)  
Explore patients’ perspectives and 
experiences of pharmacist SP in 
Scotland 
Provided 
definition of UK 
SP model 
UK  Patients who 
experienced SP 
(sample size not 
clear, RR 57.2%) 
Questionnaire 89.3% were satisfied with the 
consultation, 78.7% thought it 
was comprehensive and most 
would recommend PP to others. 
However, 65% would prefer to 
consult a doctor. 
Stewart et 
al. (2009b)  
Determine the awareness of, views on, 
and attitudes of members of the 
Scottish general public toward 
nonmedical prescribing, with an 
emphasis on PP 
Provided 
definition of UK 
models 
UK General public 
(exposed and non-
exposed to PP) 
(n=500, RR 
37.1%) 
Questionnaire 56.6% were aware of non-
medical prescribing. More than 
half supported PP. Concerns 
rose about privacy despite 
acknowledging its enhanced 
convenience. 
McCann et 
al. (2011)  
Capture information on PP in Northern 
Ireland 
Provided 
definition of UK 
models 
UK Pharmacists who 
were identified as 
qualified 
prescribers 
(n=105, RR 76%) 
Questionnaire Benefits for patient care and 
pharmacist were reported. IP 
was viewed as the way forward 
but concerns were raised about 
prescribing without a diagnosis 
or beyond the team setting. 
McIntosh et 
al. (2011)  
Investigate newly registered 
pharmacists’ awareness of PP and 
views on potential future roles as 
prescribers 
No standardised 
definition 
provided 
Great 
Britain 
Newly registered 
pharmacists (not 
exposed to PP) 
(n=1658, RR 
25.2%) 
Questionnaire 86.4% were interested in 
prescribing. Training is needed 
in clinical examination, patient 
monitoring and medico-legal 
aspects of prescribing. 66.3% 
thought the current 
requirement for SP was 
appropriate. 
Stewart et 
al. (2011)  
Evaluate the views of patients across 
primary care settings in Great Britain 
who had experienced PP 
No standardised 
definition 
provided 
Great 
Britain 
Patients who 
experienced PP 
(n=1622, RR 
29.7%) 
Questionnaire The vast majority were 
satisfied with their consultation, 
believed their pharmacist 
prescribed as safely as their GP 
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and considered them 
approachable and thorough.  
Hutchison et 
al. (2012)  
Determine reasons for the slow 
adoption of prescribing authority by 
hospital pharmacists in the Canadian 
province of Alberta 
An overview of 
PP in Canada 
presented 
Canada  Pharmacists (not 
exposed to PP) 
(n=500, RR 
62.8%) 
Questionnaire The value of PP motivates 
pharmacists to apply for PP. 
Barriers include the lengthy 
application process, increased 
liability and documentation 
requirements. 
MacLure et 
al. (2013)  
Explore the views of the Scottish 
general public on non-medical 
prescribing 
Provided 
definition of UK 
models 
UK  General 
community in 
Scotland (exposed 
and non-exposed 
to PP) (n=500, RR 
37.1%) 
Questionnaire There was lack of awareness of 
NMP knowledge and training 
but support for a limited range 
of prescribing. Barriers included 
lack of access to medical 
records and issues with privacy 
and confidentiality. 
Tinelli et al. 
(2013)  
Obtain feedback from primary care 
patients on the impact of prescribing 
by nurse independent prescribers 
(NIPs) and pharmacist independent 
prescribers (PIPs) on experiences of 
the consultation, the patient–
professional relationship, access to 
medicines, quality of care, choice, 
knowledge, patient-reported adherence 
and control of their condition 
Provided 
definition of UK 
models 
UK  Patients who 
experienced PP 
(n=975, RR 30%) 
Questionnaire Satisfaction and confidence 
with PIP were high. When 
comparing NMP to doctor 
prescribing, most reported no 
difference in their experience of 
care. 
Hill et al. 
(2014)  
Not explicitly stated: 
Explore the acceptability of PP in 
addiction services in NHS Lanarkshire 
amongst the stakeholders and service 
users 
Provided 
definition of UK 
models 
UK  Patients (n=110, 
RR 78.2%), PP 
(n=5, 100%), 
medical prescribers 
(n=12, RR 50%) 
Questionnaire PP is seen as effective and 
preferred by patients. Although 
doctors have more 
reservations, the majority 
believed it was beneficial. All 
thought IP would be more 
beneficial. 
Mansell et al. 
(2015)  
Determine whether patients prescribed 
treatment for minor ailments by a 
pharmacist symptomatically improve 
within a set time frame 
No standardised 
definition 
provided 
Canada Patients who 
experienced PP (all 
population was 
included) 
Questionnaire Condition 
significantly/completely 
improved in 80.8% with only 
4% experiencing bothersome 
side effects. Trust in 
pharmacists and convenience 
were the common reasons for 
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choosing a pharmacist over a 
physician.  
Bourne et al. 
(2016)  
Determine the current and proposed 
future IP practice of UK clinical 
pharmacists working in adult critical 
care 
No standardised 
IP definition 
provided 
UK UK Clinical 
Pharmacy 
Association 
members 
(prescribers and 
non-prescribers) 
(n=404, RR 33%) 
Questionnaire Over a third were IP, and 70% 
intended to be prescribers 
within the next 3 years. 
Experience and working in a 
team facilitated IP. Pharmacists 
reported significant positives in 
patient care and job 
satisfaction. 
Isenor et al. 
(2018)  
To identify the relationship between 
barriers and facilitators to pharmacist 
prescribing and self-reported 
prescribing activity using the 
Theoretical Domains Framework 
version 2 (TDF(v2)) 
An overview of 
PP in Nova 
Scotia (Canada) 
presented 
Canada Pharmacists 
(prescribers and 
non-prescribers) 
(n= 1100, RR 8%) 
Questionnaire The three domains most 
positively associated with 
prescribing were Knowledge 
(84 %), Reinforcement (81%) 
and Intentions (78 %). The 
largest effect on prescribing 
activity was the Skills domain. 
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Table 4.3: Characteristics and key findings of included qualitative studies (n=21) 
Author 
(Year of 
publication) 
Aim(s)/Objective(s) Definition 
and model 
of PP 
discussed 
Country 
of focus 
Stakeholder 
population studied 
(number of 
participants)  
Study design 
and methods 
Key findings 
Pre-implementation of pharmacist prescribing 
Weeks, 
Marriott and 
George 
(2010)  
Pilot a UK NMP course for Australian 
hospital pharmacists and elicit 
participants’ views on NMP and 
experiences of the training 
Provided 
definition of 
UK models 
Australia Hospital pharmacists 
(n=15) 
Focus group Confidence, competency, 
legislative constraints, 
acceptance by other health 
providers, assessment 
requirements and university 
documentation were 
highlighted. 
Hatah et al. 
(2013)  
Evaluate GPs’ perceptions of 
pharmacists’ contributions to services 
traditionally undertaken by GPs 
Provided 
definition of 
IP 
New 
Zealand 
Doctors (n=18) Interview GPs were more accepting of 
pharmacists’ medication reviews 
than of PP unless appropriate 
controls, close collaboration and 
co-location of services took 
place. 
Pojskic et al. 
(2014)  
Ascertain the initial perceptions of the 
Ontario government and health 
professional stakeholder groups 
regarding the prospect of prescriptive 
authority for pharmacists 
An overview 
of the models 
present 
internationally 
and in Ontario 
presented 
Canada  Key informants from 
the Ontario 
government and 
provincial pharmacy 
and medical 
regulatory colleges 
and professional 
associations (n=17) 
Qualitative 
study using 
policy 
documents and 
semi-
structured 
interviews 
Pharmacy organisations and 
Ontario government 
representatives supported while 
medical organisations opposed 
PP. 
Bajorek et 
al. (2015)  
Explore the perspectives of GP super 
clinic staff on current and potential 
(future) pharmacist-led services 
provided in this setting 
No 
standardised 
definition 
provided 
Australia  Doctors (n=3), 
pharmacist (n=1), 
nurse (n=1), 
business manager 
(n=1) and reception 
staff (n=3) 
Interview Positive working relationships, 
satisfaction with pharmacist’s 
current role and support for 
potential future roles were 
reported. Although GPs had 
differing views about PP, they 
saw several benefits for it. 
Auta, 
Strickland-
Hodge and 
Maz (2016)  
Investigate stakeholders’ views on 
granting prescribing authority to 
pharmacists in Nigeria 
No 
standardised 
definition 
provided 
Nigeria Policymakers, 
pharmacists, doctors 
and patient group 
representative 
(n=43) 
Interview Non-medical stakeholders 
supported PP while doctors were 
reluctant to do so. Benefits 
(access to medicines) and 
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barriers (pharmacists’ diagnosis 
skills) were stated. 
Le, 
Braunack-
Mayer and 
Laurence 
(2017)  
Explore the potential impact of a 
collaborative prescribing model for 
Opioid Substitution treatment (OST) on 
patients, pharmacists and health 
provider relationships from the 
perspective of pharmacists and patients 
No 
standardised 
definition 
provided 
Australia  OST patients (n=14) 
and community 
pharmacists (n=18) 
Interviews with 
patients and 
focus groups 
with 
pharmacists 
Benefits included improved 
continuity of care and 
convenience. Changes to 
healthcare relationships and 
ensuring adequate support of PP 
were highlighted. 
Post-implementation of pharmacist prescribing 
Lloyd and 
Hughes 
(2007)  
Explore the views and professional 
context of pharmacists and physicians 
(who acted as their training mentors), 
prior to the start of SP training 
Provided 
definition of 
UK SP model 
UK  Pharmacists 
prescribers (n=47) 
and their mentors 
(n=35) 
Focus groups 
with 
pharmacists 
and face-to-
face semi-
structured 
interviews with 
the mentors 
SP was anticipated to improve 
patient care and 
interprofessional relationships. 
Loss of diversity, deskilling of 
junior doctors, safety and 
professional encroachment were 
reported. 
Tully et al. 
(2007)  
Investigate the views and experiences of 
pharmacists in England before and after 
they registered as SP 
Provided 
definition of 
UK SP model 
UK  Pharmacists (before 
and after registering 
as SPs) (n=8) 
Interview Pharmacists thought training 
would legitimise their current 
informal prescribing. 
Pharmacists already involved 
with prescribing were more 
likely to work as prescribers. 
Blenkinsopp 
et al. (2008)  
Explore GPs perceptions of the 
advantages and disadvantages of 
pharmacist SP and the future 
introduction of IP 
Provided 
definition of 
UK models 
UK  Doctors who had 
experienced SP 
(n=13) 
Focus group Not all referred patients to the 
PP. Those GPs who referred 
patients described benefits with 
some ambivalence. 
Stewart et 
al. (2009a)  
Explore the perspectives of pharmacist 
SP, their linked independent prescribers 
and patients, across a range of settings, 
in Scotland, towards PP 
Provided 
definition of 
UK models 
UK  SP pharmacists 
(n=9), their mentors 
(n=8) and patients 
(n=18) 
Interview All were supportive of SP 
identifying benefits for patients 
and the wider healthcare. 
Pharmacists were keen on IP 
but not doctors citing 
inadequate examination skills. 
Weiss and 
Sutton 
(2009)  
Investigate the potential threat to 
medical dominance posed by the 
addition of pharmacists as prescribers in 
the UK and explore the role of 
prescribing as an indicator of 
professional power, the legitimacy and 
status of new PP and the forces 
Provided 
definition of 
UK models 
UK SP pharmacists 
(n=23) 
Interview Facilitators include blurred 
definitions of prescribing, 
competence and a team 
approach to patient 
management. 
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influencing professional jurisdictional 
claims over the task of prescribing 
Hobson, 
Scott and 
Sutton 
(2010)  
Explore the opinions of patients on the 
development of NMP 
Provided 
definition of 
UK models 
UK  Patients (exposed 
and not exposed to 
PP) (n=18) 
Interview Concerns rose about clinical 
governance, privacy and space. 
Participants acknowledged 
pharmacists’ knowledge and 
accessibility. 
Lloyd, 
Parsons, and 
Hughes 
(2010)  
Explore the context and experiences, in 
relation to the practice of SP, of 
pharmacists and physicians (who acted 
as their training mentors) at least 12 
months after pharmacists had qualified 
as SP 
Provided 
definition for 
UK IP model 
UK  SP pharmacists 
(n=40) and their 
mentors (n=31) 
Focus groups 
with 
pharmacists 
and face-to-
face semi-
structured 
interviews with 
the mentors 
PP was perceived to reduce 
doctors’ workload and improved 
continuity of care. IP was seen 
as contentious by mentors due 
to the diagnostic element. 
Tonna et al. 
(2010)  
Explore pharmacists’ perceptions of the 
feasibility and value of PP of 
antimicrobials in secondary care in 
Scotland 
Provided 
definition of 
UK models 
UK  Senior hospital 
pharmacists 
(prescribers and 
non-prescribers) 
(n=37) 
Focus group Perceived benefits included 
quicker access to medicines, 
reduced risk of resistance and 
better application of evidence-
based medicine. 
Dawoud et 
al. (2011)  
Investigate pharmacist prescribers’ views 
and experiences of the early stages of SP 
implementation 
Provided 
definition for 
independent, 
dependent 
and 
collaborative 
prescribing 
models 
UK SP pharmacists 
(n=16) 
Interview Benefits reported on patient 
care and pharmacists’ job 
satisfaction. SP limited 
pharmacists’ freedom in decision 
making. Hence, IP was 
supported. 
McCann et 
al. (2012a)  
Explore patients’ perspectives of 
pharmacists as prescribers 
Provided 
definition of 
UK models 
UK  Patients who 
experienced PP 
(n=34) 
Focus group Patients supported PP especially 
in a team setting. However, 
there was a lack of awareness of 
PP role. 
McCann et 
al. (2012b)  
Provide an in-depth understanding of PP 
from the perspective of pharmacists, 
medical colleagues and other key 
stakeholders in Northern Ireland  
Provided 
definition of 
UK SP model 
UK  PP (n=11), medical 
colleagues (n=11) 
and other key 
stakeholders (n=13) 
Interview PP resulted in a more holistic 
approach to care. Challenges 
include working within areas of 
competency, complex conditions 
and resistance by older doctors. 
Makowsky et 
al. (2013)  
Understand what factors influence 
pharmacists’ adoption of prescribing 
An overview 
of prescribing 
authority in 
Canada  Pharmacists 
(prescribers and 
Interview PP was dependent on the 
innovation itself, adopter, 
system readiness, practice 
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using a model for the Diffusion of 
Innovations in healthcare services 
Alberta 
presented 
non-prescribers) 
(n=38) 
setting, communication and 
influence. 
Deslandes, 
John and 
Deslandes 
(2015)  
Explore the views and experiences of 
patients with mental illness on being 
managed by a pharmacist SP in a 
secondary care outpatient setting 
Provided 
definition of 
UK SP model 
UK Patients with mental 
illness who 
experienced SP 
(n=11) 
Exploratory 
study using 
semi-
structured 
interviews and 
self-completion 
diaries 
Patients supported PP and felt 
they were involved in decisions 
concerning their healthcare. 
Feehan et al. 
(2016)  
Investigate the perceived demand for 
and barriers to PP in the community 
pharmacy setting 
An overview 
of prescribing 
authority in 
USA 
presented 
USA Consumers (n=19), 
community 
pharmacists (n=20) 
and re-imbursement 
decision-makers 
(n=8) (not exposed 
to PP) 
Interview Consumers opposed. 
Pharmacists supported PP for 
limited conditions. 
Reimbursement decision-makers 
were most receptive. Barriers 
included awareness of PP, 
pharmacist training, conflicts of 
interest and liability issues. 
McIntosh 
and Stewart 
(2016) 
Explore the views and reflections on PP 
of UK pre-registration pharmacy 
graduates 
No 
standardised 
definition 
provided 
UK  Pre-registration 
pharmacy graduates 
(n=12) 
Interview Support was related to 
professional development. 
Barriers included lack of 
organisational strategy, 
confidence and workload. 
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Table 4.4: Characteristics and key findings of included mixed-methods studies (n=3) 
Author 
(Year of 
publication) 
Aim(s)/Objective(s) Definition and 
model of 
pharmacist 
prescribing 
discussed 
Country 
of focus 
Stakeholder 
population studied 
(sample size) 
Study design and 
methods 
Key findings 
Pre-implementation of pharmacist prescribing 
Hanes, and 
Bajorek 
(2005)  
Explore the views of a sample of 
Australian hospital pharmacists on 
prescribing privileges 
Provided a 
definition for 
dependent 
prescribing 
Australia Hospital pharmacists 
(n=10) and teacher 
practitioners (n=5) 
(15 completed the 
questionnaire, 8 
participated in the 
focus groups) 
Questionnaire and 
focus group 
Benefits include more 
efficient/improved 
pharmaceutical care 
and reduced 
healthcare costs. 
Physician opposition 
was a barrier. 
Training and 
accreditation beyond 
registration was 
deemed necessary. 
Vracar and 
Bajorek 
(2008)  
Explore Australian GPs’ views on 
extending prescribing rights to 
pharmacists, the appropriateness of PP 
models, and the influence of GPs’ 
characteristics on their preference for a 
particular PP model 
An overview of 
international 
models 
presented 
Australia Doctors (150 
approached, 22 filled 
the questionnaire 
and 10 participated 
in the interview) 
Questionnaire and 
semi-structured 
interview 
Repeat prescribing 
and prescribing by 
referral were the most 
favoured. Safety 
issues, lack of 
awareness of 
pharmacist training 
and capabilities, 
clinical responsibility, 
GP–patient 
relationship and 
remuneration were 
raised. 
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Post-implementation of pharmacist prescribing 
Baqir (2010)  Evaluate the extent of PP and identify 
some of the barriers to maintaining and 
developing such services 
No standardised 
definition 
provided 
UK  Pharmacists who 
undertook a 
prescribing course 
(179 were invited to 
participate, 98 filled 
the questionnaire 
but not clear how 
many were involved 
in the focus groups) 
Multiple methods: 
Questionnaire, focus 
groups, documents 
review and 
interviews 
In secondary care, 
easy access to 
medical records and 
prescription pads as 
well as close working 
relationships with 
doctors were 
facilitators. The major 
barrier was lack of a 
clear strategy at 
organisational level. 
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Of the 65 studies, 29 (44.6%) were conducted prior to the implementation of 
pharmacist prescribing in the country of study (Pennock et al. 1988, Segal and 
Grines 1988, Spencer and Edwards 1992, Child, Hirsch and Berry 1998, Child 
and Cantrill 1999, Child 2001, Hanes and Bajorek 2005, George et al. 2006b, 
Kay, Bajorek and Brien 2006, Nguyen and Bajorek 2008, Vracar and Bajorek 
2008, Weeks and Marriott 2008, Hoti et al. 2010, Weeks, Marriott and George 
2010, Hoti, Hughes and Sunderland 2011, Perepelkin 2011, Erhun, Osigbesan 
and Awogbemi 2013, Hatah et al. 2013, Hoti, Hughes and Sunderland 2013, 
Auta et al. 2014, Moore, Kennedy and McCarthy 2014, Pojskic et al. 2014, 
Bajorek et al. 2015, Auta, Strickland-Hodge and Maz 2016, Hale et al. 2016, 
Ung et al. 2016, Khan et al. 2017, Le, Braunack-Mayer and Laurence 2017, Auta 
et al. 2018), while 35 (53.8%) were conducted post-implementation (Eng, 
McCormick and Kimberlin 1990, White-Means and Okunade 1992, Erwin, Britten 
and Jones 1996, George et al. 2006a, Hobson and Sewell 2006a, Hobson and 
Sewell 2006b, Smalley 2006, George et al. 2007, Lloyd and Hughes 2007, 
Blenkinsopp et al. 2008, Stewart et al. 2008, Stewart et al. 2009a, Stewart et 
al. 2009b, Weiss and Sutton 2009, Baqir 2010, Hobson, Scott and Sutton 2010, 
Lloyd, Parsons and Hughes 2010, Tonna et al. 2010, Dawoud et al. 2011, 
McCann et al. 2011, McIntosh et al. 2011, Stewart et al. 2011, Hutchison et al. 
2012, McCann et al. 2012a, McCann et al. 2012b, MacLure et al. 2013, 
Makowsky et al. 2013, Tinelli et al. 2013, Hill et al. 2014, Deslandes, John and 
Deslandes 2015, Mansell et al. 2015, Bourne et al. 2016, Feehan et al. 2016, 
McIntosh and Stewart 2016, Isenor et al. 2018). Only one study explored views 
and experiences pre- and post-registration (Tully et al. 2007). 
Most of the included studies were conducted in the UK (n=34, 52%) (Spencer 
and Edwards 1992, Erwin, Britten and Jones 1996, Child, Hirsch and Berry 1998, 
Child and Cantrill 1999, Child 2001, George et al. 2006a, George et al. 2006b, 
Hobson and Sewell 2006a, Hobson and Sewell 2006b, Smalley 2006, George et 
al. 2007, Lloyd and Hughes 2007, Tully et al. 2007, Blenkinsopp et al. 2008, 
Stewart et al. 2008, Stewart et al. 2009a, Stewart et al. 2009b, Weiss and 
Sutton 2009, Baqir 2010, Hobson, Scott and Sutton 2010, Lloyd, Parsons and 
Hughes 2010, Tonna et al. 2010, Dawoud et al. 2011, McCann et al. 2011, 
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McIntosh et al. 2011, Stewart et al. 2011, McCann et al. 2012a, McCann et al. 
2012b, MacLure et al. 2013, Tinelli et al. 2013, Hill et al. 2014, Deslandes, John 
and Deslandes 2015, Bourne et al. 2016, McIntosh and Stewart 2016), followed 
by Australia (n=13, 20%) (Hanes and Bajorek 2005, Kay, Bajorek and Brien 
2006, Nguyen and Bajorek 2008, Vracar and Bajorek 2008, Weeks and Marriott 
2008, Hoti et al. 2010, Weeks, Marriott and George 2010, Hoti, Hughes and 
Sunderland 2011, Hoti, Hughes and Sunderland 2013, Bajorek et al. 2015, Hale 
et al. 2016, Ung et al. 2016, Le, Braunack-Mayer and Laurence 2017), Canada 
(n=6, 9%) (Perepelkin 2011, Hutchison et al. 2012, Makowsky et al. 2013, 
Pojskic et al. 2014, Mansell et al. 2015, Isenor et al. 2018), US (n=5, 8%) 
(Pennock et al. 1988, Segal and Grines 1988, Eng, McCormick and Kimberlin 
1990, White-Means and Okunade 1992, Feehan et al. 2016), Nigeria (n=4, 6%) 
(Erhun, Osigbesan and Awogbemi 2013, Auta et al. 2014, Auta, Strickland-
Hodge and Maz 2016, Auta et al. 2018) and one for each of New Zealand (Hatah 
et al. 2013), Ireland (Moore, Kennedy and McCarthy 2014) and India (Khan et 
al. 2017). 
The main stakeholder group studied was pharmacists (n=27, 41.5%), including 
those registered as prescribers (George et al. 2006a, George et al. 2007, 
McCann et al. 2011, Weiss and Sutton 2009, Baqir 2010, Dawoud et al. 2011), 
non-prescribers (Hobson and Sewell 2006a, Hobson and Sewell 2006b, McIntosh 
et al. 2011, Hutchison et al. 2012, George et al. 2006b, Kay, Bajorek and Brien 
2006, Nguyen and Bajorek 2008, Weeks and Marriott 2008, Hoti et al. 2010, 
Weeks, Marriott and George 2010, Hoti, Hughes and Sunderland 2013, McIntosh 
and Stewart 2016, Ung et al. 2016, Auta et al. 2018) or mixed prescribers and 
non-prescribers (Eng, McCormick and Kimberlin 1990, White-Means and 
Okunade 1992, Tully et al. 2007, Tonna et al. 2010, Makowsky et al. 2013, 
Bourne et al. 2016, Isenor et al. 2018). In addition, different stakeholders were 
researched. The majority of papers investigated perceptions and views of 
pharmacists (Eng, McCormick and Kimberlin 1990, White-Means and Okunade 
1992, George et al. 2006a, George et al. 2006b, Hobson and Sewell 2006a, 
Hobson and Sewell 2006b, Kay, Bajorek and Brien 2006, George et al. 2007, 
Tully et al. 2007, Nguyen and Bajorek 2008, Weeks and Marriott 2008, Weiss 
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and Sutton 2009, Baqir 2010, Hoti et al. 2010, Tonna et al. 2010, Weeks, 
Marriott and George 2010, Dawoud et al. 2011, McCann et al. 2011, McIntosh et 
al. 2011, Hutchison et al. 2012, Hoti, Hughes and Sunderland 2013, Makowsky 
et al. 2013, Bourne et al. 2016, McIntosh and Stewart 2016, Ung et al. 2016, 
Auta et al. 2018, Isenor et al. 2018). Fewer studies investigated the perceptions 
of patients (n=12, 18.5%) (Pennock et al. 1988, Smalley 2006, Stewart et al. 
2008, Hobson, Scott and Sutton 2010, Hoti, Hughes and Sunderland 2011, 
Stewart et al. 2011, McCann et al. 2012a, Tinelli et al. 2013, Auta et al. 2014, 
Deslandes, John and Deslandes 2015, Mansell et al. 2015, Hale et al. 2016), 
doctors (n=6, 9.3%) (Spencer and Edwards 1992, Erwin, Britten and Jones 
1996, Child and Cantrill 1999, Blenkinsopp et al. 2008, Vracar and Bajorek 
2008, Hatah et al. 2013), the general public (n=4, 6.2%) (Stewart et al. 2009a, 
Perepelkin 2011, MacLure et al. 2013, Khan et al. 2017), nurses (n=1, 1.5%) 
(Child 2001), or policymakers (n=1, 1.5%) (Pojskic et al. 2014). Fourteen 
studies reported multiple stakeholder perspectives (Segal and Grines 1988, 
Child, Hirsch and Berry 1998, Hanes and Bajorek 2005, Lloyd and Hughes 2007, 
Stewart et al. 2009b, Lloyd, Parsons and Hughes 2010, McCann et al. 2012b, 
Erhun, Osigbesan and Awogbemi 2013, Hill et al. 2014, Moore, Kennedy and 
McCarthy 2014, Bajorek et al. 2015, Auta, Strickland-Hodge and Maz 2016, 
Feehan et al. 2016, Le, Braunack-Mayer and Laurence 2017). 
While most studies (n=41, 63%) provided a standardised or legislative definition 
of pharmacist prescribing, 24 (37%) did not (Pennock et al. 1988, Eng, 
McCormick and Kimberlin 1990, Spencer and Edwards 1992, Erwin, Britten and 
Jones 1996, Child, Hirsch and Berry 1998, Child and Cantrill 1999, Child 2001, 
Smalley 2006, Nguyen and Bajorek 2008, Baqir 2010, McIntosh et al. 2011, 
Perepelkin 2011, Stewart et al. 2011, Erhun, Osigbesan and Awogbemi 2013, 
Auta et al. 2014, Moore, Kennedy and McCarthy 2014, Bajorek et al. 2015, 
Mansell et al. 2015, Auta, Strickland-Hodge and Maz 2016, Bourne et al. 2016, 
Hale et al. 2016, McIntosh and Stewart 2016, Khan et al. 2017, Le, Braunack-
Mayer and Laurence 2017). 
For quantitative studies, the sample size ranged from 105 to 4158, with 
response rates of 6.4% to 87%. On the other hand, qualitative studies included 
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between 8 and 82 participants. For mixed methods studies, the sample size in 
the quantitative element ranged from 15 to 179, with response rates of 15% to 
100%, while the number of participants in the qualitative element ranged from 8 
to 10. 
4.3.3. Stakeholders’ views and experiences of pharmacist 
prescribing 
The majority of both pre- and post-implementation studies included reported 
support for prescribing pharmacists. 
Pre-implementation studies 
a. General public 
Two studies investigated the public’s perceptions of granting pharmacists the 
authority to prescribe in Canada and India. Respondents were generally 
supportive of prescribing by pharmacists who received training in specific 
situations, which included: the physician having made the diagnosis, prescribing 
from a limited range, in emergency situations, prescribing alternative medicines 
for the same medical condition, renewing prescriptions, or modifying the 
strength or frequency of medicines prescribed by a physician (Perepelkin 2011, 
Khan et al. 2017). 
b. Patients 
Studies of patients and patient group representatives reported support for 
pharmacist prescribing (Pennock et al. 1988, Hoti, Hughes and Sunderland 
2011, Auta et al. 2014, Auta, Strickland-Hodge and Maz 2016, Hale et al. 2016, 
Le, Braunack-Mayer and Laurence 2017), which was perceived as likely to 
improve access to healthcare generally and consultation with a trained health 
professional making better use of pharmacists’ skills (Hoti, Hughes and 
Sunderland 2011, Auta et al. 2014, Hale et al. 2016, Le, Braunack-Mayer and 
Laurence 2017). Respondents in several studies noted the need for the 
pharmacist prescribers to have undertaken additional training, after a 
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physician’s diagnosis, and that prescribing should be from a restricted list of 
medicines (Hoti, Hughes and Sunderland 2011, Auta et al. 2014, Le, Braunack-
Mayer and Laurence 2017). 
c. Pharmacists 
Pharmacists themselves were generally supportive of a prescribing role, which 
they perceived as a logical development given their expertise in medicines, their 
existing over-the-counter prescribing related activities, and their increasingly 
evolving clinical roles as part of the multidisciplinary team in secondary care. 
Moreover, they anticipated that outcomes would include quicker and easier 
patient access to medicines, promoting better utilisation of their skills with 
resultant enhanced status, as well as increased job satisfaction (Child, Hirsch 
and Berry 1998, Hanes and Bajorek 2005, Nguyen and Bajorek 2008, Weeks 
and Marriott 2008, Hoti et al. 2010, Weeks, Marriott and George 2010, Erhun, 
Osigbesan and Awogbemi 2013, Hoti, Hughes and Sunderland 2013, Moore, 
Kennedy and McCarthy 2014, Auta, Strickland-Hodge and Maz 2016, Le, 
Braunack-Mayer and Laurence 2017). There was agreement that they required 
additional training prior to assuming a prescribing role (Child, Hirsch and Berry 
1998, Kay, Bajorek and Brien 2006, Nguyen and Bajorek 2008, Ung et al. 2016, 
Le, Braunack-Mayer and Laurence 2017, Auta et al. 2018). 
There were diverse views on the models and scope of prescribing which ranged 
from prescribing within an agreed clinical management plan (CMP), repeat 
prescribing for stabilised chronic conditions, and modifying treatment based on 
the results of laboratory tests ordered by themselves (Hanes and Bajorek 2005, 
Weeks, Marriott and George 2010, Auta et al. 2018). Many respondents also 
viewed IP as appropriate for pharmacists, noting that it will be safe, effective, 
and improve patient access to medicines. They generally held the view that 
physicians would be in favour of pharmacist prescribing (Hoti, Hughes and 
Sunderland 2013, Ung et al. 2016). 
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d. Doctors 
Studies conducted pre-implementation of pharmacist prescribing reported a 
range of views from doctors (n=9). In one study conducted in the UK, the 
majority of respondents were supportive, provided that additional postgraduate 
education/training was undertaken (Child, Hirsch and Berry 1998). In other 
studies, physicians were more cautious in their support, but acknowledged that 
a model of pharmacist prescribing for limited conditions, such as minor ailments, 
was a logical development (Spencer and Edwards 1992, Erhun, Osigbesan and 
Awogbemi 2013, Hatah et al. 2013, Moore, Kennedy and McCarthy 2014, Auta, 
Strickland-Hodge and Maz 2016). 
Other studies reported physicians’ concern over: pharmacists’ lack of clinical 
assessment and diagnosis skills, lack of access to individual patient medical 
records, legal considerations such as division of clinical responsibility of care, a 
potential negative effect on the physician-patient relationship, and issues around 
communication between the pharmacist prescriber and other members of the 
multidisciplinary team (Child and Cantrill 1999, Vracar and Bajorek 2008, Moore, 
Kennedy and McCarthy 2014). 
e. Nurses 
Two UK studies reported the perspectives of nurses with respondents 
considering pharmacist prescribing for existing or new therapy very useful due 
to their knowledge in pharmacology and a belief that it will be clearer and safer 
(Child, Hirsch and Berry 1998, Child 2001). 
f. Policymakers 
Government and pharmacy policymakers from the US, Canada, and Nigeria 
anticipated benefit to pharmacist prescribing in terms of improved continuity of 
care, better patient outcomes, reduced prescribing costs, and reduced physician 
workload (Segal and Grines 1988, Pojskic et al. 2014, Auta, Strickland-Hodge 
and Maz 2016). Concerns were, however, expressed by medical policymakers in 
relation to the need for additional training and access to individual patient 
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medical records, without which there could be fragmented care (Pojskic et al. 
2014). 
Post-implementation studies 
a. General public 
Two studies reported the perspectives of samples of the public, both exposed to 
pharmacist prescribing and not exposed to it, in the UK. Findings highlighted 
general support, particularly for the management of minor ailments and issuing 
repeat prescriptions. There were some concerns around pharmacists’ training in 
diagnosis, lack of access to patients’ medical records, and potential lack of 
privacy and confidentiality within a community pharmacy setting (Stewart et al. 
2009a, MacLure et al. 2013). 
b. Patients 
Nine studies assessed the experience of patients who were exposed to 
pharmacist prescribing, while Hobson, Scott and Sutton (2010) included 
exposed and unexposed patients in the UK and Feehan et al. (2016) had US 
patients who had never been exposed to pharmacist prescribing.  
The majority of those patients who had consulted with a pharmacist prescriber 
were highly satisfied with the consultation overall, particularly the pharmacist’s 
competence and capability, considering their prescribing to be as effective and 
safe as their physician. They also gave positive feedback relating to the 
pharmacist’s personality, knowledge and communication skills as well as the 
consistency, accessibility, length and outcome of the care received (Smalley 
2006, Stewart et al. 2008, Stewart et al. 2009b, Hobson, Scott and Sutton 
2010, Stewart et al. 2011, McCann et al. 2012a, Tinelli et al. 2013, Hill et al. 
2014, Deslandes, John and Deslandes 2015, Mansell et al. 2015). 
In a recent study of prescribing by community pharmacists in the US, patients 
who had yet to experience pharmacist prescribing were of the view that 
pharmacists should only dispense and provide medicines information other than 
a possible role in prescribing for minor conditions (Feehan et al. 2016). 
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c. Pharmacists 
Twenty-four studies researched the perspectives of pharmacists post-
implementation of prescribing rights mainly in the UK (n=18), US (3), and 
Canada (3). The pharmacists sample in these studies included either prescribers 
(George et al. 2006a, George et al. 2007, Lloyd and Hughes 2007, Stewart et al. 
2009a, Weiss and Sutton 2009, Baqir 2010, Lloyd, Parsons and Hughes 2010, 
Dawoud et al. 2011, McCann et al. 2011, McCann et al. 2012b, Hill et al. 2014), 
non-prescribers (Hobson and Sewell 2006a, Hobson and Sewell 2006b, McIntosh 
et al. 2011, Hutchison et al. 2012, Feehan et al. 2016, McIntosh and Stewart 
2016), or both (Eng, McCormick and Kimberlin 1990, White-Means and Okunade 
1992, Tully et al. 2007, Tonna et al. 2010, Makowsky et al. 2013, Bourne et al. 
2016, Isenor et al. 2018). Pharmacists positively perceived this expanded 
professional role and reported that drivers to undertake pharmacist prescribing 
include developing a clinical role, better patient management, personal 
development, enhancing job and patient satisfaction, improving self-confidence 
as well as reducing cost of therapy (Eng, McCormick and Kimberlin 1990, White-
Means and Okunade 1992, George et al. 2006a, George et al. 2007, Hobson and 
Sewell 2006a, Hobson and Sewell 2006b, Lloyd and Hughes 2007, Tully et al. 
2007, Stewart et al. 2009a, Weiss and Sutton 2009, Baqir 2010, Lloyd, Parsons 
and Hughes 2010, Tonna et al. 2010, Dawoud et al. 2011, McCann et al. 2011, 
McIntosh et al. 2011, Hutchison et al. 2012, McCann et al. 2012b, Makowsky et 
al. 2013, Hill et al. 2014, Bourne et al. 2016, McIntosh and Stewart 2016, 
Isenor et al. 2018). 
Studies also concluded that implementing pharmacist prescribing was easier in 
secondary care compared to primary or community care due to logistics related 
to access to medical records and networking environment (Lloyd and Hughes 
2007, Baqir 2010, Lloyd, Parsons and Hughes 2010, McCann et al. 2011, 
Makowsky et al. 2013). 
Negative attitudes towards prescribing pharmacists were mainly related to 
increased liability, lack of time to engage in prescribing, and lack of experience 
in diagnosis in addition to medical resistance and difficulties in developing a CMP 
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for every patient (Eng, McCormick and Kimberlin 1990, Lloyd and Hughes 2007, 
Tully et al. 2007, Lloyd, Parsons and Hughes 2010, Tonna et al. 2010, McCann 
et al. 2011, Makowsky et al. 2013, McIntosh and Stewart 2016). 
Due to liability and diagnosis-related issues, pharmacists preferred SP or 
prescribing for minor and chronic conditions (Weiss and Sutton 2009, Tonna et 
al. 2010, Feehan et al. 2016). However, other studies reported that SP was not 
believed to significantly save physicians’ time or improve patient care due to the 
limited list of drugs they can prescribe under the CMP. Thus, IP will have a 
better impact (Hobson and Sewell 2006b, Stewart et al. 2009a, Weiss and 
Sutton 2009, Lloyd, Parsons and Hughes 2010, Dawoud et al. 2011, McCann et 
al. 2011, Hill et al. 2014). 
d. Doctors 
Seven studies explored doctors’ perceptions of this new role for pharmacists, all 
of which were conducted in the UK. Of those, six studies reported the 
perspectives of doctors who had worked alongside pharmacist prescribers. The 
majority supported pharmacist prescribing across the studies with some benefits 
highlighted including more holistic and continuous patient care, better utilisation 
of pharmacists’ skills, effects of enhancing physicians’ medicines knowledge, and 
drug cost saving (Lloyd and Hughes 2007, Blenkinsopp et al. 2008, Stewart et 
al. 2009a, Lloyd, Parsons and Hughes 2010, McCann et al. 2012b). While 
physicians reported reduced direct-patient workload, the need to develop 
individual patient CMPs for SP was burdensome hence the impending 
implementation of IP was welcomed (Hill et al. 2014). 
The only study that investigated doctors who were not exposed to prescribing 
pharmacists reported that, with time, doctors are more likely to accept this new 
role (Erwin, Britten and Jones 1996). 
e. Policymakers 
Only one study from the US explored the perceptions of policymakers involved 
in medical services coverage or formulary policies after the realisation of 
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pharmacist prescribing. The main findings were that these decision-makers 
responded positively to pharmacist prescribing due to pharmacists’ knowledge 
about drugs and their mechanisms of action (Feehan et al. 2016). 
4.3.4. Facilitators of and barriers to pharmacist prescribing 
implementation 
Many studies (n=27, 42%) reported facilitators and barriers to the 
implementation of pharmacist prescribers as perceived by the different 
stakeholder groups (Hanes and Bajorek 2005, George et al. 2006a, Hobson and 
Sewell 2006a, Hobson and Sewell 2006b, Kay, Bajorek and Brien 2006, George 
et al. 2007, Lloyd and Hughes 2007, Tully et al. 2007, Nguyen and Bajorek 
2008, Stewart et al. 2009a, Baqir 2010, Hobson, Scott and Sutton 2010, Hoti et 
al. 2010, Lloyd, Parsons and Hughes 2010, Dawoud et al. 2011, McCann et al. 
2011, McCann et al. 2012b, Erhun, Osigbesan and Awogbemi 2013, Hoti, 
Hughes and Sunderland 2013, Makowsky et al. 2013, Bajorek et al. 2015, Auta, 
Strickland-Hodge and Maz 2016, Bourne et al. 2016, Feehan et al. 2016, 
McIntosh and Stewart 2016, Auta et al. 2018, Isenor et al. 2018) which are 
summarised in Table 4.5. 
Table 4.5: Facilitators and barriers to pharmacist prescribing 
Facilitators • Pharmacists’ personal qualities (communication skills, training, experience, 
and enthusiasm) 
• Practice setting (secondary vs primary vs community) 
• Organisational, managerial, and medical colleagues’ support 
• Resources (workforce, space, access to medical records) 
Barriers • Pharmacists’ skills (clinical examination and diagnostic skills) 
• Resources (workforce, access to medical records, space, time) 
• Physicians and organisational support 
• Funding 
• Legal aspects (accountability, conflict of interest) 
• Pharmacy practice recognition 
 
The major facilitators to this role include pharmacist personal qualities 
(enthusiasm, communication skills, experience and training), practice setting 
(working in an interprofessional team), organisational, managerial and medical 
colleagues’ support as well as infrastructure and resources (number of 
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pharmacist available, space and access to medical records) (George et al. 
2006a, Hobson and Sewell 2006a, Lloyd and Hughes 2007, Dawoud et al. 2011, 
McCann et al. 2012b, Makowsky et al. 2013, Isenor et al. 2018). 
The main barriers reported are pharmacists’ poor clinical skills if not prescribing 
collaboratively and issues relating to resources (access to medical records, 
shortage in pharmacy workforce, funding, time), support (doctors opposition), 
logistics (accountability, conflict of interest, referral process) and poor 
recognition of pharmacy profession (Hanes and Bajorek 2005, George et al. 
2006a, Hobson and Sewell 2006b, Kay, Bajorek and Brien 2006, George et al. 
2007, Lloyd and Hughes 2007, Tully et al. 2007, Nguyen and Bajorek 2008, 
Stewart et al. 2009b, Baqir 2010, Hobson, Scott and Sutton 2010, Hoti et al. 
2010, Lloyd, Parsons and Hughes 2010, McCann et al. 2011, McCann et al. 
2012b, Erhun, Osigbesan and Awogbemi 2013, Hoti, Hughes and Sunderland 
2013, Bajorek et al. 2015, Auta, Strickland-Hodge and Maz 2016, Feehan et al. 
2016, McIntosh and Stewart 2016, Auta et al. 2018, Isenor et al. 2018). 
4.4. Discussion 
4.4.1. Summary of key findings 
This systematic review summarises the evidence around the views and 
experiences surrounding pharmacist prescribing from the perspectives of a 
diverse range of stakeholders in a range of countries and settings. 
The majority of studies pre- and post-implementation reported positive views 
and experiences with main benefits described as: increased access to healthcare 
services, perceptions of enhanced patients’ outcomes, better utilisation of 
pharmacists’ skills and knowledge, improved job satisfaction, and reduced 
physicians’ workload. However, concerns were noted around issues of: liability, 
limited pharmacists’ diagnosis skills, access to medical records, and lack of 
organisational and financial support. While review findings are derived from 
many studies of generally high methodological quality, there is a lack of mixed-
methods approaches. These are being used increasingly within healthcare and 
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allow both quantification of findings and in-depth exploration of key issues 
(Onwuegbuzie and Frels 2016). 
4.4.2. Interpretation of findings 
Healthcare policies in countries such as the UK are supporting the expansion of 
pharmacist prescribing and indeed there is a move to increase the number of 
pharmacists practicing within primary care practices (Royal College of General 
Practitioners in Scotland and Royal Pharmaceutical Society in Scotland 2016). 
The positive findings of this systematic review, together with previous reviews of 
effectiveness and safety (Kay and Brien 2004, Bhanbhro et al. 2011, Auta et al. 
2015, Faruquee and Guirguis 2015, Weeks et al. 2016), provide evidence to 
support such developments. Furthermore, such review findings are important in 
those countries and settings starting to explore and develop models of 
pharmacist prescribing (Stewart et al. 2017). Interpretation and extrapolation of 
findings from studies conducted pre-implementation are limited in that 
participants may not be fully aware of the aim, nature, and scope of the 
intervention and may be influenced by experiences of similar or diverse 
interventions. This is apparent in terms of concerns around independent 
prescribing models in the UK and pharmacists’ limited training in diagnosis. 
While this does allow assessment and prescribing of undiagnosed conditions, this 
must be within the prescribers’ competence and indeed most pharmacist 
independent prescribers’ practise with patients in whom diagnosis has already 
been established by the doctor (UK Department of Health 2006). Concerns such 
as liability and skills which were voiced pre-implementation were less common 
post-implementation as such studies allow participants to reflect on their real-
life experiences. For example, doctors who had worked alongside pharmacist 
prescribers and patients managed by the pharmacists were very supportive of 
their professionalism and skills. 
4.4.3. Gaps in literature 
While lack of access to medical records is an issue, most notably within 
community pharmacy settings, this is being addressed within the UK with 
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pharmacists having access to specific limited sections of the electronic medical 
record (Goundrey-Smith 2016). Many of the barriers and indeed facilitators can 
be explained by theories of implementation. It is therefore notable that only 
three of the 65 studies incorporated any mention of theory within the study 
design, conduct, and reporting (Hoti, Hughes and Sunderland 2011, Makowsky 
et al. 2013, Isenor et al. 2018). There is a need for implementation studies to 
focus on theory to allow more systematic and comprehensive investigation of 
facilitators and barriers. Similarly, those planning implementation should include 
key theoretical elements at the outset in order to heighten the facilitators and 
lessen the barriers such as inadequate funding, access to resources, etc. As 
described in Chapter 2, the Consolidated Framework for Implementation 
Research (CFIR) is an integrative framework derived from many different 
theories. It is described in five domains of: intervention characteristics, outer 
setting, inner setting, characteristics of the individuals involved, and the process 
of implementation (Damschroder et al. 2009). All barriers identified post-
implementation of pharmacist prescribing (e.g. funding, access issues, etc.) 
would be eliminated in advance by employing CFIR since it can serve as a guide 
for implementing an innovation. However, it is likely that these barriers reflected 
the stage of implementation and are likely to have been resolved over time.  
4.4.4. Strengths and weaknesses 
Previous reviews have been limited in nature and rigour (thematic and scoping 
reviews), focused on pre-implementation, lacked quality assessment of included 
studies, and focused on limited ranges of stakeholders in specific countries (UK 
and Canada) (Cooper et al. 2009, Faruqee and Guirguis 2015, Famiyeh and 
McCarthy 2017). This systematic review was conducted according to best 
practices and is reported in accordance with the PRISMA Statement standards 
(Moher et al. 2009). Furthermore, it was not limited to a specific country, 
setting, stakeholder group, or implementation stage. However, the 
generalisability or transferability of findings to other countries or cultures may 
be limited given that almost all studies were conducted post-implementation in 
the western world and mainly focused on pharmacists’ perspectives. Moreover, 
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several of these studies were conducted several years ago hence may no longer 
accurately reflect the current situation in those countries. While many 
implementation studies have been reported, it is still necessary to conduct such 
investigations in any country or setting planning to establish pharmacist 
prescribing to learn from the evidence-base. Future developments and studies 
should pay attention to theories of implementation and adopt mixed methods 
approaches with an inclusive range of stakeholders.  
4.5. Conclusion 
A large number of studies have reported stakeholders’ views and experiences of 
pharmacist prescribing, pre- and post-implementation. While studies were from 
a limited number of countries, the overwhelming finding was positive, 
particularly in relation to increased access to healthcare services, perceptions of 
enhanced patients’ outcomes, better utilisation of pharmacists’ skills and 
knowledge, improved job satisfaction, and reduced physicians’ workload. 
Concerns were largely identified pre-implementation and were around 
organisational issues and perceived lack of pharmacists’ diagnosis skills. 
4.6. Implications for next phase 
It is evident from this systematic review that extensive research has been 
conducted on the views and experiences of pharmacist prescribing from the 
perspectives of diverse groups of stakeholders. However, fewer studies have 
been comprehensive and also included stakeholder groups such as the general 
public, nurses and policymakers. Notably, none of the studies included all 
relevant stakeholder groups and there was a lack of studies employing a 
qualitative approach. Furthermore, none included implementation theory in the 
stages of development of data collection and generation tools, analysis and 
interpretation. 
Given that most of the studies were conducted in the UK, USA, Canada, New 
Zealand, Ireland and Australia, there is a need for primary research in the ‘Arab 
World’ where the ethnicity, culture and work practices may be considerably 
different.  
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The next phase of this research attempted to address these gaps through 
conducting primary research in Qatar, focusing on a diverse group of 
stakeholders and incorporating implementation theory throughout.  
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5. Introduction to the chapter 
This chapter provides a detailed description of the field work conducted around 
key health stakeholders’ perceptions and views on the potential of implementing 
pharmacist prescribing in Qatar. The aim and research questions are stated 
followed by the methods, key findings, conclusion and discussion. 
5.1. Research aim and objectives 
This study aimed to explore the views and perceptions of stakeholders in Qatar 
on the potential of developing and implementing pharmacist prescribing. The 
specific research objectives were to: 
• Explore stakeholders’ awareness, experiences and views of prescribing by 
non-medical health professionals 
• Determine stakeholders’ views and perceptions of clinical roles of 
pharmacists in Qatar 
• Investigate stakeholders’ views and perceptions of expanding the remit of 
pharmacists in Qatar to include prescribing 
• Examine stakeholders’ views and perceptions of facilitators, barriers and 
solutions to the development and implementation of pharmacist 
prescribing in Qatar 
5.2. Methods 
5.2.1. Study design 
A phenomenological qualitative approach was employed using semi-structured 
interviews with key health stakeholders in Qatar. Justification for this approach 
is provided in Chapter 2.  
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5.2.2. Research governance 
As shown in the appendices, prior to conducting the interviews, ethical approval 
was received from: 
• Robert Gordon University School of Pharmacy & Life Sciences Research 
Ethics Committee (Approval reference S64) 
• Ministry of Public Health Ethics Committee 
• HMC Medical Research Committee (Approval reference MRC0449/2017) 
• Qatar University Institutional Review Board (Approval reference QU-IRB 
772-E/17) 
5.2.3. Settings 
Data generation took place in Qatar, across several settings as follows: 
• Ministry of Public Health (MoPH) in Qatar. MoPH is the health regulatory 
body in Qatar, responsible for overseeing the medical marketplace as well 
as ensuring the highest quality of care. Currently, the Ministry evaluates 
and monitors both public as well as private health sectors (Qatar Ministry 
of Public Health 2016) 
• Hamad Medical Corporation (HMC). The largest hospital group in the 
State, managed by the government of Qatar and includes eight hospitals 
differing in their level and range of care to address the public’s healthcare 
needs (Qatar Supreme Council of Health 2014) 
• Aspetar Orthopaedic and Sports Medicine Hospital which is the first 
hospital to provide this specialised care in the Gulf region. 
• Primary Health Care Corporation (PHCC). PHCC is the largest 
governmental group providing primary healthcare services in the State of 
Qatar (Primary Health Care Corporation 2018a) 
• Weil Cornell Medical School. The first and main medical college in Qatar 
• College of Medicine at Qatar University. The first and only public medical 
college in the country 
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• College of Pharmacy at Qatar University. The first and only college of 
pharmacy in the State 
• Faculty of Nursing at University of Calgary. The first and only college of 
nursing in Qatar 
• Qatar Petroleum Medical Centres. The largest private primary care setting 
in the country 
• Wellcare and Khulud Groups. The largest chain of community pharmacies 
in Qatar 
These settings represented all major institutions relating to the education, 
practice, regulation and governance of pharmacists. Figure 5.1 shows each of 
the settings for data generation 
  
Ministry of Public Health Hamad Medical Corporation 
  
Aspetar Orthopaedic and Sports Medicine 
Hospital 
Primary Health Care Corporation 
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Qatar Petroleum Medical Centres Weil Cornell Medical School 
 
 
College of medicine at Qatar University College of Pharmacy at Qatar University 
  
University of Calgary’s Faculty of Nursing Wellcare Group 
 
Khulud Group 
Figure 5.1: Settings in Qatar for all data generation 
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5.2.4. Participant inclusion and exclusion criteria 
The intention was to generate data representing all key stakeholder groups and 
stakeholders in Qatar. This would ensure that data were generated from key 
experts in their respective fields and who would have policy influence to enact 
the research findings. The key groups targeted represented health professionals 
at Director level (or equivalent) involved in prescribing (medicine, pharmacy and 
nursing), policy makers, leading administrators, senior educators and regulators, 
and managers of patient safety and quality assurance. Members of the research 
team based in Qatar were excluded from the study.  
5.2.5. Sampling frame and sampling approach 
The sampling frame included all individuals meeting the inclusion and exclusion 
criteria. The names and contact details of all were collated by the local members 
of the research team using their professional networks.  
Purposive sampling was employed (as described in Chapter 2) to capture those 
individuals most likely to contribute to the achievement of the research 
objectives. Snowball sampling was also used to ensure that no key individuals 
had been omitted. This was conducted by asking each interviewee to 
recommend others that they thought were important to include. 
5.2.6. Sample size determination 
The approach to sample size determination of Francis et al. (2010) was 
employed to identify the point of data saturation for each stakeholder group (i.e. 
the point at which no new themes emerged). The initial sample size for each 
group was set at five, representing diversity of years of experience and country 
of training. The stopping criterion was one, at which point recruitment ceased 
when no additional themes were identified. However, medical and nursing 
practice leaders proved more difficult to recruit hence only five of each were 
recruited. 
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5.2.7. Development of data generation tools 
The semi-structured interview schedule was drawn from a comprehensive 
literature review and the recent umbrella and systematic reviews conducted as 
part of the doctoral research (Stewart et al. 2017, Jebara et al. 2018). As 
discussed in Chapter 2, the Consolidated Framework for Implementation 
Research (CFIR) provided the underpinning of the schedule (Damschorder et al. 
2009). Employing a theoretical framework would ensure that individual facts had 
a meaningful context and contribute towards building an integrated body of 
knowledge. The schedule was reviewed for credibility by members of the 
research team prior to piloting with five academic and practice-based 
stakeholders. The doctoral student received training in qualitative interviewing. 
In addition, the pilot interviews were shared with the principal supervisor and 
feedback given to ensure both credibility and dependability. All pilot interviews 
were not included in the dataset. The interview schedule questions and 
alignment to the research questions and CFIR are presented in Table 5.1.  
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Table 5.1: Semi-structured interview questions (Consolidated Framework for Implementation Research 2016) 
Research questions Related theory 
constructs 
Interview questions Probes 
What are stakeholders’ 
awareness, experiences and 
views of prescribing by non-
medical health professionals 
with a focus on pharmacists? 
Intervention 
Characteristics (Evidence 
Strength and Quality) 
Are you aware of the possibility of 
prescribing by health professionals 
other than physicians? 
-[If Yes] What do you know about it? 
-How did you find out about it? 
-Have you ever experienced this? Where, 
when, extent of prescribing and by 
whom? etc 
-What do you think of it? 
-[If No] What do you think of it? 
What are stakeholders’ views 
and perceptions of clinical 
roles of pharmacists in Qatar? 
Inner Setting (Tension for 
Change) 
How do you feel about current 
programmes/practices/process that 
are available related to current 
clinical pharmacist roles in Qatar? 
-Are clinical pharmacists currently 
allowed to prescribe? 
 
-Does the current practice meet the 
needs of the community in Qatar? 
-To what extent? 
What are stakeholders’ views 
and perceptions of expanding 
the remit of pharmacists in 
Qatar to include prescribing? 
Intervention 
Characteristics (Relative 
Advantage) 
Inner Setting (Tension for 
Change) 
Outer Setting (Patient 
Needs and Resources) 
What do you think about 
implementing pharmacist prescribing 
in Qatar? 
-What do you think are possible 
advantages/disadvantages of 
implementing this in Qatar on: 
- Patients 
- Health professionals 
- Your organisation 
- Qatar’s society 
Do you think implementing 
pharmacist prescribing will meet the 
health needs of the Qatari 
community? 
-In what way? Improved access, reduced 
waiting time, reduce travel time and cost 
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What are the stakeholders’ 
views and perceptions of 
facilitators, barriers and 
solutions to the development 
and implementation of 
pharmacist prescribing in 
Qatar? 
Inner Setting (Structural 
Characteristics) 
 
Process (Planning) 
What kind of changes or alterations 
do you think will need to be made to 
successfully implement pharmacist 
prescribing in Qatar? 
-Changes in scope of practice? Changes 
in formal policies? Changes in 
information systems or electronic records 
systems? Other?  
-What kind of approvals will be needed? 
Who will need to be involved?  
-Can you describe the process that will 
be needed to make these changes such 
as: 
- Training needed 
- Accreditation requirements 
- Need for monitoring and review 
Outer Setting (Patient 
Needs and Resources) 
How do you think patients will 
respond to pharmacist prescribing? 
What barriers might they face? 
Characteristics of 
Individuals (Self-efficacy) 
How confident do you think your 
colleagues feel about implementing 
the intervention? 
What gives you that level of confidence 
(or lack of confidence)? 
Inner Setting (Relative 
Priority) 
To what extent might the 
implementation take a backseat to 
other high-priority initiatives going on 
now? 
-How important do you think it is to 
implement the intervention compared to 
the other priorities?  
Inner Setting (Available 
Resources) 
Do you expect to have sufficient 
resources to implement and 
administer the intervention? 
-[If Yes] What resources are you 
counting on? Are there any other 
resources that you received, or would 
have liked to receive? 
 
-What resources will be easy to procure? 
 
-[If no] What resources will not be 
available?  
 
-What challenges do you expect to 
encounter?  
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5.2.8. Data generation 
All potential participants were emailed the participant information leaflet and 
asked to partake in this project by the HMC Executive Director of Pharmacy 
(Appendix 5B and 5H). If no response was received within two weeks, a 
reminder email was sent. If agreeing to participate, a convenient location, date 
and time of the interviews were sought via email. Prior to commencing the 
interview, the doctoral student articulated the information leaflet and obtained 
signed, informed consent (Appendix 5C). 
Interviews of approximately 45-60 minutes were digitally audio-recorded and 
transcribed verbatim by the doctoral student, indicating mannerisms and 
physical characteristics in order to capture more accurately the interaction 
between the participant and the researcher. All interviewees were offered to 
review the transcripts to promote credibility and dependability. A summary of 
the data generation process is given in Figure 5.2.  
5.2.9. Data analysis 
Thematic analysis was conducted according to the steps outlines by Howitt 
(2016), as described in Chapter 2. In summary, once the transcribing was 
complete, all interviews were inputted into NVivo®. The responses were initially 
coded then examined in order to cluster similar trends together into themes 
based on the initial coding and the different CFIR constructs. Afterwards, the 
emerging themes were reviewed against the original data then indexed and 
defined. The analysis was conducted by TJ and independently reviewed by at 
least one team member and disagreements resolved through discussion. Data 
are presented in the form of quotes made by interviewees in the results section. 
Mannerisms were found not to add any value hence were not reported as part of 
the verbatim quotes.  
 
 
156 
 
 
Figure 5.2: Summary of interview process 
 
5.2.10. Data storage 
Measures were taken to protect the anonymity of participants. All information 
recorded and transcribed was stored in secure laptops with restricted access. All 
research materials were handled in accordance with School of Pharmacy and Life 
Sciences standard operating procedures. 
 
5.3. Results 
5.3.1. Stakeholder recruitment 
Seventy-five stakeholders were invited; 11 from academia, 9 medical directors, 
10 pharmacy directors, 12 nursing directors, 22 healthcare policy developers 
and 11 patient safety advocates. Thirty-seven interviews were conducted to 
reach data saturation in each stakeholder group. The recruitment process is 
described in Figure 5.3.  
Invitation email 
sent
Invitation accepted 
and interview 
scheduled
Interview conductedTranscription
Analysis
 
Data saturation 
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Figure 5.3: Process followed in recruiting stakeholders 
Stakeholders that agreed to participate
Academic 
Leaders (n=9)
Medicine (n=2)
Pharmacy and 
Pharmacy 
Technician (n=5)
Nursing (n=2)
Medical Practice 
Leaders (n=5)
Pharmacy Practice 
Leaders (n=6)
Nursing Practice 
Leaders (n=5)
Healthcare Policy 
Developers (n=6)
Patient Safety 
Advocates (n=6)
Invitation email sent to:
Academic 
Leaders (n=11)
Medicine (n=4)
Pharmacy and 
Pharmacy 
Technician (n=5)
Nursing (n=2)
Medical Practice 
Leaders (n=9)
Pharmacy 
Practice Leaders 
(n=10)
Nursing Practice 
Leaders (n=12)
Healthcare Policy 
Developers 
(n=22)
Patient Safety 
Advocates (n=11)
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The practice settings of stakeholders were diverse, as described in Table 5.2  
Table 5.2: Characteristics of included stakeholders according to practice setting 
Stakeholders’ category Setting: Number of participants 
Academic Leaders • Medicine: 2 
• Pharmacy and Pharmacy technician: 5 
• Nursing: 2 
Healthcare Policy 
Developers 
• Primary care/Community: 1 
• Secondary care: 1 
• Tertiary care: 2 
• Corporate/Ministry: 2 
Medical Practice Leaders • Secondary care: 2 
• Tertiary care: 3 
Pharmacy Practice 
Leaders 
• Primary care/Community: 2 
• Secondary care: 1 
• Tertiary care: 2 
• Corporate/Ministry: 1 
Nursing Practice Leaders • Secondary care: 1 
• Tertiary care: 2 
• Corporate/Ministry: 2 
Patient Safety Advocates • Primary care/Community: 1 
• Secondary care: 1 
• Tertiary care: 4 
Note that further demographic details of the participants are not given to protect their 
identities thus maintaining anonymity. 
5.3.2. Key themes 
The results are presented as two main sections. The first relates to the views 
and perceptions of patient-facing roles of pharmacists in Qatar. This is followed 
by the results relating to aspects of pharmacist prescribing generally, and 
specifically in terms of the potential for developing and implementing in Qatar. 
For ease of reading, both sections are presented according to the domains and 
constructs of CFIR.  
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a. Results: Pharmacy Practice in Qatar 
At the outset of the interviews, all were asked their views and perceptions of the 
pharmacist’s clinical activities irrespective of sector.  
Innovation characteristics  
In terms of the innovation of clinical pharmacy practice, there was recognition 
that this role was developing at pace, particularly within the secondary care 
setting of HMC. There was description of the clinical pharmacy service in general 
and exemplified through specialist activities such as the pharmacist led 
anticoagulation clinic. 
1. Innovation source 
There was recognition that the anticoagulant service had significantly developed 
in recent years. This was expressed by participants from all groups of 
stakeholders. 
“The clinical pharmacists’ role has developed quite significantly in the recent 
years like for example in Al Wakrah Hospital there is the anticoagulation 
clinic that is run by pharmacists.”   Academic Leader 1 
 
The clinical service had extended to allow dose adjustment. 
“We call it the anticoagulation clinic where the clinical pharmacists are on the 
front line, meeting the patients usually not new initiation of medication but 
rather continuation of warfarin, checking the INR and then adjusting the dose 
so they make the decision.”    Medical Practice Leader 5 
 
There was also recognition of other examples of clinical services.  
“Also in clozapine clinic in mental health, there is a direct contact with the 
patient for monitoring the side effect and recording if require changing the 
dose or any side effects…”    Pharmacy Practice Leader 4 
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2. Evidence strength and quality 
The expansion of the numbers of clinical pharmacist within HMC was considered 
to be an indication of effectiveness, efficiency and acceptability. 
“I don’t really have the statistics but the number of clinical pharmacists now 
in Hamad [Hamad General Hospital] is really big. We started only with 10. 
Today maybe we are talking about 60-70 pharmacists. So why did we have 
this expansion if the role is not really important?” 
Academic Leader 3 
3. Relative advantage 
Clinical practice was perceived to bring many advantages including professional 
autonomy which was considered a springboard to further developments.  
“… It will give you more confidence in what you are doing, your clinical skills, 
would help increase the trust that is given to the pharmacists and maybe 
help them gain more roles in the future in doing more collaborative practice 
agreement. We were thinking about implementing that to include other 
specialties like heart failure.”   Academic Leader 6 
“…because they have all the qualifications and they feel that their skills are 
underutilised…things that they have studied they are really [applying].” 
Patient Safety Advocate 4 
 
There were also examples of positive feedback from patients.  
“Generally our feedback with like warfarin clinics and such that we have is 
very positive… patients don’t wait for months to get an appointment. I don’t 
think they feel any different from what the physician is doing. I actually 
believe that pharmacists maybe give more time to explain about medications 
and potential side effects and interactions than what physicians do.” 
Healthcare Policy Leader 2 
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This clinical service was also reported to reduce pressure on physicians.  
“The most important advantage I see from the side of physicians is that it 
will free their time to do more skilled work definitely….”  
Academic Leader 6 
 
There was also the view that patient health outcomes were improving.  
“Being able to be seen on time would improve definitely the outcomes as far 
as efficacy and safety. We have already a study looking into patients seen by 
a physician versus a pharmacist and we can see definitely that the 
anticoagulation outcomes have been better with those monitored by 
pharmacists.” 
Academic Leader 6 
 
4. Design quality and packaging 
Mandatory continuing professional development for pharmacists was considered 
a positive development contributing to the quality of services.  
“I think they are efficient. They keep continuous educations so they have 
weekly sessions so they are updating themselves.” 
       Healthcare Policy Leader 1 
 
Furthermore, those involved in the delivery of new and specialised services had 
to undertake further education and training.  
“It is a condensed course that focuses on anticoagulation, how to dose, what 
are the guidelines available and the pathophysiology.” 
Pharmacy Practice Leader 3 
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While these developments were in HMC settings, it was highlighted that they 
could also be in primary healthcare centres. 
“Now it is in Heart Hospital, now it is in Wakrah Hospital. They don't have it 
in primary healthcare the warfarin clinic. But if the volume of the patients 
increase, it can be in primary healthcare, why not?” 
Medical Practice Leader 5 
 
Outer setting 
1. Needs and resources of those served by the organisation 
There was a feeling that the general public was not aware of the skillset of 
pharmacists and that this could act as a barrier to expanding scope of practice. 
“Patients are barriers because they don’t really value the role of the 
pharmacist… Unfortunately, at the moment, pharmacist role is still under-
utilised in terms of public perception. Anytime you speak about pharmacist, 
shop keeper image pops to their mind. Pharmacists need to try to promote 
their profession not just to the public and the patients but also to the other 
healthcare professionals.”    Academic Leader 1 
“The role of the pharmacists and nurses as well is extremely poor. It is not 
well known, it is not well advertised… Patients don’t understand and if we 
start implementing pharmacist prescribing, they will be ups and downs.” 
Patient Safety Advocate 3 
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Inner setting 
1. Structural characteristics 
Many participants highlighted that while the public sector was highly regulated 
with focus on quality of care, the private sector was profit oriented. 
“The public sector I think it is more structured because they are accredited, 
they know about the rules, they have some policies, they have some 
guidelines to follow and they have a reporting system...but in private, 
nothing. They don't have the policies, they don't have guidelines, they are 
more or less looking for money.”   Healthcare Policy Leader 3 
 
There were contradictory views around the influence and power of the medical 
profession around these developments in clinical pharmacy practice.  
“It is still completely physician driven. There is still a hierarchy.” 
        Academic Leader 8 
“In the cancer centre they have a very intimate collaboration with them and 
communication and they really are valued [as an] equivalent member of the 
team. There is no hierarchy.”   Medical Practice Leader 1 
 
One overwhelming theme was that clinical pharmacy practice varied greatly with 
setting. There was recognition that HMC was much further advanced than other 
settings.  
“Initially [in HMC], we didn't have clinical pharmacists and everything we 
were doing we did it by ourselves. It is like brainstorming even for us 
physicians to know the doses adjustment based on the level, based on the 
creatinine clearance, based on the body weight… But when the pharmacists 
joined us, it made my life easy because I will depend on someone else, he 
will do everything for me.”    Medical Practice Leader 2 
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“As for practice, hospitals are better than community since community is not 
well developed because it lacks assessment and clinical practice.” 
        Pharmacy Practice Leader 6 
“In primary healthcare centres, they are developing now, they are in a better 
position if you compare them to the community pharmacists. But I have to 
say that still they need to work more on themselves. Comparing the 
community pharmacists to primary healthcare corporation pharmacists, 
profits in the community pharmacy come as a priority which is not the case 
in the primary healthcare corporation.”   
          Academic Leader 3 
“In secondary care, it is much more developed and so you have established 
clinical pharmacy programmes in place where you have pharmacists trained 
and working in wards.”    Patient Safety Advocate 3 
 
2. Networks and communication 
There were mixed views on the degree of integration of the pharmacist within 
the multidisciplinary team and therefore the communication networks in 
operation.  
“I have really good relationship here with my pharmacist as well. We have 
dialogue with regard to if there is any issue with nurses and administration 
for instances as well.”     Nursing Practice Leader 3 
“In the psychiatric hospital, the pharmacist was always in a little back room. 
And not on the floor at all… I just think that you need to open up the 
interprofessionalism, the collaboration.”   
      Academic Leader 8 
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Trust, relationships and communication were thought key to the anticoagulation 
clinic.  
“For the collaborative agreement, from the beginning we had very strong and 
very positive relationship with the medical directors…They are trusting me a 
lot. When I shared with them something, an idea, and when I explain it to 
them, approach them, they trust me “go ahead”. Building the trust and 
having good relationships with the team it will facilitate everything.” 
        Pharmacy Practice Leader 6 
 
3. Culture 
Despite the positive developments in clinical practice in HMC, there was still the 
view that pharmacists were generally undervalued. This view was shared across 
all practice settings.  
“I think pharmacists feel they are not appreciated by other members of the 
healthcare team. I think for example physicians they feel threatened by the 
advancement in the role of the pharmacists.”  
       Academic Leader 1 
“I suspect that there is a traditional view about the dispensing type 
pharmacist rather than that understanding of them having the kind of clinical 
background knowledge as well.”   Nursing Practice Leader 1 
 
One factor thought contributing to this lack of awareness and lack of value was 
the large number of expatriated health professionals.  
“We have physicians from very different backgrounds and parts of the world 
and all the different cultural heritages and there are sometimes adjustments 
needed to understand that other professional groups are just as valuable as 
their professional group is.”    Medical Practice Leader 1 
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4. Implementation climate 
a. Tension for change 
Almost all acknowledged that while clinical practice had developed, there was 
potential for further developments. Reasons cited including meeting the needs of 
the population and reducing physician workload.  
“Definitely there is a lot of room for improvement. There has been quite a lot 
of changes to the pharmacist role but there is a lot of space for further 
improvement.”      Academic Leader 1 
“The pharmacist should be going back-and-forth between each [ward] and 
reviewing all of their charts and their medications and their usage and they 
should also be part of the multidisciplinary team.”  
      Academic Leader 8 
b. Compatibility 
There was some appreciation that the clinical pharmacy practice service in HMC 
could be benchmarked to practice in western countries.  
“I left the UK thinking that I had a very good pharmacy service. I have come 
to Qatar and there is a better pharmacy service here in my view. I think the 
level of clinical pharmacy, the level of liaison with the physicians, the work 
that has been done on medicine reconciliation and medicine safety and the 
data that can be produced is second to none in my view.” 
        Healthcare Policy Leader 5 
The level of technology and automation available within HMC was considered a 
positive facilitator of clinical pharmacy development  
“The level of automation that goes into packages like Cerner is clearly 
already demonstrating that pharmacists can take on a more assertive role on 
behalf of the patients to protect their safety…” 
        Healthcare Policy Leader 4 
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While the clinical anticoagulation clinic was well-established, it was noted that 
this took time, with the development accelerated once physicians had evidence 
of positive outcomes. 
“At the beginning, when they don’t have much experience with it, they may 
be a little bit suspicious about the abilities of the pharmacists to do that 
appropriately. But then after a while, after they saw our abilities and how 
really the patients have been stable and monitored appropriately, I think 
they got more and more confident about our abilities to do it and they 
started to refer more patients even.”  Academic Leader 6 
 
c. Relative priority 
Developments in clinical practice were felt to align to the Qatar National Vision 
hence were considered beneficial. 
“…It will relieve the physician time a little bit… I think this is a very important 
part to be considered in the priorities of the national health over here.” 
Academic Leader 6 
 
5. Readiness for implementation 
a. Leadership engagement 
The support of the pharmacy leaders was considered a main influential factor in 
clinical development.  
“I think the Director of Pharmacy, she is really a pioneer in introducing this 
programme into Women’s Hospital. This started I think seven years ago and 
now we have very good clinical pharmacists who are eager to work and to do 
further responsibilities.”    Medical Practice Leader 3 
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“This is the role of [the pharmacy] directors, their immediate supervisors, to 
speak to the stakeholders, to the top level managers, that this is the role and 
they do… it is not obvious.”    Patient Safety Advocate 1 
b. Available resources 
There was a perception that the number of skilled clinical pharmacists was a 
barrier to further service development.  
“You may have enough [pharmacists] but you need specific skills, you need 
people with clinical practice, competencies and clinical background not 
traditional type of education. Qatar lacks the number of clinically qualified 
and skilled professionals.”    Pharmacy Practice Leader 6 
 
This was noted to be a particular issues during times of staff absences.  
“If you have only one pharmacist covering the service, it gets difficult 
sometimes when they need to be on leave for conference or vacation.  
       Academic Leader 6 
 
Characteristics of individuals 
1. Knowledge and beliefs about the innovation 
There was general agreement that, given their education and training, 
pharmacists should be maximising their input to patient care.  
“When I look at the education of pharmacists, I think they should be working 
to full scope… I think by maximising their scope, it is better for the system 
and it is better for the patients.”   Academic Leader 9 
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2. Self-efficacy 
There was recognition that while some pharmacists were motivate to develop 
their clinical practice, there were many likely to be less motivated.  
“Pharmacy like any other profession, you will find the group of people who 
are really motivated to do more work, motivated to do, love the profession, 
would like to serve more and other…and other pharmacists who are still 
[not].”       Academic Leader 3 
 
Notably those involved in establishing the anticoagulation clinic were highly 
committed despite their existing workload. 
“The people I had on the team were very committed and enthusiastic to the 
project despite being already overwhelmed with their original work. They 
were working very hard and they were very proud.” 
        Pharmacy Practice Leader 6 
 
3. Other personal attributes 
The personal development of the pharmacists in Qatar was appreciated and 
thought related to their extensive training, and rigid recruitment and licensing 
standards. 
“I think they improved a lot from maybe 17-18 years ago. There is a lot of 
improvements in pharmacy practice and we appreciate that there is this 
change and improvement.”    Healthcare Policy Leader 6 
“We have a very tight process for recruiting pharmacists so we are looking 
for quality first. So we have very good quality pharmacists with us.” 
        Pharmacy Practice Leader 2 
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There was, however, recognition that practice in community pharmacy centred 
on dispensing. 
“Unfortunately, I have to say that community pharmacy is one of the major 
gaps that we do really have here in Qatar… The role that is played by the 
community pharmacists in Qatar is still the traditional role in which they just 
sell medications and maybe provide some recommendations or counselling 
from time to time.”     Academic Leader 3 
 
Process 
1. Planning 
When developing and implementing clinical pharmacy services, there were 
several key factors for successful implementation. The need for involvement and 
communication with other health professionals was vital.  
“From the beginning before we started anything, we communicated in a very 
nice way with the physicians. So we started to talk to them in friendly ways, 
unofficially, from time to time… So none of the physicians felt threatened… 
We brought everything in a very professional way, with the proper 
communication and they were very supportive. We were very scientific, very 
friendly with them… I was appreciating them all the time by emails or 
verbally…”      Pharmacy Practice Leader 6 
 
The development of clear guidelines and policies was cited as being important.  
“We have developed and approved the policies, we developed the guidelines 
for all of the anticoagulants and antiplatelets and we decided on and 
approved the workflow as well… We decided that pharmacists have to go 
through certain competency certification… So they have been through that 
course and we sponsored them. And then we started and we continued 
monitoring the work, take feedback from physicians and from patients to 
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improve the process. We prepared the collaborative agreement itself and it 
was reviewed and approved by the medical director.” 
Pharmacy Practice Leader 6 
 
2. Engaging 
a. Key stakeholders 
The need for effective communication with all key stakeholders as part of 
implementation was highlighted.  
“And the consultant here was very happy about this idea and he supported it 
especially since he came from Canada and he knew how the system was 
running and he supported this. Otherwise it wouldn’t have worked.” 
Patient Safety Advocate 4 
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b. Results: Pharmacist prescribing 
The remainder of the interview results are those relating specifically to views 
and perspectives on pharmacist prescribing. As before, the themes are provided 
under each of the CFIR constructs. 
Innovation characteristics 
1. Innovation source 
Many of the interviewees across all stakeholder groups were aware of the 
concept of non-medical, and specifically pharmacist, prescribing either from 
their experiences or through the published literature. 
“I think with being trained in the UK and I did my MSc in Prescribing Sciences 
I am very familiar with pharmacist or other healthcare professionals 
prescribing… I think under some kind of agreement, pharmacists are able to 
prescribe certain kind of medications or sometimes repeat prescriptions.” 
Academic Leader 1 
“I know in some countries like in Canada, there were efforts to let the 
pharmacists to start prescribing. And I know in the States, in some states, 
the nurse practitioners and physician assistants can also prescribe some 
medications.”      Academic Leader 2 
“From previous experience being in the anticoagulation clinic in the States. 
We have been in a collaborative practice agreement where we do prescribe 
but after the patient has been referred with an initial diagnosis. We had the 
opportunity to alter the dose of warfarin, sometimes switch from warfarin to 
one of the new oral anticoagulants at that time, prescribe vitamin K, 
enoxaparin. So anything related to anticoagulation, I actually experienced it 
myself.”       Academic Leader 6 
“Worldwide, there are different and many models of prescribing. So there is 
the North American model which is usually in most cases more of a 
collaborative framework where physicians agree with pharmacists or nurses 
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to prescribe within a limited scope… However, in the UK they started a 
decade or two ago to have independent prescribing models for both nurses 
and pharmacists where they can, with certain certifications and courses with 
some diagnosis skills, they can have full authority to prescribe different kinds 
of medications… But even many other countries have started to do that.” 
        Healthcare Policy Leader 2 
“I did my fellowship in USA… I noticed that even the pharmacists are coming 
sometimes to change the management or to change the treatment or to 
change the doses… That means that they are allowing them to prescribe or 
even to increase the dose or frequency based on their judgement.” 
Medical Practice Leader 2 
“Yes, being British obviously [I am aware] and in fact I was involved in 
setting up both supplementary and basically open prescribing at the 
University of Bedford when I worked there… So yes I am familiar with both 
systems, supplementary and independent prescribing.” 
        Nursing Practice Leader 2 
 
Several were, however, less aware of non-medical prescribing practice. 
“Honestly, my knowledge is very low because in Denmark where I come from 
it is not used. There are very few cases where nurses have been able to 
prescribe like statins but that is the only thing I know about it.” 
Academic Leader 5 
“I am not sure actually. Where I come from in Germany or Switzerland that 
is not the case. In the United States, I think it is the case but I don’t know to 
what extent.”      Medical Practice Leader 1 
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In general, interviewees highlighted prescribing by pharmacists was not 
currently within scope of practice in Qatar. 
“No [pharmacists in Qatar cannot prescribe] to the best of my knowledge and 
I am talking about Hamad Medical Corporation… They help us a lot in 
designing the medication [regimen] and how to monitor and follow up the 
levels but they don’t really dictate any further actions.” 
Medical Practice Leader 3 
“They will advise the doctor that this is right or you need to modify… But not 
a direct dealing with prescribing.”   Patient Safety Advocate 2 
“They see the patient, evaluate, monitor, document side effects and 
monitoring the whole safety issues then after that there is no prescribing but 
they refer the patient to the original prescriber.” 
Pharmacy Practice Leader 4 
 
As described in the previous section, there was also recognition of the role 
development within anticoagulation which required physicians’ co-signatures. 
“I only know at Heart Hospital, they have anticoagulation clinic where the 
pharmacists are involved although I don’t think that they are actually 
prescribing. I think they are recommending the doses and the doctors will 
agree.”       Academic Leader 4 
“They could also write the prescription but there is always the supervision by 
a doctor who is observing all the clinics.”   
Medical Practice Leader 5 
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There was also recognition that the potential for developing and implementing 
pharmacists prescribing was being discussed at many levels within Qatar. As 
described by one interviewee, the scope of practice had been recently extended 
to include prescribing, a role which was likely to require additional certification.  
“[In Qatar], they added prescribing to the scope but they requested that the 
person who will be allowed to prescribe has to have additional certification… 
[However], it is not implemented yet.” 
Healthcare Policy Leader 6 
 
2. Evidence strength and quality 
Most considered that the evidence base of safety and effectiveness of 
pharmacist prescribing was of sufficient quantity, robustness and rigour to 
support developments in other countries. There was awareness of the published 
peer-reviewed literature on specific models (e.g. UK and Canada). 
“Pharmacist prescribing privileges in the UK… has been established since long 
time and there is also enough data to show the effectiveness and the 
efficiency of such initiative… this is supported by data and supported by 
strong research and supported by other experiences.” 
Academic Leader 3 
“Prescribing for example.. in any model I think we should be doing this 
because first of all there are many, many positive examples from all over the 
world. But I don’t think our pharmacists are less than these countries where 
these models occurred.”    Healthcare Policy Leader 2 
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3. Relative advantage 
The implementation of pharmacist prescribing in Qatar was considered by most 
to bring many advantages. For example, there were particular advantages to the 
pharmacists themselves, with likely increased in professional satisfaction and 
confidence.  
“I think it is important for pharmacists. It is good use of their skills… I think it 
fits nicely with the training that they get during their undergraduate or their 
postgraduate training… It will increase their self-confidence, they will feel 
that they are able to contribute more to society, they will feel that they are 
really a valued member of the healthcare team.”  
Academic Leader 1 
“Empowering the pharmacists or the staff working in the pharmacy, I think it 
will be good for them, they will feel they are empowered… and having them 
connected with certain organisation which is accredited, certified or known at 
least, it will give them some kind of pride.”  
Patient Safety Advocate 1 
“You are motivating pharmacists to give them something more to aim for… 
We need to create a structure within pharmacy that gives pharmacists who 
are ambitious a career structure.”    
Patient Safety Advocate 3 
 
There were benefits for physicians, with reduced time spent on prescribing 
allowing them to focus on other aspects of patient care.  
“This will definitely have an impact on the level of care that is provided to the 
patients. This will also reduce the pressure that we put on the physicians… 
especially since physicians are always complaining from the time given per 
patient.”       Academic Leader 3 
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“I think we need to assist some of our doctors to have more time to 
formulate the plan, to think about the treatment and so on. If we can bring 
additional capacity and expertise to build in then it is going to be better for 
patients. So it becomes more of a team effort than just one person.” 
Healthcare Policy Leader 5 
 
Notably, there was the view that pharmacist prescribing could lead to more 
timely access to care as well as that care being more holistic. Overall that could 
lead to improved patient satisfaction. 
“That would also enhance the patient experience itself in terms of waiting 
time, quick access to healthcare professionals as well as, especially for more 
chronic patients, many studies show that pharmacists can be as good as, if 
not better than, physicians.”    Healthcare Policy Leader 2 
“They are the easiest healthcare professional to access. [Patients] don't have 
to pay the fees, they don't have to be in a big queue, anytime they can enter 
the pharmacy they will find the pharmacist and if the pharmacist have a 
bigger role especially in prescribing and counselling and all those things, 
definitely that will help a lot.”   Pharmacy Practice Leader 2 
“I think it might make healthcare a lot more accessible particularly for 
example this [HMC] overpopulation.”  Nursing Practice Leader 5 
 
There was also general agreement that pharmacist prescribers could be more 
effective and safer than physicians given their extensive and focused education 
and training on medication.  
“When I look at the data we currently have, there is definitely room for 
improvement in terms of optimal prescribing and I think having people who 
are specifically trained and experienced in that area has got to be better.” 
Healthcare Policy Leader 5 
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“Sometimes physicians are not aware of the advancement around new drugs. 
The pharmacists will know because this is their area of expertise. So this will 
advance the practice.”     Healthcare Policy Leader 6 
“It will be safer, better and more economical. With pharmacists on site and 
pharmacists contributing, we will have less unwanted drug interactions and 
less toxicities therefore more efficiency and maybe also efficacy.” 
Medical Practice Leader 1  
 
There was also the potential for reducing the cost of healthcare, an outcome 
associated with many reasons including redistributed workload, reduced drug 
costs and reduced rates of hospital admissions. 
“This may have an impact on the cost because when you make the 
physicians’ time available for more complicated cases, this may be associated 
with cost reduction.”     Academic Leader 3 
“Is it going to be more expensive for pharmacists to prescribe? I don’t think 
so. Would you actually be able to cut cost or economise? I think pharmacists 
might be very instrumental and say “you don’t need this” or “you can take an 
alternative”.”      Academic Leader 7 
“A transformed pharmacy will save money, it will prevent readmissions which 
frees beds.”      Healthcare Policy Leader 4 
 
 
 
 
 
179 
 
Implementing pharmacist prescribing was also considered to align with the 
aspirations of the Qatar National Vision 2030 of a healthier society by better 
utilising the skills of healthcare professionals. 
“To policy makers, I think having a skill-mixed profession is very important. 
It is in-line with Qatar National Vision where they want to have a healthier 
society, they want to make sure that they are graduating skilled healthcare 
professionals… So, I think it fits quite nicely to achieve its vision.” 
   Academic Leader 1 
 
Pharmacists assuming responsibility for prescribing could also impact the roles 
and responsibilities of pharmacy technicians. 
“I know pharmacy technicians will obviously have more responsibilities 
because the pharmacists will have to spend time with the patients.” 
   Academic Leader 4 
 
One further benefit was that if pharmacists were to prescribe the image of the 
profession may improve resulting in increased applications to study pharmacy at 
the College of Pharmacy in Qatar.  
“Having privileges for pharmacists to prescribe medications will really help in 
improving the pharmacy picture in the community… It will help in recruiting 
more national pharmacists which is a major issue to the college and the 
country as a whole.”     Academic Leader 3 
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4. Adaptability 
Many commented on the potential to adapt models of pharmacist prescribing 
developed in other countries to meet the needs in Qatar, particularly around 
chronic conditions prevalent in Qatar.  
“[It is] definitely important especially in diabetes, in heart failure as well as 
the antithrombotic overall… Those are all areas that could… have 
collaborative practice agreement and… being pharmacist-run.” 
Academic Leader 4 
 
One interviewee voiced the opinion that pharmacists should prescribe in defined 
areas where there was a clear need. 
“One of the best ways of doing this is to take a service that might be very 
under pressure and develop the role of the pharmacist within that service… It 
has to be more about the service and the need of the service not the need of 
the individual.”      Nursing Practice Leader 1 
 
5. Trialability 
One theme which emerged particularly strongly was the need to start slowly by 
piloting pharmacist prescribing in defined areas and collecting data on aspects of 
effectiveness prior to implementing on a wider scale.  
“Cost-effectiveness has to be calculated, do some sort of pilot economic 
studies to see to what extent this is going to help patients, what are the risks 
of it.”       Academic Leader 6 
“I would strongly advocate that we start small and build and demonstrate the 
benefits, so not a big launch… If it demonstrates and achieves benefits, then 
that is the reason to try a bit more probably. ” Healthcare Policy Leader 5 
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“… do piloting in one unit to see or like one specialty or one hospital… and 
you will see the system, it is [beneficial] on not.”  
        Medical Practice Leader 2 
 
The need for robust piloting was also emphasised.  
“I think you would have to pilot it within some very strict sort of piloting rules 
and see what the results [are].”      Nursing Practice Leader 4 
“You have to pilot it many times, not only one time. You have to pilot it in 
different situations, and different timing with different personnel, with a 
different facility and different clinic. Then after piloting, you have to adjust 
your action plan.”        Healthcare Policy Leader 3 
 
6. Complexity 
There were some comments on issues around the potential complexity of 
pharmacist prescribing, dependent on the model to be implemented. This was 
particularly noted in relation to diagnostic skills. 
“So, you can play through scenarios where if it is left to the pharmacist to 
make a clinical diagnosis and write a prescription, that to me, is beyond the 
scope, I think.”      Patient Safety Advocate 5 
 
Embedding sufficient quality assurance within any prescribing model was 
considered to add to the complexity.  
“The challenge is just to secure the quality that is needed to make this a 
reality.”        Medical Practice Leader 1 
 
 
182 
 
There was also a concern that pharmacist prescribing could potentially lead to 
conflict with physicians, particularly associated with an independent prescribing 
model.  
“The disadvantage would be the conflict... because if you create some kind of 
independency among clinical pharmacist, he might work away from the 
physicians’ direction.”     Medical Practice Leader 3 
 
There was potential for conflict with other key stakeholder groups including 
nurses and the Ministry of Health.  
“Changing the workload for the doctors, nurses, and pharmacists… the 
doctors [will say] "I will not prescribe?" it is a big thing for the doctor. And 
the nurse "I assist doctor before. Now I am assisting pharmacist. Why I have 
to do [that]?"      Patient Safety Advocate 4 
“First of all [you will face challenges] from the other professional provider. 
Physician of course they will strike for this… and some of the population, the 
people at the same time. I don't think the Ministry of Health, they will not… 
[pose a] challenge unless if they need to change the rules, the regulation.” 
        Pharmacy Practice Leader 1 
 
One concern highlighted was that implementing prescribing by another group of 
health professionals could result in very complex networks of communication 
which could be problematic.  
“If the pharmacist somewhere in HMC was changing the medication orders or 
the prescription for the patient in the absence of a conversation with the 
doctors, I think, from the nurses’ perspective, if we're administering the 
medications, we would want to understand what's going on here.” 
        Nursing Practice Leader 4 
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This issue could also be complex at the level of the individual patient. 
“The doctors, in a hospital setting, have the relationship with the patient 
which is about managing their healthcare. The pharmacists don't have that 
level of relationship with the patient.” 
          Nursing Practice Leader 4 
 
Some interviewees highlighted that the current legislative framework could be a 
barrier to be overcome.  
“You have to change the law which is not easy… How you are going to handle 
this legal framework? How are you going to make it legal for the 
pharmacists?”      Healthcare Policy Leader 3 
 
Another concern was raised over possibility of overburdening pharmacists who 
would need to juggle their clinical and prescribing roles. 
“The other disadvantage is if we don’t get the workload balance correct 
and the workforce balance correct, in other words overburdening the 
pharmacists with prescribing duties as well as clinical duties on the ward.” 
       Patient Safety Advocate 3 
7. Design quality and packaging 
In relation to the actual model of pharmacist prescribing and how it could be 
implemented, there was the overwhelming view that it would be best to be more 
conservative, particularly in the initial stages, prior to proceeding to a more 
autonomous model. This was highlighted by all stakeholder groups.  
“I think at the beginning it has got to be collaborative… But as the 
pharmacists get more experienced, they can go to independent.” 
Academic Leader 4 
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“Collaboration is the whole concept in this. If we were to go on the 
independent route, there may be limited cases where we talk to each other… 
Even in the medical team, we always generate a consensus according to the 
level of experience. So if it then comes to ordering medications and the 
treatment, I think that it is more needed that we communicate.” 
Medical Practice Leader 1 
“[Independent prescribing] is a fairly big step up from what I've seen… with 
the collaborative/supplementary one… I think that can be a good step 
because it would then require an interdisciplinary sort of activity where the 
doctor actually establishes a clear plan of care and then the pharmacist 
works within it… The collaborative model is safer at this stage.” 
Nursing Practice Leader 4 
“At the time being, I believe that [collaborative prescribing] will be the 
foundation for things that we have then after that we will focus on 
independent… Independent, I don’t believe that we are in this stage… I 
believe that first let us start with this, wait 5 years to see the impact for that 
then we can ask for independent prescribing.”   
Pharmacy Practice Leader 3 
 
A further key theme relating to model design was that there had to be a clear 
need for pharmacist prescribing and to potentially target key therapeutic areas 
of patient groups. Targeting should also consider the skills and competencies of 
the pharmacists. 
“I think it is also important to see that there is a need for it. Not just do it in 
all the areas, no.”      Academic Leader 1 
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“I am internist and specialist, I cannot write chemotherapy, I cannot write 
anti-diabetologists and endocrine or certain limited restricted medications. So 
it should be the same… So he cannot prescribe something different beyond 
his specialty… They have to have their own sub-specialities.” 
Medical Practice Leader 2 
“I do believe having it for certain diseases would be better then you can start 
to expand… Then within one disease, within one category, you can start to 
add. So, the pharmacist will be more competent and more confident.” 
Patient Safety Advocate 1 
 
However, several other interviewees held the opposite view that by limiting 
pharmacist prescribing to specific conditions or medicines could reduce the 
potential for holistic care and review of all medicines. 
“If you restrict the medications, you will mess with the experience of the 
pharmacist on how to handle a different disease or a different situation.” 
Healthcare Policy Leader 3 
“I think it is very hard to limit yourself to one section of the formulary 
because again just going back to diabetes the likelihood is that people have 
multiple co-morbidities and again we don't want to get into a situation where 
we see the patients and we will say" I can only prescribe this bit”.” 
Nursing Practice Leader 1 
 
In addition to themes relating to the prescribing model and patients to target, 
there was wide-ranging discussion on the appropriate settings for implementing 
pharmacist prescribing. While it appeared that there was more support for 
implementation in the hospital sector, there was also potential for later 
implementation in all settings including community pharmacy. This centred on 
186 
 
better communication within hospital and greater clinical skills and experiences 
of hospital pharmacists.  
“At the time being, I believe that the hospitals should be the first people to 
implement it just to establish the fundamental things then after than we can 
expand it to PHCC and the community pharmacies because, to be honest, it 
is well known that there is a difference in competencies between community 
and hospital pharmacists.”    Pharmacy Practice Leader 3 
“It is a very good idea if there is a collaboration between the pharmacist and 
the physician anywhere, any place, this would be perfect… I would love to 
see in the hospital set up, health centre set up, but not in the community 
pharmacies.”      Medical Practice Leader 3 
 
While possessing a postgraduate qualification in clinical pharmacy or related 
area was important, this was not essential provided that sufficient training was 
provided. 
“I wouldn’t prefer to have necessarily like a masters or a PhD. Of course, that 
is a bonus but I don’t think it is essential as far as that the course you will 
implement, certification or competency course, is certified by QCHP and it 
gets really developed by people who are experts in this.” 
       Healthcare Policy Leader 2 
 
There was, however, overwhelming agreement that pharmacist prescribers 
should undertake specific education and training prior to prescribing, 
irrespective of any prior qualifications.  
“Train the pharmacists. It is not only training once. You have to have a 
certification done. It has to be on several episodes; we train them, we 
assess, we train, we assess. So, it has to be over a long period so that you 
ensure the sustainability of the skills and the knowledge they have obtained… 
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You don’t want the pharmacists prescribing wrong medication or a wrong 
dose if they are not competent enough.”  Academic Leader 2 
“There should be a training programme for all the pharmacists on how to 
start prescribing, when they should stop, they should know their limit…” 
Healthcare Policy Leader 1 
“…so, no-one will work until he passed this training and he have to be 
privileged by QCHP.”     Healthcare Policy Leader 3 
 
Supervision was considered to be a key element of the programme to allow 
assessment of prescribing in practice.  
“You should have the proctoring system… Somebody have to, in the 
beginning, proctor them and say that this individual is expert now, they can 
continue, and they don't need to be under supervision.” 
        Healthcare Policy Leader 6 
“I think a period of supervised practice would be helpful. So I think finding a 
medical colleague who is really supportive that can kind of support the 
pharmacist through the process.”   Nursing Practice Leader 1 
  
The need for continuing professional development evidence through 
accumulation of credit was highlighted, emphasising that this development 
should be within the field of prescribing practice.  
“People who have prescribing authority should have so many credits and 
keeping current with that particular specialty which they are going to be 
authorised in.”      Academic Leader 4 
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Outer setting 
1. Needs and resources of those served by the organisation 
Many interviewees across all stakeholder groups highlighted that public 
perceptions of pharmacists, their training and abilities may hinder 
implementation of pharmacist prescribing.  
“Is the patient ready for this as well? Not only the pharmacist… Many 
patients, especially in the Arab region, will tell you “Ah, pharmacist? He just 
dispense medication. I would trust the physician more” because still the 
physician is at the top of the hierarchy.”  
Academic Leader 2 
“For outpatient setting, I think patients will totally resist the change. You 
have to think how you are going to overcome this resistance.” 
Healthcare Policy Leader 3 
 
2. Cosmopolitan 
The fact that pharmacist prescribing had been successfully implemented in other 
countries, and particularly developed Western countries, was perceived as a 
positive influence on implementation in Qatar.  
“You have to connect them with other experience or to be affiliated with 
another organisation whom they have the same programme for example 
prescribing in Canada, USA, UK wherever which is well developed… Having 
them connected with certain organisation which is accredited, certified or 
known at least… They are doing it in this way. We can do it. Let us try it.” 
Patient Safety Advocate 1 
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Inner setting 
1. Networks and communication 
Interviewees highlighted that those health professionals working alongside 
pharmacists in the hospital setting were fully aware of the pharmacists’ clinical 
roles. This, however, was not the case for those in community settings.  
“Talking about physicians and nurses because they are in a daily contact with 
the pharmacists, they are aware of the pharmacist’s role especially when we 
say in the hospitals… So, I have to say that because of the communications 
or because of the contact between them and the pharmacists, they more or 
less know the role that the pharmacists play. But talking about maybe 
community, I think no. Still the role is not clear to them.” 
        Academic Leader 3 
 
2. Culture 
There were mixed views relating to organisational culture within Qatar in that 
while some may embrace change, others would be more resistant.  
“I have been through the process of implementing a brand-new role. And you 
will always get people who embrace the change very, very quickly and you 
always get people who are really kind of slow to adopt the change.” 
        Nursing Practice Leader 1 
 
3. Implementation climate 
a. Tension for change 
Interviewees perceived several factors which could act as positive drivers for 
change. One key factor was the lack of physicians.  
“I think in Qatar particularly there is a great need because you need to 
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distribute a lot of the tasks away from the doctors because they are too 
overwhelmed and have too many patients.”   
      Academic Leader 5 
“With the increased costs of healthcare and shortage of healthcare providers 
including physicians of course, there is a need to widen the scope of 
prescribing for other healthcare professionals…” 
        Healthcare Policy Leader 2 
 
b. Compatibility 
The presence of the College of Pharmacy in Qatar and the quality of the 
programme was felt to align very strongly with implementing pharmacist 
prescribing.  
“I think you have probably got more chances of getting pharmacists 
prescribing than nurses. There is a very strong academic programme for 
pharmacists in Qatar…”    Nursing Practice Leader 1 
 
Pharmacist prescribing was perceived as being compatible with the hospital 
setting where prescribing was considered a natural extension to pharmacists’ 
existing clinical roles. Within that setting there were existing channels of 
communication and training programmes.  
“Within Hamad hospitals, there are clinical pharmacists that have direct 
patient roles…”      Academic Leader 1 
“In Hamad, they started the PGY1 and this PGY1 programme got the 
accreditation only last week. So, if we are able to establish a residency 
programme and get it accredited from an international accreditation agency, 
we will be able to achieve a pharmacist prescribing project easily with the 
motivated people that we have.”   Academic Leader 3 
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In contrast, community and primary healthcare pharmacy practice was 
considered to be much less compatible with pharmacist prescribing due to the 
nature and volume of work.  
“…but if I talk about primary healthcare, when I have 500 prescriptions to 
dispense per day, what kind of counselling or cognitive service do you expect 
from these pharmacists if they cannot even go for their lunch break? Do you 
want to bombard them with prescribing in addition to dispensing?” 
       Academic Leader 2 
 
c. Relative priority 
Developing and implementing pharmacist prescribing was perceived as a priority 
which was in keeping with the aims and ambitions of Qatar National Vision 2030 
and the National Health Strategy.  
“I haven’t seen any national priority that did not mention health as part of it. 
Now talking about pharmacist prescribing, it comes under the umbrella of 
health… So I think pharmacist prescribing project comes in the core of an 
important pillar of all these.”    Academic Leader 3 
“The triple aims that are set out in the National Health Strategy I think 
almost require us to think about pharmacist prescribing more because a 
major part of it is about safe care and if pharmacist prescribing can improve 
the safety of our care then it is a key plank over National Strategy and 
certainly a major priority within Hamad.” 
        Healthcare Policy Leader 6 
 
Other noted that while pharmacist prescribing was important, other initiatives 
were more important. There were several reasons for this, one of which was 
that there were existing models of physician prescribing.  
“In the context of multidisciplinary and structured approach, I think it is in 
192 
 
the upper half of the priorities. I mean the bigger ones are things like beds 
and recruitments.”     Healthcare Policy Leader 4 
“I cannot say it is priority one because physicians are prescribing, and 
physicians have been prescribing for many years.” 
       Healthcare Policy Leader 6 
 
Several noted that these other competing priorities could limit the resources 
available for the development and implementation of pharmacist prescribing in 
Qatar. 
“It depends on what other things they are trying to implement in terms with 
the healthcare strategy… They need to look at this and see do we have 
enough resources to do this all in the same time or do we have to do this 
phased.”       Academic Leader 4 
“So, frankly speaking, it might not compete with [other priorities] to be on 
the front line as a priority… We need to cover all the oncology patients with 
the best technology available for example. We need for example to provide 
best home healthcare services rather than to occupy the beds in the 
hospitals.”      Pharmacy Practice Leader 5 
 
4. Readiness for implementation 
a. Leadership engagement 
Within the hospital setting, there was clear support for pharmacist prescribing, 
with discussions on extending pharmacist clinical activities currently taking 
place.  
“For my end, I have no objection to it and I am already pushing it ahead now 
with a fairly senior consultant… he is very keen on pharmaceutical-led 
practice and we have been trying to almost beat up our pharmacists to 
understand that their job is to prevent death… Their role is to make doctors 
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accountable for the safety of our patients and that is what we have been 
telling them in the meetings and telling them how we want to reorganise our 
pharmacies.”      Healthcare Policy Leader 4 
 
b. Available resources 
Positive comments were received in relation to key resources which would be 
required for implementing pharmacist prescribing. These resources included 
human resources, access to clinical records and space. While these seemed to 
be available in all settings, most comments were received in relation to the 
hospital setting.  
“Resources in Qatar are always available…Human resources are also 
available. So I cannot see resources as a challenge…Access to medical 
records now is granted to the majority of healthcare providers even 
researchers.”      Academic Leader 3 
“In [my organisation], we have consultation rooms for pharmacists only. So 
space is available.”     Healthcare Policy Leader 1 
“In Hamad Medical Corporation, they are really having a vast and huge range 
of resources that we are so proud of. And Cerner is very helpful, this is a 
major resource. And we have a huge medical library.” 
       Medical Practice Leader 3 
“Within HMC, I think that the pharmacists probably do have good access [to 
medical records]…We have a good number of pharmacists and that the 
support staff is often the issue.”   Nursing Practice Leader 1 
“I can only talk about it from a hospital perspective but I have never worked 
in such well resourced environment from a pharmacy perspective. So I think 
it may just be about reengineering and looking at different ways of practice.” 
Nursing Practice Leader 5 
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There were particularly favourable comments in relation to the electronic health 
record system [Cerner] which was utilised throughout Qatar permitting shared 
access to patient information. While this did not currently extend to community 
pharmacies, this was not considered to be a major barrier. 
“We have got a great opportunity here in Qatar because of Cerner that is 
currently linked with family doctors and hospitals. If that was linked with 
chemists as well then it could be really extraordinary what pharmacists could 
do in primary healthcare in terms of all sorts of medication reconciliation.” 
       Nursing Practice Leader 2 
 
Some interviewees held contrary views, expressing views that additional 
resources would be required to implement pharmacist prescribing. These 
resources included human resources, space, access to clinical records and 
funding for related research.  
“Right now, I think if I just look at HMC, there is not enough resources to just 
deliver care. So, I think, with this, it will be a resource intense effort because 
again you will be talking about putting structures which means faculty, 
curriculum, monitoring, measuring, governing, regulating… so do you have 
the capacity now to put something like that together?” 
       Patient Safety Advocate 5 
“We don’t have enough number of clinical [pharmacists] to shift those with 
proper qualification to be independent or supplementary prescribers.” 
       Pharmacy Practice Leader 4 
“It needs space and we have space issue in HMC.” 
       Healthcare Policy Leader 2 
“I think definitely one of the things that you have to have is access to 
medical records… otherwise you are doing it blindly…I think if the Ministry 
and others don’t have the money, there are going to be difficult to procure 
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[resources needed].”      Academic Leader 9 
 
Characteristics of individuals 
1. Knowledge and beliefs about the innovation 
Many commented with regard to the existing knowledge base of the pharmacists 
and how this would facilitate pharmacist prescribing. 
“It should be a good thing especially for us pharmacists as we know all about 
medications and even we are usually teaching and consulting doctors about 
medication use.”     Healthcare Policy Leader 2 
“I think pharmacists certainly from my contacts have a tremendous amount 
of knowledge. They need to be supported in expanding their scope of 
practice.”       Academic Leader 9 
 
There was also acknowledgment of the knowledge base of students graduating 
from the College of Pharmacy at Qatar University.  
“We teach our students. We give them the skills, we give them the 
knowledge to make the right recommendation. So, from an education 
perspective, we will be happy because we already train our students to do 
this.”       Academic Leader 2 
 
2. Self-efficacy 
There were many comments in relation to pharmacists’ self-efficacy (perceived 
competence) to undertake pharmacist prescribing.  
“Pharmacists perceptions about their own roles and responsibility, maybe 
about their own self-confidence, maybe they don’t feel ready that they can 
do.”       Academic Leader 1 
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“Sometimes [pharmacists] themselves, they don't have the confidence that 
they can do it I think.      Healthcare Policy Leader 6 
 
3. Other personal attributes 
While interviewees felt that pharmacists may not be confident in their 
competence, others were much more convinced.  
“I don’t think our pharmacists are less than these countries where these 
models occurred especially that you always have these tests or requirements 
to get competence so that wouldn’t be a problem.” 
       Healthcare Policy Leader 2 
“I would be expecting them to be as up to date as any clinician in our 
multidisciplinary team about the latest guidelines, the latest drug 
innovations, the latest generic etc.”  Healthcare Policy Leader 5 
“I think pharmacists would probably have a greater body of expertise in 
medical stuff and I think it is something they should be able to do.” 
Nursing Practice Leader 5 
 
It was however noted that due to curriculum changes not all pharmacists would 
be considered to have the up-to-date knowledge required for prescribing.  
“The curriculum changes within years. So, maybe they are not prepared into 
the level that, it gives them the confidence that they can prescribe or they 
have the knowledge as a practitioner to make decisions.” 
       Healthcare Policy Leader 6 
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Interviewees across all professional groups highlighted the need to have gained 
experience in clinical practice prior to undertaking prescribing practice. There 
were comments that it was not an appropriate role for new graduates 
irrespective of their clinical training and exposure. 
“I would be hesitant on the fresh graduates. I would say that they should 
definitely have at least five years of experience because I think those also 
build your confidence and your skills and you can begin to see patterns in 
patients.”      Academic Leader 9 
“We have to focus our recruitment far more on pharmacists who have 
worked in multidisciplinary environments in hospitals of X size and with X 
amount of experience… I think they need to have minimum years. So, if we 
are asking for minimum three years in hospital care for someone to be a 
pharmacist so he can start.”    Healthcare Policy Leader 4 
“I think you have got to have some experience but that is my personal 
priority. I think you need to know your primary role first before getting into 
something a bit more different.”   Nursing Practice Leader 3 
 
Some also expressed concern over setting an arbitrary number of years of 
clinical experience prior to prescribing and that the nature and depth of the 
experience had also to be taken into account.  
“If we put a number of years on things, it is generally arbitrary. I think it is 
more about how active you are within the role that you are in now.” 
       Nursing Practice Leader 1 
“It depends on the field that he has experience with; maybe two years’ 
experience in critical care unit equal 20 years in a private clinic setting. So it 
is not really about the years of experience.”  
        Patient Safety Advocate 4 
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Some also considered that new graduates should be eligible for pharmacist 
prescribing training, depending on the institution and programme studied as an 
undergraduate and that this would be like graduates of medicine.  
“There is no reason why fresh graduates shouldn’t take part if they are 
coming from a qualified programme.”  Academic Leader 4 
“That is like asking for a freshly graduated physician needing to have 
additional and continuing training in order to qualify him/her as safe… I mean 
there is no label on someone it is always an evolution.” 
        Medical Practice Leader 1 
“I do believe in the fresh graduates a lot because they have the enthusiasm 
to do more. If they find a good coach, good mentor, I think they would 
exceed their mentors.”    Patient Safety Advocate 1 
 
Process 
1. Planning 
In relation to planning for the implementation of pharmacists prescribing, 
multiple factors were highlighted as being key. One theme which emerged very 
strongly was the need to engage with other stakeholder groups, to identify their 
awareness, support and reluctance to overcome these barriers well in advance 
of implementation. This was likely to take time, patience and providing 
reassurance.  
“The problem with doing new things is you always need to be very patient in 
the beginning and very careful that the nurses are supporting, the doctors 
are supporting, the pharmacists who have not been trained are supporting it. 
So really make a lot of political work and continue meeting groups and get 
joined support.”     Academic Leader 5 
“First, the pharmacy division needs to sell the concept based on international 
practice and evidence that it can work and what the benefits are and win 
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some medical champions… Then they should choose few areas where you can 
get the maximum benefit for using a pharmacist… It is probably the best way 
forward to win over people.”    Healthcare Policy Leader 4 
“I would then be looking at a stakeholder consultation to say this is what we 
believe from all the review work that we have done, what are the issues for 
the various stakeholders.”    Nursing Practice Leader 4 
 
Effort should also be dedicated to having clear role definition, particularly in 
relation to collaborative working and assuming a role which had previously 
involved only physicians. The need to avoid conflict was discussed by many 
interviewees.  
“Collaborative practice is very important, and it is not a competitive 
practice… You have to see the physicians’ acceptability, maybe you need to 
give them some ideas about the pharmacists role, maybe you need to 
educate the physicians that this is what the pharmacist is going to do so that 
everybody is on the same page. Role clarification is very important.” 
Academic Leader 2 
 
In addition to role definition, other aspects of governance were considered key 
to successful implementation. Clearly describing the prescribing framework, 
model and limits of prescribing were important.  
“You need to have a framework or you need to have guidelines also in place 
even if you were going to go ahead with this programme, pharmacists should 
know their boundaries; when I should refer, when I can still treat.” 
Academic Leader 2 
“Then I would set up some sort of clear governance framework for it and so 
it is very clear at which point decisions are made and who is responsible and 
accountable for them… and there would probably be some work that would 
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need to be done around the development of the models that you are 
proposing and a consultation around preferred models.” 
Nursing Practice Leader 4 
 
The need to ensure that pharmacist prescribing was in adherence with legislative 
frameworks was also emphasised.  
“First of all, you have to allow pharmacists to do it. So that is form a 
regulatory point of view, they need to be allowed to do it.” 
Healthcare Policy Leader 2 
“You would have to change all policies or the Emiri decree here. I think in 
Hamad, we would have to have a massive revolution in our policies.” 
Nursing Practice Leader 2 
 
As part of planning for implementation, many discussed the requirement for 
setting out a business case, highlighting the weaknesses of the current system 
and the likely benefits to be gained.  
“You have to submit a good proposal showing the strengths and weaknesses, 
the SWOT analysis and you should show them of course that this would be 
good; for patients quicker access, it is cheaper care with the same quality I 
believe because pharmacists salaries are less than physicians and also 
probably more patient satisfaction I assume with having more time to 
patients, quicker access to healthcare professionals and medications.” 
Healthcare Policy Leader 2 
“I have no doubt that it could be very safe and could be very cost-effective 
and could be a very good thing to be doing. However, we need to understand 
what is making it safe and why it is safe… So, I would try and build a very 
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strong case for doing this and I would use whatever literature there is that 
talks about cost-effectiveness or about safety of care.” 
Nursing Practice Leader 4 
“We need to look at what the benefits are and we need to prove that it works 
and we need to prove it is successful then we can share those results with 
others.”       Patient Safety Advocate 3 
 
Interviewees also recommended a detailed planning process which would involve 
all relevant stakeholder groups. At all stages, the need to protect patients and 
maintain safety in prescribing was emphasised.  
“I think implementation is always an issue in that you have to carefully look 
at really planning it out well and do you have all the stakeholders… and really 
being definite in knowing the roles about who is going to implement, how you 
are going to implement it, designing the implementation and then looking at 
if there are any issues.”    Academic Leader 9 
“If it is done quickly or it was not planned enough, or the certification 
processes were not adequate enough, of course there are risks to patient 
care and also this will impact negatively on the pharmacy image.” 
Healthcare Policy Leader 2 
 
2. Engaging 
a. Champions 
Interviewees highlighted that successful implementation would require support 
from senior physicians who could act as champions for pharmacist prescribing.  
“What I’ll be looking for would be a medical colleague who would want to 
support something similar.”    Healthcare Policy Leader 5 
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b. External change agents 
There was also a role for external experts who could act as change agents as a 
key part of the implementation process. Ideally, these individuals should also 
have specific expertise in the development and implementation of pharmacist 
prescribing.  
“Look at the best centre in the world having a good [pharmacist prescribing 
experience] and invite them to help us set this project.” 
       Medical Practice Leader 3 
 
c. Key stakeholders 
The need to consult and engage with a wide-range group of key stakeholders as 
part of the implementation process was evident across all interviews.  
“It is much easier to achieve change if you have everybody engaged and 
they will be more agreeable to a change because it is not being a change 
applied to them, it is applied with them.”  Patient Safety Advocate 3 
“A lot of the criticism and perhaps worry is about when things are done 
without everybody being involved, when people feel that they are on the 
outside of decision making.”    Patient Safety Advocate 6 
 
Given that patients were at the centre of healthcare and the prescribing process, 
it was essential that their views were taken into account hence the need to 
engage as part of the development, planning and implementation of pharmacist 
prescribing. Many interviewees highlighted that this would be a great change for 
patients and many would need much convincing.  
“Patients are big stakeholders. I think it will take a while to convince them 
around the skills and the knowledge [of pharmacists] …I think it would be 
important to actually interview patients to find out what is important to them 
as a stakeholder group.”    Academic leader 9 
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“My advice is to involve the patients as early as possible in the process of 
planning so even if they didn’t accept it, you will know why they are not 
going to accept it. You will know that in advance.” 
       Pharmacy Practice Leader 5 
 
Policy makers across many health institutions in Qatar were also considered vital 
to the implementation process hence their views needed to be captured.  
“I am quite positive that healthcare policy makers need to be on board. You 
need to get their buy-in to be able to promote it. I think leaders within either 
the healthcare institutions or within the Ministry of Public Health need to 
believe and realise the importance of this.” 
      Academic Leader 1 
“You need the support of the ministry, the Primary Health Care Corporation, 
Hamad Medical Corporation, all these entities.”   
        Academic Leader 2 
“I think you are going to have to have several people. You have to have the 
Ministry of Public Heath in terms of the views of public health and certainly 
when you look at stakeholders certainly Qatar Foundation is going to be a 
key one when you begin to look at Sidra and other hospitals, Primary Health 
Care Corporation.”     Academic Leader 9 
“We have Pharmacy and Drug Control they have to be involved. Quality 
Improvement, Patient Safety they have to be involved. Licensing and 
Accreditation department I think it is better to be involved… QHCP; Qatar 
Health Care Practitioners you have to discuss this model with them. How 
they can adapt to the new changes of pharmacists privileges.” 
       Healthcare Policy Leader 3 
“I think first, Qatar Council for Healthcare Professionals. There should be a 
policy written about it and everything clear; what type of 
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qualification/certification this individual needs and from what school is 
accepted. And then the healthcare organisation follows this direction because 
the healthcare organisations have to develop the policy and develop the 
process of proctoring or supervision to the individual.” 
        Healthcare Policy Leader 6 
“If there are any regulatory entities/bodies basically involve them. And then 
if there is an equivalent of pharmacy board to say you have met the 
qualifications to be able to do this.”   Patient Safety Advocate 5 
 
Support from pharmacy leaders was also considered crucial, with interviewees 
discussing the need for appropriate remuneration for a prescribing role and to 
ensure appropriate workload and balance.  
“We need to get the pharmacy managers on board so that basically 
pharmacists are reimbursed for doing this extra job.”  
       Academic Leader 2 
“Say you have the staff already committed to do their own work, you need to 
give them protected time [to be able to prescribe] and here you need the 
leaders to be involved so they can help you with this.” 
       Pharmacy Practice Leader 5 
Academics were highlighted as being key to the implementation of pharmacist 
prescribing. This was particularly important in relation to education and training, 
and to ensuring appropriate standards of practice.  
“When we talk about educational side, I think we should involve of course 
even the basic education like the undergraduate education. Of course we 
have here only one college [of pharmacy] which is Qatar University and they 
should be involved in starting this from the beginning.” 
Healthcare Policy Leader 2 
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“I think for developing the competency or developing the guidelines maybe 
we will need the academic people.”   Pharmacy Practice Leader 3 
 
All interviewees highlighted the importance of early engagement with all other 
health professional groups in all states of development and implementation. Full 
engagement at the outset was considered essential to identify any likely issues 
and resolve these at a very early stage.  
“You need to consider other healthcare professionals what do they think. You 
don’t want a clash with them at the end of the day so we want them to be 
supporting that…You have to look at the pharmacists themselves. You need 
to explain to them that and to get their support because they are your 
population of healthcare professionals who actually are applying for this.” 
        Healthcare Policy Leader 2 
“We have to work with the physicians, we have to work with the healthcare 
organisation management team to tell them that these individuals can 
practice on that level… We should get support of our team; the physicians, 
the department itself, pharmacy…etc they have to accept this.” 
        Healthcare Policy Leader 6 
“I think you are going to have to get medical staff engagement and buy-in 
because otherwise you are just going to get obstacles and resistance.” 
Nursing Practice Leader 5 
“So we need nursing involved, we need allied healthcare professionals 
involved, we need doctors, probably attract some leading doctors, to be 
involved in saying that this is the right way forward.” 
Patient Safety Advocate 6 
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On discussing engaging with the drug industry, many interviewees highlighted 
their concerns over involving industry in the development and implementation of 
pharmacist prescribing.  
“You might want to have a representative as an observer, that is fine. But I 
don’t think they can actually have any input because they would be biased.” 
       Academic Leader 7 
 
3. Reflecting and evaluating 
A major theme which emerged was that pharmacist prescribing should be 
monitored very carefully, to identify standards of practice, allowing the early 
identification thus resolution of any issues. Terms used included ‘complaints’, 
‘fall short’, ‘expected standards’, ‘audit and feedback’ etc. The monitoring should 
be continuous rather than just a one-off exercise.  
“They need to be monitoring patients’ complaints. So, if there is ever 
complaints against pharmacists that do advanced prescribing then that 
pharmacist needs to be reviewed…”  Academic Leader 4 
“The privilege is not given only written, somebody has to criticise their level 
of knowledge and it needs continuous monitoring...” 
       Pharmacy Practice Leader 4 
“I think that it has to be carefully monitored and so it really is looking at who 
are your pharmacists, what is their comfort level around prescribing… 
because audit and feedback is really useful to look at people’s practices… to 
see how they are, how they are doing. I think that is going to be really 
important and to make sure if you want to improve, how do you improve.” 
Academic Leader 9 
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Several interviewees also highlighted that measures should be put in place to 
measure the success, or otherwise, of pharmacist prescribing and to determine 
whether this had added value to the healthcare system.  
“We will do it, test it, then we will see the results… Then we will analyse the 
data, what are the pros, the cons, values and [do] we get added value or it is 
a waste.”       Patient Safety Advocate 1 
 
The key themes, described as facilitators and barriers, relating to each of the 
CFIR domains are given in Table 5.3. 
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Table 5.3: Themes of facilitators and barriers to the implementation of pharmacist prescribing in Qatar mapped to CFIR domains and 
constructs 
CFIR Domain CFIR construct Corresponding factors Classification 
(Facilitator/Barrier) 
Innovation 
characteristics 
Innovation source Awareness of NMP and especially pharmacist prescribing practice globally Facilitator 
Prescribing not currently within the scope of pharmacy practice in Qatar Barrier 
Establishing the pharmacist-led anticoagulation clinic Facilitator 
Evidence strength and 
quality 
Robust and rigorous evidence of effectiveness and safety reported globally Facilitator 
Relative advantage Potential to: 
-Increase pharmacists’ job satisfaction and confidence 
-Reduce doctors’ workload  
-Provide timely and holistic care, increasing patients’ experience and 
satisfaction 
-Reduce cost of healthcare 
-Improve image of the profession 
-Expand role of pharmacy technicians 
Facilitator 
Adaptability Potential to adapt models of pharmacist prescribing developed and 
implemented in other countries 
Facilitator 
Trialability Potential to pilot on a small scale to determine effectiveness Facilitator 
Complexity Lack of pharmacists’ diagnostic skills Barrier  
Need to ensure sufficient quality when prescribing Facilitator/ Barrier 
Potential for conflict with physicians and others, most notably if an 
independently prescribing developed and implemented 
Barrier 
Pharmacist prescribing could result in complex network of communication Barrier 
Current legislative framework in Qatar Barrier 
Design quality and 
packaging 
Implementing collaborative prescribing before proceeding to a more 
autonomous model 
Facilitator 
Need to prescribe in defined areas of clear need Facilitator 
Scope of prescribing must align with pharmacists’ competencies Facilitator 
Preference to initially implement in secondary care prior to extending to other 
settings  
Facilitator 
Requirement to provide additional education and supervised training Facilitator 
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Requirement to provide continuing professional development within field of 
prescribing practice 
Facilitator 
Outer setting Needs and resources of 
those served by the 
organisation 
Public and healthcare professionals’ perceptions of pharmacists’ education, 
training and practice 
Barrier 
Cosmopolitan Ability to collaborate with other countries experienced in pharmacist prescribing 
implementation  
Facilitator 
Inner setting Networks and 
communication 
Existing communication channels in secondary care Facilitator 
Im
pl
em
en
ta
tio
n 
cl
im
at
e 
Tension for change Shortage in the number of medical prescribers Facilitator 
Compatibility Quality of academic programme at the College of Pharmacy Facilitator 
Current clinical pharmacist roles in secondary care Facilitator 
Nature and volume of workload in primary care and community Barrier 
Relative priority Goals and ambitions of the National Health Strategy and Qatar National Vison 
2030 
Facilitator 
Competing priorities Barrier 
R
ea
di
ne
ss
 f
or
 
im
pl
em
en
ta
tio
n 
Leadership 
engagement 
Current discussions to extend pharmacists’ clinical activities Facilitator 
Available resources Availability of human resources, access to clinical records and space, most 
notably in secondary and primary care settings 
Facilitator 
Lack of access to clinical records in community pharmacies Barrier 
Characteristics 
of individuals 
Knowledge and beliefs about 
the innovation 
Current knowledge base of practicing pharmacists Facilitator 
Self-efficacy Pharmacists’ lack of confidence to undertake a prescribing role Barrier 
Other personal attributes Pharmacy practice in Qatar considered as advanced as in Qatar as those 
countries which have implemented pharmacist prescribing 
Facilitator 
Differences in pharmacy curricula studied by pharmacists in Qatar Barrier 
Requirement for pharmacist prescribers to have experience in clinical area Facilitator 
Process Planning Engagement of other stakeholder groups to identify potential barriers Facilitator 
Requirement to develop robust governance mechanisms (role definition, 
prescribing framework, model, etc.) 
 
 
Facilitator 
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En
ga
gi
ng
 Champions Need for support from doctors Facilitator 
External change 
agents 
Engagement of experts in developing and implementing pharmacist prescribing Facilitator 
Key stakeholders Early engagement of a wide range of stakeholders (pharmacy leaders, policy 
makers, patients, other providers, academics etc.) 
Facilitator 
Reflecting and evaluating Requirement to plan to monitor prescribing practice regularly Facilitator 
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5.4. Discussion 
5.4.1. Summary of key findings 
The aim of this phase of the research was to explore the views and 
perceptions of stakeholders regarding the development and implementation 
of pharmacist prescribing in Qatar. Interviews based on CFIR were conducted 
with key stakeholders in positions of power and influence in Qatar, with data 
saturation achieved on completion of 37 interviews. The interviewees were 
generally aware of models of pharmacist prescribing in other countries and 
the clinical activities of pharmacists in Qatar, most notably in Hamad Medical 
Corporation. These activities included working as a member of the 
multidisciplinary team, conducting medication reconciliation, and providing 
recommendations for individual patients. There was awareness and 
appreciation of and the recently established pharmacist-run anticoagulation 
clinic. There was also support for the development and implementation of 
pharmacist prescribing in Qatar, with many potential benefits highlighted. 
CFIR identified key themes of facilitators and barriers to implementation 
aligned to each of the five CFIR domains. While there are many more 
facilitators than barrier, particularly in the hospital setting within HMC, it was 
clear that there was a requirement to systematically plan the development 
and implementation of pharmacist prescribing with reference to all five 
domains.  
5.4.2. Interpretation of findings 
This is the first study on pharmacist prescribing which used a theoretical 
framework of implementation throughout the research processes of 
developing the research aim and objectives, interview schedule development, 
data generation, and analysis hence represents an original contribution to 
knowledge. The findings aligned well to the domains and constructs of CFIR.  
The themes derived in relation to the first two research objectives 
(awareness of non-medical prescribing models and clinical activities of 
pharmacists in Qatar) demonstrated the very positive perception of these 
models and clinical pharmacy practice, particularly within Hamad Medical 
Corporation. Together with the specific themes of CFIR-related facilitators, 
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these findings are very positive in relation to the implementation of 
pharmacist prescribing in Qatar. Furthermore, data saturation was observed 
across all stakeholder groups, as well as the population of interviewees, 
hence the rigour of the findings and likelihood of implementation increased.  
As noted earlier, the analysis of data generated from stakeholders across all 
participant groups identified facilitators and barriers to pharmacist prescribing 
implementation, with many more facilitators than barriers. These were 
reported around the five CFIR domains: 
• The innovation, highlighting the preference for a collaborative 
prescribing model rather than an independent prescribing model. While 
the model has been developed elsewhere, and supported by evidence, 
there was need to adapt, refine, trial, define the education and training 
and governance processes 
• The outer setting in terms of the need to articulate clearly the 
education, training and practice of pharmacists and to collaborate with 
those countries experienced in implementation 
• The inner setting with secondary care the preferred setting initially due 
to the maturity, culture, communication channels, readiness and 
clinical pharmacy practice 
• The individuals, highlighting that while clinical pharmacy practice in 
secondary care was perceived as well-advanced, effort is required in 
ensuring that pharmacists have the confidence and belief in their 
competence to undertake a prescribing role 
• The process in relation to discussion and engagement with wide-
ranging groups of stakeholders, to appoint product champions to plan 
and execute implementation, with robust governance policies and 
processes, and robust and rigorous evaluation to determine whether 
anticipated outcomes are realised 
While the systematic review of stakeholders’ views and experiences of 
pharmacist prescribing presented in Chapter 4 identified more than 60 
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studies, none of these were conducted in the Middle East. Furthermore, only 
29 were conducted pre-implementation and only six of these were of a 
qualitative methodology. 
There are, however, some similarities between the findings of this interview 
study and the systematic review. Several studies in the systematic review 
highlighted that major facilitators identified pre-implementation included 
pharmacists’ personal qualities (e.g. their clinical experience, and education 
and training) and the perceived benefits of pharmacist prescribing (e.g. 
improved patient access to care and better utilisation of pharmacists’ skills) 
(Hanes and Bajorek 2005, Auta, Strickland-Hodge and Maz 2016, Auta et al. 
2018). Studies conducted to identify facilitators in post-implementation also 
reported the importance of pharmacists’ training and experience, resources 
(easy access to medical records and prescription pads), having close working 
relationships with medical prescribers, working in an interprofessional team 
and perceptions of patient management (George et al. 2006a, Hobson and 
Sewell 2006b, George et al. 2007, Baqir 2010, Bourne et al. 2016). 
The systematic review also identified similar barriers in pre-implementation 
studies including concerns over pharmacists’ poor clinical skills in assessment 
and diagnosing, which were key issues in relation to independent models of 
prescribing practice (Hanes and Bajorek 2005, Nguyen and Bajorek 2008, 
Hoti et al. 2010, Erhun, Osigbesan and Awogbemi 2013, Auta, Strickland-
Hodge and Maz 2016, Auta et al. 2018). These concerns were reiterated in 
post-implementation studies and may indicate a misunderstanding of the UK 
independent prescribing model which does not actually require the diagnosis 
to be made by the pharmacist independent prescriber. In fact, the UK 
Department of Health definition of independent prescribing is “prescribing by 
a practitioner (e.g. doctor, dentist, nurse, pharmacist) responsible and 
accountable for the assessment of patients with undiagnosed or diagnosed 
conditions and for decisions about the clinical management required, 
including prescribing” (UK Department of Health 2006). 
Other similar barriers identified post-implementation were lack of funding to 
sustain services, potential liability issues, resources (space, privacy) and the 
lack of a clear organisational strategy to support pharmacist prescribers 
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(George et al. 2006a, Hobson and Sewell 2006b, George et al. 2007, Baqir 
2010, Hobson, Scott and Sutton 2010, McCann et al. 2011, McCann et al. 
2012b, Feehan et al. 2016, McIntosh and Stewart 2016). 
It is notable that these facilitators and barriers have been identified with 
groups of non-medical prescribers other than pharmacists, as highlighted in 
the umbrella review described in Chapter 3. Facilitators were non-prescribers’ 
experience as health professionals, the application of evidence-based 
guidelines and treatment protocols, peer support, and encouragement from 
medical practitioners and patients. Barriers included the lack of clearly 
defined roles for non-medical prescribers, no dedicated time allocated to 
prescribing activities, other competing tasks, lack of confidence of some 
NMPs, and the lack of acceptance of the role by other health professionals 
and patients. 
Given that none of these studies had adopted CFIR or a similar framework, it 
is not surprising that they did not comprehensively report the facilitators and 
barriers. Using CFIR in the interviews identified additional facilitators and 
barriers of: 
• The innovation in relation to awareness of pharmacist prescribing  
• The outer setting highlighting the need to educate the public and other 
healthcare providers on pharmacists’ education and training; and the 
potential to collaborative with other countries that have implemented 
pharmacist prescribing 
• The inner setting in terms of the goals and ambitions of the health 
setting in Qatar; the quality of pharmacy education and practice; and 
the readiness for implementation in Qatar 
• The individuals, highlighting the need to improve pharmacists’ 
confidence to undertake a prescribing role 
• The process in relation to need for robust governance; involving a 
diverse group of stakeholders in the design, implementation and 
evaluation of innovation 
These additional facilitators and barriers highlight the benefit of adopting a 
theoretical framework in research. Identifying these pre-implementation can 
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allow for a more tailored implementation which emphasises the facilitators 
and with action to overcome as many barriers as possible. This is likely to 
result in more successful and sustained implementation with better outcomes 
for patients, professionals and the organisation. Theoretical frameworks used 
in preparation for implementation, such as CFIR, can also help in guiding 
translation of research into practice, identifying influences on implementation 
outcomes, and evaluating implementation (Damschroder et al. 2009, Nilsen 
2015, Consolidated Framework for Implementation Research 2016). There is 
therefore merit in adopting CFIR in all subsequent stages of development and 
implementation of pharmacist prescribing in Qatar. 
In the UK where implementation of pharmacist prescribing is most advanced, 
many factors have contributed to sustained action. Healthcare structures and 
processes, particularly those relating to clinical pharmacy practice, had 
evolved over several decades, with accumulated evidence of benefit. These 
aspects relate to all five CFIR domains and were facilitators for 
implementation of prescribing. Furthermore, government initiated key reports 
such as the Cumberlege and Crown reports advocated extending prescribing 
privileges to other groups of healthcare professionals (Crown 1999, Auta et 
al. 2015, Cope, Abuzour and Tully 2016). Pharmacist prescribers must 
complete a GPhC accredited prescribing course, aligning to the CFIR 
innovation characteristics domain (General Pharmaceutical Council 2018). 
Along with a legislative framework, national guidance documents also 
facilitated prescribing. These included ‘Principles of Good Prescribing’ (British 
Pharmacological Society 2010), ‘A Guidance for Good Prescribing Practice for 
Prescribing Pharmacists in NHS Scotland’ (NHS Education for Scotland 2012) 
and ‘A Competency Framework for all Prescribers’ (Royal Pharmaceutical 
Society 2016). Publishing these documents aligns with two CFIR domains 
(innovation characteristics and process).  
Qatar is currently in the process of revolutionising its healthcare structure as 
outlined in its National Vision 2030 (Qatar General Secretariat for 
Development Planning and Statistics 2008) and the National Health Strategy 
2018-2022 (Qatar Ministry of Public Health 2018). These aim to establish a 
world-class healthcare by better utilisation of the knowledge and skills of 
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health professionals such as pharmacists. These can also facilitate the 
development and implementation of pharmacist prescribing (aligning to CFIR 
inner setting domain) 
5.4.3. Strengths and weaknesses 
There are many strengths to this study: 
1. A qualitative methodology was selected to generate in-depth, rich data 
allowing detailed description and understanding of perspectives that 
would facilitate the next phase of this doctoral research (Jensen and 
Laurie, 2016). Furthermore, this chapter is reported according to the 
Consolidated Criteria for Reporting Qualitative Research (COREQ) 
guidance (Tong, Sainsbury and Craig 2007). 
2. Key stakeholders in positions of power and influence were recruited. 
Gathering data on their perspectives would enable actual 
implementation of pharmacist prescribing later. Every effort was taken 
to ensure that all key stakeholder groups were identified and included.  
3. The interview schedule was based on comprehensive reviews of the 
literature (Chapters 3 and 4). Furthermore, the use of CFIR as a 
theoretical framework allowed a much more detailed exploration of all 
facilitators and barriers to implementation (Damschroder et al. 2009), 
also allowing the data and findings to be considered within a wider and 
more meaningful context (Nilsen 2015). 
4. An evidence-based approach to determining the point of data 
saturation in the stakeholder group as a whole as well as the individual 
groups was adopted (Francis et al. 2010). 
5. Many steps were taken to enhance the trustworthiness of the research 
data and findings as follows: 
a. Research team included experienced researchers, some of which 
were not from a pharmacy background (dependability, 
Confirmability) 
b. The methodological approach was logical, clearly documented 
and the data generation tool piloted prior to use (dependability) 
c. Careful consideration in the selection and recruitment of 
participants (credibility) 
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d. Independent analysis of data by more than one researcher 
(credibility) 
e. Analysis was mapped to the CFIR constructs (confirmability) 
f. Use of verbatim quotes to support all themes reported 
(credibility) 
The main limitation of this research is that the data were generated in Qatar 
hence the findings may lack transferability to other countries in the Middle 
East and beyond. Attention has been paid to describing the research setting, 
methods and participants to allow readers to consider likely transferability to 
their own settings and individuals. The findings may also have been limited 
through the following biases  
1. Recruitment bias with those more interested in the topic more likely to 
participate 
2. Interviewer bias as the doctoral student is a graduate of the College of 
Pharmacy, Qatar University 
3. Social desirability bias, with participants expressing views potentially 
expected by the researchers 
 
5.5. Conclusion 
The majority of stakeholders interviewed held positive views of the current 
pharmacy practice in Qatar, were aware of non-medical prescribing globally, 
and supported such a role for pharmacists in Qatar. Key facilitators 
highlighted include adopting a more conservative model and providing 
additional training to pharmacists prior to commencing prescribing. Main 
barriers were around the current legislative framework and potential initial 
opposition by doctors and the public. 
5.6. Implications for next phase 
Together with the findings of the umbrella and systematic review, the 
interview findings highlight the potential to develop and implement a 
framework for pharmacist prescribing in Qatar. These findings were used in 
the next and final phase of the doctoral research which focused on 
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determining the levels of agreement amongst key stakeholders in Qatar 
around the development of pharmacist prescribing frameworks. 
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Chapter 6: 
A Delphi study to determine the 
level of agreement relating to the 
development of pharmacist 
prescribing frameworks in Qatar 
  
Phase 1 Phase 2 Phase 3 Phase 4
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6. Introduction to the chapter 
The following chapter outlines the aim and objectives, methods, results, and 
discussion of the final phase of the doctoral research relating to the 
development of framework(s) for pharmacist prescribing in Qatar. 
6.1. Research aim and objectives 
The aim of this phase of the doctoral research was to determine the levels of 
agreement amongst key stakeholders in Qatar around the development of 
pharmacist prescribing frameworks. The scope of the framework developed 
included: definitions and scope of prescribing; education and training; 
competence; accreditation; prescribing models; and governance. 
The specific research objectives were to: 
• Develop and validate a series of statements in relation to the 
framework of pharmacist prescribing, as described above  
• Determine the levels of agreement of key stakeholders around these 
statements 
• Determine any additional statements derived from the expert panel 
members’ feedback 
• Determine any reasons for not achieving consensus 
6.2. Methods 
6.2.1. Study design 
As described in Chapter 2, data were collected using a descriptive 
observational survey-based modified Delphi technique with key health 
stakeholders in Qatar. 
6.2.2. Research governance 
Prior to conducting the research, ethical approvals were obtained from: 
• Robert Gordon University School of Pharmacy and Life Sciences 
Research Ethics Committee (S104) 
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• Hamad Medical Corporation Medical Research Committee (MRC-01-17-
115) 
• Qatar University Institutional Review Board (QU-IRB 865-E/17) 
6.2.3. Setting 
Similar to the previous phase of this doctoral project, data collection took 
place in Qatar, across several settings as follows: 
• Ministry of Public Health (MoPH) in Qatar. MoPH is the health 
regulatory body in Qatar, responsible for overseeing the medical 
marketplace as well as ensuring the highest quality of care. Currently, 
the Ministry evaluates and monitors both public as well as private 
health sectors (Qatar Ministry of Public Health 2016) 
• Hamad Medical Corporation (HMC). The largest hospital group in the 
State, managed by the government of Qatar and includes eight 
hospitals differing in their level and range of care to address the 
public’s healthcare needs (Qatar Supreme Council of Health 2014) 
• Aspetar Orthopaedic and Sports Medicine Hospital which is the first 
hospital to provide this specialised care in the Gulf region. 
• Primary Health Care Corporation (PHCC). PHCC is the largest 
governmental group providing primary health care services in the 
State of Qatar (Primary Health Care Corporation 2018a) 
• Weil Cornell Medical School. The first and main medical college in 
Qatar 
• College of Medicine at Qatar University. The first and only public 
medical college in the country 
• College of Pharmacy at Qatar University. The first and only college of 
pharmacy in the State 
• Faculty of Nursing at University of Calgary. The first and only college of 
nursing in Qatar 
• Qatar Petroleum Medical Centres. The largest private primary care 
setting in the country 
• Wellcare and Khulud Groups. The largest chain of community 
pharmacies in Qatar 
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6.2.4. Expert Panel 
The expert panel consisted of key health stakeholders in Qatar with 
knowledge and significant influence on the healthcare system, holding 
positions of responsibility that could impact the implementation of pharmacist 
prescribing. 
6.2.5. Sampling frame and sampling approach 
The sampling frame for each stakeholder group from the qualitative study 
(Chapter 5) was utilised for this phase. The sampling categories were: 
• Academic leaders 
• Healthcare policy makers 
• Medical leaders 
• Nursing leaders 
• Pharmacy and pharmacy technician leaders 
• Safety, quality and patient group representatives 
6.2.6. Sample size determination 
As discussed in Chapter 2, there is no consensus on the ideal sample size of 
the Delphi panel. Thus, the aim was to recruit at least five stakeholders from 
each of these categories giving an estimated panel size of 35. This sample 
size was chosen after discussion with the research team and based on the 
recommendation of Delbecq, Van de Ven, and Gustafson (1975) to recruit the 
minimal number of participants to address the research needs.  
6.2.7. Development of data collection tools 
The Delphi statements were developed based on the umbrella review 
(Chapter 3), the systematic review (Chapter 4), and the qualitative 
interviews (Chapter 5). The Consolidated Framework for Implementation 
Research (see Chapter 2) provided the theoretical grounding for the 
statements (Damschorder et al. 2009). Furthermore, pharmacist prescribing 
frameworks of other countries described in Chapter 1 were also consulted 
which include Canada (National Association of Pharmacy Regulatory 
Authorities 2009), the US (Centers for Disease Control and Prevention 2013), 
223 
 
New Zealand (Pharmacy Council of New Zealand 2013) and the UK 
(Pharmaceutical Society of Northern Ireland 2013, Royal Pharmaceutical 
Society 2016). The expertise of the research team in pharmacist prescribing 
education and research also contributed to statements development.  
Following the development of the draft statements, these were sent via email 
to eight experts in Scotland and Qatar (identified from professional networks) 
in relation to pharmacist prescribing and use of the Delphi technique (other 
than the ones included for the actual study) for comments relating to face 
and content validity. Responses were received from all eight, as presented in 
Table 6.1.  
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Table 6.1: Details of comments on draft Delphi statements, and actions taken 
 
 
 
 
 
 
Statements 
Experts Comments  
 
 
 
 
Actions 
Taken 
Senior Research 
Fellow & 
Lecturer 
Academic 
Strategic Lead 
– Clinical 
Practice 
Associate 
Professor of 
Pharmacy 
Practice 
(Qatar) 
Assistant 
Director of 
Pharmacy 
Department, 
Co-Head of 
Pharmacy 
Continuing 
Professional 
Development & 
Hospital 
Research Officer 
(Qatar) 
Pharmacist 
Independent 
Prescribing 
Module Leader 
Senior 
Pharmacy 
Practice 
Lecturer 
Independent 
Pharmacist 
Prescriber & 
Lecturer 
Lead for 
pharmacist 
prescribing, 
NHS 
Education for 
Scotland 
Definitions, Models, and Scope 
1.1 Pharmacist Collaborative Prescribing 
1.1.1 A 
collaborative 
model of 
pharmacist 
prescribing is 
appropriate for 
Qatar. 
“Collaborative 
Pharmacist 
Prescribing” 
appears in 
some form for 
every 
statement so 
move to the 
blue bar and 
have the 
reduced text 
listed 
-Do not like 
the numbers 
format – Just 
exclude and 
have 
statements 
-May be 
appropriate 
but most 
appropriate? 
What are the 
other options 
– difficult to 
determine 
unless 
considered in 
relation to 
something 
else 
 
 
 
   No 
Comments 
 No 
Comments 
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1.1.2 The 
protocol for 
collaborative 
pharmacist 
prescribing 
should have a 
defined format 
approved by 
Qatar Council 
for Healthcare 
Professionals 
(QCHP). 
 Is this 
generally or 
for specific 
patients – not 
clear and 
ambiguous 
   No 
Comments 
 No 
Comments 
Changed to 
‘defined 
generic 
format’ 
1.1.3 The 
protocol for 
collaborative 
pharmacist 
prescribing 
must state the 
targeted 
medical 
condition(s). 
Is it only 
medical? 
Must or 
should? better 
for Likert 
Scale use – 
less strict and 
directive 
   No 
Comments 
 No 
Comments 
 
1.1.4 The 
protocol for 
collaborative 
pharmacist 
prescribing 
must state the 
scope of 
prescribing for 
the 
pharmacists 
(e.g. what, 
when, and how 
to 
initiate/continu
e/discontinue/
change drugs, 
dose, 
duration…). 
 
 
    No mention 
here of patient 
groups 
No 
Comments 
 No 
Comments 
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1.1.5 The 
protocol for 
collaborative 
pharmacist 
prescribing 
must be 
approved and 
signed by the 
pharmacist 
prescriber(s), 
physician(s), 
and the 
pharmacy 
leader within 
the 
organisation. 
Do not think 
these need to 
be plural and 
will look neater 
without 
  Medical 
leadership, 
pharmacy 
leadership and 
committees 
responsible 
such as 
pharmacy and 
therapeutics 
(both facility 
and corporate), 
pharmacists 
and physicians 
will have a say 
but need not 
sign to approve 
Lead 
pharmacist? Is 
this clear or 
should you give 
a couple of 
examples? 
No 
Comments 
 No 
Comments 
Change 
‘pharmacy 
leader’ to 
‘pharmacy 
director’ 
+ 
Remove ‘and 
signed by’ 
1.1.6 Only the 
pharmacist 
prescribers 
that have 
signed the 
protocol can 
prescribe 
collaboratively 
for that patient 
group. 
 Or could …. 
Not in place 
and you are 
asking them 
opinions? 
I doubt if 
that is the 
norm. 
Protocol is 
usually 
approved 
by 
leadership 
sometimes 
including 
Pharmacy 
and 
Therapeutic
s 
Committee. 
The 
statement 
sounds as if 
all 
pharmacist 
prescribers 
have to 
sign the 
protocol. 
The 
Our setting is 
different, all 
privileges need 
to be agreed 
and approved 
by the leaders 
and, 
pharmacists 
need to follow. 
Because the 
protocol is not 
applied for 
individual 
pharmacists, it 
should apply for 
all the 
pharmacists 
with prescribing 
privileges in 
specialised 
areas 
-Only 
pharmacist 
prescribers who 
have signed the 
protocol may 
prescribe 
collaboratively 
for the specified 
patient group. 
-watch the 
difference 
between can’ 
and ‘may’. I 
won’t comment 
again 
No 
Comments 
 No 
Comments 
Deleted 
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protocol is 
the 
agreement. 
1.1.7 Under the 
Collaborative 
Pharmacist 
Prescribing 
model, 
pharmacists 
can prescribe 
any licensed 
over-the-
counter drug 
stated in the 
protocol. 
Suggest not 
using underline 
as it denotes a 
hyperlink and 
can be difficult 
to read 
 Please 
make sure 
you check 
the “Qatar 
Pharmacy 
Law”. This 
is very 
CRITICAL, 
because if 
it is 
WRONG, 
then many 
things 
below will 
not be in 
good shape 
There are no 
over the 
counter drugs in 
HMC, all needs 
to be 
prescribed. 
Over the 
counter is only 
in the 
community 
pharmacy 
Included in the 
protocol? I 
won’t comment 
on this again. 
No 
Comments 
 No 
Comments 
Removed 
‘licensed’ 
1.1.8 Under the 
Collaborative 
Pharmacist 
Prescribing 
model, 
pharmacists 
can prescribe 
any licensed 
prescription-
only drug 
stated in the 
protocol 
     No 
Comments 
 No 
Comments 
Removed 
‘licensed’ 
1.1.9 Under the 
Collaborative 
Pharmacist 
Prescribing 
model, 
pharmacists 
can prescribe 
any licensed 
controlled drug 
     No 
Comments 
 No 
Comments 
Removed 
‘licensed’ 
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stated in the 
protocol 
1.1.10 Under the 
Collaborative 
Pharmacist 
Prescribing 
model, 
pharmacists 
can prescribe 
any off-label 
over-the-
counter drug 
stated in the 
protocol. 
    Will your 
participants all 
know what this 
means? Should 
you give an 
example? 
No 
Comments 
 No 
Comments 
Deleted  
1.1.11 Under the 
Collaborative 
Pharmacist 
Prescribing 
model, 
pharmacists 
can prescribe 
any off-label 
prescription-
only drug 
stated in the 
protocol. 
     No 
Comments 
 No 
Comments 
Deleted 
1.1.12 Under the 
Collaborative 
Pharmacist 
Prescribing 
model, 
pharmacists 
can prescribe 
any off-label 
controlled drug 
stated in the 
protocol. 
 
 
 
 
     No 
Comments 
 No 
Comments 
Deleted 
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1.1.13 Under the 
Collaborative 
Pharmacist 
Prescribing 
model, 
pharmacists 
can prescribe 
any unlicensed 
drug stated in 
the protocol. 
   Research 
purpose? 
 No 
Comments 
 
 No 
Comments 
Deleted 
1.2 Pharmacist Independent Prescribing for medical conditions previously diagnosed by a physician 
1.2.1 An 
independent 
model of 
pharmacist 
prescribing for 
diagnosed 
medical 
conditions is 
appropriate for 
Qatar. 
Comments as 
above 
   -In the 
definition, I 
think the 
wording is 
‘previously 
diagnosed 
conditions’ – do 
you need to 
make clear that 
again that these 
have been 
diagnosed by a 
doctor, if that’s 
what you 
mean? This is 
likely to be a 
sticking point 
with doctors 
and possibly 
others.  
-Confusing – I 
suggest 
something like 
‘Pharmacist 
independent 
prescribing for 
previously 
diagnosed 
conditions is an 
No 
Comments 
Applies to all 
subsequent 
rows: “it is 
“pharmacist 
independent 
prescribing – 
PIP” not IPP 
No 
Comments 
Reworded  
+  
Changed 
‘Independent 
Pharmacist 
Prescribing’ 
to 
‘Pharmacist 
Independent 
Prescribing’ 
in all 
subsequent 
statements 
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appropriate 
model … 
-These words 
should match 
those below and 
make clear 
exactly what 
you mean. 
1.2.2 A physician 
must diagnose 
the medical 
condition 
before the 
pharmacist can 
prescribe. 
 Add ‘Under 
the 
Independent 
Pharmacist 
Prescribing’ 
 
   No 
Comments 
 No 
Comments 
Added 
‘Under the 
Independent 
Pharmacist 
Prescribing 
for 
previously 
diagnosed 
conditions 
model’ 
1.2.3 Under the 
Independent 
Pharmacist 
Prescribing for 
previously 
diagnosed 
conditions 
model, 
pharmacists 
can prescribe 
any licensed 
over-the-
counter drugs 
within their 
competence. 
 Very wordy 
and repetitive 
– must be 
some way to 
have this as a 
stem and then 
statements 
under to make 
it read better 
 For community 
 
 No 
Comments 
 No 
Comments 
Removed 
‘licensed’ 
1.2.4 Under the 
Independent 
Pharmacist 
Prescribing for 
previously 
diagnosed 
conditions 
model, 
     No 
Comments 
 No 
Comments 
Removed 
‘licensed’ 
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pharmacists 
can prescribe 
any licensed 
prescription-
only drugs 
within their 
competence. 
1.2.5 Under the 
Independent 
Pharmacist 
Prescribing for 
previously 
diagnosed 
conditions 
model, 
pharmacists 
can prescribe 
any licensed 
controlled 
drugs within 
their 
competence. 
     No 
Comments 
 No 
Comments 
Removed 
‘licensed’ 
1.2.6 Under the 
Independent 
Pharmacist 
Prescribing for 
previously 
diagnosed 
conditions 
model, 
pharmacists 
can prescribe 
any off-label 
over-the-
counter drugs 
within their 
competence. 
 
 
 
 
     No 
Comments 
 No 
Comments 
Deleted 
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1.2.7 Under the 
Independent 
Pharmacist 
Prescribing for 
previously 
diagnosed 
conditions 
model, 
pharmacists 
can prescribe 
any off-label 
prescription-
only drugs 
within their 
competence. 
     No 
Comments 
 No 
Comments 
Deleted 
1.2.8 Under the 
Independent 
Pharmacist 
Prescribing for 
previously 
diagnosed 
conditions 
model, 
pharmacists 
can prescribe 
any off-label 
controlled 
drugs within 
their 
competence. 
     No 
Comments 
 No 
Comments 
Deleted 
1.2.9 Under the 
Independent 
Pharmacist 
Prescribing for 
previously 
diagnosed 
conditions 
model, 
pharmacists 
can prescribe 
any unlicensed 
Colleagues at 
RGU refer to as 
PIP rather than 
IPP 
  Participants 
may not 
understand this 
terms until we 
elaborate on 
this, so as to 
why do we use 
unlicensed 
drug? 
 No 
Comments 
 No 
Comments 
Deleted 
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drugs within 
their 
competence. 
1.3 Pharmacist Independent Prescribing for medical conditions not previously diagnosed by a physician 
1.3.1 An 
independent 
model of 
pharmacist 
prescribing for 
undiagnosed 
medical 
conditions is 
appropriate for 
Qatar. 
    -Minor ailment 
is not in the 
definition 
although it’s 
fine if you want 
to add it. 
-diagnosed and 
previously 
undiagnosed 
conditions. I 
won’t comment 
again but 
suggest you 
add this 
throughout. 
No 
Comments 
 No 
Comments 
Reworded + 
Changed 
‘Independent 
Pharmacist 
Prescribing’ 
to 
‘Pharmacist 
Independent 
Prescribing’ 
in all 
subsequent 
statements 
1.3.2 All 
pharmacist 
prescribers 
under this 
model must be 
authorised to 
prescribe for 
undiagnosed 
conditions 
including 
minor ailments 
within their 
competence. 
    by whom? No 
Comments 
 No 
Comments 
Deleted 
1.3.3 Under the 
Independent 
Pharmacist 
Prescribing for 
undiagnosed 
conditions 
model, 
pharmacists 
     No 
Comments 
 
 
See above No 
Comments 
Removed 
‘licensed’ 
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can prescribe 
any licensed 
over-the-
counter drugs 
within their 
competence. 
1.3.4 Under the 
Independent 
Pharmacist 
Prescribing for 
undiagnosed 
conditions 
model, 
pharmacists 
can prescribe 
any licensed 
prescription-
only drugs 
within their 
competence. 
     No 
Comments 
 No 
Comments 
Removed 
‘licensed’ 
1.3.5 Under the 
Independent 
Pharmacist 
Prescribing for 
undiagnosed 
conditions 
model, 
pharmacists 
can prescribe 
any licensed 
controlled 
drugs within 
their 
competence. 
     No 
Comments 
 No 
Comments 
Removed 
‘licensed’ 
1.3.6 Under the 
Independent 
Pharmacist 
Prescribing for 
undiagnosed 
conditions 
model, 
     No 
Comments 
 No 
Comments 
Deleted 
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pharmacists 
can prescribe 
any off-label 
over-the-
counter drugs 
within their 
competence. 
1.3.7 Under the 
Independent 
Pharmacist 
Prescribing for 
undiagnosed 
conditions 
model, 
pharmacists 
can prescribe 
any off-label 
prescription-
only drugs 
within their 
competence. 
     No 
Comments 
 No 
Comments 
Deleted 
1.3.8 Under the 
Independent 
Pharmacist 
Prescribing for 
undiagnosed 
conditions 
model, 
pharmacists 
can prescribe 
any off-label 
controlled 
drugs within 
their 
competence. 
     No 
Comments 
 No 
Comments 
Deleted 
1.3.9 Under the 
Independent 
Pharmacist 
Prescribing for 
undiagnosed 
conditions 
   Same as above  No 
Comments 
 No 
Comments 
Deleted 
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model, 
pharmacists 
can prescribe 
any unlicensed 
drugs within 
their 
competence. 
2. Education and Training 
2.1 All pharmacist 
prescribers 
must complete 
a university-
led education 
and training 
programme 
accredited by 
Qatar Council 
for Healthcare 
Professionals 
(QCHP). 
At diploma or 
Masters level? 
-What if they 
feel that some 
need and 
some do not 
-You call it 
‘prescribing 
programme’ 
below - 
consistency? 
  Independent 
prescribers? 
No 
Comments 
 No 
Comments 
Deleted 
‘Qatar 
Council for 
Healthcare 
Professionals
’ 
2.2 The education 
and training 
programme 
must be 
related to the 
medical 
condition/ 
patient group 
area in which 
the pharmacist 
is planning to 
prescribe. 
 What if this is 
broad? I.e 
they want to 
focus on more 
than one 
the medical 
condition 
‘or’ patient 
group area 
  No 
Comments 
What is a 
“patient group 
area”? 
No 
Comments 
Deleted 
‘patient 
group area’ 
2.3 The education 
and training 
programme 
must include a 
period of 
learning in 
practice 
relating to the 
 Definition of 
this – need to 
be clear 
-period of 
learning in 
practice 
(i.e. 
experiential 
training) 
-the 
medical 
  No 
Comments 
 No 
Comments 
Added ‘(i.e 
training)’ 
after ‘period 
of learning in 
practice’ 
+ 
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medical 
condition/ 
patient group 
in which the 
pharmacist is 
planning to 
prescribe. 
condition 
‘or’ patient 
group area 
Deleted 
‘patient 
group area’ 
 
2.4 The period of 
learning in 
practice must 
be supervised 
by a senior 
physician. 
Why senior? 
Designated 
medical 
professional? 
What is a 
senior 
physician – 
define 
  Do you need to 
define this role?  
No 
Comments 
What is a 
“senior 
physician”? 
How many 
years of 
practical 
experience as 
a prescriber 
should they 
have as a 
minimum? 
No 
Comments 
 
2.5 The senior 
physician 
supervising the 
period of 
learning in 
practice must 
be familiar 
with the 
programme’s 
aims and 
objectives. 
What is the 
quality control 
of the 
supervising 
physician? 
   Which 
programme? 
No 
Comments 
 No 
Comments 
Added 
‘education 
and training’ 
before 
‘programme’
s aims and 
objectives. 
2.6 All pharmacists 
enrolling in the 
prescribing 
programme 
must have a 
postgraduate 
qualification in 
clinical 
pharmacy or a 
related field. 
What are the 
options for this? 
Suggest delete 
this part 
 Need to 
define or 
give clear 
example in 
bracket. 
Example is 
PharmD 
degree 
from QU vs. 
Canada vs. 
USA 
Not sure, this 
will mostly 
apply for 
hospital 
pharmacists 
Do you need to 
define what this 
might be?  
No 
Comments 
 No 
Comments 
Changed 
‘prescribing 
programme’ 
to ‘education 
and training 
programme’ 
+ 
Removed ‘or 
a related 
field’ 
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considered 
as such. 
2.7 All pharmacists 
enrolling in the 
prescribing 
programme 
must have at 
least 2 years 
of direct 
clinical patient 
care 
experience in 
the medical 
condition/ 
patient group 
area in which 
they are 
planning to 
prescribe, with 
the application 
endorsed by 
the senior 
physician 
responsible for 
the period of 
learning in 
practice. 
This is two 
statements 
   This is quite 
tight and may 
be too 
restrictive. Do 
you want to re-
word it or leave 
it and see what 
response you 
get? 
No 
Comments 
 No 
Comments 
Split into 
two 
statements 
2.8 All pharmacists 
enrolling for 
the prescribing 
programme 
must have the 
endorsement 
of the 
pharmacy 
leader in their 
organisation. 
 
 
 Meaning of 
pharmacy 
leader 
  As before. Lead 
pharmacist or 
other title – 
whatever is 
used  
No 
Comments 
 No 
Comments 
Changed 
‘prescribing 
programme’ 
to ‘education 
and training 
programme’ 
and 
‘pharmacy 
leader’ to 
‘pharmacy 
director’ 
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2.9 All pharmacists 
enrolling in the 
prescribing 
programme 
must submit a 
portfolio 
outlining the 
set of skills 
and experience 
they possess 
and how they 
plan to 
develop 
further. 
A pre-
templated 
portfolio? 
Portfolio is 
really about 
‘evidence’ of 
these skills 
   No 
Comments 
When is the 
portfolio to be 
submitted – 
before they 
start, or when 
they finish 
their learning 
in practice? 
No 
Comments 
Reworded 
2.10 All 
pharmacists 
enrolling in the 
prescribing 
programme 
must 
demonstrate 
that there is a 
clinical need 
for their role 
endorsed by a 
physician. 
 Within their 
workplace / 
area of 
practice? 
   No 
Comments 
 No 
Comments 
Reworded 
2.11 Prior to 
registration 
with QCHP as 
a prescriber, 
pharmacists 
must have 
completed the 
education and 
training 
programme 
and be 
deemed by the 
senior 
physician 
responsible for 
    I would think 
about re-
wording this: 
On successful 
completion of 
the education 
and training 
programme and 
certification as 
competent by 
the senior 
physician 
responsible for 
the period of 
learning in 
No 
Comments 
 No 
Comments 
Reworded 
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the period of 
learning in 
practice as 
competent. 
practice, the 
pharmacist is 
eligible for 
registration with 
the QCHP. 
 
2.12 Pharmacist 
prescribers 
registered in 
countries other 
than Qatar 
must be 
registered with 
QCHP prior to 
commencing 
prescribing 
practice.  
    This is 
assuming that 
pharmacist 
prescribing 
becomes 
possible in 
Qatar? 
No 
Comments 
Would you 
want to insert 
the word 
“independent” 
here? 
No 
Comments 
 
3. Prescribing Practice and Governance 
3.1 Pharmacist 
prescribers 
must not 
commence 
prescribing 
practice until 
registered with 
Qatar Council 
for Healthcare 
Professionals 
(QCHP). 
 Why QCHP full 
here when 
abbreviated 
elsewhere? 
  Sometimes you 
only use the 
abbreviation, 
other times the 
name and 
abbreviation. 
Decide which 
you want to use 
and be 
consistent 
No 
Comments 
See above No 
Comments 
Deleted 
‘Qatar 
Council for 
Healthcare 
Professionals
’ 
3.2 All newly 
registered 
pharmacist 
prescribers 
must first 
practise 
collaborative 
prescribing for 
a period of 
time prior to 
progressing to 
    Now I’m getting 
confused. I 
think you need 
some more 
explanatory 
text here. 
No 
Comments 
Now the 
above two 
statements 
become 
clearer. 
No 
Comments 
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independent 
prescribing. 
3.3 The job 
description of 
the pharmacist 
prescribers 
must be 
amended to 
include 
prescribing. 
  “scope of 
practice”? 
 What does this 
mean? Could 
you make it 
clearer?  
No 
Comments 
 No 
Comments 
 
3.4 If in doubt, the 
pharmacist 
prescriber 
must refer the 
patient back to 
the physician. 
 If in doubt 
about what? 
 This looks out 
of place 
Need to be 
clearer. If in 
doubt about 
what? Could say 
something 
about the 
importance of 
the PIP 
recognising the 
limits of their 
competence 
and referring 
patients on to 
physicians if 
appropriate 
No 
Comments 
 No 
Comments 
Reworded 
3.5 All pharmacist 
prescribers 
must prescribe 
according to 
local policies, 
guidelines and 
protocols 
available at 
their 
organisation. 
    What about 
national ones?  
No 
Comments 
 No 
Comments 
Changed 
‘available at’ 
to ‘of’ 
3.6 Pharmacist 
prescribers are 
legally 
accountable 
for their 
 Cannot really 
answer this 
with Likert – 
either it is 
legal or not 
   No 
Comments 
 No 
Comments 
Deleted 
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prescribing 
actions. 
3.7 Once 
registered, all 
pharmacist 
prescribers 
must 
undertake 
Continuing 
Professional 
Development 
(CPD) within 
the medical 
conditions/ 
patient 
population in 
which they are 
prescribing. 
    You’re very 
definite about 
these medical 
conditions but 
pharmacist 
prescribing has 
moved on in the 
UK so that 
some PIPs are 
prescribing for a 
wide range of 
patients and 
conditions. 
No 
Comments 
You called 
them “patient 
GROUP” 
earlier – 
change? 
No 
Comments 
Deleted 
‘patient 
population’ 
3.8 All CPD 
sessions must 
be accredited 
by Qatar 
Council for 
Healthcare 
Professionals 
(QCHP). 
 CPD sessions 
for what? 
 Some activities 
are not 
accredited but 
still recognised 
and accepted 
(such as ACPE, 
ASHP). There 
are self-learning 
online sessions 
which does not 
need QCHP 
accreditation 
(category 2 & 
3) 
Is this usual 
practice? 
No 
Comments 
 No 
Comments 
Deleted 
3.9 All pharmacist 
prescribers 
must have 
ready access 
to all pertinent 
sources of 
patient 
information. 
 
 Meaning of 
pertinent 
sources? 
Includes 
what? 
  What does this 
mean? How will 
this happen? 
Any issues? 
Legislation to 
support? 
No 
Comments 
 No 
Comments 
Reworded 
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3.10 All 
pharmacist 
prescribers 
must 
document 
every 
prescribing 
action in the 
patient clinical 
records. 
    -Will PIPs have 
contemp-
oraneous 
access to 
these? If not, 
what will they 
do?  
-What is a 
prescribing 
action? 
No 
Comments 
 No 
Comments 
Changed 
‘action’ to 
‘activity’ 
3.11 All 
pharmacist 
prescribers 
must have the 
authority to 
order 
laboratory 
tests. 
    -Where is all 
this going to 
occur? 
-‘appropriate? 
laboratory tests 
for their 
patients, or to 
inform their 
prescribing 
decisions’? 
No 
Comments 
 No 
Comments 
Reworded 
3.12 All 
pharmacist 
prescribers 
must have the 
authority to 
order other 
relevant tests 
and 
investigations 
(e.g. ECG, X-
ray..). 
Not keen on 
open lists but if 
doing this it 
must be three… 
   As above No 
Comments 
 No 
Comments 
Changed 
points of 
ellipsis to 
three 
3.13 All 
pharmacist 
prescribers 
must NOT 
have any role 
in the 
dispensing 
process for the 
patients in 
Does not need 
‘all’ – check 
other 
statements 
   -‘for whom’ 
they prescribe 
-Do you mean 
this, or do you 
mean that they 
may not have a 
role in 
dispending 
prescriptions 
No 
Comments 
‘For whom’ 
they prescribe 
instead of ‘in 
which’ 
No 
Comments 
Changed ‘in 
which they 
prescribe’ to 
‘for whom’ 
they 
prescribe’ 
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which they 
prescribe. 
which they have 
written? 
3.14 All 
pharmacist 
prescribers 
must report 
prescribing 
errors 
according to 
the policy of 
their 
organisation. 
    -what does this 
mean? Is there 
national 
guidance or 
what currently 
happens? 
-How will these 
be defined? 
Good to think 
about this but 
very hard to pin 
down. What to 
doctors 
currently do? 
You could ask 
about eg 
‘significant 
prescribing-
related events’ 
or similar – 
make sure you 
capture what 
you want to 
capture. 
No 
Comments 
 No 
Comments 
 
3.15 All 
pharmacist 
prescribers 
must report 
adverse drug 
reactions 
(ADRs) 
according to 
the policy of 
their 
organisation. 
 
 
 
 
    As above No 
Comments 
 No 
Comments 
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3.16 Pharmacist
s’ prescribing 
practise must 
be audited 
regularly 
against set and 
accepted 
standards. 
 By whom? 
How? 
  What will these 
be? Who will set 
them? Again 
what happens 
with doctors? I 
think this would 
be a huge job. 
No 
Comments 
Practice with 
two Cs– it is a 
noun here 
No 
Comments 
Changed 
‘practise’ to 
‘practice’ 
3.17 Patients’ 
feedback on 
the prescribing 
practise must 
be collected 
regularly, 
using 
standardised 
tools. 
 ‘Practice’   Again, what do 
you mean? Do 
these tools 
exist? Are they 
currently used? 
Try not to tie 
yourself in 
knots. 
No 
Comments 
See above No 
Comments 
Changed 
‘practise’ to 
‘practice’ 
3.18 A state-
wide campaign 
should be 
launched to 
educate the 
general public 
about 
pharmacist 
prescribing. 
  ‘statewide’  Sounds a bit 
draconian, sorry 
(as do some of 
the statements 
above). Could 
you word it 
differently? 
Same below. 
No 
Comments 
 No 
Comments 
 
3.19 A state-
wide campaign 
should be 
launched to 
educate 
healthcare 
providers 
about 
pharmacist 
prescribing. 
  ‘statewide’   No 
Comments 
 No 
Comments 
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The final list of statements used in this modified Delphi is presented in Table 
6.2. 
Statements were updated then formatted in Survey Monkey® (Survey 
Monkey Inc., San Mateo, California, USA), an online survey development 
cloud-based software. 
Throughout the different rounds of the Delphi, experts were asked to rate the 
statements according to a 6-point scale (strongly disagree — disagree — 
somewhat disagree - somewhat agree — agree — strongly agree). No neutral 
option was provided to ensure that the participants provided a rating that 
was either in agreement or disagreement.  
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Table 6.2: Statements included in the modified Delphi project 
 
 
Statements 
Responses  
 
Additional 
comments 
Strongly 
Disagree 
Disagree Somewhat 
Disagree 
Somewhat 
Agree 
Agree Strongly 
Agree 
1. Definitions, models and scope 
1.1 Pharmacist Collaborative Prescribing 
1.1.1 A collaborative model of pharmacist prescribing is appropriate for 
Qatar. 
       
1.1.2 The protocol for collaborative pharmacist prescribing should have a 
defined generic format approved by Qatar Council for Healthcare 
Professionals (QCHP). 
       
1.1.3 The protocol for collaborative pharmacist prescribing must state the 
targeted medical condition(s). 
       
1.1.4 The protocol for collaborative pharmacist prescribing must state the 
scope of prescribing for the pharmacists (e.g. what, when, and how to 
initiate/continue/discontinue/change drugs, dose, duration…). 
       
1.1.5 The protocol for collaborative pharmacist prescribing must be 
approved by the pharmacist prescriber(s), physician(s), and the 
pharmacy director within the organisation. 
       
1.1.6 Under the Collaborative Pharmacist Prescribing model, pharmacists 
can prescribe, within their competence, any over-the-counter drug 
stated in the protocol. 
       
1.1.7 Under the Collaborative Pharmacist Prescribing model, pharmacists 
can prescribe, within their competence, any prescription-only drug 
stated in the protocol. 
       
1.1.8 Under the Collaborative Pharmacist Prescribing model, pharmacists 
can prescribe, within their competence, any controlled drug stated in the 
protocol. 
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1.2 Pharmacist Independent Prescribing for medical conditions previously diagnosed by a physician 
1.2.1 Pharmacist Independent Prescribing for previously diagnosed 
medical conditions is an appropriate model for Qatar. 
       
1.2.2 Under the Pharmacist Independent Prescribing for previously 
diagnosed conditions model, a physician must diagnose the medical 
condition before the pharmacist can prescribe. 
       
1.2.3 Under the Pharmacist Independent Prescribing for previously 
diagnosed conditions model, pharmacists can prescribe, within their 
competence, any over-the-counter drugs. 
       
1.2.4 Under the Pharmacist Independent Prescribing for previously 
diagnosed conditions model, pharmacists can prescribe, within their 
competence, any prescription-only drugs. 
       
1.2.5 Under the Pharmacist Independent Prescribing for previously 
diagnosed conditions model, pharmacists can prescribe, within their 
competence, any controlled drugs. 
       
1.3 Pharmacist Independent Prescribing for medical conditions which have not been previously diagnosed by a physician 
1.3.1 Pharmacist Independent Prescribing for undiagnosed medical 
conditions is an appropriate model for Qatar. 
       
1.3.2 Under the Pharmacist Independent Prescribing for undiagnosed 
conditions model, pharmacists can prescribe, within their competence, 
any over-the-counter drugs. 
       
1.3.3 Under the Pharmacist Independent Prescribing for undiagnosed 
conditions model, pharmacists can prescribe, within their competence, 
any prescription-only drugs. 
       
1.3.4 Under the Pharmacist Independent Prescribing for undiagnosed 
conditions model, pharmacists can prescribe, within their competence, 
any controlled drugs. 
       
2. Education & Training 
2.1 All pharmacist prescribers must complete a university-led education and 
training programme accredited by QCHP. 
       
2.2 The education and training programme must be related to the medical 
condition(s) in which the pharmacist is planning to prescribe. 
       
2.3 The education and training programme must include a period of learning 
in practice (i.e training) relating to the medical condition(s) in which the 
pharmacist is planning to prescribe. 
       
2.4 The period of learning in practice must be supervised by a senior 
physician. 
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2.5 The senior physician supervising the period of learning in practice must 
be familiar with the education and training programme’s aims and 
objectives. 
       
2.6 All pharmacists enrolling in the education and training programme must 
have a postgraduate qualification in clinical pharmacy. 
       
2.7 All pharmacists enrolling in the education and training programme must 
have at least 2 years of direct clinical patient care experience in the 
medical condition(s) in which they are planning to prescribe. 
       
2.8 All pharmacists enrolling in the education and training programme must 
have their application endorsed by the senior physician responsible for 
the period of learning in practice. 
       
2.9 All pharmacists enrolling for the education and training programme must 
have the endorsement of the pharmacy director in their organisation. 
       
2.10 All pharmacists planning to enrol in the education and training 
programme must submit a portfolio outlining the set of skills and 
experience they possess and how they plan to develop further. 
       
2.11 All pharmacists enrolling in the education and training programme 
must demonstrate that, within their area of practice, there is a clinical 
need for their role endorsed by a physician. 
       
2.12 Prior to registration with QCHP as a prescriber, pharmacists must 
successfully complete the education and training programme and be 
deemed competent by the senior physician responsible for the period of 
learning in practice. 
       
2.13 Pharmacist prescribers registered in countries other than Qatar must 
be registered with QCHP prior to commencing prescribing practice.  
       
3. Prescribing Practice & Governance 
3.1 Pharmacist prescribers must not commence prescribing practice until 
registered with QCHP. 
       
3.2 All newly registered pharmacist prescribers must first practise 
collaborative prescribing for a period of time prior to progressing to 
independent prescribing. 
       
3.3 The job description of the pharmacist prescribers must be amended to 
include prescribing. 
       
3.4 If in doubt about their ability to prescribe for a patient, the pharmacist 
prescriber must refer him/her back to the physician. 
       
3.5 All pharmacist prescribers must prescribe according to local policies, 
guidelines and protocols of their organisation. 
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3.6 Once registered, all pharmacist prescribers must undertake Continuing 
Professional Development (CPD) within the medical condition(s) in which 
they are prescribing. 
       
3.7 All pharmacist prescribers must have ready access to patient clinical 
records. 
       
3.8 All pharmacist prescribers must document every prescribing activity in 
the patient clinical records. 
       
3.9 All pharmacist prescribers must have the authority to order appropriate 
laboratory tests to inform their prescribing decisions. 
       
3.10 All pharmacist prescribers must have the authority to order other 
relevant tests and investigations (e.g. ECG, X-ray...). 
       
3.11 All pharmacist prescribers must NOT have any role in the dispensing 
process for the patients for whom they prescribe. 
       
3.12 All pharmacist prescribers must report prescribing errors according 
to the policy of their organisation. 
       
3.13 All pharmacist prescribers must report adverse drug reactions 
(ADRs) according to the policy of their organisation. 
       
3.14 Pharmacists’ prescribing practice must be audited regularly against 
set and accepted standards. 
       
3.15 Patients’ feedback on the prescribing practice must be collected 
regularly, using standardised tools. 
       
3.16 A state-wide campaign should be launched to educate the general 
public about pharmacist prescribing. 
       
3.17 A state-wide campaign should be launched to educate healthcare 
providers about pharmacist prescribing. 
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6.2.8. Data collection 
a. Recruitment 
Once a list of all key health stakeholders in Qatar was created, invitation 
emails were sent to: 
• All academic stakeholders 
• At least two HMC, one PHCC and one MoPH medical, nursing, 
pharmacy, and quality improvement directors 
• At least one director of the largest chain community pharmacies 
• At least one representatives from Qatar Council of Health Practitioners 
All stakeholders were sent emails by one of the research members detailing 
the project’s title, researchers, objectives, brief description of the topic in 
question in addition to the significance of this study along with a participant 
information sheet (Appendices 6D and 6E). The content of the email was 
drafted and approved by the investigators before it was sent. A reminder 
email was sent on two-weekly basis if no response was received. Invitation 
and reminder emails were sent until at least five representatives from each 
group agreed to participate or all stakeholders on the list were contacted. 
Once the stakeholders confirmed their participation, a second email was sent 
with instructions and a link for the online survey containing the Delphi 
statements. 
b. Delphi rounds 
The Delphi rounds took place from June 10th till July 19th 2018. All data were 
handled primarily by TJ under the supervision of the other research team 
members for quality assurance. 
In order to collect enough information to answer the current project 
objectives and to ensure the robustness, validity and reliability of the 
collected data, there were two rounds. Each round was heterogeneous (i.e. 
different expertise and professions included) in order to ensure that all 
relevant aspects of the topic are deliberated (Von der Gracht 2012). 
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As detailed by Hsu and Sandford (2007), the rounds were as follow: 
 Round one: A link for the online Delphi questionnaire prepared was 
sent to each expert for review via email. They were all requested to rate the 
items to establish priorities as well as provide comments on each statement. 
They were also offered the opportunity to add any additional comments or 
statements they wish to be included. The experts were allowed two weeks in 
order to provide their feedback. Once responses were received, the rate of 
agreement was calculated and for statements that did not reach consensus 
were circulated again during the second round either unchanged or after 
revision depending on the comments provided by the experts. As stated in 
Chapter 2, consensus was achieved if a statement achieved 70% agreement 
(summative of agree/strongly agree) and less than 15% disagreement 
(summative of disagree/strongly disagree) between the panel members to 
ensure that there was no strong disagreement to any statement. 
 Round two: Expert panel members during this round received a 
questionnaire with the rating and comments collected from the previous 
round and were allowed two weeks to provide their feedback only on the 
statements that did not meet the cut-off point. Similar to previous round, the 
rate of agreement was also calculated. Depending on the feedback provided, 
a third round was considered unnecessary. 
The scheme, described in Figure 6.1, was followed in circulating the 
questionnaire items in each round. 
253 
 
Figure 6.1: Stopping criteria for Delphi studies (modified from Von der Gracht 
2012) 
 
Questionnaire 
Statement
Consensus 
(≥70% agreement + 
≤15% disagreement)
Terminate
Disagreement
Rephrase
New Round
Terminate
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Figure 6.2: Summary of the modified Delphi study 
Round 1 Round 2
Final 
statement 
set
Analysis 
Combined 
list of 
statements
Umbrella review
Systematic review
Interviews
CFIR
Other countries' prescribing
frameworks
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6.2.9. Data analysis 
Numerical voting was employed to rate the ideas generated by the experts. 
Thus, Microsoft Excel 2010 (Microsoft Office 2010, Microsoft Corp. Redmond, 
WA, USA) was used which is a spreadsheet programme that allows basic and 
complex mathematical functions. The votes were reported descriptively as 
frequencies and percentages. Open comments and panel members’ feedback 
were analysed using content analysis to determine trends often reported by 
the experts. 
6.2.10. Data storage 
The identity of the participants and their personal information remained 
anonymous. In addition, all data provided by participants were stored in 
secure laptops with restricted access granted only to researchers taking part 
in the current project. All research materials including informed consents will 
be handled and stored for 10 years and subsequently destroyed in 
accordance with School of Pharmacy and Life Sciences standard operating 
procedures. 
6.3. Results 
6.3.1. Expert panel 
Of the 61 stakeholders invited, 33 agreed to participate in this Delphi study 
representing academia (n=5), medicine (n=3), pharmacy (n=8), nursing (n= 
5), healthcare policy makers (n= 8) and patient safety (n=4). The panel 
composition is summarised in Figure 6.3. 
 
  
256 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Process followed in recruiting the expert panel 
Invitation email sent to:
Academic 
Leaders (n=5)
Medicine (n=1)
Pharmacy and 
Pharmacy 
Technician (n=3)
Nursing (n=1)
Medical Practice 
Leaders (n=13)
Pharmacy 
Practice Leaders 
(n=17)
Nursing Practice 
Leaders (n=12)
Healthcare Policy 
Developers 
(n=10)
Patient Safety 
Advocates (n=4)
Stakeholders that agreed to participate
Academic 
Leaders (n=5)
Medicine (n=1)
Pharmacy and 
Pharmacy 
Technician (n=3)
Nursing (n=1)
Medical Practice 
Leaders (n=3)
Pharmacy Practice 
Leaders (n=8)
Nursing Practice 
Leaders (n=5)
Healthcare Policy 
Developers (n=8)
Patient Safety 
Advocates (n=4)
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The practice settings of the experts included in this phase were diverse and 
ranged from primary, secondary and tertiary care as well as from the 
different health academic institutions, and the ministry. 
Table 6.3: Characteristics of included experts according to practice setting 
Expert category Setting: Number of experts 
Academic Leaders • Medicine: 1 
• Pharmacy and pharmacy technician: 3 
• Nursing: 1 
Healthcare Policy 
Developers 
• Secondary care: 1 
• Tertiary care: 1 
• Corporate/Ministry: 6 
Medical Practice Leaders • Primary care/Community: 1 
• Secondary care: 1 
• Tertiary care: 1 
Pharmacy Practice Leaders • Primary care/Community: 3 
• Secondary care: 1 
• Tertiary care: 4 
Nursing Practice Leaders • Secondary care: 2 
• Tertiary care: 1 
• Corporate/Ministry: 2 
Patient Safety Advocates • Primary care/Community: 1 
• Tertiary care: 2 
• Corporate/Ministry: 1 
6.3.2. Round 1 
Out of 33 experts who agreed to participate, 31 completed Round 1 
(Response rate= 94%). Of the 47 statements, consensus was achieved for 
32. The following section presents the level of consensus on each statement, 
the feedback provided by the experts as well as any changes made to 
statements that did not reach consensus. 
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Section 1: Definitions, Models, and Scope 
1.1 Pharmacist Collaborative Prescribing 
Statement 1.1.1: A collaborative model of pharmacist prescribing is 
appropriate for Qatar.           *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
1 
(3.2) 
0 
(0) 
10 
(32.3) 
7 
(22.6) 
13 
(41.9) 
1 
(3.2) 
20 
(64.5) 
Comments were received from 8 panel members in themes of: 
1. need for physician involvement: “Should be in touch with the physician of care when prescribing any 
new medication.” 
2. need for governance: “Requires a robust legislative structure to support individual practitioners.” 
3. resistance from physicians: “Some physicians may find this hard to accept in Qatar.” 
→ Based on the response and comments, the statement was not 
altered. 
 
Statement 1.1.2: The protocol for collaborative pharmacist prescribing should 
have a defined generic format approved by Qatar Council for Healthcare 
Professionals (QCHP).           *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.2) 
0 
(0) 
1 
(3.2) 
1 
(3.2) 
8 
(25.8) 
20 
(64.5) 
1 
(3.2) 
28 
(90.3) 
Comments were received from 6 panel members in themes of: 
1. need of governance: “There needs to be a standardised approach to achieve a minimal safe and 
professional level of service.” 
2. importance of QCHP involvement: “recognition by QCHP about this model will help in spreading the 
awareness about this essential service.” 
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Statement 1.1.3: The protocol for collaborative pharmacist prescribing must 
state the targeted medical condition(s).        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
1 
(3.2) 
0 
(0) 
1 
(3.2) 
15 
(48.4) 
14 
(45.2) 
1 
(3.2) 
29 
(93.5) 
Comments were received from 6 panel members in themes of: 
1. benefits: “This is required to ensure pharmacists remain inside the competency boundaries and do not go 
outside of them.” 
2. future expansion: “As practice develops and advances, this could be reassessed in the future.” 
 
Statement 1.1.4: The protocol for collaborative pharmacist prescribing must 
state the scope of prescribing for the pharmacists (e.g. what, when, and how 
to initiate/continue/discontinue/change drugs, dose, duration…).*Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
2 
(6.5) 
2 
(6.5) 
6 
(19.4) 
21 
(67.7) 
0 
(0) 
27 
(87.1) 
Comments were received from 5 panel members in themes of: 
1. need for governance: “There needs to be a quality and safety and governance framework in place to 
support this.” 
2. need to an unconstrained practice: “Your protocol must not be too restrictive. Otherwise, the 
pharmacist will be impotent.” 
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Statement 1.1.5: The protocol for collaborative pharmacist prescribing must 
be approved by the pharmacist prescriber(s), physician(s), and the pharmacy 
director within the organisation.         *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
1 
(3.2) 
1 
(3.2) 
4 
(12.9
) 
8 
(25.8) 
17 
(54.8) 
1 
(3.2) 
25 
(80.6) 
Comments were received from 6 panel members in themes of: 
1. process and patient care: “If the process will not take long and there will be smooth discharge.” 
2. applicability to all settings: “This raises a barrier to community pharmacy practitioners.” 
 
Statement 1.1.6: Under the Collaborative Pharmacist Prescribing model, 
pharmacists can prescribe, within their competence, any over-the-counter 
drug stated in the protocol.          *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.2) 
1 
(3.2) 
0 
(0) 
1 
(3.2) 
11 
(35.5) 
17 
(54.8) 
2 
(6.5) 
28 
(90.3) 
Comments were received from 3 panel members in the theme of: 
1. focus on prescription medicines: “Let's not dilute the power of the Prescribing Pharmacist by talking 
about OTC medication, but focus on Prescription Medication where they can have the biggest impact.” 
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Statement 1.1.7: Under the Collaborative Pharmacist Prescribing model, 
pharmacists can prescribe, within their competence, any prescription-only 
drug stated in the protocol.         *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
2 
(6.5) 
3 
(9.7) 
16 
(51.6) 
10 
(32.3) 
0 
(0) 
26 
(83.9) 
Comments were received from 10 panel members in themes of: 
1. need for governance: “As long as there are robust systems in place to support the model and the 
pharmacist.” 
2. need to practice within competence: “Yes within their training and assured competence.” 
 
Statement 1.1.8: Under the Collaborative Pharmacist Prescribing model, 
pharmacists can prescribe, within their competence, any controlled drug 
stated in the protocol.        *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
2 
(6.5) 
9 
(29) 
1 
(3.2) 
8 
(25.8) 
7 
(22.6) 
4 
(12.9) 
11 
(35.5) 
11 
(35.5) 
Comments were received from 8 panel members in themes of: 
1. need for physician involvement: “I think this would need consultation with a physician for the INITIAL 
prescription.” 
2. need for additional training: “I would suggest this be phased in as prescribing pharmacists get more 
experience in this competency.” 
→ Based on the response and comments, the statement was not 
altered. 
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1.2 Pharmacist Independent Prescribing for medical conditions previously 
diagnosed by a physician 
Statement 1.2.1: Pharmacist Independent Prescribing for previously 
diagnosed medical conditions is an appropriate model for Qatar.                 
*No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.2) 
4 
(12.9) 
5 
(16.1) 
5 
(16.1) 
12 
(38.7) 
4 
(12.9) 
5 
(16.1) 
16 
(51.6) 
Comments were received from 9 panel members in themes of: 
1. risk associated with independent prescribing: “It will increase the risk of duplicating medications and 
fragmenting patient's care among healthcare providers.” 
2. maturity of the organisation: “I don't think Qatar with its diverse recruitment and training of 
pharmacists is mature enough for this step.” 
3. possibility for role development: “Although ideal, this model would not suit the Qatar market from a 
patient safety point of view. However, over time, this would be the model to inspire to in the future.” 
→ Based on the response and comments, the statement was not 
altered. 
 
Statement 1.2.2: Under the Pharmacist Independent Prescribing for 
previously diagnosed conditions model, a physician must diagnose the 
medical condition before the pharmacist can prescribe.         *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
0 
(0) 
2 
(6.5) 
15 
(48.4) 
14 
(45.2) 
0 
(0) 
29 
(93.5) 
Comments were received from 3 panel members in the theme of: 
1. need for physician involvement: “Yes, you can't expect the pharmacist to suddenly develop diagnostic 
skills too.” 
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Statement 1.2.3: Under the Pharmacist Independent Prescribing for 
previously diagnosed conditions model, pharmacists can prescribe, within 
their competence, any over-the-counter drugs.         *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
2 
(6.5) 
2 
(6.5) 
0 
(0) 
3 
(9.7) 
13 
(41.9) 
11 
(35.5) 
4 
(12.9) 
24 
(77.4) 
Comments were received from 6 panel members in themes of: 
1. need for governance: “The number of non-prescription drugs in Qatar is much greater than the UK 
or North America, so I would suggest this list be developed in comparison with those countries.” 
2. need for defined roles: “Let's allow our basic Pharmacists to recommend OTC meds for patients with 
minor ailments e.g. coughs, colds, hay fever, cold sores etc. and keep this distinct from the more 
clinically challenging role of Prescribing Pharmacists.” 
 
Statement 1.2.4: Under the Pharmacist Independent Prescribing for 
previously diagnosed conditions model, pharmacists can prescribe, within 
their competence, any prescription-only drugs.          *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.2) 
5 
(16.1) 
3 
(9.7) 
7 
(22.6) 
12 
(38.7) 
3 
(9.7) 
6 
(19.4) 
15 
(48.4) 
Comments were received from 6 panel members in themes of: 
1. need for a defined clinical area: “better to become a specialist in one area and then focus on 
prescribing those meds.” 
2. need for competent pharmacists: “As long as trained and competence assured.” 
3. need for physician involvement: “Only with medical input.” 
→ Based on the response and comments, the statement was not 
altered. 
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Statement 1.2.5: Under the Pharmacist Independent Prescribing for 
previously diagnosed conditions model, pharmacists can prescribe, within 
their competence, any controlled drugs.          *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
5 
(16.1) 
11 
(35.5) 
2 
(6.5) 
5 
(16.1) 
6 
(19.4) 
2 
(6.5) 
16 
(51.6) 
8 
(25.8) 
Comments were received from 5 panel members in themes of: 
1. need for physician involvement: “More to dosing/ titrating the drug; starting and discontinuation 
should be done by the physician.” 
2. risks associated with independent prescribing: “If independent of physicians looking after the 
patient, I feel this would be putting them at risk given the current legal situation in Qatar.” 
→ Based on the response and comments, the statement was not 
altered. 
 
1.3 Pharmacist Independent Prescribing for medical conditions NOT 
previously diagnosed by a physician 
Statement 1.3.1: Pharmacist Independent Prescribing for undiagnosed 
medical conditions is an appropriate model for Qatar.       *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
14 
(45.2) 
10 
(32.3) 
2 
(6.5) 
2 
(6.5) 
1 
(3.2) 
2 
(6.5) 
24 
(77.4) 
3 
(9.7) 
Comments were received from 7 panel members in themes of: 
1. risks associated with independent prescribing: :This would be unsafe and cause patient harm.” 
2. maturity of the organisation: “Definitely too much of a leap from current practice.” 
3. need for training and governance: “We need to have well-defined roles and structured regulations 
plus extensive education to empower pharmacists to implement this model confidently.” 
→ Based on the response and comments, the statement was not 
altered. 
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Statement 1.3.2: Under the Pharmacist Independent Prescribing for 
undiagnosed conditions model, pharmacists can prescribe, within their 
competence, any over-the-counter drugs.       *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
4 
(12.9) 
3 
(9.7) 
2 
(6.5) 
10 
(32.3) 
9 
(29) 
3 
(9.7) 
7 
(22.6) 
12 
(38.7) 
Comments were received from 6 panel members in themes of: 
1. need for defined roles: “Have a separate Minor Ailments Scheme where the basic pharmacist can 
diagnose simple conditions and make recommendations to purchase OTC meds - no need for physician 
involvement at all here.” 
2. need for governance: “With the proviso that regular reporting and auditing of adverse events is 
essential as part of the annual appraisal and credentialing of the independent pharmacist.” 
→ Based on the response and comments, the statement was not 
altered. 
 
Statement 1.3.3: Under the Pharmacist Independent Prescribing for 
undiagnosed conditions model, pharmacists can prescribe, within their 
competence, any prescription-only drugs.       *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
8 
(25.8) 
10 
(32.3) 
5 
(16.1) 
3 
(9.7) 
3 
(9.7) 
2 
(6.5) 
18 
(58.1) 
5 
(16.1) 
Comments were received from 4 panel members in themes of: 
1. need for physician involvement: “Yes but I still feel diagnosis needs support by a physician.” 
2. need for an agreed list: “There needs to be an agreed formulary.” 
→ Based on the response and comments, the statement was not 
altered. 
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Statement 1.3.4: Under the Pharmacist Independent Prescribing for 
undiagnosed conditions model, pharmacists can prescribe, within their 
competence, any controlled drugs.       *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
13 
(41.9) 
12 
(38.7) 
3 
(9.7) 
2 
(6.5) 
0 
(0) 
1 
(3.2) 
25 
(80.6) 
1 
(3.2) 
Comments were received from 4 panel members in themes of: 
1. lack of diagnostic skills: “Pharmacists practicing in Qatar have not been trained in diagnosis, and a 
short certification programme would not be sufficient to ensure competency for the variety of medical 
conditions that exist.” 
2. risks associated with independent prescribing: “It is too much of a risk within the legal setting in 
Qatar.” 
→ Based on the response and comments, the statement was not 
altered. 
 
Section 2: Education and Training 
Statement 2.1: All pharmacist prescribers must complete a university-led 
education and training programme accredited by QCHP.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
1 
(3.2) 
1 
(3.2) 
8 
(25.8) 
21 
(67.7) 
0 
(0) 
29 
(93.5) 
Comments were received from 5 panel members in the theme of: 
1. need for a robust training programme: “This needs to be evidence based and supported with 
international standards.” 
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Statement 2.2: The education and training programme must be related to the 
medical condition(s) in which the pharmacist is planning to prescribe.       
*Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
1 
(3.2) 
0 
(0) 
3 
(9.7) 
10 
(32.3) 
17 
(54.8) 
1 
(3.2) 
27 
(87.1) 
Comments were received from 4 panel members in themes of: 
1. need for a robust programme: ”The University course must have two levels: Level 1 - Basic 
prescribing principles, disease aetiology, pathology, investigations etc. - covering all major diseases  
Level 2 - Disease Specialisation, once Level 1 has been mastered.” 
2. importance of practising within a specialised area: “it would be much better to study for, and work 
within specialist areas within which a pharmacist can gain considerable expertise.” 
 
Statement 2.3: The education and training programme must include a period 
of learning in practice (i.e. training) relating to the medical condition(s) in 
which the pharmacist is planning to prescribe.       *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.2) 
0 
(0) 
1 
(3.2) 
1 
(3.2) 
10 
(32.3) 
18 
(58.1) 
1 
(3.2) 
28 
(90.3) 
Comments were received from 3 panel members in the theme of: 
1. preferred structure of learning: “Preferably closely aligned to a physician who embraces the idea 
and pharmacists already working in the area.” 
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Statement 2.4: The period of learning in practice must be supervised by a 
senior physician.       *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
2 
(6.5) 
2 
(6.5) 
7 
(22.6) 
7 
(22.6) 
13 
(41.9) 
2 
(6.5) 
20 
(64.5) 
Comments were received from 8 panel members in themes of: 
1. criteria for supervising physician: “If we want safe Pharmacist Prescribers, we must have excellent 
mentors who can identify weaknesses and unsafe practices to ensure our Prescribing Pharmacists are 
fully competent to practice and not just good in a paper exam.” 
2. potential for other health professionals to supervise: “Any certified competent trainer/health 
professional.” 
3. need for senior pharmacist involvement: “I would suggest a senior pharmacist needs to be involved 
here.” 
→ Based on the response and comments, the statement was revised to: 
“The period of learning in practice must be supervised by a senior 
physician with a particular interest in prescribing.” 
 
Statement 2.5: The senior physician supervising the period of learning in 
practice must be familiar with the education and training programme’s aims 
and objectives.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.2) 
1 
(3.2) 
0 
(0) 
1 
(3.2) 
5 
(16.1) 
23 
(74.2) 
2 
(6.5) 
28 
(90.3) 
No relevant comments were received. 
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Statement 2.6: All pharmacists enrolling in the education and training 
programme must have a postgraduate qualification in clinical pharmacy.        
*No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.2) 
3 
(9.7) 
2 
(6.5) 
4 
(12.9) 
7 
(22.6) 
14 
(45.2) 
4 
(12.9) 
21 
(67.7) 
Comments were received from 10 panel members in themes of: 
1. need for support regardless of practice setting: “I feel this restricts prescribing only to Hospital 
based pharmacists, and in countries where this is most successful, community based pharmacists are 
also involved.” 
2. need for clinically trained pharmacists: “Or advanced pharmacy training like "structured clinical 
training".” 
→ Based on the response and comments, the statement was revised to: 
“All pharmacists enrolling in the education and training programme 
must have a postgraduate qualification in clinical pharmacy or a 
related field.” 
 
Statement 2.7: All pharmacists enrolling in the education and training 
programme must have at least 2 years of direct clinical patient care 
experience in the medical condition(s) in which they are planning to 
prescribe.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
1 
(3.2) 
2 
(6.5) 
5 
(16.1) 
9 
(29) 
14 
(45.2) 
1 
(3.2) 
23 
(74.2) 
Comments were received from 10 panel members in themes of: 
1. differing views on clinical practice experience: “we should be asking these candidates to come with 
at least 10 years’ experience and then 5 years specialisation”; “I think two years too long, one year is 
okay”;  
2. definition of direct clinical experience: “Community pharmacy service should be considered as direct 
clinical patient care experience.” 
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Statement 2.8: All pharmacists enrolling in the education and training 
programme must have their application endorsed by the senior physician 
responsible for the period of learning in practice.        *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
2 
(6.5) 
3 
(9.7) 
5 
(16.1) 
14 
(45.2) 
7 
(22.6) 
2 
(6.5) 
21 
(67.7) 
Comments were received from 3 panel members in the theme of: 
1. criteria for senior physician: “Important that physician really embraces and understands what is 
needed and the full scope of the role.” 
→ Based on the response and comments, the statement was not 
altered. 
 
Statement 2.9: All pharmacists enrolling for the education and training 
programme must have the endorsement of the pharmacy director in their 
organisation.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
3 
(9.7) 
2 
(6.5) 
10 
(32.3) 
16 
(51.6) 
0 
(0) 
26 
(83.9) 
No relevant comments were received. 
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Statement 2.10: All pharmacists planning to enrol in the education and 
training programme must submit a portfolio outlining the set of skills and 
experience they possess and how they plan to develop further.      
*Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
0 
(0) 
2 
(6.5) 
15 
(48.4) 
14 
(45.2) 
0 
(0) 
29 
(93.5) 
No relevant comments were received. 
 
Statement 2.11: All pharmacists enrolling in the education and training 
programme must demonstrate that, within their area of practice, there is a 
clinical need for their role endorsed by a physician.        *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
4 
(12.9) 
1 
(3.2) 
10 
(32.3) 
11 
(35.5) 
5 
(16.1) 
4 
(12.9) 
16 
(51.6) 
Comments were received from 9 panel members in the theme of: 
1. resistance from physicians: “Physician resistance and fear of the unknown new pharmacist 
prescribers may hinder the introduction of new innovative services.” 
→ Based on the response and comments, the statement was revised to: 
“All pharmacists enrolling in the education and training programme 
must demonstrate that, within their area of practice, there is a clinical 
need for their prescribing role.” 
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Statement 2.12: Prior to registration with QCHP as a prescriber, pharmacists 
must successfully complete the education and training programme and be 
deemed competent by the senior physician responsible for the period of 
learning in practice.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.2) 
1 
(3.2) 
3 
(9.7) 
3 
(9.7) 
9 
(29) 
14 
(45.2) 
2 
(6.5) 
23 
(74.2) 
Comments were received from 6 panel members in the theme of: 
1. need for senior pharmacist involvement: “A senior competent pharmacist needs to be involved as 
well.” 
 
Statement 2.13: Pharmacist prescribers registered in countries other than 
Qatar must be registered with QCHP prior to commencing prescribing 
practice.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.2) 
1 
(3.2) 
0 
(0) 
2 
(6.5) 
10 
(32.3) 
17 
(54.8) 
2 
(6.5) 
27 
(87.1) 
Comments were received from 5 panel members in the theme of: 
1. need for competency assessment: “With evidence of fitness to practice prescribing and a safety 
record e.g. number of prescribing errors and patient harm caused.” 
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Section 3: Prescribing Practice & Governance 
Statement 3.1: Pharmacist prescribers must not commence prescribing 
practice until registered with QCHP.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
0 
(0) 
2 
(6.5) 
9 
(29) 
20 
(64.5) 
0 
(0) 
29 
(93.5) 
No relevant comments were received. 
 
Statement 3.2: All newly registered pharmacist prescribers must first practise 
collaborative prescribing for a period of time prior to progressing to 
independent prescribing.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
3 
(9.7) 
0 
(0) 
3 
(9.7) 
12 
(38.7) 
13 
(41.9) 
3 
(9.7) 
25 
(80.6) 
No relevant comments were received. 
 
Statement 3.3: The job description of the pharmacist prescribers must be 
amended to include prescribing.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
2 
(6.5) 
0 
(0) 
0 
(0) 
1 
(3.2) 
10 
(32.3) 
18 
(58.1) 
2 
(6.5) 
28 
(90.3) 
No relevant comments were received. 
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Statement 3.4: If in doubt about their ability to prescribe for a patient, the 
pharmacist prescriber must refer him/her back to the physician.        
*Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
7 
(22.6) 
24 
(77.4) 
0 
(0) 
31 
(100) 
Comments were received from 5 panel members in themes of: 
1. culture: “Unfortunately, the culture in the Arab World does not lend itself to being open, honest and 
transparent when admitting to mistakes or having a lack of knowledge.” 
2. need for clear referral process: “There should be a clear referral and referral- back mechanism.” 
 
Statement 3.5: All pharmacist prescribers must prescribe according to local 
policies, guidelines and protocols of their organisation.   *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
5 
(16.1) 
26 
(83.9) 
0 
(0) 
31 
(100) 
Comments were received from 4 panel members in themes of: 
1. safety implications: “Following protocol ensures greater prescribing safety.” 
2. need for robust guidelines: “But validated protocols approved by multidisciplinary committees.” 
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Statement 3.6: Once registered, all pharmacist prescribers must undertake 
Continuing Professional Development (CPD) within the medical condition(s) in 
which they are prescribing.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
8 
(25.8) 
23 
(74.2) 
0 
(0) 
31 
(100) 
Comments were received from 6 panel members in themes of: 
1. need for control: “Agree but not additional to the current burden of CPD.” 
2. need for CPD: “It should not only be the medical condition, as they must have general CPD for 
regular pharmacy knowledge as well.” 
 
Statement 3.7: All pharmacist prescribers must have ready access to patient 
clinical records.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
1 
(3.2) 
1 
(3.2) 
5 
(16.1) 
24 
(77.4) 
0 
(0) 
29 
(93.5) 
Comments were received from 6 panel members in themes of: 
1. benefits: “This is an key tool that must be accessible for successful and safe prescribing practice.” 
2. need for integration across settings: “need to see interactions for that patient across the whole 
sector to get the full picture (i.e. PHCC and HMC and other providers etc).” 
 
Statement 3.8: All pharmacist prescribers must document every prescribing 
activity in the patient clinical records.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
6 
(19.4) 
25 
(80.6) 
0 
(0) 
31 
(100) 
No relevant comments were received. 
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Statement 3.9: All pharmacist prescribers must have the authority to order 
appropriate laboratory tests to inform their prescribing decisions.        
*Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
1 
(3.2) 
1 
(3.2) 
2 
(6.5) 
8 
(25.8) 
19 
(61.3) 
1 
(3.2) 
27 
(87.1) 
Comments were received from 8 panel members in themes of: 
1. need for protocol: “Within pre-agreed limits relevant to the conditions they are licensed to treat.” 
2. communication: “Communication and coordination with medical team to prevent any unnecessary 
additional blood drawing.” 
 
Statement 3.10: All pharmacist prescribers must have the authority to order 
other relevant tests and investigations (e.g. ECG, X-ray...).       *No 
Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
4 
(12.9) 
2 
(6.5) 
11 
(35.5) 
5 
(16.1) 
9 
(29) 
4 
(12.9) 
14 
(45.2) 
Comments were received from 7 panel members in themes of: 
1. risk: “This could lead to a confusion of roles.” 
2. benefit: “Don't see any point in restriction if they have this much responsibility.” 
3. need for evidence-based practice: “This needs to be supported with international best practice.” 
→ Based on the response and comments, the statement was revised to: 
“All pharmacist prescribers must have the authority to order other 
relevant tests and investigations (e.g. ECG, X-ray...) if clinically 
indicated.” 
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Statement 3.11: All pharmacist prescribers must NOT have any role in the 
dispensing process for the patients for whom they prescribe.                        
*No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.2) 
2 
(6.5) 
2 
(6.5) 
10 
(32.3) 
7 
(22.6) 
9 
(29) 
3 
(9.7) 
16 
(51.6) 
Comments were received from 7 panel members in themes of: 
1. importance of separating roles: “Conflict of interest” and “To ensure the double check 
methodology.” 
2. confusion over need for separation: “In Canada there is no restriction.” and “Not sure what the 
issue is here: is it financial? probity issues?” and “Where there is a sound CIS like Cerner CIS at HMC 
and PHCC or a facility has an auditable electronic record the risk of fraud is low.” 
→ Based on the response and comments, the statement was not 
altered. 
 
Statement 3.12: All pharmacist prescribers must report prescribing errors 
according to the policy of their organisation.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
6 
(19.4) 
25 
(80.6) 
0 
(0) 
31 
(100) 
No relevant comments were received. 
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Statement 3.13: All pharmacist prescribers must report adverse drug 
reactions (ADRs) according to the policy of their organisation.       
*Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
4 
(12.9) 
27 
(87.1) 
0 
(0) 
31 
(100) 
Comments were received from 3 panel members in the theme of: 
1. need for a national repository: “There should be a common standard across Qatar, should not be 
just linked to one organisation, there should be centralised collection and analysis.” 
 
Statement 3.14: Pharmacists’ prescribing practice must be audited regularly 
against set and accepted standards.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
0 
(0) 
1 
(3.2) 
8 
(25.8) 
22 
(71) 
0 
(0) 
30 
(96.8) 
Comments were received from 5 panel members in the theme of: 
1. importance: “This will be highly required as quality control for new practice.” 
 
Statement 3.15: Patients’ feedback on the prescribing practice must be 
collected regularly, using standardised tools.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
0 
(0) 
4 
(12.9) 
13 
(41.9) 
14 
(45.2) 
0 
(0) 
27 
(87.1) 
Comments were received from 7 panel members in themes of: 
1. importance: “It would be interesting to measure patient satisfaction before implementation and 
after. This would support the initiative.” and “Especially in the first few years.” 
2. need for other sources of feedback: “Also other HCPs feedback on process.” 
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3. disadvantages: “May be a complete waste of time.” and “It a good idea but we need to avoid extra-
work by having it done as random audit not regularly.” 
 
Statement 3.16: A state-wide campaign should be launched to educate the 
general public about pharmacist prescribing.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
0 
(0) 
5 
(16.1) 
6 
(19.4) 
20 
(64.5) 
0 
(0) 
26 
(83.9) 
No relevant comments were received. 
 
Statement 3.17: A state-wide campaign should be launched to educate 
healthcare providers about pharmacist prescribing.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
0 
(0) 
0 
(0) 
1 
(3.2) 
10 
(32.3) 
20 
(64.5) 
0 
(0) 
30 
(96.8) 
No relevant comments were received. 
 
Section 4: Additional comments 
Comments were received from 3 panel members in themes of: 
1. benefits: “this programme will almost certainly make a very significant impact on OP waiting times 
as many slots filled with request for drug refills etc.” 
2. need for support: “Pharmacists advanced role need to be recognised and acknowledged by the 
hospital administration.” 
3. need for education about role: “A lot of work is needed to enhance the role of the pharmacists to the 
public, other healthcare professionals and to the hospital administration.” 
4. need for defined roles: “For every patient there should be ONE defined medical lead. This special 
competency pharmacists is adding in and supporting this. No DUAL leadership!” 
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6.3.3. Round 2 
Out of 33 experts who agreed to participate, 30 completed Round 2 
(response rate= 91%). The 15 statements that did not reach consensus 
during Round 1 were revised and shared again with the experts during this 
round. Consensus was reach in six of them. The following section presents 
the level of consensus on each statement as well as the feedback provided by 
the experts. 
Section 1: Definitions, Models, and Scope 
1.1 Pharmacist Collaborative Prescribing 
Statement 1.1.1: A collaborative model of pharmacist prescribing is 
appropriate for Qatar.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.3) 
0 
(0) 
1 
(3.3) 
2 
(6.7) 
11 
(36.7) 
15 
(50) 
1 
(3.3) 
26 
(86.7) 
No relevant comments were received. 
 
Statement 1.1.8: Under the Collaborative Pharmacist Prescribing model, 
pharmacists can prescribe, within their competence, any controlled drug 
stated in the protocol.        *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
2 
(6.7) 
4 
(13.3) 
3 
(10) 
6 
(20) 
13 
(43.3) 
2 
(6.7) 
6 
(20) 
15 
(50) 
Comments were received from 12 panel members in themes of: 
1. criteria for prescribing: “It is possible if the qualified well-trained pharmacist has a very defined role 
clearly stated in the written collaborative agreement protocol.” 
2. need for training and governance: “I feel this needs additional training and very tight governance if 
we are to adopt it, particularly in Qatar.” 
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3. potential for role development: “This approach should work well in Qatar before moving forward to 
full independent pharmacist prescribing in the future.” 
4. need for physician involvement: “I agree that the initial decision to prescribe should be taken in 
conjunction with the physician who has overall responsibility for the patient.” 
 
1.2 Pharmacist Independent Prescribing for medical conditions previously 
diagnosed by a physician 
Statement 1.2.1: Pharmacist Independent Prescribing for previously 
diagnosed medical conditions is an appropriate model for Qatar.              
*No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
3 
(10) 
6 
(20) 
3 
(10) 
6 
(20) 
7 
(23.3) 
5 
(16.7) 
9 
(30) 
12 
(40) 
Comments were received from 13 panel members in themes of: 
1. maturity of the organisation: “Qatar is not ready for this approach yet – but yes in the future when 
the processes have matured and there is greater acceptance from physicians.” 
2. need for training and governance: “I am guarded about its adoption without good additional training 
and governance.” 
3. need for guidelines and piloting: “There should be protocols to support this and small steps/pilots 
should start to develop experience and learning.” 
4. risks: “I think that this model blurs the lines between the role of doctor and pharmacist. There are 
risks that pharmacists may practice outside their levels of experience and competence and also there 
are risks that too many different people will be involved in care without talking to each other.” 
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Statement 1.2.4: Under the Pharmacist Independent Prescribing for 
previously diagnosed conditions model, pharmacists can prescribe, within 
their competence, any prescription-only drugs.          *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
2 
(6.7) 
3 
(10) 
0 
(0) 
5 
(16.7) 
15 
(50) 
5 
(16.7) 
5 
(16.7) 
20 
(66.7) 
Comments were received from 9 panel members in themes of: 
1. need for competent pharmacists: “If having competencies in specific specialty.” 
2. need for change: “We need to have a strategic plan in which all pharmacy sectors work together on 
changing laws and policies, train and educate pharmacists, standardise practices, utilise technologies 
that help to implement and hold the responsibility to such privilege in the future.” 
3. need for physician involvement: “I do not think that the pharmacist should be managing the patient 
separately from the clinicians.” 
 
Statement 1.2.5: Under the Pharmacist Independent Prescribing for 
previously diagnosed conditions model, pharmacists can prescribe, within 
their competence, any controlled drugs.          *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
5 
(16.1) 
11 
(35.5) 
2 
(6.5) 
5 
(16.1) 
6 
(19.4) 
2 
(6.5) 
16 
(51.6) 
8 
(25.8) 
No relevant comments were received. 
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1.3 Pharmacist Independent Prescribing for medical conditions NOT 
previously diagnosed by a physician 
Statement 1.3.1: Pharmacist Independent Prescribing for undiagnosed 
medical conditions is an appropriate model for Qatar.       *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
14 
(46.7) 
9 
(30) 
2 
(6.7) 
1 
(3.3) 
3 
(10) 
1 
(3.3) 
23 
(76.7) 
4 
(13.3) 
Comments were received from 9 panel members in themes of: 
1. lack of sustainability: “I feel that that is not a suitable model as pharmacists are not trained in 
diagnosis, and even a short certification programme is not sufficient for the best patient care 
outcomes.” 
2. need for training, education and governance: “Pharmacists should be trained, public should be aware 
of the new expanding pharmacist role and there should be laws governing the practice.” 
 
Statement 1.3.2: Under the Pharmacist Independent Prescribing for 
undiagnosed conditions model, pharmacists can prescribe, within their 
competence, any over-the-counter drugs.       *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
2 
(6.7) 
0 
(0) 
7 
(23.3) 
11 
(36.7) 
10 
(33.3) 
2 
(6.7) 
21 
(70) 
Comments were received from 8 panel members in themes of: 
1. risk: “No different to what happens already in any chemist shop BUT there is a risk that a diagnosis 
may be missed.” 
2. need for training: “With proper training this is possible, where I come from it is done all the time.” 
3. need for change in laws: “I would recommend that the OTC drug list become more restrictive than 
the current list. There are many more drugs in Qatar that are available without prescription than in 
North American or European countries.” 
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Statement 1.3.3: Under the Pharmacist Independent Prescribing for 
undiagnosed conditions model, pharmacists can prescribe, within their 
competence, any prescription-only drugs.       *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
9 
(30) 
11 
(36.7) 
3 
(10) 
3 
(10) 
3 
(10) 
1 
(3.3) 
20 
(66.7) 
4 
(13.3) 
Comments were received from 7 panel members in themes of: 
1. need for physician involvement: “Must have a diagnosis first.” 
2. need for training: “pharmacists training would need to be broader and more extensive to allow this 
to happen safely.” 
 
Statement 1.3.4: Under the Pharmacist Independent Prescribing for 
undiagnosed conditions model, pharmacists can prescribe, within their 
competence, any controlled drugs.       *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
16 
(53.3) 
7 
(23.3) 
2 
(6.7) 
1 
(3.3) 
2 
(6.7) 
2 
(6.7) 
23 
(76.7) 
4 
(13.3) 
Comments were received from 6 panel members in the theme of: 
1. maturity of the organisation: “The medico-legal situation and the lack of current training and 
experience makes this a dangerous step.” 
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Section 2: Education and Training 
Statement 2.4: The period of learning in practice must be supervised by a 
senior physician with a particular interest in prescribing.       *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.3) 
2 
(6.7) 
0 
(0) 
6 
(20) 
11 
(36.7) 
10 
(33.3) 
3 
(10) 
21 
(70) 
Comments were received from 7 panel members in themes of: 
1. benefits: “Indeed the physician must have a really strong interest in good prescribing practice for this 
to be a suitable training/ supervisory period.” and “This would assist with learning and promote medicine 
safety.” 
2. potential for other providers to supervise: “They may need mentorship and supervision  at the 
beginning but not necessarily by a physician.” 
3. need for adapting to community setting: “I feel that this eliminate any community pharmacy 
practitioner and some method should be formulated to ensure they have an opportunity to be trained in 
prescribing as well.” 
 
Statement 2.6: All pharmacists enrolling in the education and training 
programme must have a postgraduate qualification in clinical pharmacy or a 
related field.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.3) 
1 
(3.3) 
0 
(0) 
3 
(10) 
15 
(50) 
10 
(33.3) 
2 
(6.7) 
25 
(83.3) 
Comments were received from 8 panel members in the theme of: 
1. criteria for postgraduate qualification: “As long as the possible qualifications are accessible by all 
appropriate pharmacists.” and “Need a list of international agreed qualifications or equivalence list.” 
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Statement 2.8: All pharmacists enrolling in the education and training 
programme must have their application endorsed by the senior physician 
responsible for the period of learning in practice.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
3 
(10) 
0 
(0) 
4 
(13.3) 
17 
(56.7) 
6 
(20) 
3 
(10) 
23 
(76.7) 
Comments were received from 3 panel members in the theme of: 
1. criteria for senior physician: “those supervisors must be carefully selected as proper support is really 
needed here.” 
 
Statement 2.11: All pharmacists enrolling in the education and training 
programme must demonstrate that, within their area of practice, there is a 
clinical need for their prescribing role.        *Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
2 
(6.7) 
0 
(0) 
3 
(10) 
23 
(76.7) 
2 
(6.7) 
2 
(6.7) 
25 
(83.3) 
Comments were received from 5 panel members in the theme of: 
1. need for endorsement of role: “It still needs senior endorsement. Perhaps a facility director of 
pharmacy in conjunction with the chief medical officer (CMO).” 
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Section 3: Prescribing Practice & Governance 
Statement 3.10: All pharmacist prescribers must have the authority to order 
other relevant tests and investigations (e.g. ECG, X-ray...) if clinically 
indicated.      *No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
1 
(3.3) 
2 
(6.7) 
1 
(3.3) 
7 
(23.3) 
12 
(40) 
7 
(23.3) 
3 
(10) 
19 
(63.3) 
Comments were received from 9 panel members in themes of: 
1. need for physician involvement: “Shall also be under supervision from the treating clinician/team.” 
2. need for training and governance: “They would need specific training. This must subject to regular 
audit.” 
3. need for a pre-agreed list: “The list of tests which can be ordered by the pharmacist should be 
specified in the collaborative agreement.” 
4. need for evidence-based practice: “Should be in line with international best practice.” 
5. risks: “Who decides what is clinically indicated? Again we risk blurring the lines about responsibilities 
of different individuals in the team and fragmenting care.” 
 
Statement 3.11: All pharmacist prescribers must NOT have any role in the 
dispensing process for the patients for whom they prescribe.                        
*No Consensus 
Responses n (%) Level of Consensus n (%) 
Strongly 
Disagree Disagree 
Some 
what 
Disagree 
Some 
what 
Agree 
Agree Strongly Agree Disagreement Agreement 
0 
(0) 
4 
(13.3) 
4 
(13.3) 
4 
(13.3) 
12 
(40) 
6 
(20) 
4 
(13.3) 
18 
(60) 
Comments were received from 7 panel members in themes of: 
1. importance of separating roles: “Conflict of interest may arise” and “Ensures every prescription is 
double checked as it is now. Nothing less is acceptable.” 
2. confusion over need for separation: “What is the point in having a pharmacist prescribe and then 
having a patient go to a different pharmacy to get the medication dispensed, if no other pharmacist is 
on staff?” 
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Section 4: Additional comments 
Comments were received from 2 panel members in themes of: 
1. potential for combining prescribing and dispensing: “Pharmacists could have role in dispensing if 
medication verified by other pharmacists.” 
2. need for more research: “There should be a comprehensive study on (1) the benefits to the society 
by the current practice of pharmacists dispensing medicines for minor ailments, (2) Possible benefits of 
pharmacists prescribing models, (3) Prescription errors in the current system, (4) Pharmacist 
intervention on these prescription errors, (5) Gaps in the knowledge and training required for full 
prescribing rights.” 
 
Although nine statements did not reach consensus following Rounds 1 and 2 
(See Table 6.4), another round was deemed unnecessary based on the open 
comments provided by the panel members. These comments highlighted that 
independent prescribing was not considered appropriate at this point in time 
of developing pharmacy practice in Qatar. Consensus was not achieved for 
most statements on independent prescribing and stakeholder views were 
unlikely to alter in further rounds.  
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Table 6.4: Summary of Delphi consensus for Rounds 1 and 2 results 
Statements Level of consensus 
1. Definitions, models and scope 
1.1. Pharmacist Collaborative Prescribing 
1.1.1 A collaborative model of pharmacist prescribing is appropriate for Qatar. Consensus 
1.1.2 The protocol for collaborative pharmacist prescribing should have a defined generic format approved by Qatar Council for 
 Healthcare Professionals (QCHP). Consensus 
1.1.3 The protocol for collaborative pharmacist prescribing must state the targeted medical condition(s). Consensus 
1.1.4 The protocol for collaborative pharmacist prescribing must state the scope of prescribing for the pharmacists (e.g. what, when, 
 and how to initiate/continue/discontinue/change drugs, dose, duration…). Consensus 
1.1.5 The protocol for collaborative pharmacist prescribing must be approved by the pharmacist prescriber(s), physician(s), and the 
 pharmacy director within the organisation. Consensus 
1.1.6 Under the Collaborative Pharmacist Prescribing model, pharmacists can prescribe, within their competence, any over-the-
 counter drug stated in the protocol. Consensus 
1.1.7 Under the Collaborative Pharmacist Prescribing model, pharmacists can prescribe, within their competence, any prescription-
 only drug stated in the protocol. Consensus 
1.1.8 Under the Collaborative Pharmacist Prescribing model, pharmacists can prescribe, within their competence, any controlled drug 
 stated in the protocol. No Consensus 
1.2. Pharmacist Independent Prescribing for medical conditions previously diagnosed by a physician 
1.2.1 Pharmacist Independent Prescribing for previously diagnosed medical conditions is an appropriate model for Qatar. No Consensus 
1.2.2 Under the Pharmacist Independent Prescribing for previously diagnosed conditions model, a physician must diagnose the 
 medical condition before the pharmacist can prescribe. Consensus 
1.2.3 Under the Pharmacist Independent Prescribing for previously diagnosed conditions model, pharmacists can prescribe, within 
 their competence, any over-the-counter drugs. Consensus 
1.2.4 Under the Pharmacist Independent Prescribing for previously diagnosed conditions model, pharmacists can prescribe, within 
 their competence, any prescription-only drugs. No Consensus 
1.2.5 Under the Pharmacist Independent Prescribing for previously diagnosed conditions model, pharmacists can prescribe, within 
 their competence, any controlled drugs. No Consensus 
1.3. Pharmacist Independent Prescribing for medical conditions which have not been previously diagnosed by a physician 
1.3.1 Pharmacist Independent Prescribing for undiagnosed medical conditions is an appropriate model for Qatar. No Consensus 
1.3.2 Under the Pharmacist Independent Prescribing for undiagnosed conditions model, pharmacists can prescribe, within their 
 competence, any over-the-counter drugs. Consensus 
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1.3.3 Under the Pharmacist Independent Prescribing for undiagnosed conditions model, pharmacists can prescribe, within their 
 competence, any prescription-only drugs. No Consensus 
1.3.4 Under the Pharmacist Independent Prescribing for undiagnosed conditions model, pharmacists can prescribe, within their 
 competence, any controlled drugs. No Consensus 
2. Education & Training 
2.1  All pharmacist prescribers must complete a university-led education and training programme accredited by QCHP. Consensus 
2.2  The education and training programme must be related to the medical condition(s) in which the pharmacist is planning to 
prescribe. Consensus 
2.3  The education and training programme must include a period of learning in practice (i.e training) relating to the medical 
 condition(s) in which the pharmacist is planning to prescribe. Consensus 
2.4  The period of learning in practice must be supervised by a senior physician with a particular interest in prescribing. Consensus 
2.5  The senior physician supervising the period of learning in practice must be familiar with the education and training 
 programme’s aims and objectives. Consensus 
2.6  All pharmacists enrolling in the education and training programme must have a postgraduate qualification in clinical pharmacy 
 or a related field. Consensus 
2.7  All pharmacists enrolling in the education and training programme must have at least 2 years of direct clinical patient care 
 experience in the medical condition(s) in which they are planning to prescribe. Consensus 
2.8  All pharmacists enrolling in the education and training programme must have their application endorsed by the senior physician 
 responsible for the period of learning in practice. Consensus 
2.9  All pharmacists enrolling for the education and training programme must have the endorsement of the pharmacy director in 
 their organisation. Consensus 
2.10 All pharmacists planning to enrol in the education and training programme must submit a portfolio outlining the set of skills 
 and experience they possess and how they plan to develop further. Consensus 
2.11 All pharmacists enrolling in the education and training programme must demonstrate that, within their area of practice, there is 
 a clinical need for their prescribing role. Consensus 
2.12 Prior to registration with QCHP as a prescriber, pharmacists must successfully complete the education and training programme 
 and be deemed competent by the senior physician responsible for the period of learning in practice. Consensus 
2.13 Pharmacist prescribers registered in countries other than Qatar must be registered with QCHP prior to commencing prescribing 
 practice.  Consensus 
3. Prescribing Practice & Governance 
3.1  Pharmacist prescribers must not commence prescribing practice until registered with QCHP. Consensus 
3.2  All newly registered pharmacist prescribers must first practise collaborative prescribing for a period of time prior to progressing 
 to independent prescribing. Consensus 
3.3  The job description of the pharmacist prescribers must be amended to include prescribing. Consensus 
3.4  If in doubt about their ability to prescribe for a patient, the pharmacist prescriber must refer him/her back to the physician. Consensus 
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3.5  All pharmacist prescribers must prescribe according to local policies, guidelines and protocols of their organisation. Consensus 
3.6  Once registered, all pharmacist prescribers must undertake Continuing Professional Development (CPD) within the medical 
condition(s) in which they are prescribing. Consensus 
3.7  All pharmacist prescribers must have ready access to patient clinical records. Consensus 
3.8  All pharmacist prescribers must document every prescribing activity in the patient clinical records. Consensus 
3.9  All pharmacist prescribers must have the authority to order appropriate laboratory tests to inform their prescribing decisions. Consensus 
3.10 All pharmacist prescribers must have the authority to order other relevant tests and investigations (e.g. ECG, X-ray...) if 
 clinically indicated. No Consensus 
3.11 All pharmacist prescribers must NOT have any role in the dispensing process for the patients for whom they prescribe. No Consensus 
3.12 All pharmacist prescribers must report prescribing errors according to the policy of their organisation. Consensus 
3.13 All pharmacist prescribers must report adverse drug reactions (ADRs) according to the policy of their organisation. Consensus 
3.14 Pharmacists’ prescribing practice must be audited regularly against set and accepted standards. Consensus 
3.15 Patients’ feedback on the prescribing practice must be collected regularly, using standardised tools. Consensus 
3.16 A state-wide campaign should be launched to educate the general public about pharmacist prescribing. Consensus 
3.17 A state-wide campaign should be launched to educate healthcare providers about pharmacist prescribing. Consensus 
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6.4. Discussion 
6.4.1. Summary of key findings 
The aim of this phase of the research was to determine consensus around the 
most appropriate framework for pharmacist prescribing in Qatar. Of the 47 
statements, consensus was achieved for 38, with high levels of agreement for 
statements relating to the Collaborative Pharmacist Prescribing model, thus 
indicating it as being the most appropriate for Qatar. There was also very 
strong agreement that pharmacist prescribers in Qatar must undergo 
additional training and have experience in the clinical area in which they plan 
to prescribe. The need for robust governance to support pharmacist 
prescribing training and practice was highlighted.  
Consensus was not reached around adopting a pharmacist independent 
prescribing for Qatar, nor was it reached in relation to pharmacists 
prescribing any controlled drugs, with comments from panel members 
indicating that this may be due to the immaturity of pharmacy practice and 
strict regulations to be imposed when prescribing these controlled substances 
in Qatar. While the statement that pharmacist prescribers must not have any 
role in the dispensing process for the patients they prescribe did not reach 
consensus, almost two thirds of panel members agreed with this statement, 
highlighting the need to explore this issue further.  
6.4.2. Interpretation of findings 
This Delphi study identified that the most appropriate prescribing model for 
pharmacist prescribing in Qatar is the collaborative model. Such model has 
been successfully implemented in countries such as the USA and New 
Zealand. Collaborative Pharmacist Prescribing permits trained pharmacist 
prescribers practising within an interprofessional team setting to initiate or 
modify therapy (including discontinuation or maintenance of therapy 
originally initiated by another prescriber) according to a defined plan. 
Consensus was not obtained for independent prescribing, which has been 
successfully implemented in the UK and allows the pharmacist prescriber to 
practice more autonomously.  
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Opting for a collaborative model initially for pharmacist prescribing in Qatar 
prior to advancing to the more autonomous independent practice is very 
similar to progress in other countries, as described in Chapter 1. In the US, 
the pharmacist prescribing model is one of ‘Collaborative Drug Therapy 
Management’ which allows pharmacists to assess patients, order laboratory 
tests, choose and monitor drug therapy, and prescribe drugs according to a 
predefined protocol (Centers for Disease Control and Prevention 2013). This 
model has been implemented in more than 75% of USA’s States and the 
armed forces (Gauvin, Lavis and McCarthy 2015). A randomised trial 
conducted in 2014 comparing pharmacist managed hypertension to usual 
care gave significantly better blood pressure control in pharmacist managed 
group (81% achieved target vs. 44% at 6 months; 70% vs. 52% at 9 
months) and had significantly less encounters with their healthcare providers 
compared to the usual care group (p = 0.001) (Hirsch et al. 2014). Currently, 
there are no plans for pharmacist prescribers in the US to progress to an 
independent prescribing model. 
New Zealand, the most recent country to legislate pharmacist prescribing, 
has also opted for a collaborative model (New Zealand Ministry of Health 
2014). As of August 2016, there were 18 pharmacist prescribers, half of 
which were working in primary care or between primary and secondary care 
(New Zealand Ministry of Health 2017). Studies on the impact of collaborative 
prescribing in New Zealand are beginning to emerge. Collaborative 
pharmacist prescribers were acknowledged by health professionals 
(psychiatrists, nurses, and pharmacists) and mental health consumers as 
being vital members of the healthcare team, with the pharmacists perceiving 
improved patient care (Wheeler et al. 2012). The need for additional 
education and training and established relationships with physicians were 
highlighted as being crucial to counter concerns of competence, public 
perception and encroaching physician roles (Wheeler et al. 2012). These 
findings are consistent with the level of agreement achieved in Qatar and also 
evident in the themes derived from the open comments, highlighting the 
need for additional training, robust educational programme, practising within 
competence, thorough planning, and importance of QCHP and physician 
involvement in Qatar to accommodate for this new role. 
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Furthermore, panel members also supported adopting the UK prescribing 
training programme structure of a university-provided element and a period 
of learning in practice under the supervision and support of a designated 
medical practitioner (General Pharmaceutical Council 2018). To be eligible to 
enrol into the UK programme, applicants must: be registered as pharmacists 
with the General Pharmaceutical Council; have at least two years of patient-
orientated experience; have identified a need for their future prescribing 
practice; demonstrate how they reflect on their own performance and take 
responsibility for their own continuing professional development; and have an 
appropriate designated medical practitioner to supervise their learning in 
practice. Consensus was reached for adopting these criteria in Qatar, which 
will also provide confidence by benchmarking to the UK where pharmacist 
prescribing has been part of the legislative framework for 15 years.  
A Delphi study by Tonna et al. (2014) aimed to develop consensus guidance 
to facilitate service redesign around pharmacist prescribing in a UK hospital 
setting. Similar to the current research, the authors reported high level of 
consensus around aspects related to ‘service development’ (e.g. succession 
planning, multidisciplinary working, quality evaluation, practice development 
and outcome measures) and ‘pharmacist prescribing role development’ (e.g. 
education and future orientation of service).  
As noted earlier, there was no agreement to implement pharmacist 
independent prescribing in Qatar, with comments around concerns over 
pharmacist diagnosis skills and the relative immaturity of pharmacy practice. 
These findings are consistent with those of the systematic review presented 
in Chapter 4, which identified similar patient safety concerns in studies pre-
implementation of pharmacist prescribing. Interestingly, these issues were 
not identified in the post-implementation studies highlighting the value of the 
lived experiences and published research.  
There may, however, be scope to progress to an independent prescribing 
model in the future. This would be similar to the UK which legalised 
supplementary prescribing in 2003, allowing pharmacist prescribers to 
implement an agreed patient-specific clinical management plan (CMP) agreed 
with the physician and the patient (UK Department of Health 2003). At a 
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later point in time, the exemptions around controlled drugs (other than 
schedule 1) and unlicensed medicines were removed. In 2006, additional 
legislation was introduced to permit pharmacist independent prescribing, 
which removed many of the obstacles experienced with supplementary 
prescribing (e.g. the need for each patient to have an agreed CMP) (Cooper 
et al. 2008).  
The lack of agreement for pharmacist prescribers to prescribe controlled 
drugs, either collaboratively or independently in Qatar, is likely to be due to 
the strict legislations governing their handling and use. For instance, Article 
17 in Law 9 of 1987 on ‘Control and Regulation of Narcotic Drugs and 
Dangerous Psychotropic Substances (NDDPS)’ forbids pharmacists from 
dispensing controlled drugs, except with a prescription from a licensed 
physician or upon permission from the Ministry of Public Health (Al Thani 
1987). 
Interestingly, agreement was not achieved for separating prescribing and 
dispensing by the same pharmacist. While consensus was not achieved, 60% 
of panel members agreed with this statement. Those disagreeing gave 
comments highlighting concern that this would limit implementation to 
hospital setting or community pharmacies employing more than one 
pharmacist. In New Zealand, although not stated in the Medicines 
(Designated Pharmacist Prescribers) Regulations of 2013 (New Zealand 
Government 2013), the pharmacist prescribing competency framework 
clearly states under Principle 6 that each organisation must ‘have robust 
procedures in place to ensure the separation of prescribing and dispensing’ in 
order to promote public trust and confidence in pharmacists and enhance the 
reputation of the profession (Pharmacy Council of New Zealand 2013). The 
rationale for the separation is to protect patient safety. 
While the key themes derived from the open comments are unlikely to be at 
the level of saturation (given the relatively low numbers), these could be 
mapped to CFIR: innovation characteristics (need to ensure that 
implementation is evidence-based and gradual), outer setting (need to tailor 
service to patient needs), inner setting (need to consider benefits and risks 
and ensure compatibility with healthcare structure, pharmacy practice and 
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organisation’s goals mostly by involving physicians and practising within a 
specialised area), characteristics of individuals (need for training, experience 
and competence), and process (need for governance, planning and 
engagement of key stakeholders). There is therefore merit in adopting CFIR 
in all subsequent stages of development and implementation of pharmacist 
prescribing in Qatar. 
6.4.3. Strengths and weaknesses 
This study employed a consensus approach in developing pharmacist 
prescribing frameworks in Qatar. As described in Chapter 2, this approach 
was particularly appropriate for synthesising accumulated expert opinions, 
facilitating policy development, supporting quality improvement and clinical 
governance, and stimulating debate around areas of limited evidence or 
uncertainty (Campbell and Cantrill 2001, Nair, Aggarwal and Khanna 2011). 
Applying a research-based consensus approach to developing any non-
medical prescribing framework is novel. While Tonna et al. (2014) described 
a similar approach around pharmacist prescribing, the aim was to determine 
standards of practice according to the legislative framework in the UK. 
Courtenay et al. (2018) also used the Delphi approach to define the 
conditions which community practitioner nurse prescribers could manage.  
One strength of this phase is that all Delphi statements were developed 
comprehensively, being based on an extensive review of literature, the 
findings presented in Chapters 3-5 and review of pharmacist prescribing 
frameworks in other countries. This phase also had a theoretical foundation 
with CFIR underpinning the research questions, developing the data collection 
tools, and data analysis (Damschroder et al. 2009). Using theory also allows 
the data and findings to be presented in a more meaningful context and 
contribute towards building an integrated body of knowledge around 
implementation (Nilsen 2015). Further strengths include the high response 
rates in all rounds, with engagement from a diverse group of stakeholders 
with strategic positions in Qatar in policy development, leadership and 
academia. 
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Although it appears that there was over-representation of pharmacy leaders 
and under-representation of physician leaders, it is worthy to note that many 
of the experts held dual positions. For instance, in the Healthcare Policy 
Leaders group, three of the experts were physicians, two were nurses, two 
have a healthcare and business administration background and one was a 
pharmacist. Thus, overall, there was a good representation of all the key 
healthcare professions in this study. 
On the other hand, data were collected in Qatar. Hence, the findings may 
lack generalisability to other countries. However, it is likely that statements 
relating to education and training as well as prescribing practice and 
governance may be relevant to other healthcare professions and other 
countries. It is also likely that all the findings may be applicable to many 
countries within the ‘Arab World’, especially the Gulf Cooperation Council 
(GCC) and the Middle East and North Africa (MENA) regions. This is because 
most of the GCC countries share similar healthcare systems as well as similar 
demographics and backgrounds for healthcare practitioners. 
6.5. Conclusion 
High levels of agreement were obtained for statements which can constitute 
a framework for the development and implementation of pharmacist 
prescribing in Qatar. Implications, impact, further development and research 
are considered in Chapter 7. 
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7. Introduction to the chapter 
This chapter reiterates the overall aim of the doctoral research, the aim and 
key findings of each phase, highlighting the originality and potential impact of 
the research. Future work related to the implementation (development, 
trialability and evaluation) of pharmacist prescribing in Qatar is described. 
7.1. Aims and key findings 
The overall aim of the doctoral research was to explore the development of 
frameworks of pharmacist prescribing in Qatar. As part of the research, the 
framework was described in terms of: definitions, models and scope of 
prescribing; education and training; and prescribing practice and governance. 
The research was conducted in four phases, each building upon the findings 
of the previous phase(s), underpinned by a comprehensive theoretical 
framework of implementation, and the peer-reviewed literature and policy 
guidance on pharmacist prescribing. 
7.1.1. Phase 1: Umbrella review 
Chapter 1 highlighted that nonmedical prescribers’ training, competencies 
and ongoing continuing professional development may lead to safe and 
effective prescribing. There remained, however, a need for robust and 
rigorous evidence of NMP safety and effectiveness on which to base future 
developments. While there were multiple published literature reviews 
exploring different aspects of NMP, there had been no comprehensive 
overview.  
Thus, the first phase of this doctoral research was an umbrella review that 
aimed to collate and summarise all the published systematic reviews on NMP 
in order to report aspects, including, but not limited to: models and 
definitions; legal frameworks; outcomes and benefits; perceptions and 
satisfaction of different stakeholders (e.g. general public, patients, health 
professionals and decision makers); and facilitators and barriers to 
implementing NMP. 
The umbrella review identified seven systematic reviews of: influences on 
prescribing decision-making; processes of prescribing; and barriers and 
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facilitators to implementation. Decision-making was reported as complex with 
many, and often conflicting, influences. Facilitators of NMP included perceived 
improved patient care and professional autonomy, while barriers included 
lack of defined roles and resource pressures. Three systematic reviews 
explored patient outcomes that were noted to be equivalent or better to 
physician prescribing. Despite positive findings, authors highlighted high bias, 
poor definition and description of ‘prescribing’ and the ‘prescribing process’ 
and difficulty in separating NMP effects from the contributions of other 
healthcare team members. 
7.1.2. Phase 2: Systematic review 
The umbrella review conducted identified that no published systematic review 
had synthesised studies on stakeholders’ views and experiences of NMP. 
Feedback from key stakeholder groups of their views and experiences on 
pharmacist prescribing is vital to determine the possible factors influencing its 
implementation and thus inform the development and realisation of such 
initiatives in other countries. This is also necessary to explore whether views 
of stakeholders prior to implementing pharmacist prescribing would change 
upon experiencing the service, and to determine whether post-
implementation studies described similar facilitators and barriers to studies 
conducted pre-implementation. 
The aim of this phase was therefore to critically appraise, synthesise and 
present the available evidence on the views and experiences of stakeholders 
on pharmacist prescribing, including potential facilitators and barriers, 
regardless of implementation status. 
Most studies included in the systematic review pre- and post-implementation 
reported positive views and experiences with main benefits described as: 
increased access to healthcare services; perceptions of enhanced patients’ 
outcomes; better utilisation of pharmacists’ skills and knowledge; improved 
job satisfaction; and reduced physicians’ workload. However, concerns were 
noted around issues of: liability; limited pharmacists’ diagnosis skills; access 
to medical records; and lack of organisational and financial support. While 
review findings were derived from many studies of generally high 
methodological quality, there was a lack of mixed-methods approaches. 
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7.1.3. Phase 3: Qualitative semi-structured interviews 
In addition to the key findings described above, the systematic review also 
identified a gap and therefore the need for primary research to be conducted 
in the ‘Arab World’. There are several reasons why findings from studies 
conducted in other parts of the world cannot easily be generalised or 
transferred including differences in ethnicity, culture and work practices. 
Furthermore, it became evident that there was a lack of studies researching 
diverse stakeholder groups, of qualitative studies and studies grounded in 
implementation theory.  
The research conducted in Phase 3 aimed to determine key health 
stakeholders’ (patients, physicians, nurses, pharmacists, hospital 
administrators, regulatory bodies’ representatives) expectations, attitudes 
and beliefs around implementing pharmacist prescribing in Qatar. Data 
saturation was achieved following 37 interviews. The interviewees were 
generally aware of models of pharmacist prescribing in other countries and 
the clinical activities of pharmacist in Qatar, most notably in Hamad Medical 
Corporation. There was also support for the development and implementation 
of pharmacist prescribing in Qatar, with many potential benefits, facilitators, 
and barriers highlighted. It was also clear that there was a requirement to 
systematically plan the development and implementation of pharmacist 
prescribing, with reference to all five domains of CFIR.  
7.1.4. Phase 4: Quantitative modified-Delphi study 
The previous phase highlighted support for the potential development and 
implementation of pharmacist prescribing in Qatar. The aim of the final phase 
of the doctoral research was to determine the levels of agreement amongst 
key stakeholders in Qatar around the development of pharmacist prescribing 
frameworks. 
Of the 47 statements included in a Delphi study, consensus was achieved for 
38, with high levels of agreement for statements relating to the collaborative 
pharmacist prescribing model thus indicating it as being most appropriate for 
Qatar. There was also very strong agreement that pharmacist prescribers in 
Qatar must undergo additional training and have experience in the clinical 
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area in which they planned to prescribe. The need for robust governance to 
support pharmacist prescribing training and practice was highlighted. 
However, consensus was not reached around adopting a pharmacist 
independent prescribing for Qatar, nor was it reached in relation to 
pharmacists prescribing any controlled drugs and for separating prescribing 
and dispensing. 
A summary of the methods and key highlights of this doctoral research is 
provided in Figure 7.1. A detailed discussion of the strengths, limitations, and 
interpretation of findings of each phase was described in their respective 
chapters. 
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Phase 1: 
Umbrella Review 
Phase 2: 
Systematic Review 
Phase 3: 
Qualitative Interviews 
Phase 4: 
Quantitative Consensus 
(Delphi) 
Pharmacist 
Prescribing 
Framework for 
Qatar 
Figure 7.1: Summary of the methods and key findings of doctoral project 
No comprehensive systematic 
review on views and 
experiences around Non-
Medical Prescribing 
Lack of qualitative theory-
based studies conducted in 
non-western countries 
Support for the potential 
development and 
implementation of Pharmacist 
Prescribing in Qatar 
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7.2. Interpretation of findings  
The positive findings of the two literature reviews conducted as part of this 
doctoral research, together with previous reviews of effectiveness and safety 
(Kay and Brien 2004, Bhanbhro et al. 2011, Auta et al. 2015, Faruquee and 
Guirguis 2015, Weeks et al. 2016), provide evidence to support the 
expansion of pharmacist prescribing. However, it is worthy to note that 
interpretation and extrapolation of findings from studies conducted pre-
implementation are limited in that participants were not necessarily aware of 
the aim, nature, and scope of the planned models of prescribing and may 
also have been influenced by either positive or negative experiences of 
similar or diverse interventions. The qualitative semi-structured interviews 
with key health stakeholders in Qatar demonstrated the very positive 
appreciation of clinical pharmacy practice, particularly within Hamad Medical 
Corporation and high awareness of NMP implementation in other parts of the 
world. These aspects add credibility to the positive views expressed and 
themes which emerged around the potential to develop and implement 
pharmacist prescribing in Qatar. 
The umbrella and systematic reviews, together with the interviews identified 
that major facilitators pre-implementation included pharmacists’ personal 
qualities (e.g. their clinical experience, education and training) and the 
perceived benefits of pharmacist prescribing (e.g. improved patient access to 
care and better utilisation of pharmacists’ skills). Barriers included the 
potential lack of acceptance by patients and other healthcare providers, and 
concerns over pharmacists’ poor clinical skills relating to assessment and 
diagnosing. While the latter may be components of independent models of 
prescribing practice, this may indicate some confusion of the UK independent 
prescribing model which does not actually require the diagnosis to be made 
by the pharmacist independent prescriber (UK Department of Health 2006). 
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Adopting CFIR throughout the primary research allowed a more 
comprehensive assessment of facilitators and barriers. This framework had 
not been included in any of the studies retrieved as part of the umbrella and 
systematic reviews. CFIR identified the following: 
• The need to educate the public and other healthcare providers on 
pharmacists’ education and training 
• The potential to collaborate with other countries that had successfully 
implemented pharmacist prescribing 
• The readiness for implementation, particularly within Hamad Medical 
Corporation 
• The need to improve pharmacists’ confidence to undertake prescribing 
• The need for robust governance 
• Involving a diverse group of stakeholders in the design, 
implementation, and evaluation of innovation 
The Delphi study identified that a collaborative model of pharmacist 
prescribing was the most appropriate prescribing model for Qatar. Opting for 
a more conservative prescribing model initially prior to advancing to the more 
autonomous independent prescribing is very similar to progress in other 
countries such as the UK, as described in Chapter 1. 
The interviews and the Delphi study also highlighted the importance of 
undertaking additional education and training and pharmacists prescribing 
within their competence. There was support for adopting the UK prescribing 
training programme eligibility, and structure of a university provided element 
and a period of learning in practice under the supervision and support of a 
designated medical practitioner (General Pharmaceutical Council 2018). 
Together with the involvement of QCHP in accrediting the training 
programme and registering the prescribers will add confidence in the abilities 
of pharmacist prescribers in Qatar.  
While not yet being considered in Qatar, in certain countries, other healthcare 
providers such as nurses are also allowed to prescribe. Nurse prescribing was 
introduced in many countries (e.g. the US, Canada, UK, and New Zealand) to 
counteract physician shortages. Although this role was first legalised in the 
US in the 1960s, its development is most advanced in the UK (Lim, North and 
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Shaw 2014). As described in previous chapters, the Cumberlege Report in 
1986 first recommended expanding prescribing privileges to other healthcare 
professionals to improve access, reduce cost, and allow greater flexibility in 
healthcare services and delivery with district nurses and health visitors being 
the first to take up such responsibility (Department of Health and Social 
Security 1986, Lim, North and Shaw 2014). Nurse prescribing was first 
introduced in 1994 in pilot sites and, in 1998, on a national level with the 
introduction of extended formulary independent nurse prescribing in 2002. 
However, it was not until 2003 when nurses were given the opportunity to 
train as supplementary prescribers. This led to the introduction of nurse 
independent prescribing in 2006 which allowed qualified nurses to prescribe 
any licensed medicine for any medical condition including some controlled 
drugs (Ryan-Woolley, McHugh and Luker 2008). Before being allowed to 
prescribe, nurses must undertake an accredited educational preparation 
programme which comprises of 26 taught days, additional self-directed 
learning, and 12 days learning in practice with a medical mentor (Nursing 
and Midwifery Council 2018).  
Multiple studies have been published to explore key factors influencing 
implementation of nurse prescribing. Similar to some findings of the doctoral 
research, benefits related to professional development (e.g. enhanced job 
satisfaction, autonomy, increased knowledge and skills, career progression), 
patient care (e.g. safe, efficient and quicker access to care, patient 
satisfaction), and to overall healthcare (e.g. promoting evidence-based 
practice, reducing hospital admissions and cost of care) (Ryan-Woolley, 
McHugh and Luker 2008, O’Connell et al. 2009, Coull et al. 2013, Creedon et 
al. 2015, McBrien 2015). The need for appropriate levels of education and 
training programmes to support nurse prescribers was also reported (McBrien 
2015). Barriers to the implementation of nurse prescribing were reported, 
specifically apprehension in relation to the qualifications and training of nurse 
prescribers, resources, nurses’ knowledge and skills (especially diagnosis 
expertise), current workload, limited time availability, lack of support from 
medical colleagues and healthcare organisations (Ryan-Woolley, McHugh and 
Luker 2008, Coull et al. 2013, Creedon et al. 2015, McBrien 2015). One key 
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limitation of the literature on nurse prescribing is the failure to include 
implementation theory in any stages of the research. 
7.3. Originality of the research 
7.3.1. Novelty of design 
The scientific design of this doctoral research is original as no other studies of 
pharmacist prescribing development and implementation have reported a 
systematic approach with phase building on the findings of the previous 
phases, namely the umbrella review (Stewart et al. 2017) and the systematic 
review (Jebara et al. 2016, Jebara et al. 2018). These were followed by 
theory driven (CFIR) interviews and a further rapid review of the literature 
conducted mid-November 2018 that identified no newly published studies of 
pharmacist prescribing (or any other model of NMP) which used 
implementation theory. The final phase was a Delphi study and while Tonna 
et al. (2014) employed a similar consensus approach, their aim was to 
achieve consensus guidance to facilitate service redesign around pharmacist 
prescribing in UK hospital settings.  
As described in Chapter 2 and throughout the later chapters, to ensure the 
quality of this project, multiple steps were taken to promote validity and 
reliability (quantitative study) and trustworthiness (qualitative study) thus 
optimising the robustness and rigour of the research. The quality of the 
primary research was enhanced through incorporating CFIR into the stages of 
data collection and generation tool design, analysis, and reporting. 
7.3.2. Novelty of concepts and ideas 
Currently, pharmacist prescribing is considered a novel, and somewhat 
advanced, field of practice not only in the ‘Arab World’ but also globally. As 
highlighted in Chapter 1, only a limited number of countries in the ‘Western 
World’ have introduced legislation allowing the implementation of pharmacist 
prescribing. Furthermore, no published studies have been conducted in the 
‘Arab World’ and the findings of studies conducted in other parts of the world 
cannot necessarily be generalised or transferred to the ‘Arab World’ due to 
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major differences in healthcare structures, processes, and ethnic cultures, as 
outlined in Chapter 1.  
7.3.3. Dissemination of findings 
As a result of the original findings emerging from this doctoral research, a 
detailed dissemination strategy was formulated to highlight these findings to 
as wide an audience as possible. As highlighted at the start of this thesis, the 
findings have been disseminated at several national and international 
meetings and through peer-reviewed publications. It was also considered 
important to publish study findings in journals read by pharmacists, other 
health professionals, and policy makers etc. A further three peer-reviewed 
papers are planned from the semi-structured interviews and Delphi study. In 
addition, key findings will be fed back to all research participants and shared 
with key stakeholders in Qatar, including the Ministry of Public Health, in an 
effort to further the implementation of pharmacist prescribing in Qatar.  
7.4. Pharmacist prescribing framework for Qatar 
As described in Chapter 1, there is potential to extend the clinical role of 
pharmacists to include prescribing in Qatar. This is aligned to several 
strategic documents: Qatar National Vision 2030 (Qatar General Secretariat 
for Development Planning and Statistics 2008); Qatar National Research 
Strategy (Qatar National Research Fund 2014); and the National Health 
Strategy 2018-2022 (Qatar Ministry of Public Health 2018). These strategies 
have common goals of increasing access to an integrated world-class health 
system, the transfer of care from secondary and tertiary care to primary 
care, better utilisation of the skilled and motivated workforce, and 
encouraging research. 
As described earlier, the comprehensive research phases and the robust and 
rigorous findings of this doctoral research will advance the case for 
implementing pharmacist prescribing. The framework for pharmacist 
prescribing in Qatar is given in Table 7.1, in terms of definitions, models and 
scope of prescribing; education and training; prescribing practice and 
governance. 
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Table 7.1: Pharmacist prescribing framework for Qatar 
1. Definitions, models and scope 
1.1. Pharmacist Collaborative Prescribing 
1.1.1 A collaborative model of pharmacist prescribing is appropriate for Qatar. 
1.1.2 The protocol for collaborative pharmacist prescribing should have a defined generic format approved by Qatar Council for Healthcare Professionals (QCHP). 
1.1.3 The protocol for collaborative pharmacist prescribing must state the targeted medical condition(s). 
1.1.4 The protocol for collaborative pharmacist prescribing must state the scope of prescribing for the pharmacists (e.g. what, when, and how to 
initiate/continue/discontinue/change drugs, dose, duration…). 
1.1.5 The protocol for collaborative pharmacist prescribing must be approved by the pharmacist prescriber(s), physician(s), and the pharmacy director within the organisation. 
1.1.6 Under the Collaborative Pharmacist Prescribing model, pharmacists can prescribe, within their competence, any over-the-counter drug stated in the protocol. 
1.1.7 Under the Collaborative Pharmacist Prescribing model, pharmacists can prescribe, within their competence, any prescription-only drug stated in the protocol. 
2. Education and Training 
2.1 All pharmacist prescribers must complete a university-led education and training programme accredited by QCHP. 
2.2 The education and training programme must be related to the medical condition(s) in which the pharmacist is planning to prescribe. 
2.3 The education and training programme must include a period of learning in practice (i.e training) relating to the medical condition(s) in which the pharmacist is planning to 
prescribe. 
2.4 The period of learning in practice must be supervised by a senior physician with a particular interest in prescribing. 
2.5 The senior physician supervising the period of learning in practice must be familiar with the education and training programme’s aims and objectives. 
2.6 All pharmacists enrolling in the education and training programme must have a postgraduate qualification in clinical pharmacy or a related field. 
2.7 All pharmacists enrolling in the education and training programme must have at least 2 years of direct clinical patient care experience in the medical condition(s) in which they 
are planning to prescribe. 
2.8 All pharmacists enrolling in the education and training programme must have their application endorsed by the senior physician responsible for the period of learning in 
practice. 
2.9 All pharmacists enrolling for the education and training programme must have the endorsement of the pharmacy director in their organisation. 
2.10 All pharmacists planning to enrol in the education and training programme must submit a portfolio outlining the set of skills and experience they possess and how they plan to 
develop further. 
2.11 All pharmacists enrolling in the education and training programme must demonstrate that, within their area of practice, there is a clinical need for their prescribing role. 
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2.12 Prior to registration with QCHP as a prescriber, pharmacists must successfully complete the education and training programme and be deemed competent by the senior 
physician responsible for the period of learning in practice. 
2.13 Pharmacist prescribers registered in countries other than Qatar must be registered with QCHP prior to commencing prescribing practice.  
3. Prescribing Practice & Governance 
3.1 Pharmacist prescribers must not commence prescribing practice until registered with QCHP. 
3.2 All newly registered pharmacist prescribers must first practise collaborative prescribing for a period of time prior to progressing to independent prescribing. 
3.3 The job description of the pharmacist prescribers must be amended to include prescribing. 
3.4 If in doubt about their ability to prescribe for a patient, the pharmacist prescriber must refer him/her back to the physician. 
3.5 All pharmacist prescribers must prescribe according to local policies, guidelines and protocols of their organisation. 
3.6 Once registered, all pharmacist prescribers must undertake Continuing Professional Development (CPD) within the medical condition(s) in which they are prescribing. 
3.7 All pharmacist prescribers must have ready access to patient clinical records. 
3.8 All pharmacist prescribers must document every prescribing activity in the patient clinical records. 
3.9 All pharmacist prescribers must have the authority to order appropriate laboratory tests to inform their prescribing decisions. 
3.10 All pharmacist prescribers must report prescribing errors according to the policy of their organisation. 
3.11 All pharmacist prescribers must report adverse drug reactions (ADRs) according to the policy of their organisation. 
3.12 Pharmacists’ prescribing practice must be audited regularly against set and accepted standards. 
3.13 Patients’ feedback on the prescribing practice must be collected regularly, using standardised tools. 
3.14 A state-wide campaign should be launched to educate the general public about pharmacist prescribing. 
3.15 A state-wide campaign should be launched to educate healthcare providers about pharmacist prescribing. 
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7.5. Future work 
In addition to this doctoral research, two related studies are currently taking 
place in Qatar. These are studies of the views of pharmacists (in all settings) 
and pharmacy academics on the implementation of pharmacist prescribing. 
Results of these studies will add to the knowledge and evidence gathered in 
the doctoral research. 
As with all research, the results and findings described in this thesis will 
stimulate further research, as outlined below. All studies will also be 
grounded in implementation theory. 
7.5.1. Study 1: Defining the curriculum content for the 
education and training of pharmacist prescribers 
Research aim 
To define and scope the curriculum content for the education and training of 
pharmacist prescribers 
Research philosophy 
This study will adopt a positivist stance by attempting to gain consensus on 
the specific aspects of the curriculum.  
Methodology and methods 
A nominal group consensus approach will be adopted in an attempt to reach 
collective agreement around the desired design, learning outcomes, content, 
delivery, and assessment of the programme. The basis for discussion will be 
around the domains of CFIR and the approaches used in other countries 
which have implemented collaborative models of prescribing such as the US 
(Centers for Disease Control and Prevention 2013) and New Zealand (New 
Zealand Ministry of Health 2014). The nominal group technique involves face-
to-face meetings between experts and the determination of consensus using 
individual as well as group voting. (Nair, Aggarwal and Khanna 2011). 
Following the steps outlined by McMillan, King and Tully (2016), participants 
will first be sent one or two questions in advance related to the proposed 
training programme to implement. Once all participants gather, they will be 
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given around 20 minutes to reflect silently on the topic. Each participant will 
then be asked to present one idea to the group, moving to the other 
members until no new ideas emerge. Once similar ideas are grouped, 
participants will be provided with a ranking sheet containing all the grouped 
ideas and asked to rate their top preferences. Scores will then be summed up 
and presented for further discussion by all participants. 
A nominal group approach has been selected in preference to a Delphi study 
as it gathers all experts at the same time and location, allowing for 
generation of a larger number of ideas (van Teijlingen et al. 2006, 
Humphrey-Murto et al. 2017). 
7.5.2. Study 2: Exploring pharmacist and ‘designated medical 
practitioner’ perceptions of the prescribing education and 
training programme 
Research aim 
To examine pharmacists and their linked ‘designated medical practitioners’ 
(exact term to be decided) perceptions of the prescribing education and 
training programme, and the degree to which it prepared pharmacists for 
their prescribing role. 
Research philosophy 
This study will adopt a pragmatic approach, the focus of which is exploratory 
allowing examination of a phenomena in multiple contexts, conditions, or 
perspectives thus researchers often use mixed methods (Creswell 2007, 
Onwuegbuzie and Frels 2016). A pragmatic stance is most appropriate, 
allowing researchers to use all approaches available to understand 
phenomena by drawing from quantitative and qualitative assumptions 
(Creswell 2018). 
Methodology and methods 
An explanatory sequential mixed methodology will be employed by first 
conducting a survey-based study to determine pharmacists’ perspectives. The 
online questionnaire will be developed from the literature, reviewed for face 
and content validity, and piloted prior to use. Respondents will be given the 
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option of participating in focus group discussions, selected purposively to 
represent strata of age, years of experience as a pharmacist, and clinical 
setting. These pharmacists will also be requested to pass invitations to their 
‘designated medical practitioners’ to attend the focus groups. The focus group 
topic guide will be developed from the questionnaire responses, with 
emphasis on suitability of education and training for prescribing practice and 
any improvements which could be made.  
Following these two initial studies, later studies will focus on the impact of 
pharmacist prescribing on objective measures of economic, clinical, and 
humanistic outcomes. Depending on how pharmacist prescribing is 
implemented, this could be a randomised controlled trial, uncontrolled before 
and after study, or cohort study.  
7.6. Impact of the research 
UK Research and Innovation (2018) defines impact as “the demonstrable 
contribution that excellent research makes to society and the economy”. 
Impact can occur in variety of ways such as creating and sharing knowledge, 
inventing products/companies/jobs, developing or improving existing services 
and policies, enhancing health and quality of life etc. 
There are two main types of research impact; academic as well as economic 
and societal. The first relates to the scientific advances in areas such as 
understanding, method, theory, and application while the latter refers to the 
contribution to society, economy, individuals, organisations, and nations. 
UK Research and Innovation also outlines potential pathways to impact 
summarised in Figure 7.2. 
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Figure 7.2: Pathways to impact (UK Research and Innovation 2018) 
 
The impact of the current doctoral project can be mapped to these different 
pathways as shown in Figure 7.3. 
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Figure 7.3: Doctoral research impact mapped to UK Research and Innovation 
pathways  
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The doctoral research has impacted: 
• The doctoral student by developing her knowledge and skills in 
conducting research, using theory, and building collaboration and 
networking 
• Research team by introducing them to a new theoretical framework 
(CFIR) 
• Participants by giving them the opportunity to be part of potential 
policy changes and practice development 
• The likelihood of development and implementation in Qatar could also 
have an impact on: 
o patients by increasing their access to healthcare services and 
improving their health outcomes 
o healthcare structure and delivery by redirecting care and 
reducing workload from physicians 
o pharmacists by providing an opportunity for professional 
development and possibly enhancing job satisfaction 
o academic and especially those that will be responsible for the 
prescribing education and training programme 
o Qatar as it will be the first country in the ‘Arab World’ to 
implement such innovation 
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7.7. Conclusion 
Prior to conducting this doctoral research, there was a wealth of literature on 
the development, implementation and impact of pharmacist prescribing on a 
number of key outcomes. There had, however, been no published research at 
all relating to the ‘Arab World’. Given the various health-strategies and 
aspirations in Qatar, together with the level of clinical pharmacy in Hamad 
Medical Corporation, exploration of developing frameworks to enable the 
implementation of pharmacist prescribing was warranted. 
This research has provided original, robust and rigorous findings which can 
support implementation. Through a staged programme of research, evidence 
has been provided on the existing evidence on non-medical prescribing 
practice, derived from an umbrella review of systematic reviews. This was 
augmented by a systematic review of a large number of studies researching 
stakeholders’ views and experiences. While findings were generally positive 
pre- and post-implementation, there was a lack of studies grounded in 
theories of implementation and qualitative studies in particular. These 
findings were incorporated into the next study of qualitative interviews with a 
range of key individuals, including those in strategic positions of power. CFIR 
was employed to ensure comprehensive coverage of different aspects related 
to implementation. Again, findings were positive and incorporated into the 
final Delphi stage, which achieved consensus on aspects of a framework 
supporting implementation of pharmacist prescribing. 
On completion of the study, a framework has been proposed which will be 
disseminated widely within Qatar and beyond. Further research-based 
developmental work is required to translate this framework into an approved 
education and training course and practice.  
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Appendix 4B: PRISMA-P Checklist 
Section/topic # Checklist item 
Information 
reported Page 
number(s) 
Yes No 
ADMINISTRATIVE INFORMATION   
Title  
  Identification  1a Identify the report as a protocol of a systematic review   1 
  Update  1b If the protocol is for an update of a previous systematic review, identify as such 
  N/A 
Registration  2 If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract 
  1 
Authors  
  Contact  3a Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author 
  3-4 
  Contributions  3b Describe contributions of protocol authors and identify the guarantor of the review 
   
Amendments  4 
If the protocol represents an amendment of a previously completed or 
published protocol, identify as such and list changes; otherwise, state 
plan for documenting important protocol amendments 
  N/A 
Support  
  Sources  5a Indicate sources of financial or other support for the review   4 
  Sponsor  5b Provide name for the review funder and/or sponsor   4 
  Role of 
sponsor/funder  5c 
Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in 
developing the protocol 
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Section/topic # Checklist item 
Information 
reported Page 
number(s) 
Yes No 
INTRODUCTION  
Rationale  6 Describe the rationale for the review in the context of what is already known 
  2 
Objectives  7 
Provide an explicit statement of the question(s) the review will address 
with reference to participants, interventions, comparators, and 
outcomes (PICO) 
 
  1 
METHODS  
Eligibility criteria  8 
Specify the study characteristics (e.g., PICO, study design, setting, 
time frame) and report characteristics (e.g., years considered, 
language, publication status) to be used as criteria for eligibility for the 
review 
  1-2 
Information 
sources  9 
Describe all intended information sources (e.g., electronic databases, 
contact with study authors, trial registers, or other grey literature 
sources) with planned dates of coverage 
  1 
Search strategy  10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated 
  1 
STUDY RECORDS  
  Data 
management  11a 
Describe the mechanism(s) that will be used to manage records and 
data throughout the review 
   
  Selection 
process  11b 
State the process that will be used for selecting studies (e.g., two 
independent reviewers) through each phase of the review (i.e., 
screening, eligibility, and inclusion in meta-analysis) 
  1 
  Data collection 
process  11c 
Describe planned method of extracting data from reports (e.g., piloting 
forms, done independently, in duplicate), any processes for obtaining 
and confirming data from investigators 
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Section/topic # Checklist item 
Information 
reported Page 
number(s) 
Yes No 
Data items  12 
List and define all variables for which data will be sought (e.g., PICO 
items, funding sources), any pre-planned data assumptions and 
simplifications 
  3 
Outcomes and 
prioritization  13 
List and define all outcomes for which data will be sought, including 
prioritization of main and additional outcomes, with rationale 
  2-3 
Risk of bias in 
individual studies  14 
Describe anticipated methods for assessing risk of bias of individual 
studies, including whether this will be done at the outcome or study 
level, or both; state how this information will be used in data synthesis 
  3 
DATA 
Synthesis  
15a Describe criteria under which study data will be quantitatively synthesized 
  3 
15b 
If data are appropriate for quantitative synthesis, describe planned 
summary measures, methods of handling data, and methods of 
combining data from studies, including any planned exploration of 
consistency (e.g., I 2, Kendall’s tau) 
  3 
15c Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression) 
  3 
15d If quantitative synthesis is not appropriate, describe the type of summary planned 
  3 
Meta-bias(es)  16 Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies) 
   
Confidence in 
cumulative 
evidence  
17 Describe how the strength of the body of evidence will be assessed (e.g., GRADE) 
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Appendix 5A: Sample interview protocol 
Interview Protocol Project: A Study of the Development of Pharmacist 
Prescribing Frameworks in Qatar 
Time of interview:                                              Date: 
Place: 
Interviewer:                                                       Interviewee: 
Position of interviewee: 
Brief description of the project: 
Welcome to the "A Study of the Development of Pharmacist Prescribing 
Frameworks in Qatar” project. The objective is to explore patients, 
physicians, nurses, pharmacists, hospital administrators and regulatory 
bodies’ representatives’ views on implementing pharmacist prescribing in 
Qatar. 
This is part of a PhD thesis done by Robert Gordon University in United 
Kingdom in collaboration with Hamad Medical Corporation and Qatar 
University. 
The results of this interview can be used to guide the implementation of 
new regulations to improve health care delivery in Qatar. 
As a major health stakeholder in the country, your opinion matters. Thus, 
we kindly ask you to spend 1 hour to discuss this topic. 
There are no harms or risks associated with joining this study. Your 
participation is voluntary and anonymous. You can refuse or withdraw your 
consent to participate at any time without any penalty. 
 
Additional remarks made by participant: 
_________________________________________________ 
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Appendix 5B: Information sheet 
   
Information sheet 
Information to participants 
1. You are free to ask as many questions as you like before, during or after 
this session, should you decide to consent to participate in this research 
study. 
2. The information in this form is only meant to better inform you of all 
possible risks or benefits. Your participation in this study is entirely voluntary. 
3. You are entitled to participate in this study if you satisfy certain eligibility 
criteria 
4. You do not have to take part in this study, and your refusal to participate 
will involve no penalty or loss of rights to which you are entitled. 
5. You may decide not to participate in this study at any time without penalty 
or any loss of rights or other benefits to which you are otherwise entitled. 
Project Title: A Study of the Development of Pharmacist Prescribing 
Frameworks in Qatar  
Name of Investigators: 
1Tesnime Jebara, 1Prof Derek Stewart, 1Dr Scott Cunningham, 1Dr Katie 
MacLure, 2Dr. Ahmed Awaisu, 3Dr Moza Al Hail, 3Dr P V Abdulrouf 
1School of Pharmacy and Life Sciences, Robert Gordon University, UK 
2College of Pharmacy, Qatar University, Qatar 
3Women’s Hospital, Hamad Medical Corporation, Qatar 
Contact address and phone number: 
Dr. ABDUL ROUF, BPharm, MPharm, MSc (Clinical Pharmacology), PhD, UK 
Assistant Director, Pharmacy Department, Women’s Hospital-HMC 
Phone: 00974-44393154  
Cell: 00974-70406657 
Email: pabdulrouf@hmc.org.qa 
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1. Introduction: 
Pharmacist prescribing (PP) can have positive impact on patient care 
especially in ensuring rational drug use, improving access to health services 
as well as deceasing cost of treatment. That is why, Robert Gordon University 
in collaboration with Hamad Medical Corporation and Qatar University are 
conducting a study to assess the perspectives of key stakeholders in Qatar 
towards implementing pharmacist prescribing in the country. The study will 
involve performing interviews that last 1 hour. 
There is no cost associated with participating in the study. 
You have been selected as a participant in this project as you are either a 
patient, physician, nurses, pharmacist, hospital administrator or a regulatory 
bodies’ representative. 
2. Purpose of the research study:  
This study aims to answer the following research questions: 
1. What are stakeholders’ views and perceptions of clinical roles of 
pharmacists in Qatar? 
2. What are stakeholders’ views and perceptions of expanding the remit 
of pharmacists in Qatar to include prescribing? 
3. What are the stakeholders’ views and perceptions of facilitators, 
barriers and solutions to the development and implementation of 
pharmacist prescribing in Qatar?  
3. Description of the procedures that will be followed during the 
research:  
If you accept to participate in the study, you will be asked to express your 
opinion on legalising pharmacist prescribing in Qatar as well as to discuss 
possible barriers to implement it in this country. 
Answers will be audio-recorded then transcribed later in order to examine 
and analyse responses. Your data will be stored on password protected 
computers that can only be accessed by the study investigators. All 
information will be handled in a confidential manner. No personal identifiers 
such as your name or contact details will be disclosed. 
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4. Description of any foreseeable risks or discomforts to the 
participants:  
There are no physiological, psychological or social risks associated with 
participation in this project. 
5. Description of any benefits to the participant or to others which 
might be reasonably expected from the research:  
By participating in this study, you will be part of the first study to explore the 
concept of pharmacist prescribing in the Middle East. Moreover, this study 
has the ability to create a research infrastructure which will trigger more 
studies in this area, instigate public discussions as well as guide pharmacy 
practice initiatives. Furthermore, the proposed project will enrich the current 
available literature about pharmacy practice in Qatar and promote excellence 
in scientific research and clinical practice in the country. 
There are no financial re-numeration to be given for your participation. 
The study results will be published nationally and internationally and you will 
have the chance to look at the results at the end of the study if you are 
interested. 
6. Confidentiality: 
The study will take place in a private area in Hamad Medical Corporation that 
is secluded enough to ensure adequate confidentiality. All your data will be 
stored on password protected computers that can only be accessed by the 
study investigators. The study data will be handled in a confidential manner. 
No information regarding your name or contact information will be disclosed. 
All related study documentation (contact information etc) will be retained in a 
locked cabinet. 
I, ----------------------------------------------- have fully explained to Mr. / 
Mrs. --------------------- the nature and purposes of the above describe 
research project. I believe that he/ she understands the nature, purpose and 
risks of the study. I have also offered to answer any questions relating to this 
study that he/she might have and I declare hereby that I have completely 
and fully answered all such queries. 
Signature of the person obtaining the consent: 
Name of the person obtaining the consent:                               Date:  
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Appendix 5D: Robert Gordon University’s ethical approval letter 
 
  
371 
 
Appendix 5E: Ministry of Public Health’s support letter 
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Appendix 5F: Qatar University’s ethical approval letter 
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Appendix 5G: Hamad Medical Corporation’s ethical approval letter 
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Appendix 5H: Interview invitation email 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
On behalf of Dr. Moza Al Hail – Executive Director of Pharmacy, HMC; 
 
Dears, 
The Pharmacy Department at Hamad Medical Corporation (Qatar) in 
collaboration with Robert Gordon University (UK) and Qatar University (Qatar) 
are investigating key stakeholders’ views and perceptions on implementing 
pharmacist prescribing in Qatar. 
As a major health stakeholder in the country, your opinion matters. Thus, we 
kindly ask you to participate in this research. You will be expected to spend 30-
45 minutes discussing this topic with one of our research members. 
There are no harms or risks associated with joining this study. Your participation 
is voluntary and anonymous. You can refuse or withdraw your consent to 
participate at any time without any penalty. 
If you have any questions or enquiries, you can contact the research team 
anytime. 
If, however, you are willing to take part in this research, please reply to this 
email and we will be in touch with you to schedule a suitable time and place to 
conduct the interviews. 
Regards, 
Prof Moza Al Hail 
Executive Director- Pharmacy Department  
Hamad Medical Corporation 
375 
 
Appendix 6A: Robert Gordon University’s ethical approval letter 
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Appendix 6B: Qatar University’s ethical approval letter 
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Appendix 6C: Hamad Medical Corporation’s ethical approval letter 
 
378 
 
Appendix 6D: Research information sheet 
          
 
RESEARCH INFORMATION SHEET 
 
Dear Participant: 
You are invited to participate in Project entitled: “A Delphi study to determine 
the level of agreement relating to the development of pharmacist prescribing 
frameworks in Qatar”. 
 
Name of Principal Investigator: 
Tesnime Jebara, 
Pharmacy Postgraduate Research Student 
Robert Gordon University 
 
Robert Gordon University (UK) in collaboration with Hamad Medical 
Corporation and Qatar University are conducting this research. As an expert 
in health practice in Qatar, we are inviting you to join because we would like 
your input in developing a framework for pharmacist prescribing in Qatar. 
The research will involve approximately 35 different major health 
stakeholders in Qatar who are experts in terms of their knowledge and policy 
influence. Key individuals representing the different professions (medicine, 
pharmacy and nursing), hospital administrators as well as the Ministry of 
Public Health will be involved. In addition, there will be representation of 
those with expertise in patient safety. 
If you accept to participate in the study, you will be asked to rate and 
express your opinion on certain statements related to legalising pharmacist 
prescribing in Qatar according to a 6-point Likert scale (strongly disagree-
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disagree-somewhat disagree- somewhat agree-agree-strongly agree). 
Answers will be collected via Survey Monkey® anonymously.  
You will be sent the survey three times. For the first round, you will be sent a 
set of statements related to pharmacist prescribing legalisation in Qatar. 
During the subsequent rounds, you will be only provided with the statements 
where consensus was not reached and asked to rate them again after 
reviewing other stakeholders’ comments. 
Your participation in this study is completely voluntary. You can stop 
participating at any time and we will not hold it against you.  
There is no risk with participating in this study. Your choice to participate or 
not will not affect your employment status; and your immediate 
supervisors/managers will not know your participation answers. 
There are no direct benefits to you by taking part in the research. However, 
possible benefits to others include helping in building pharmacists’ capacities 
in Qatar, creating a research infrastructure which will trigger more studies in 
this area, instigating public discussions as well as guiding pharmacy practice 
initiatives. 
There are no financial compensation for your participation 
This research is part of a self-funded PhD project. 
Your participation is anonymous, and all information will be kept confidential.  
You have the right of knowing the results of this study at the end of it. 
If you have questions or concerns, or if you think the research has hurt you, 
please contact the research team. 
  
380 
 
Appendix 6E: Delphi invitation email and informed consent 
 
On behalf of Dr. Moza Al Hail – Executive Director of Pharmacy, HMC; 
 
Dears, 
You are being invited to participate in a research project which forms part of a 
PhD at Robert Gordon University (UK) and is in collaboration with Hamad 
Medical Corporation and Qatar University. The overall aim of the study is to 
explore the development of a framework for pharmacist prescribing in Qatar. 
You have been identified as a major stakeholder in healthcare in Qatar hence 
your participation will be highly valuable. All study information is provided in 
the attached leaflet. This study will employ a three-round modified-Delphi 
technique to determine the level of agreement among key stakeholders on 
aspects of pharmacist prescribing, specifically: models and scope of pharmacist 
prescribing; education and training; and prescribing practice and governance.  
Participation involves completion of a series of questionnaires (maximum of 3) 
rating the extent to which you agree or disagree with a series of statements. 
Each should take no longer than 20 minutes. 
If you agree to participate, please read the attached Participant Information 
Sheet and complete and return via email the form at the end of this email. 
____________________________________________________________ 
Please place your initials alongside each statement if you agree to the 
following: 
I confirm that I have read and understood the participant 
information sheet sent and been provided with adequate 
opportunity to ask any questions.  
______________ 
I understand that my participation is voluntary and that 
I am free to withdraw at any point during the study.  
______________ 
I understand that the data collected during this study 
will be used for research purposes including publication 
of anonymised findings. I grant permission to do so on 
the basis that my confidentiality will be protected.  
 
______________ 
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I agree to take part in round 1 of this study.  
 
______________ 
I agree to take part in round 2 of this study.  
 
______________ 
I agree to take part in round 3 of this study.  
 
 
______________ 
Name:       Date: 
 
Preferred email address 
 
Regards, 
Dr Moza Al Hail 
Executive Director, Pharmacy Department - Hamad Medical Corporation 
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Appendix 6F: Screenshot of Survey Monkey® 
 
 
 
